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ABSTRACT 
Tamoxifen remains a widely used hormone therapy for pre and post-
menopausal women with hormone receptor positive breast cancer in both 
adjuvant and metastatic disease settings.  Resistance to this well tolerated 
and cost-effective drug limits its use.  Only an improved understanding of the 
mechanisms of tamoxifen resistance will provide the basis for overcoming this 
phenomenon.   
Expression profiles from tamoxifen-resistant and sensitive MCF7 
derived breast cancer cell lines were prepared, using Affymetrix HG_U133A 
cDNA microarrays.  The data generated was analysed to identify novel 
pathways and genes associated with tamoxifen resistance or sensitivity.  
Selected genes, whose expression correlates with response to tamoxifen, 
were validated using RT-PCR in cell lines and following this, in situ 
hybridisation and immunohistochemistry on cell lines.  Functional analyses of 
these genes were carried out: genes that were down-regulated in tamoxifen 
resistant MCF7 cells (HRASLS3, CTSD, CAXII) were selectively knocked 
down using RNA interference. Cell lines stably over-expressing genes up-
regulated in the tamoxifen resistant MCF7s (ATP1B1, SOCS2, NR4A2) were 
selected.  These manipulated cells were subsequently tested for their 
response to anti-oestrogen treatment.   
Another major marker in breast cancer is the ERBB2 proto-oncogene; 
overexpressed in 20% of breast carcinomas, it is associated with poor 
prognosis and hormone resistance.  The transcriptional deregulation of 
ERBB2 in breast cancer may in part be mediated by the transcription factors 
AP-2α and γ.  Previous studies have shown that ERBB2 expression is 
repressed by oestrogen activated oestrogen receptor and that AP-2 binding 
sites within the ERBB2 promoter and the intronic enhancer are required for 
this oestrogenic repression.   
Using RNA interference, AP-2α and γ were successfully knocked down 
in breast cancer cell lines MCF7, T47D and ZR75-1.  These have been used 
to investigate the effect of AP-2 loss on ERBB2 expression in hormonally 
manipulated cells. 
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CHAPTER 1 – INTRODUCTION
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1 INTRODUCTION 
1.1 Breast Cancer  
1.1.1 Incidence and mortality 
Breast cancer is the commonest malignancy to affect women in the UK, with a 
lifetime risk of 1 in 9.  In 2005, 45,947 new cases of breast cancer were 
diagnosed in the UK19.  
 
Figure 1.1 Age standardised incidence and mortality rates, female breast 
cancer, UK 1975-2006 19.  
 
From Figure 1.1, it can be seen that while the UK incidence of breast cancer 
increased during the period 1975-2006, mortality rates have steadily declined.  
In 1989, 15,625 women died from the disease, compared with 12,319 in 2006.  
The reasons for this are multiple: increased awareness of the disease and a 
national screening programme with mammograms for women aged 50-70 
have made early diagnosis more common and reduced mortality20.  
Improvements in treatment have also contributed; part of the reduction in 
mortality seen has been attributed to the use of tamoxifen for hormone 
receptor positive disease 21. 
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Figure 1.2 shows breast cancer mortality in an age-specific manner and 
reveals the high rates of death in elderly women.  This reflects the higher 
incidence of breast cancer at advanced age and co-morbidity; however, there 
are also concerns that elderly patients are in danger of missing out on the 
latest improvements in breast cancer diagnosis and treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Number of deaths and age-specific mortality rates, female 
breast cancer, UK 2006 19. 
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Figure 1.3: Age-specific mortality rates, breast cancer, females, UK, 1971 
– 2005 19. 
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Figure 1.3 shows age specific mortality rates for women in the UK over the 
past 34 years.  This demonstrates the higher mortality rates in elderly women, 
(>70 years) and that the recent improvements in mortality vary between 
different age groups: between 1989 and 2005 the breast cancer mortality rate 
fell by 43% in women aged 40-49 years; by 39% in women aged 50-69; by 
32% in women aged 15-39; but only by 16% in women over 70 19. 
 
The reasons for higher mortality and slower improvement in mortality rates in 
the elderly are multiple: routine national mammographic screening stops over 
the age of 70.  There is a lack of awareness that breast cancer incidence 
increases with age; in a survey of UK women aged 40-80 questioned in 
2004/5, about half replied that the risk of getting breast cancer did not vary 
with age, only 2% correctly picked the oldest group of women (aged >70) as 
being at greatest risk of the disease 20.   
 
General frailty and co-morbidity in elderly women means they are less likely to 
tolerate intensive cytotoxic chemotherapy.  Clinical trial data show the benefits 
of chemotherapy decline with age, while the benefit of hormone therapy 
persists with age.  Professor Carlson, chair of the NCCN’s task force on 
breast cancer in the older woman argued that “the benefit of treatment needs 
to be relatively bigger to be worth it in an absolute sense because of 
competing causes of death” 22.  Hormone treatment is therefore of particular 
value in the elderly population, not only because of its tolerability but also 
because of the greater preponderance of oestrogen receptor (ER) positive 
tumours in elderly women.  Analysis of the US-SEER database shows the 
increased incidence of breast cancer in the elderly can be attributed solely to 
an increase in the incidence of ER positive tumours over the age of 50.  
Furthermore, they found ER expression in tumour tissue increased with 
increasing age (>50), while levels of ER in adjacent normal tissue remained 
stable, suggesting that deregulation of ER expression may underlie the 
observed age-specific increase in breast cancer incidence23. 
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There is a paucity of data to guide the management of breast cancer in the 
elderly.  Clinical trials investigating the toxicity and efficacy of novel treatments 
and regimens rarely include the elderly in their study population.  For example 
in the adjuvant tamoxifen trials, only 10% of the women involved were over 
70, yet 40% of breast cancers occur in this age group 24.  Though 
understandable in terms of investigators not wishing to have results 
confounded by adverse events unrelated to the intervention and the need for 
long term follow up to ascertain overall survival data, it means that treatment 
regimens are not designed for optimum tolerability or efficacy in the elderly.  
Considering that the majority of women with the disease are over 60 and that 
our population as a whole is ageing, this is of some concern.  The applicability 
of study findings derived from a population skewed towards younger patients 
into the majority population of older breast cancer sufferers is not certain; 
particularly given this disease’s heterogeneity, its known hormonal influences 
and the physiological changes that occur with age.   
 
1.1.2 Heterogeneity of breast cancer, prognosis prediction, rationing 
treatment 
Breast cancer is a heterogeneous disease in terms of the pathological 
findings, disease behaviour and therapeutic strategies.  The pathological 
description of a breast tumour includes: the tumour size and stage (its extent 
of spread); its appearance under the microscope or morphology, which 
reflects the cell of origin; the tumour grade, which reveals the degree of 
differentiation from the cell of origin; immunohistochemical (IHC) studies 
demonstrate the presence or absence of receptors, (importantly ErbB2, ER, 
PgR).  These features are used to stratify the disease into categories based 
on the risk of recurrent disease following initial diagnosis and treatment, (for 
example, using the Nottingham Prognostic Index25).  They are used to provide 
recommendations for treatment options for example, according to the St 
Gallen Consensus criteria 26.   
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Table 1.1 “Traditional” clinico-pathological factors to predict prognosis 
in breast cancer. 
Factor: Good Prognosis Poor Prognosis 
Patient Age >35 years <35 years 
Tumour size <2cm >2cm 
Grade 1 2 or 3  
Lymph Node status negative positive 
ER/PgR positive negative 
ErbB2 negative positive 
 
Resources such as Adjuvant! Online (http://www.adjuvantonline.com/) enable 
an estimate of the likely survival benefit of adjuvant treatment for a given 
patient (ie chemotherapy and / or hormone therapy following surgery and 
radiotherapy).  Clinicians enter various parameters, including the patient's 
age, tumour size, grade, ER, PgR and ErbB2 status.  The programme’s 
algorithm, based on meta-analysis of clinical trial data provides estimates of 
the risk of cancer-related mortality without adjuvant therapy, the reduction of 
risk with therapy and risk of therapy side effects.   
 
Despite cautions regarding an over-reliance on meta-analysis as a 
methodology and the limitations of attempting to translate an estimated 
population-based risk into an estimate of an individual’s risk, such tools are 
valuable for both patients and clinicians; allowing an evidence-based decision 
on whether or not to embark on adjuvant treatment.   
 
However, in spite of many large-scale randomised clinical trials, our ability to 
predict disease behaviour (pattern of metastases, tempo of disease 
progression, and response to therapy) for an individual remains elusive.   
Current prognostic indicators cannot pick out those apparently “low risk” 
patients who will relapse without adjuvant chemotherapy.  In advanced 
disease, treatment choice is often empirical, based on running though a list of 
treatments with decreasing activity. 
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Disease behaviour can be thought of as a result of the interplay of tumour 
factors, (for example: grade, cell of origin, rate of proliferation, ER status, 
residual tumour volume following initial treatment) and individual factors (such 
as genetic background, immune status, menopausal status, obesity) with 
environmental factors (such as treatment with surgery, radiotherapy, 
cytotoxics, hormone therapies, exogenous mutagens, diet).  Predicting the 
behaviour of an individual tumour is therefore necessarily complex and 
challenging.  It is analogous to the ancient debate over whether “nature or 
nurture“ is of primordial importance in determining an individual’s abilities and 
behaviour.    
 
Increased awareness of breast cancer and population screening has 
facilitated the detection of earlier tumours; however this leads to a clinical 
dilemma as the balance of “risk versus benefit” for adjuvant therapy shifts.  
Currently, 60-70% of patients present at an early stage with no lymph node 
involvement, 70-80% of such women will survive for over 10 years without 
adjuvant chemotherapy 27.  As the pattern of disease shifts, increasing 
numbers of patients effectively cured by surgery and radiotherapy will be 
offered unnecessary cytotoxic treatment, at a cost both to the patients and 
their healthcare system. 
 
It is hoped that increased knowledge of the gene expression patterns will 
allow more accurate prediction of tumour behaviour and response to 
treatment.  The ultimate aim of such knowledge will be to individualise 
treatment; enabling the avoidance of unnecessary cytotoxic treatment in some 
cases and prompting aggressive combination treatment or including targeted 
agents in others.  This would benefit individual patients by reducing 
unnecessary treatment and side effects, but may also result in cost savings if 
either fewer therapies are recommended overall, or if “tailored follow up” could 
be instituted.   
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The advent of new, targeted anti-cancer agents has brought the realisation 
that they maybe unaffordable to all. Focusing their use on patients at highest 
risk may be a more effective, acceptable method of rationing their use.  The 
overall cost effectiveness of such a strategy would depend on the cost of 
expression analysis, risk assessment and the rates and cost of treatment 
recommended.   
 
1.2 Oestrogen 
1.2.1  Breast cancer and Oestrogen 
Figure 1.4 illustrates the hormone dependant changes, which occur in 
physiological breast development.  As described in the Figure legend, breast 
tissue is cyclically remodelled throughout life under the influence of hormones 
and growth factors.  It has been postulated that it is the dynamic nature of 
breast cells, their ability to be continuously remodelled and influenced which 
makes them particularly susceptible to carcinogenesis9.    
 
Post menopausally, the breasts involute, the numbers of lobules and ducts 
reduce, the glandular epithelium and interlobular connective tissue is replaced 
by fat.  This reduction in tissue density explains why mammographic 
screening in women over 49 years is more effective than in younger women. 9 
 
Figure 1.5 shows the biochemical pathways involved in the synthesis of 
endogenous steroids from cholesterol.  In pre-menopausal women, ovarian 
granulosa cells produce the majority of 17β-oestradiol, with smaller amounts 
synthesized in the adrenal glands.  Peripherally, precursor hormones such as 
testosterone are converted by aromatisation to 17β-oestradiol.  Adipose tissue 
actively converts precursors to 17β-oestradiol, this process continues post-
menopausally and becomes a dominant source of endogenous steroids.  17β-
oestradiol is also produced in the brain and in arterial endothelium. 
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Figure 1.4 Murine Mammary gland development from Hennighausen 
& Robinson 3. 
Embryogenesis: A small placode in the ectoderm develops into a bud.  
At the base of the bud, rapid epithelial proliferation forms several ducts 
that grow towards a fat pad.  Finally, mesenchyme derived structures form 
the nipple. In humans, from 28 weeks gestation, two distinct cell 
populations are distinguishable: inner luminal separated from the 
basement membrane by the outer myoepithelial layer 9 Puberty: Cyclical 
ovarian production of oestrogen & progesterone accelerates epithelial 
duct outgrowth. In humans, “end-bud like structures” proliferate rapidly 
and form the terminal duct lobular units9. In the mature gland, ductal side 
branches form and disappear with each oestrogen cycle. Pregnancy: 
Placental lactogens, prolactin, and progesterone stimulate cell 
proliferation, alveolar bud (AB) formation and alveolar expansion.  
Lactation: During lactation, luminal cells of mature alveoli synthesise 
milk, which is transported through the ducts to the nipple.  Regression: 
On cessation of feeding, apoptosis occurs in the secretory epithelium, the 
surrounding stroma is remodelled to replace apoptosed cells. Finally, 
cyclical production of ovarian oestrogen and progesterone returns.  
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Figure 1.5  Human Steroidogenesis, (Figure taken from Wikipedia28) 
This illustrates the steps involved in converting cholesterol to 17β-oestradiol.  
The major classes of hormones are colour coded as follows: Androgens 
(blue), progestagens (yellow), oestrogens (pink), mineralocorticoids (purple) 
and glucocorticoids (green).   
Androstenedione, a key intermediary in the pathway is either converted to 
testosterone, which undergoes aromatisation to 17β-oestradiol, or to oestrone 
and converted to 17β-oestradiol by 17β-hydroxysteroid reductase (17βHSD).   
Aromatase is the key enzyme inhibited by aromatase inhibitors, such as 
exemestane and anastrazole. 
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Epidemiological studies indicate that high cumulative exposure to oestrogen 
increases the risk of breast cancer.  Summarised in Table 1.2, the risk factors 
for breast cancer equate to an increased lifetime oestrogen exposure, while 
protective factors reduce overall oestrogen exposure 29.    
 
Table 1.2 Oestrogen-associated breast cancer risk factors.  
Risk Factors:  Protective factors: 
Early Menarche29 Late Menarche29 
Late Menopause29 Early Menopause29 
Nulliparity29 Early pregnancy29 
No breastfeeding29 Prolonged breastfeeding29 
HRT29 
Post menopausal obesity29 
Excess Alcohol29 
Polymorphisms in oestrogen 
metabolising enzymes: COMT, 
SULT1A1, UGT1A1, GST.31 
Dietary phyto-oestrogens 
(which may competitively 
inhibit oestrogen) 30 
 
Ercole Cavalieri put forward the oestrogen initiation and promotion theory 
explaining the link between oestrogen exposure and breast cancer risk.  This 
involves two processes; firstly that formation of genotoxic metabolites of 17β-
oestradiol, (such as chatechol-oestrogens and catechol-quinones) bind to 
DNA, cause depurination, resulting in mutation.  Secondly that binding of 17β-
oestradiol to the oestrogen receptor (ER) alpha stimulates cell proliferation.  
Errors in DNA occurring during replication result in fixed mutations when not 
repaired32.  
 
There is evidence that polymorphisms of the enzymes involved in the 
formation of (chatechol-oestrogens and catechol-quinones) metabolites 
modulate the risk of breast cancer. 33-38 
 
17β-oestradiol and 4-OH-17β-oestradiol causes mutations in cell culture 
systems and can transform benign MCF-10F cells. Loss of heterozygosity and 
gains and losses of DNA segments can be seen in these cells using 
comparative genomic hybridization32.  
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The double transgenic, ERalpha knockout / Wnt-1 knockin mouse model 
enables analysis of ER-mediated and ER-independent actions of estradiol.  
Knockout of ER alpha delays the onset of breast tumors in this model, 
demonstrating a role of receptor-mediated actions.  While oophorectomy 
delays the onset of tumors and reduces overall incidence, providing evidence 
for a genotoxic ER-independent effect32.  
 
There is also evidence to support the theory that oestrogen causes breast 
cancer via its pro-proliferative effects on breast tissue; though only 15-25% of 
normal breast epithelial cells express oestrogen receptors, over 60% of breast 
cancers are ER-positive and depend on oestrogen for growth.  Furthermore, 
ER expression is higher in the normal breast tissue of women with breast 
cancer than in women without the disease 24,39. 
 
As early as 1896, Beatson demonstrated that depriving breast cancer of 
endogenous oestrogen, through oopherectomy resulted in control of 
metastatic disease in ~30% of patients40.  Today, various pharmacological 
strategies are used to reduce oestrogen and control the disease, as follows: 
 
i) GnRH analogues, (e.g. goserelin) and GnRH antagonists (eg 
cetrorelix) are used in pre-menopausal women to reduce ovarian production 
of oestrogen41,42.  (Gonadotropin-releasing hormone, GnRH is produced by 
the hypothalamus, GnRH secretion results in the synthesis and secretion of 
the gonadotropins, LH and FSH from the pituitary gland, which stimulate 
ovarian function and synthesis of oetrogens.)  
 
ii) Aromatase inhibitors prevent the synthesis of oestrogen in breast 
cancer cells, the ovaries and peripheral tissues; for example: exemestane is a 
suicide substrate while anastrazole is a competitive inhibitor of aromatase43.  
See Figure 1.5: aromatase, also known as CYP19 is depicted in the 
steroidogenesis pathway, catalysing the conversion of androstenedione to 
estrone and the conversion of testosterone to 17β-oestradiol28. 
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iii) Oestrogen receptor (ER) antagonists are also widely used; these 
can be divided into pure anti-oestrogens such as: Fulvestrant (ICI 182,780) 
and Selective Estrogen Receptor Modulators, (SERMs) such as tamoxifen 
and raloxifene43.  
 
Tamoxifen and anastrazole have proven to be effective in the treatment and 
prevention of breast cancer; they are both widely used in these contexts, (see 
Section 1.3.3)44-46. 
 
1.2.2 The Oestrogen Receptor (ER) 
The effects of oestrogen are mediated through the oestrogen receptor ER, 
which exists in two forms: ERα and ERβ, encoded by separate genes.  
Oestrogen receptors belong to the nuclear hormone receptor superfamily, a 
large family of ligand-regulated, zinc finger-containing transcription factors, 
which share a characteristic structure (see Figure 1.6).   ERα and ERβ have 
distinct tissue expression patterns: (ERα is found in the endometrium, breast, 
ovaries and pituitary while ERβ occurs in kidney, bone, brain, heart, lungs, 
intestinal mucosa, prostate and endothelial cells)47-49.   
 αα   1  180  263 302  553  595  38  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Oestrogen Receptor-α (ER-α) structure 
Consists of six domains: closest to the N-terminal, AF-1 the ligand-
independent transactivation domain, followed by zinc finger containing 
domains, which bind DNA.  At the C-terminal, the ligand-binding domain 
incorporates the dimerisation domains and AF-2, the ligand-dependant 
transactivation domain.   
 A B D C E F N C
AF-1 AF-2 
Zn Fingers 
DNA binding 
Dimerisation 
Ligand binding 
Transactivation 
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Figure 1.7: ER co-activator recruitment, from Deroo + Korach 
2006.   
Upon binding ER ligands, (ER agonists, antagonists, or SERMs) the 
receptor undergoes a conformational change, which regulates the 
recruitment of co-regulatory proteins and the resulting transcriptional 
apparatus.  Co-activators such as SRC1 bind to the active (agonist-
bound) receptor and activate transcription, while co-repressors 
interact with the antagonist-bound receptor, inhibiting transcription.  
Depending on the cell and promoter context, unique and overlapping 
sets of genes are regulated 2. 
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1.2.3 ER: Mechanisms of action 
ERα has been extensively studied and is thought to play a dominant role in 
the promotion and progression of breast cancer; it is over-expressed in the 
majority of breast cancers, (>60%).  By contrast, ERβ may have a tumour 
suppressor role; expression is reduced in malignancies of the breast, ovary, 
prostate and colon, and overexpression of ERβ inhibits proliferation and 
invasion of breast and prostate cancers 50. 
 
Oestrogen is thought to act via several different mechanisms, as follows: 
i) In the “classical” model of ligand dependant ER activation; upon 
oestrogen binding, the receptor undergoes a conformational change, 
dissociates from chaperone proteins (such as Hsp90), it dimerises, is 
phosphorylated and targeted to the nucleus.  In the nucleus, the oestrogen-
bound ERα dimer binds DNA at an oestrogen response element (ERE), a 
palindromic consensus sequence present in the gene regulatory regions of 
ER-responsive genes, (5’-GGTCAnnnTGACC-3’).  Recent genome wide 
analysis of ER binding sites has revealed that only a small proportion of ER 
binding sites (~4%) map to proximal promoter regions (PPR), leading to the 
surprising realisation that for many genes, the PPR is unlikely to be the 
primary site of ER-mediated regulation51. 
 
Transcription of oestrogen responsive genes is activated through interaction 
with the basal transcription machinery and recruitment of co-regulatory 
proteins: co-activators and histone acetyltransferases for activation of gene 
transcription or co-repressors and histone deacetylases for suppression of 
transcription.  See Figure 1.7: ER co-activator recruitment and Table 1.3, 
summarising oestrogen receptor co-activators and co repressors2. 
 
Pioneer factors are a recently identified, important group of ER cofactors, 
required for ER binding to chromatin, they act by bringing the ER in contact 
with the chromatin.  FOXA1 and GATA3 are the most fully characterised so 
far, (reviewed by Green and Carroll52).  FOXA1, a forkhead box protein has 
been shown to be essential for changes in chromatin structure during 
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oestrogenic induction of the cyclin D1 gene.   FOXA1 binding sites are 
enriched at the regulatory regions of ER target genes throughout the genome.  
GATA3, has recently been identified as an essential gene in mammary gland 
development.  Both GATA3 and FOXA1 are oestrogen-regulated proteins 
whose presence correlates with ER expression in breast cancer cells. 
 
ii) Ligand bound ER can also function via a “non-classical” model, where 
the activated ER-ligand-co-factor complex interacts with other transcription 
factors (such as AP-1, Sp1, NF-κB) and activates transcription of their target 
genes, for example; adenosine deaminase and retinoic acid receptor α1 via 
interaction with Sp1 53,54.  
 
iii) “Non-genomic” mechanism: It is known that a proportion of ER 
localizes to the plasma membrane and signals mainly though coupling to G 
proteins.  In response to steroid, signal transduction can result in non-
transcriptional events, (in addition to transcriptional events)55.  This non-
genomic pathway has been proposed as an explanation for the rapid 
responses observed within seconds of treatment with 17β-oestradiol in tissue 
culture.  A recent paper examined a small number of ER positive breast 
tumour samples; various cell fractions were separated and interestingly they 
found phosphorylated ER in the membrane fraction of the invasive cancer 
specimens but none in either DCIS or normal breast tissue56. 
  
It is thought that cross-talk from membrane-localized ERs to nuclear ERs can 
be mediated through growth factor receptor tyrosine kinases, see below. 
 
iv) Ligand-independent activation of ER occurs in the cytoplasm via cross 
talk with other signalling pathways (such as: EGFR, ErbB2, IGFR, Insulin).  
Activation of these pathways can cause phosphorylation of key amino acid 
residues in the AF-1 domain of ERα, (via the MAPK/ERK or PI3K/AKT 
pathways) altering the level of activation of ER, resulting in dimerisation and 
transcription of ER responsive genes, this can occur in the absence of sex 
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steroid55,57,58.  Phosphorylation of co-regulator proteins can also occur, 
altering their activity and thus modulating the transcriptional activity of ER59. 
 
The effects of the growth factor signalling pathways on the ER are two-way; 
activated ER can activate growth factor receptors and their downstream 
kinases, for example IGFR, ErbB2, and EGFR 60-62. 
 
Intracellular levels of ERα depend on the binding of different ligands: in MCF7 
cells; unbound ERα has a half-life of 4 hours, binding of oestrogen reduces 
this to 3 hours 63, brought about by reduced transcription of ERα mRNA and 
increased receptor degradation 64.  Binding of a partial agonist such as 
tamoxifen prolongs the receptor half-life and stabilises ERα levels65.  In 
contrast, the binding of Fulvestrant (ICI 182,780), a pure anti-oestrogen 
directs ERα to the cytoplasm and causes rapid depletion of the receptor66.  It 
is thought that ubiquitination of ERα and its co-activators targets them for 
proteasomal degradation67.  Thus, changes in ERα turnover modulate the 
response to oestrogen by altering levels of the receptor 64. 
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Table 1.3 Oestrogen receptor co-regulators  
 
CO-ACTIVATORS:  
Factor Recep. Function Ref 
BRG-1 ER ⁭  transcription activity,  
interacts with SRC-1 
5 
CBP ER 
RAR 
TR 
⁭  ER activity, interacts with SRC-1,2,3 HAT 
activity. 
Integrates signals from other pathways 
10 
L7/SPA ER 
PgR 
Antagonist specific co-activator – increases 
agonist activity of tamoxifen, but not of agonists/ 
pure antagonists 
13 
p68 ER Binds AF-1. Interacts with CBP in vitro 
↑activity of oestrogen or tamoxifen bound ER. 
Potentiated by MAPK-induced phosphorylation of 
ER. 
14 
p300 ER Binds CBP, SRC-1  
HAT activity 
5 
PBP ER, 
RAR, 
TR 
⁭  ER activity  
Overexpressed in breast cancer 
15 
SRC-1 ER, 
PgR, 
AR 
Required for ER activity, binds AF-1+2 
Interacts with p300. Intrinsic HAT activity 
Overexpression ↑tamoxifen agonist activity in 
vitro.Knockout→tamoxifen resistance  
Co-activates AP-1 + NF-κB 
5,16 
SRC-2 ER, 
PgR, 
AR 
 ↑ ER activity 
Interacts with CBP 
10 
SRC-3 ER, 
PgR, 
AR 
↑ ER activity (ERα > Erβ) 
Overexpressed in breast / ovarian cancer 
Required for normal breast development 
Intrinsic HAT activity 
Overexpression ↑tamoxifen agonist activity in 
vitro  
17,18 
 CO-REPRESSORS:  
Factor Recep Function Ref 
NCoR ER, 
PR, 
RAR, 
TR 
Recruits CoR/Sin3/HDAC1/HDAC2 
Often deleted in malignancy 
Low expression associated with tamoxifen 
resistance in clinical samples + a mouse model 
11,12 
REA ER ↑antioestrogen activity,↓oestrogen activity 
Competitive inhibitor of SRC-1 
↑expression correlates with good prognosis in 
breast cancer 
5 
NCoR2 
(SMRT) 
RXR, 
TR 
Ubiquitously expressed 
Recruits histone deacetylation complex, HDAC 1 
↓ SERM agonist activity 
11,13 
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1.3 Tamoxifen 
1.3.1  Structure of tamoxifen 
Tamoxifen is a selective oestrogen receptor modulator (SERM), in some 
tissues, such as breast tissue; tamoxifen acts as an oestrogen antagonist 
while it exhibits oestrogenic, agonist activity in other tissues (bone, uterus, 
cardiovascular system).  Figure 1.8 shows the structure of tamoxifen (see also 
Figure 1.5). 
 
 
 
 
 
 
 
 
 
Figure 1.8: Structure of 4-OH Tamoxifen 68 
 
1.3.2 Tamoxifen: Mechanism of action, (see Figure 1.7) 
Like oestrogen, tamoxifen acts by binding ERα, causing dimerisation and 
nuclear localisation.  Tamoxifen is a larger molecule than 17-β oestradiol, 
when bound to ER, it alters the receptor conformation, reducing co-activator 
binding69.  In breast tissue, tamoxifen-bound ERα recruits co-repressors and 
histone deacetylases to the ligand-receptor-co-regulator complex on 
oestrogen responsive genes, thus reducing their expression5.  Whilst in other 
tissues, such as endometrium tamoxifen acts as an agonist at the ER.  The 
differential effect of tamoxifen in different tissues is proposed to be due to a 
combination of factors including:   
 
i) Levels of co-regulators are rate limiting for transcriptional activation, the 
relative levels of co-activators and co-repressors in different tissues are 
thought to determine tissue specific agonist / antagonist activity70,71. 
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ii) The ratio of ER subtypes; ie whether ERα or ERβ predominates in a 
cell is also thought to be a factor 2,5.   
 
iii) In addition to ii), the regulatory sequences on the promoter of the target 
gene may influence the selective action of SERMs Eg AP-1 sites: In 
transfected HeLa cells, oestrogen induces and tamoxifen inhibits ERα induced 
stimulation via (non-classical) AP-1 stimulation.  The reverse is true of ERβ -
mediated AP-1 activity 72 
 
iv) ER pathway cross talk with other signalling pathways (eg growth factor 
/ tyrosine kinase signalling) may also vary in different tissues, modulating ER 
activity and therefore the tissue specific response to tamoxifen.     
 
1.3.3 Use of tamoxifen and other hormonal therapies 
Early clinical trials with tamoxifen established it’s value in advanced breast 
cancer73,74.  Originally, tamoxifen was given to all patients with breast cancer, 
however it’s current use is restricted to hormone receptor positive tumours.  
For decades, tamoxifen has been the gold standard treatment for ER positive 
disease in both metastatic and adjuvant settings.  
 
Tamoxifen’s safety and efficacy has been established in randomised 
controlled trials (RCT) involving approximately 30,000 women.  Adjuvant 
treatment with tamoxifen for women with ER positive disease results in a 51% 
reduction in recurrence rate and 28% reduction in death.  Standard treatment 
is for 5 years24, although preliminary results from the ATLAS trial suggest 
there may be additional benefit from 10 years adjuvant of tamoxifen75. 
 
The advantages of tamoxifen in clinical practice include its cost effectiveness 
and a safety profile developed from lengthy, widespread use.  It has been 
shown to lower serum cholesterol levels and lower the risk of osteoporotic 
fracture in post-menopausal women76-78.  The less desirable side effects of 
tamoxifen include: hot flushes, an increased risk of uterine cancers, 
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(endometrial carcinoma and uterine sarcoma), thromboembolism and 
elevated triglycerides46,79,80.   
 
The observation that tamoxifen reduced the incidence of cancer in the 
contralateral breast by 54% after 5 years prompted further investigation for its 
use as a chemopreventative.  Placebo controlled trials in over 25,000 women 
showed that tamoxifen reduced breast cancer risk by about 40% and 
osteoporotic fracture risk by about 32%, (IBIS-1, (International Breast Cancer 
Intervention Study-1), Royal Marsden Hospital Chemoprevention trial, Italian 
tamoxifen prevention study and NSABP-P1, (National Surgical Adjuvant 
Breast and Bowel Project P-1) trials). Concerns over the significant 
gynaecological toxicity, (endometrial atypia, polyps and cancer) has limited 
the use of tamoxifen for prevention of breast cancer in healthy women 
(Reviewed by Cuzick et al.)81. 
 
Similarly, large-scale placebo-controlled trials show that raloxifene, (another 
SERM with less oestrogen agonist effect in the uterus) reduces breast cancer 
risk by 44-72% and osteoporotic vertebral fractures by 30-50% (Multiple 
Outcomes of Raloxifene Evaluation (MORE), (CORE) and Raloxifene Use for 
the Heart (RUTH)). These studies showed an increase in thromboembolism 
but no evidence of increased endometrial problems.  Reviewed by Powles 82. 
 
The Study of Tamoxifen and Raloxifene, (STAR) and NSABP P2 directly 
compared tamoxifen with raloxifene for chemoprevention.  Both studies 
showed similar risk reduction for invasive breast cancer and osteoporotic 
fractures with less toxicity for raloxifene.  Intriguingly, both trials suggested 
that tamoxifen had greater activity in the prevention of non-invasive breast 
cancer (carcinoma in situ – DCIS and LCIS) 83. 
 
Long term follow up from some of these studies (IBIS-1 and Marsden) has 
confirmed that the chemoprotective effects for prevention of invasive breast 
cancer continue long after the end of treatment, while the side effects resolve 
more quickly, suggesting an increase in the risk benefit profile after the end of 
 39
active treatment84,85.  (Indeed, the interim analysis of the RMH trial and the 
Italian tamoxifen prevention study showed no significant benefit). 
 
Over the past 5-10 years, a growing body of evidence has accumulated 
establishing the clinical superiority of more modern agents, aromatase 
inhibitors (AIs) in the treatment of hormone responsive breast cancer in 
postmenopausal women.  Meta-analysis of data from 25 trials in the 
metastatic setting (comprising 8504 patients) demonstrated a significant 
overall survival advantage with aromatase inhibitors compared with tamoxifen 
(11% Relative hazard reduction, (95%CI=1%-19%; P=0.03) 86. 
 
In the adjuvant setting, several trials have shown the superior efficacy of 
aromatase inhibitors compared to tamoxifen as primary adjuvant treatment 
(ATAC, ITA, ARNO/ABCSG 8) and also as a planned switch after 2-3 years of 
adjuvant tamoxifen (ARNO 95, IES).  The 100 month data from the ATAC, 
(Arimidex, Tamoxifen, Alone or in Combination) trial, a large double-blind RCT 
comparing anastrozole with tamoxifen for adjuvant treatment of breast cancer 
indicate an advantage for anastrozole in reducing the risk of relapse, reducing 
the risk of distant metastases and although the beneficial effects of reduced 
relapse and increased disease free survival continue to increase after 
completion of treatment, no significant difference in overall survival has been 
seen between the tamoxifen and anastrazole arms of the study.  As for their 
relative side effect profiles: women taking anastrozole experienced more 
sexual dysfunction, myalgia and an increased risk of osteoporotic fractures, 
while tamoxifen was associated with an increased risk of thrombosis and 
endometrial cancer 44,45,87,88.  
 
At present, tamoxifen remains in widespread use for numerous reasons: 
aromatase inhibitors are contraindicated in pre-menopausal women; arguably, 
clinicians are intrinsically reluctant to change their practice.  In the UK, current 
guidance from the National Institute of Clinical Excellence (NICE) allows 
patients and their clinicians to choose the appropriate adjuvant hormone 
therapy from an AI or tamoxifen.  No recommendation has been made for one 
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AI over another 89.  The American Society of Clinical Oncology, ASCO has 
recommended the use of an AI “at some point” in their treatment for all 
postmenopausal women with ER positive breast cancer.  There are 
differences in their side effect profile, which means that some women tolerate 
one or other class of drug more easily.  Tamoxifen is still established as an 
effective treatment for metastatic disease and if patients are given adjuvant 
AIs, if they relapse they are often given tamoxifen at this point.  Therefore one 
can expect tamoxifen to continue to be in widespread use for some time to 
come. 
 
In the metastatic disease setting, ~50% of patients exhibit de novo resistance 
to tamoxifen, however eventually all patients develop tamoxifen resistance 
and this clearly limits the use of the drug16,90.   
 
1.4 Tamoxifen resistance   
The complexity of ER activation and tamoxifen’s interaction with ER provides 
multiple mechanisms by which tamoxifen resistance may occur.  Much 
research has been carried out to elucidate these mechanisms, although 
progress has been made; no unifying theory has emerged.  This section 
summarises various proposed mechanisms of tamoxifen resistance. 
 
1) Loss of ERα expression / altered function:  
Since the effects of tamoxifen are mediated through ER, and ERα expression 
predicts response to tamoxifen, it is logical that loss of ERα expression 
confers resistance to therapy.  However, IHC studies looking at paired 
tamoxifen sensitive and resistant tumours show that although ERα expression 
may be lost in some patients who develop tamoxifen resistance, 60-80% 
continue to express ERα on disease progression91,92.  In addition, ~20% of 
patients demonstrate a response to further hormone therapy following failure 
of tamoxifen, suggesting that the ER continues to regulate growth in many 
tamoxifen-resistant patients 93,94.  Similarly, cell line models of tamoxifen 
resistance, such as the ones used in this project continue to respond to 17β-
oestradiol.   
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Mutations of the ERα gene may lead to a non-functioning receptor without 
loss of expression.  However, although ERα mutations altering the effects of 
bound ligand can be generated in vitro and detected in some resistant cell 
lines, they are thought to be relatively uncommon clinically95,96.  In a screen of 
30 metastatic breast tumours, three ERα mutations were identified, only one 
of which conferred constitutive ERα transcriptional activity, unaffected by 
tamoxifen97.  
 
A single amino acid substitution (lysine 303 → arginine) was detected in 20 of 
59 hyperplastic breast lesions98. This mutation produced a hypersensitive 
receptor, with enhanced binding of co-activators in low oestrogen conditions 
and altered the cross talk between ERα and pathways that normally 
downregulate ER signalling99.  
 
Epigenetic changes may also reduce expression of ER or oestrogen target 
genes.  A study analysing the DNA methylation status of 148 primary breast 
tumors found that hypermethylation of the ERα gene, (ESR1) outperformed 
hormone receptor status as a predictor of clinical response in tamoxifen 
treated patients.  Also of interest, promoter methylation of CYP1B1, which 
encodes a tamoxifen and oestradiol-metabolizing cytochrome p450, was a 
highly significant predictor of clinical response in tamoxifen-treated patients, 
whilst unpredictive in non-tamoxifen-treated patients100.   
 
A similar study by Martens et al. examined methylation of 117 candidate 
genes thought likely to have a role in endocrine resistance in 200 ER-positive 
metastatic tumours treated with tamoxifen.  They were unable to replicate 
Widschwendter’s findings in these samples.  However, methylation of ten 
genes was significantly associated with tamoxifen response.  The strongest 
predictor of tamoxifen sensitivity was hypermethylation of PSAT1, 
(phosphoserine aminotransferase 1)101. 
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2) Altered expression of ERβ  
There is evidence that ERα and ERβ can homo or heterodimerise102, and that 
their dimers have different actions at oestrogen response elements and AP1 
sites which appear to depend on the concentration and nature of the ER 
ligand 72.  Transient co-expression of ERα and ERβ in cell lines results in ERβ 
induced reduction in ERα activity at low ligand concentrations103, prompting 
the theory that ERβ can directly inhibit ERα activity.  There is evidence that 
ERβ expression is reduced whilst ERα expression is increased during breast 
tumorigenesis 104,105. 
 
Increased ERβ expression and / or activity has been suggested as a 
mechanism of tamoxifen resistance, but the data are controversial:  Speirs et 
al. showed median ERβ mRNA levels measured by RT-PCR were 2-fold 
higher than ERα in tamoxifen-resistant tumours compared with tamoxifen-
sensitive tumours106, however cell line studies examining the effects of 
exogenous ERβ expression in MCF7 cells have demonstrated either no 
change in tamoxifen resistance107 or increased tamoxifen sensitivity108 with 
increased ERβ expression. 
 
3) Pharmacological tolerance 
A classic mechanism of drug resistance is via reduced intracellular 
concentrations of drug as a result of decreased influx or increased efflux.  A 
study analyzing serum and intra-tumoural tamoxifen levels suggested that 
acquired resistance is associated with reduced intra-tumoural tamoxifen 
concentrations in the presence of maintained serum levels 109. 
Increased metabolism of tamoxifen to active, agonist metabolites is another 
potential mechanism of resistance110.  Recent studies have demonstrated the 
importance of endoxifen, (4-OH-N-desmethyl-tamoxifen) a potent tamoxifen 
metabolite produced by the action of the cytochrome P450 enzyme, 
CYP2D6111.  Polymorphisms in the CYP2D6 gene affect the plasma 
concentration of endoxifen and clinical outcome of women given hormone 
therapy.  In the NCCTG 89-30-52 study, a retrospective analysis of 256 
tamoxifen-treated patients, CYP2D6 genotypes were determined from 
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paraffin-embedded blocks.  Women with the CYP2D6 *4/*4 genotype (the less 
active phenotype comprising ~7% of the European population) had a higher 
risk of disease relapse and a lower incidence of hot flashes than women with 
the wildtype allele68.  
A prior study noted that patients with wildtype CYP2D6, treated with 
paroxetine had a decreased plasma concentration of endoxifen, indicating 
that both pharmacogenomics and drug interactions may alter tamoxifen 
efficacy 112. 
These studies have formed the basis for the design and marketing of the 
Amplichip by Roche, aimed at detecting CYP2D6 deficiency at the DNA level 
in the germ line of newly diagnosed breast cancer patients, in order to predict 
tamoxifen response, (see Table 1.4). 
 
4) Alterations in co-regulatory proteins: (see Table 1.3) 
Co-activators 
SRC-3 is an ER co-activator overexpressed in >50% of breast tumours18.  In 
cell line studies, SRC-3 enhances the agonist activity of tamoxifen113.  SRC-3 
expression was measured by western blot, comparing 187 patients treated 
with adjuvant tamoxifen, with 119 patients who received no adjuvant therapy.  
In the untreated group, high SRC-3 levels were associated with good 
prognosis, while in tamoxifen-treated patients, high SRC-3 expression was 
associated with a worse disease free survival114.  
 
Experimental data suggest that overexpression of other co-activators eg SRC-
1 may also enhance the agonist activity of 4-OH tamoxifen70,115. An IHC study 
examining levels of SRC1 expression in 70 primary breast tumours of known 
ErbB2 status (ErbB2 positive, n = 35) and normal breast tissue found over-
expression of SRC-1 was significantly associated with disease recurrence in 
ErbB2 positive patients treated with tamoxifen 116. 
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Co-repressors 
Reduced co-repressor activity may also enhance the agonist effects of 
tamoxifen on the ER, thus contributing to resistance.  Lavinsky et al. showed 
in a mouse xenograft model of tamoxifen resistance, NCoR levels declined in 
many of the tumours that acquired resistance to the anti-proliferative effects of 
tamoxifen, compared to tumours that retained sensitivity to tamoxifen11.  
 
5) Kinase / signal transduction pathways:  
Growth factor signalling 
ERK1/2 expression and activity is increased in several breast cancer cell-line 
models of endocrine resistance117,118.  Increased ERK 1/2 activity (assessed 
by phosphorylated MAPK immunostaining) correlates with shorter duration of 
response to endocrine therapy in clinical breast cancer119.   
 
Kinase-mediated growth factor signaling may also modulate ER activity by 
enhancing the activity of co-activators and attenuating co-repressor activity 
11,120
, for example by phosphorylation of coregulators121,122. Up-regulation of 
tyrosine-kinase growth factor receptor pathways may therefore contribute to 
tamoxifen resistance.  Growth factor pathways and their cross talk with ER are 
implicated mainly in de novo tamoxifen resistance. (The role of ErbB2 cross 
talk in tamoxifen resistance is discussed in more detail in Section 1.8.2.) 
 
PI3K cell survival pathway  
Two cell line studies have addressed the possible involvement of this pathway 
with tamoxifen resistance.  Campbell et al. found that transfecting MCF7 cells 
with AKT reduced the inhibition of cell growth by tamoxifen, suggesting 
overexpression of AKT may contribute to tamoxifen resistance123.  Clark et al. 
measured tamoxifen-induced apoptosis with and without the PI3K pathway 
inhibitor LY294002. Addition of LY294002 significantly increased the pro-
apoptotic effects of tamoxifen, particularly in the cell line with the highest 
endogenous levels of AKT activity 124. 
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Stress-activated protein kinase/c-junNH2 terminal kinase (SAPK/JNK).  ER 
can interact with the SAPK/JNK pathway either via binding AP-1 or by direct 
activation of ER and co-regulators by p38 MAPK.   
 
AP-1 transcriptional activity increases with increased abundance of the 
components of the transcription complex or by their phosphorylation by JNK 
or SAPK.  These enzymes are activated by cellular stresses including 
oxidative stress125.  Increased AP-1 DNA binding accompanies the 
development of tamoxifen resistance in MCF7 cells126.  This has also been 
shown in a panel of 30 primary breast tumours with acquired tamoxifen 
resistance, compared with 27 untreated controls127.  Using a mouse xenograft 
model: compared with oestrogen-treated tumours, tamoxifen-resistant 
tumours had increased AP-1 dependent transcription and phosphorylated c-
Jun and JNK levels128.  Furthermore, conversion to a resistant phenotype was 
associated with an increase in oxidative stress (as measured by increases in 
superoxide dismutase and glutathione-S-transferase).  These data are 
consistent with a model where tamoxifen-induced oxidative stress leads to 
activation of JNK and increased AP-1 activity124,128. 
 
Activation of the p38 MAPK pathway occurs in response to a number of 
extracellular stimuli including growth factors, cytokines, physical and chemical 
stress129. The downstream targets of p38 MAPK include further protein 
kinases and transcription factors. In cell lines expressing ER; 4-OH tamoxifen 
has been shown to activate the p38 MAPK pathway and induce apoptosis130. 
Under these circumstances, inhibition of the p38 signaling pathway greatly 
reduces the ability of tamoxifen to induce apoptosis.   In paired biopsy 
samples taken pre-treatment and on relapse from patients treated with 
adjuvant tamoxifen; tumours that were ER positive and ErbB2 positive at 
relapse showed uniformly high expression of p38 MAPK, suggesting that in a 
subset of patients, activation of ER may have occurred by this route131. 
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1.4.1 Why study tamoxifen resistance?  
Tamoxifen resistance is a fascinating problem and of high clinical relevance; 
more complex than most “classical “ forms of drug resistance; it seems the 
acquisition of tamoxifen resistance instead represents a switch from ER 
antagonist activity to agonist activity.  Evidence for this includes the observed 
clinical phenomenon of a withdrawal response in a proportion of women with 
tamoxifen resistant disease (up to 40%132) seen on stopping the drug.  The 
study of this switch in breast cancer cells has provided us with insights into 
the cross talk of multiple cellular pathways and the fundamental control of 
gene transcription. 
 
Targeting the ER and tamoxifen resistance is relevant to the majority of 
patients with breast cancer; progress in this area is therefore widely 
applicable. If tamoxifen resistance could be prevented or manipulated in 
breast cancer, it would mean the prolongation of a safe, non-toxic treatment.  
This would provide particular benefits to the elderly population, since this may 
be their only feasible treatment strategy; a modest improvement in the length 
of disease stabilisation in this group may result in substantial improvements in 
the proportion of women dying with breast cancer, rather than dying of  the 
disease.   
 
Through pharmacogenetics, it may be possible to predict which ER positive 
women stand to benefit most from tamoxifen.  Using assumptions drawn from 
the retrospective endoxifen study (NCCTG 89-30-52, (See Section 1.468), 
Punglia et al. built a mathematical model to determine whether tamoxifen or 
aromatase inhibitor monotherapy maximized 5-year disease-free survival for 
patients with the wildtype CYP2D6 genotype (wt/wt). Applying this model to 
results produced from the Breast International Group 1-98 trial, one of the 
large prospective RCT to compare tamoxifen with the aromatase inhibitor 
letrozole, they conclude that among patients who are wild type for CYP2D6, 5-
year disease-free survival outcomes are similar to or superior using tamoxifen 
rather than aromatase inhibitors. If this model is accurate, CYP2D6 genotype 
testing would be critical for selecting the optimal adjuvant endocrine treatment 
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for women with ER-positive breast cancer because it implies that >90% of 
women (wildtype CYP2D6) would have better outcomes if they received 
tamoxifen and those who are homozygous for inactivating variant alleles 
should take an AI133.  The Roche Amplichip, (the first microarray approved for 
clinical use by the FDA) designates the patient’s CYP2D6 genotype, (see 
Table 1.4).   
 
A proportion of ER negative tumours respond to tamoxifen; most clinicians 
would recommend hormone treatment for the small proportion of tumours 
classified as ER negative / PgR positive134,135.  The identification of such 
tumours may be an artefact of techniques used to quantify ER in clinical 
samples136.  If there were a class of truly ER negative, hormone responsive 
tumours, it may be possible to extend the use of tamoxifen. 
 
Mechanistically, tamoxifen remains an interesting drug to study since it sits on 
the cusp of the “helpful” and “unhelpful” effects of oestrogen.  It is hoped that 
an improved understanding of tamoxifen may provide foundations for the 
development of an “ideal” SERM combining the beneficial effects of 
oestrogen, (such as: cardiovascular protection and prevention of 
osteoporosis) without increasing the risk of uterine cancer.    
 
Studies of the effect of synthetic oestrogens and SERMs may also prove 
relevant to improvements in hormone replacement treatment, or the oral 
contraceptive pill.  Pharmacological female hormone manipulation is 
ubiquitous and shows no sign of abating; therefore any incremental 
improvements in the rate of rare side effects of these drugs could still have 
important benefits to large numbers of women.  
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1.5  Gene expression profiling 
Patterns of gene expression in multicellular organisms are regulated by 
complex mechanisms.  The level of expression of a given gene depends on a 
variety of factors: tissue of origin, developmental stage and physiological 
state.  Studying the temporal and spatial patterns of gene expression in an 
organism may reveal information about a gene’s function and the likely 
influences altering expression.   
 
The development of DNA sequencing as a high throughput technology has 
enabled the development of functional genomics, which may be defined as 
monitoring levels of all proteins or genes in a given biological system, as 
opposed to single genes.  It is characterized by high throughput experimental 
techniques combined with statistical, computational analysis of results. 
 
Microarray techniques were developed from Southern blotting, where labelled 
nucleic acid probes are used to detect specific sequences of DNA fragments, 
separated by gel electrophoresis and fixed on a nylon membrane137.  In 1996, 
by placing 1000 probes on a solid surface, “arrays” were produced and 
hybridised with labelled fragments of DNA138.  The technology has been 
developed so that vast numbers of hybridisation reactions occur 
simultaneously, thus the expression levels of thousands of genes in a sample 
can be assigned in a single experiment.   
 
1.5.1 Microarray Study design 
The biological questions one can answer with microarray expression analysis 
fall into two main categories:  
 
1) A “local” approach provides information on the response of cells to a given 
stimulus.  Studies using this strategy have given considerable insights into 
specific biological pathways such as the recognition of potential target genes 
for the transcription factors c-Myc139, WT1 (Wilms' Tumour)140 and p53141.  
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2) The “global” approach uses microarrays to obtain expression profiles of 
multiple representative samples from a population, for example tumour 
samples.  This is an exploratory approach and has been used for tumour 
profiling and outcome prediction 142-145. 
 
1.5.2 Microarray Platforms 
DNA microarrays can be categorised based on the length of DNA molecule 
immobilized on the slide.  Thus, expression arrays are defined as either 
“cDNA” or “oligonucleotide” microarrays.  Oligonucleotide arrays typically 
contain 20-80mer oligonucleotides while cDNA arrays are printed with 500-
5000 base pair polymerase chain reaction, (PCR) products. 
 
High-density oligonucleotide arrays  
The market leaders in these technologies are Affymetrix and Agilent1,146.  
Affymetrix have developed a system where short oligonucleotide probes, 20-
25 bases in length are synthesised in situ by photolithography onto silicon 
wafers 147.  With this technique, the “feature size” on the array is kept to a 
minimum (currently 11µm), allowing >40,000 probes to be synthesized on a 
chip area of 1.25 cm2, see Figure 1.9.  Agilent Technologies print 
presynthesised 60-mer oligonucleotides onto glass slides by ink-jet 
technology. This platform has also been working hard to shrink their feature 
size and currently achieves 224,000 features on a 1” by 3” array.    
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Using oligonucleotide arrays, “probes” are the immobilised DNA on the slide, 
while “target” refers to the sample mRNA, reverse transcribed into cDNA and 
then copied into biotinylated cRNA.  After hybridisation of the target, the 
arrays are stained with a streptavidin-phycoerythrin conjugate, washed and 
scanned (see Figure 1.10). Image analysis of the derived raw data and data 
analysis is carried out, comparing separate microarray datasets in order to 
characterise differentially expressed genes. 
 
“Spotted” cDNA microarrays 
In this system, the nomenclature is reversed: “target” refers to the immobilised 
DNA on the slide while “probe” is the labelled sample.  The probes are made 
from two distinct RNA populations via reverse transcription; each cDNA is 
labelled with a different fluorophore, typically Cy3 and Cy5.  Gene expression 
patterns are compared by determining the ratio of fluorescent intensity of the 
two dyes after hybridisation with target.  With spotted cDNA arrays, “target” 
consists of cDNA fragments ~600-2400 bases long, usually PCR products 
generated from cDNA libraries or clone collections. Robots mechanically 
deposit purified cDNA fragments as spots in specific locations on a support 
matrix, the spots are typically 100-300µm in size and the matrix used is a 
glass microscope slide 138, (see Figure 1.11). 
 
Figure 1.9: HU133 Plus 2.0 Affymetrix 
GeneChip 
The current human genome expression array 
consists of 1.3 million 25-mer oligonucleotide 
probes representing 47,000 different mRNA 
species, synthesised onto a single chip measuring 
1.25cm by 1.25cm.  It is shown with a matchstick 
for scale. 
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cDNA arrays are relatively cheap to buy and flexible to manufacture, they can 
be easily customised for a specific project; the risk of non-specific 
hybridisation is reduced since large pieces of cDNA are spotted onto the chip.  
However, technical problems with the transfer of material onto slides can 
result in variation in spot quality, concentration or slide coating.  In addition, 
some aspects in processing and analysis of spotted arrays are subjective and 
highly labour intensive; for example the visual assessment of individual spots 
prior to scanning. 
 
1.5.3 Comparison of cDNA and high-density oligonucleotide arrays 
An important difference between the two platforms lies in preparation of test 
material: cDNA arrays rely on the differential labelling of probe i.e. two 
fluorophores, while high-density oligonucleotide arrays use a single 
fluorophore.  For cDNA arrays, test and reference samples are co-hybridised 
to the microarray slide, returning a relative expression ratio of test to 
reference, whereas oligonucleotide arrays return absolute expression values.  
This leads to differences in the design and analysis of microarray 
experiments.  Using oligonucleotide arrays requires “inter-array” 
normalisation; so comparison of data generated by separate arrays is possible 
due to the high reproducibility of in situ synthesis148.   In the case of cDNA 
spotted arrays, the gridding process is not accurate enough to allow direct 
comparison of different arrays.   
 
An advantage of oligonucleotide arrays is that probes are designed in silico, 
using sequence information, obviating the need for time-consuming 
verification and quantitation of clones, cDNAs and PCR products.  Moreover, 
there is no risk of a misidentified tube, clone, cDNA or spot, therefore 
enhancing the reliability of the array annotation.   
 
Although short oligonucleotides may result in less specific hybridisation and 
reduced sensitivity when compared to longer cDNA probes; this is accounted 
for in the Affymetrix chip design, where each gene is represented by 11 probe 
pairs, (=one “probe set”).  This probe redundancy increases the accuracy of 
 52
RNA quantitation, eliminates false positives and diminishes effects due to 
cross hybridisation.  Each probe pair consists of a perfect match (PM) and a 
mismatch (MM) sequence, (containing a mutation at the middle base).  The 
ratio of PM/MM for a given probe pair, designates its absolute hybridisation to 
the specific oligonucleotide. The use of mismatch probes (MM) helps to 
ascertain background, cross hybridisation signal and non-specific 
hybridisation.  In addition, synthetic probes are designed to represent the 
most “unique” part of a transcript; Affymetrix probes are designed with a bias 
towards the 3’ end of the transcript, since this is the region preserved in the 
transcribed, labelled target population. 
 
Using cDNA arrays, unintended labelled probes with sequence identity greater 
than 70% will cross-hybridise with spotted cDNA target, limiting their ability to 
separate closely related gene family members or for example, splice variants.  
The precision of data obtained by the two types of array platform has been 
determined by replicating experiments using the same RNA samples149. 
Differentially expressed genes demonstrated low standard deviations, 
showing efficient reproducibility of measurements for both types of array. 
However, the combined problems of poor sequence specificity and high 
identity error in cDNA clones, estimated as a 10-30% error rate in cDNA 
arrays of higher organisms150, has led to speculation that spotted cDNA arrays 
will be replaced by oligonucleotide arrays151.  This has resulted in 
oligonucleotide arrays achieving pre-eminence despite their inherent lack of 
flexibility in array design and the high cost of chips and reagents.  It is 
estimated that Affymetrix commands ~80% of the DNA microarray market152. 
 
The extent of use of the Affymetrix platform has become a virtue in itself; the 
platform is widely recognised as a valid technique and a community of 
experienced users has evolved (e.g. UK Affymetrix Users Group153,154) 
offering support for technical difficulties.  The quantity of data published using 
these chips offers further opportunities for validation of data.  The 
disadvantages of this platform include its cost, the potential problems of being 
“tied in” to a single manufacturer, and finally, Affymetrix MAS 5.0 software is a 
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“black box” through which all data passes after scanning.  Increasingly users 
are taking the raw data and processing via alternative software packages, 
notably Bioconductor155 (http://www.bioconductor.org/). 
 
 
 
 
 
 
Figure 1.10: Overview of eukaryotic target labelling using 
Affymetrix GeneChips – high density oligonucleotide arrays.  
Target mRNA is reverse transcribed into cDNA, copied into biotinylated 
cRNA. Following hybridisation of target to the probe array, arrays are 
stained with streptavidin-phycoerythrin, washed and scanned.  Following 
data analysis, differentially expressed genes can be identified.  Adapted 
from Affymetrix website1.  
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Figure 1.11: Overview of cDNA microarray process.  
Templates for genes of interest are obtained and amplified by 
PCR. A robotic spotter deposits the cDNA probes on the glass 
slide.  Total RNA from test and reference samples is reverse 
transcribed and labelled with either Cy3- or Cy5-dCTP. The 
fluorescent targets are co-hybridised. The hybridised arrays are 
imaged to measure the green and red fluorescence intensities for 
each spot on the array, using a laser confocal scanner. Adapted 
from Duggan et al. 19997. 
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1.5.4 Gene expression profiling studies in breast cancer 
At the beginning of my clinical fellowship, microarray expression analysis was 
emerging as a revolutionary technology, surrounded by great interest and 
expectation.  It provided a new opportunity to estimate levels of expression of 
10,000s of genes simultaneously from small samples; with new software, 
bioinformatics expertise and computer power.  New statistical algorithms were 
able to analyse and present these enormous quantities of data in a palatable 
form.  It was hoped that the portraits of gene expression obtained would 
provide answers to many important questions surrounding the basic biology of 
cancer; that obtaining highly detailed information would provide a novel 
definition of cancer145,156,157.  Furthermore, that such detailed characterisation 
of tumours would yield improvements in prognosis prediction and 
individualised treatment.  
 
As mentioned previously, two main approaches to microarray studies are 
seen, (see Section 1.5.1).  Breast cancer has been intensively studied, using 
both strategies: analysing the response of cells to a given stimulus the “local” 
approach has been used in the following examples: discovering genes related 
to tamoxifen exposure158,  selecting tumour cells on their metastatic activity 
and predicting prometastatic markers159,160.  
 
In addition, several large scale (“global”) experiments have been carried out, 
looking for consistent patterns of expression replicated across groups of 
samples, associated with important clinical parameters161.  For example: 
profiling tumours and predicting outcome142,143,161-163, distinguishing hereditary 
versus spontaneous breast cancer144,164, predicting response of high risk 
breast tumours to neoadjuvant docetaxol165,166. 
 
1.5.5 Prediction of tumour behaviour from primary tumour 
The concept of being able to entirely predict disease behaviour using gene 
expression data from a primary tumour may seem intrinsically flawed; it 
seems very “deterministic” and at odds with the idea that tumour cells evolve 
through clonal expansion and selection.  The ability of breast cancer to recur 
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after long periods of quiescence may present particular difficulties in this 
tumour type to predict those tumours that will recur.  One would imagine that a 
metastatic or multiply treated tumour arising many years after excision of the 
primary would be a “long way” genetically from the primary, and that the 
distance and direction of travel in the cancer cell’s “genetic journey” is 
unpredictable since it occurs by random mutation.  Intuitively, one would not 
necessarily anticipate that the characteristics of a primary tumour could wholly 
predict its future.   
 
However, there is evidence to suggest:   
I) Primary tumours and metastases are strikingly similar, both 
morphologically and when examined with expression analysis159-
161,167,168
. 
II) Many cancers share characteristic mutations or mutations in shared 
pathways169,170. 
iii) It is possible to categorise primary tumours and predict their 
subsequent behaviour and / or response to treatment 142,162,163,168,171 
 
Since many mutations are lethal, the changes occurring in tumour cells are 
constrained by biological boundaries and are not truly random, so tumour 
evolution is not infinitely pluripotent. Once mutations are accumulated; they 
are likely to be maintained, therefore observations from the primary can inform 
us regarding subsequent properties of the disease.  A primary tumour, even 
when detected at an early stage (<2 cm), has already travelled a long way in 
terms of tumour evolution, even though the patient’s “cancer journey” has only 
just begun.  The genetic changes that occur are modulated by the cell’s 
milieu; that is, the endocrine, autocrine, immunological and pharmacological 
signals received.  These signals provide selection pressure for further 
mutation.   
 
Microarray and bioinformatics technology (including CGH, expression and 
tissue microarrays) allow the global analysis of changes in gene copy number, 
gene expression and the linking of this data with clinical information.  Building 
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large databases of high quality data with long term clinical follow up will 
hopefully provide us with an increasingly refined ability to predict tumour 
behaviour for an individual, greater understanding of the mechanisms 
underlying tumour behaviour and will generate hypotheses for subsequent 
investigation and tools to recognise and select optimal treatments.   
 
However, the factors confounding expression analysis; such as sampling 
error, heterogeneity of tumour cells in an individual and the myriad of potential 
genetic pathways may mean that ultimate predictability is an impossible 
goal27.   
 
1.5.6 What progress has been made? 
Seminal work by Sorlie et al. using microarray technology has provided a new 
classification of breast cancer based on gene expression analysis, 
distinguishing groups of patients with different clinical outcomes and 
generating the basis for new clinical approaches.  65 primary breast cancer 
specimens from 42 patients and 17 established breast cancer cell lines were 
analysed.  A subset of genes were identified which showed high variation 
between matched tumour/normal pairs, hierarchical clustering was performed 
on the tumours based on these genes.  Five main subgroups of tumours were 
identified comprising: Luminal subtype A, Luminal subtype B, ERBB2+, Basal, 
and normal breast like, (see Figure 1.12)161. 
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Figure 1.12. Hierarchical clustering of breast-cancer samples on 
basis of microarray gene expression data (Sorlie et al., 2003).  
Heat map of all samples clustered according to intrinsic gene set (534 
genes) used for analysis (A) and dendrogram (B) shows segregation of 
breast cancers into five major subgroups, including a tightly clustered 
basal-like cluster. Red colouration for a given gene (listed vertically 
along right hand side of heat map) denotes relative up-regulation of 
expression, and green denotes relative down-regulation. Heat maps of 
gene clusters define the ERBB2+ (C), luminal subtype B (D), basal-like 
(E), normal breast-like (F), and luminal subtype A (G) subgroups of 
breast cancer. 
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Luminal A and B tumours are characteristically ER positive with ER 
expression being particularly high in Luminal group A.  This group also have a 
higher proportion of p53 wildtype cells and are of low or intermediate grade.  
Of note, both GATA3 and FOXA1, the pioneer factors mentioned in Section 
1.2.3, are among the genes that define the ER positive luminal breast cancer 
gene signature, (see Section 1.2.3)52.   
 
“Basal” and ERBB2+ tumours are characteristically high grade and ER 
negative.  Subsequent analysis, further refining the molecular portraits and 
correlating clinical outcome with these subtypes, revealed the poor prognosis 
of “basal” subtype, marking this group of tumours out for particular attention 
143,172
.   
 
The basal subtype, accounting for ~15% of breast cancers was noted to be 
negative for the conventional markers ERRB2, ER/PgR, thus the only 
pharmaceutical agents available for their treatment are conventional 
cytotoxics.  Further analysis of the expression data revealed a high proportion 
of basal subtype tumours overexpress EGFR.  Recently, a novel mechanism 
for p63 dependant cisplatin sensitivity was identified in such “triple-negative” 
breast cancers173.  A number of clinical trials are currently underway, including 
one testing the use of Cetuximab, an antibody against EGFR, in combination 
with cisplatin, aimed at treating this group of women.  “Triple negative” status 
defined by IHC for ErbB2, ER and PgR is being used as a surrogate marker to 
enrich for “basal-like” patients in these trials since expression analysis is not 
yet widely available in the clinical setting.  For these patients, expression 
analysis was able to highlight their tumour subtype and provided the basis for 
a novel, rational approach to their treatment.  
 
Van’t Veer et al. used microarray expression analysis to identify a gene 
signature associated with poor prognosis in early stage breast cancer.  117 
patients (<55 years) with lymph-node-negative disease at diagnosis were 
involved, the patient’s clinical outcome was used as the basis for supervised 
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analysis of the expression data.  The authors were able to define a 70-gene 
profile predictive of poor prognosis142.  
 
A major challenge for statistical interpretation of microarray data is the huge 
disproportion between the number of variables tested (the genes’ expression 
values) and the number of samples.  This causes problems of a high false 
discovery rate and “overfitting” of statistical models. The van’t Veer study was 
criticised for providing an internal validation of their dataset without separating 
the “training” and “test” cases’ data, resulting in an overestimation of their 
classifier’s accuracy174.   
 
A further study by Van de Vijver et al. was used to independently validate the 
70-gene prognosis predictor.  Stored primary tumour samples from 295 young 
(<53 years old), stage I-II breast cancer patients, including both lymph-node-
negative and positive cases were classified by expression analysis to the 
good or poor prognosis signature based on the predefined 70 gene set and 
then patient outcome was analysed.  Patients whose tumour had a good-
prognosis signature were largely free of metastases at the ten-year follow-up 
(85%) compared with patients whose tumour had a poor prognosis signature 
(50%).  The poor prognosis signature also strongly correlated with high 
histological grade and ER negative status163.   
 
The 70-gene signature provides the basis for the MammaPrint assay, a 
commercial expression microarray, marketed by Agendia, (see table 1.4).  
Further validation for MammaPrint was provided in a retrospective analysis 
using an independent cohort of 307 stored tumour samples.  In this study, the 
MammaPrint assay was superior to the St Gallen criteria in classifying both 
extremes of low risk or high risk patients and could further risk stratify patients 
within the Adjuvant! Online categories175.  The US Food and Drugs 
Administration, (FDA) has recently approved the marketing of MammaPrint for 
predicting time to distant metastasis in women aged under 61 with lymph 
node negative, stage I or II disease.    
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The “Microarray in Node-negative Disease may Avoid Chemotherapy Trial”, 
(MINDACT) a prospective study, recruiting since August 2007 aims to test the 
value of the MammaPrint assay over traditional clinicopathological parameters 
in Adjuvant! Online, (see Section 1.1.2).  In MINDACT: if both MammaPrint 
and Adjuvant! Online agree a patient is high risk they receive adjuvant 
chemotherapy, where they both indicate low risk no adjuvant chemotherapy is 
given.  When the results are discordant, patients are randomised to receive 
treatment either based on the molecular or clinical prediction results176. 
 
Another commercially available prognostic and predictive assay, Oncotype 
Dx® uses a 21-gene panel to assess recurrence risk in lymph node-negative, 
ERα positive, early-stage breast cancer.  The assay is a multiplex RT-PCR 
but the informative genes were discovered by expression profiling177.  A cost 
analysis of the Oncotype Dx® test, comparing treatment based on their 
recurrence score (RS) to using the National Comprehensive Cancer Network 
(NCCN) guidelines has been performed.  Using ERα positive, Lymph node 
negative samples from the NSABP B-14 study, the NCCN guidelines 
classified 615/668 patients (92%) as high risk for recurrence, recommending 
chemotherapy. The RS classified 181 patients as high risk (27%), 149 as 
intermediate risk, (22%), and 338 as low risk, (51%).  Assuming the low-risk 
group did not receive chemotherapy and the intermediate and high groups did 
have chemotherapy (49%), RS was predicted to increase quality-adjusted 
survival by 8.6 years and reduce overall costs by $202,828 per 100 
patients178.   
 
Further validation of the Oncotype Dx® test was reported using 1200 patients 
randomized to either tamoxifen or combined chemotherapy and tamoxifen on 
NSABP B-20 and B-14 studies.  Retrospectively, patients were stratified by 
RS into high, intermediate or low risk for distant recurrence. Cost-
effectiveness ratios were estimated for RS-guided treatment compared with 
the randomized trial treatment.  Distant recurrence was reported in RS low-
risk, intermediate-risk, and high-risk patients at 10 years in 3.7%, 17.8%, and 
38.3% receiving tamoxifen alone and 5.0%, 10.1%, and 11.1% receiving the 
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chemotherapy and tamoxifen.  RS-guided therapy was associated with a gain 
in individual life expectancy of 2.2 years compared with tamoxifen alone and 
similar life expectancy for combination treatment. RS-guided therapy was 
estimated to provide an incremental cost-effectiveness ratio of $1944 per life 
year saved compared with tamoxifen alone179.  
 
Since January 2004, >6000 physicians have ordered OncotypeDx test for 
>33,000 patients.  Considerable interest therefore surrounds the results of the 
TAILORx trial, (Trial assigning individualised Options for treatment) a 
prospective study (which began in 2006) aiming to recruit 10,000 patients with 
ER/PgR positive, ErbB2 negative and LN negative breast cancer.  The aim of 
TAILORx is to determine if ER positive patients with an intermediate RS score 
benefit from adjuvant chemotherapy.  Patients with RS <10 will receive 
adjuvant hormone treatment, those with a score >26 will be given adjuvant 
chemotherapy and those between 11-25 will be randomised to receive 
hormone treatment or hormone treatment plus chemotherapy. 
 
Certainly in the UK, commercially available multigene predictive or prognostic 
tests have not yet been taken up in widespread practice.  They are generally 
aimed at younger women with early stage disease as an aid to decide 
whether to have adjuvant chemotherapy.  Clinicians’ reluctance to use such 
tools may be due to their innate conservatism and fear of under-treating 
women, (a fear shared by clinicians, patients and “big pharma” alike!)  
However, there remain important concerns about the applicability of these 
tests to wider populations, which can only be answered with prospective 
clinical trials.    
 
The overview of gene expression enabled by microarray technology has 
broadened our basic understanding of cancer; for example it has heightened 
awareness that many of the genetic changes seen in malignancy occur in 
metabolic pathways rather than exclusively via “traditional” oncogenes.  These 
studies have created a new molecular taxonomy for breast cancer that is still 
being developed. The characteristic features demonstrated through 
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expression profiling reflect previously recognised clinicopathological features 
such as ER and ErbB2 status, proliferation indices, p53 status and build upon 
them further 142,143,172,180-182.  
 
Standards in carrying out and reporting microarray expression analysis 
experiments have been defined by MGED (the Microarray Gene Expression 
Data Working Group) with the MIAME (Minimum Information In A Microarray 
Experiment) criteria.  Such standards increase the supplementary information 
about expression data and make the data published more comparable.  This 
enhances the value of smaller experiments; enabling a library of data to be 
built up from different investigators183,184.  There is an ongoing struggle to 
enable cross-platform comparison of data185,186.  Another improvement in 
microarray technology has been the development of publically available 
databases and tools for data analysis, for example; Oncomine combines 
>28,000 cancer expression profiles with analysis, data-mining and 
visualization tools (http://www.oncomine.org). 
 
The heterogeneity of breast cancer still presents a problem; for example the 
heterogeneity of “basal like” tumours was revealed in recent studies that sub-
classified these tumours into further sub groups 187,188. Using global 
approaches to characterise breast cancer, large numbers of clinical samples 
are necessary and therefore large resources are required to handle and 
analyse both the samples and the resulting data.  Long term follow up on the 
samples is necessary to determine the clinical outcome, particularly given the 
ability of the disease to recur after many years of quiescence.  
 
Some studies have questioned the ability of expression profiling to improve on 
previous methods of risk stratification.  Eden et al. compared 70 gene profile 
results based on expression data to the Nottingham Prognostic Index, (NPI) 
based on conventional markers, using the data from 97 patients in the Van’t 
veer study 163. The gene expression profiler did not perform better than the 
NPI189. 
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Some groups have suggested that combining traditional clinicopathological 
features (such as ER status and grade) with expression analysis may improve 
the predictive accuracy of expression profiles.  Sotiriou et al. built a prognosis 
predictor for grade II breast tumours and concluded that incorporation of 
expression analysis into histological classification could improve the accuracy 
of grading190. 
 
As the volume of expression data has increased and various different 
prognostic indices have emerged, one of the puzzling features has been the 
inconsistency or lack of concordance of genes featuring in the discriminating 
gene sets.  For example, only one gene is common between the OncotypeDx 
and MammaPrint assays.  An interesting study addressed the question of 
concordance of gene sets from different expression based prognosis 
predictors in breast cancer; they compared the predictions derived from 5 
different gene sets applied to 295 samples. The five expression-based models 
were as follows: intrinsic subtypes, 70-gene profile, wound response, 
recurrence score (RS), and the two-gene ratio for tamoxifen treated patients.  
Almost all tumors identified as having basal-like, ErbB2-positive and ER-
negative, or luminal B (associated with a poor prognosis) subtypes were also 
classified as having a poor 70-gene profile, activated wound response, and 
high recurrence score. The 70-gene and recurrence-score models, showed 
77-81% agreement in outcome classification.  They concluded that since four 
of the five tests showed significant agreement in outcome predictions for 
individual patients, they are effectively “tracking a common set of phenotypes 
through different genes” 191.  
 
Perhaps partly because of the diversity of prognostic gene signatures, it 
seems relatively little progress has been made in unpicking the molecular 
pathways and targets underlying the expression profiles identified.  It can be 
hoped that microarray technology has far greater potential for improving our 
understanding of oncogenesis and tumour behaviour.  One study attempting 
to start this process in cell lines identified various oncogenic “pathway 
dysregulation signatures” (such as Ras, Myc, Src).  These were used to 
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classify tumour cell line models and their response to various anti-cancer 
drugs was then correlated with their pathway status192.  The ultimate aim 
would be to use such signatures to guide the use of combination targeted 
agents.  
 
The quantity of data generated by microarray experiments generates further 
questions such as: where to place cut offs in data analysis and which genes to 
investigate further.  While stringent bioinformatics techniques are used 
carefully in an effort to avoid bias throughout all stages of data analysis, 
subsequent experiments often seem unduly influenced by the interests of the 
investigators.  This phenomenon may improve since large publicly accessible 
databases now allow data mining by interested individuals and newer analysis 
tools allow automated prioritisation of targets for study. 
 
1.6 Studying tamoxifen resistance with expression analysis 
One surprising finding from microarray analysis of tamoxifen resistance was 
the report of the “2 gene predictor”.  Ma et al. analysed expression profiles of 
hormone receptor-positive primary breast cancers from 60 patients treated 
with adjuvant tamoxifen. The expression signature was reduced to a two-gene 
ratio, HOXB13:IL17BR that predicted clinical outcome193.  Various groups 
have subsequently tried to validate these results in larger clinical studies with 
mixed results. 
 
Ma et al. used RT-PCR to quantitate expression of HOXB13, IL17BR, CHDH, 
ER and PgR in 852 paraffin-embedded primary breast cancers from 566 
untreated and 286 tamoxifen-treated patients. They found the 
HOXB13:IL17BR ratio predicted clinical outcome (relapse free survival, 
(RFS)) independently of treatment, particularly in node-negative patients194.  
Independent work agreed that a high HOXB13:IL17BR ratio was predictive of 
worse RFS and OS in 130 ER positive, node-negative patients, independent 
of standard prognostic markers.  In the ER positive, node-positive cohort (n = 
86), the HOXB13:IL-17BR ratio was not associated with either relapse or 
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survival195.  However in a smaller study, Reid et al. were unable to validate the 
performance of the two-gene predictor in 58 ER positive tumours196. 
  
More recently, Jerevell et al. examined whether the same ratio could predict 
the benefit of 5 years vs. 2 years of tamoxifen in postmenopausal patients and 
also investigated the prognostic effects of the ratio in untreated 
premenopausal patients.  They used samples from 264 randomized 
postmenopausal patients and 93 untreated premenopausal patients.  The 
HOXB13:IL17BR ratio predicted recurrence-free survival after endocrine 
treatment; the benefit from prolonged treatment in ER-positive patients 
correlated to a low HOXB13:IL17BR ratio while no difference in recurrence-
free survival was seen for a high ratio.  The predictive value of 
HOXB13:IL17BR was significant in multivariate analysis. In untreated patients, 
only IL17BR showed independent prognostic significance197.   
 
H/I, a 6 gene multiplex prognostic RT PCR assay is based on the two gene 
expression ratio and aimed at lymph node negative, ER positive women.  This 
and further commercial tests available for prediction of response to tamoxifen 
in breast cancer are summarized in Table 1.4, adapted from Ross et al. 198.  
 
The Roche Amplichip (see Section 1.4.1) featured above in Table 1.4 aims to 
genotype CYP2D6 and CYP2C19 from genomic DNA, (two cytochrome P450 
enzymes thought to be of relevance to the metabolism of many drugs)199. 
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Test Mammostrat Oncotype 
DX 
Two-gene 
ratio 
Celera 
Metastasi
s Score 
NuvoSelect Roche 
Amplichip 
Manufacturer Applied 
Genomics 
Genomic 
Health, 
Inc 
AviaraDx/ 
Quest 
Celera/La
bcorp 
Nuvera 
Biosciences 
Roche 
Method IHC RT-PCR RT-PCR RT-PCR Microarray Microarray 
Sample FFPE: 
Resection / 
Core Biopsy 
FFPE: 
Resection 
/ Core 
Biopsy 
FFPE: 
Resection 
FFPE: Fresh 
Frozen 
Resection / 
Core Biopsy 
Whole Blood 
No of genes 5 21 6 14 200 2(30 isotypes) 
Indication ER +ve; LN –
ve 
ER+ve; 
LN –ve 
ER+ve; ER +ve 
LN -ve 
ER+ve 
LN +ve/-ve 
ER +ve 
Guide to 
specific 
therapy 
Tamoxifen Tamoxifen 
/ adjuvant 
CMF 
Tamoxifen Tamoxifen Tamoxifen, 
neo-
adjuvant 
TFAC 
Tamoxifen 
FDA status Exempt Exempt Not 
submitted 
Not 
submitted 
Not 
submitted 
Approved 
Cost ~$600 $3,460 $1,400 Unknown Unknown Unknown 
 
Table 1.4 Summarising commercially available multigene prognostic 
tests to guide therapy with tamoxifen, (Adapted from Ross et al 198.) 
 
Independent validation of the Celera metastasis score has recently 
reported200.  This 14 gene signature was derived by combining the genelists 
form various expression profiles resulting in a panel of 197 genes162,201,202.  
qRT-PCR was used to measure their expression in a “training set” of 142 LN 
negative, ER positive early stage (T1/2) tumours. This data was analysed to 
produce the 14 gene metastasis score, containing predominantly proliferation-
associated genes.  Analysis of the scores in 279 LN negative, ER positive, 
early stage tumours showed the hazard ratios (HR) of the high risk compared 
to low risk groups were 4.02 (95% CI 1.91-8.44) for the endpoint of distant 
relapse free survival (DRFS) and 1.97 (95% CI 1.28 to 3.04) for overall 
survival.  Analysis for an independent set of 45 tamoxifen treated patients 
failed to reach significance, (thought to be due to insufficient sample size)200. 
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NuvoSelect is commencing prospective studies using its predictors of 
endocrine and chemotherapy sensitivities.  Their sensitivity to endocrine 
therapy (SET index) has been reported in two independent validation cohorts 
as predictive of DRFS in ER positive, LN negative patients treated with 
adjuvant tamoxifen, but was not prognostic in untreated patients with ER 
positive invasive breast cancer (presented at SABCS 2006 and ASCO 
2007)203,204. 
 
For my research, I was interested in a specific question regarding tamoxifen 
resistance: 
i) The identification of genes or pathways associated with resistance 
and sensitivity to tamoxifen - mechanisms of resistance 
ii) Can these genes be identified in primary tumours as markers for 
response to tamoxifen?  -  prognostic markers 
 
Since acquired tamoxifen resistance takes time to emerge, it is important to 
measure the long-term clinical response.  There are limited numbers of 
available fresh frozen tissue samples with long term, comprehensive clinical 
follow up.  In the UK, tumour banks have been set up on an ad hoc basis over 
the years and the samples stored represent a patchwork of samples received 
by individual pathology departments. 
 
Concentrating on response to a single treatment presents a challenge in 
experimental design of a clinical study since patients are routinely treated with 
multi-modal therapies, (receiving surgery, radiotherapy, +/- neo-adjuvant / 
adjuvant chemotherapy, +/- herceptin and hormone treatment).  It is 
impossible with retrospective analysis to unpick the contribution of each 
different therapy to a “cure”.   
 
The combination of factors, including; the heterogeneity of individual patients, 
tumour types, treatments received and the need for long term follow up make 
the analysis of expression patterns associated with tamoxifen resistance 
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difficult.  Samples obtained recently are more likely to be of high quality and 
are perhaps more easily available, however they have the disadvantages of 
shorter follow-up and exposure to more treatment modalities.  Selection of 
tumours from patients who receive only surgical and hormone therapy would 
effectively exclude most samples in current clinical practice, since 
radiotherapy is a necessary adjunct to breast conserving surgery.  
 
Another consideration in planning an expression analysis experiment is the 
data analysis required. When assaying >30,000 genes simultaneously, 
experimenters can become overloaded with the data generated.  There are 
always finite resources, which limit the number of genes that can be 
investigated further.  Reducing the numbers of genes identified as 
differentially expressed decreases the number of spurious results and allows 
an investigator to focus resources on investigating a smaller number of hits.  
 
This “data reduction” can be done by increasing the stringency of the 
statistical cut off for differential expression e.g. to a p-value of 0.01 to reduce 
the numbers of genes identified or increase the level of fold change necessary 
for identification. However, this is a crude oversimplification of the outcome 
data, so that only the largest changes in gene expression are identified.  This 
approach does not necessarily enrich the data for biologically interesting 
changes in gene expression.  In order to maximise the efficiency of a 
microarray experiment it is essential to minimise changes in gene expression 
due to factors other than those one is interested in.  
 
One also needs to minimise differences in profile due to technical differences 
between chips, such as chip manufacture / RNA preparation, target 
preparation, hybridisation and scanning, but also one should aim to ensure 
the samples for analysis are closely comparable.  Ideally, one should aim to 
compare expression profiles that are as similar as possible to each other, 
except in ways relevant to the study question.  Sources of such biological 
variation between samples include the heterogeneity of species, individuals, 
tissue and cell types, all of which will have an effect on the expression profile 
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obtained.  These issues are especially important when considering expression 
analysis of clinical samples, because with only limited amounts of tissue 
available, it may not be possible to perform replicate chips on the samples. 
 
 As the numbers of genes represented on a single microarray chip expands, 
and databases of expression profiles from other investigators, the quality 
rather than the quantity of the data obtained from a microarray study will 
become increasingly precious. 
 
Little is known about how individual genetic variation affects expression 
profiling.  Studies examining paired samples from the same person have 
revealed a striking “maintenance” of the expression profile of breast 
carcinoma within an individual161,205,206.  Therefore, it can be anticipated that 
by analysing paired primary and recurrent tumour samples from the same 
individual much of the “noise” due to individual and tumour heterogeneity may 
be excluded from the analysis, enabling the identification of a smaller group of 
biologically relevant genes which characterise tamoxifen resistance. 
 
1.7 AP-2 Transcription factors 
The Activator Protein-2 (AP-2) family of transcription factors play an important 
role in embryogenesis, where their coordinated expression appears essential 
for epithelial-mesenchymal transition (EMT) during craniofacial and limb bud 
development207.  Aberrant expression of the AP-2 proteins is associated with 
carcinogenesis.  Multiple studies have contributed to our current 
understanding of how AP-2 proteins control both transcriptional activation and 
repression of their target genes.  The involvement of AP-2γ and AP-2α in 
breast cancer has been closely examined, as has their role in ERBB2 
overexpression.  
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The AP-2 family of transcription factors comprises five members in mammals: 
AP-2α, 208 AP-2β, 209 AP-2γ, 210 AP-2δ, 211 and AP-2ε 212,213.  A separate gene 
encodes each protein, although they are evolutionarily closely related.  The 
basic structure of the family members is shown in Figure 1.13, including the 
main regions of functional significance.  AP-2 proteins are ~50kDa and 
characterised by a unique C-terminal helix-span-helix region, responsible for 
their homo- and heterodimerisation.  Overlapping the dimerisation domain is a 
conserved DNA binding domain.  The proteins bind DNA as dimers at a 
palindromic consensus sequence, (5’-GCCN3/4GGC-3’), although there is 
variation in the binding avidity and promiscuity of each family member 
211,214,215
. 
 
1.7.1 AP-2α and AP-2γ factors during vertebrate embryogenesis 
AP-2α is a retinoic acid (RA) responsive gene expressed in tissues 
undergoing morphogenic change during vertebrate embryogenesis 216.  The 
mouse homologue is detected during neural crest development and persists 
 
 
Figure 1.13 Structure of AP-2 proteins.  
AP-2 proteins consist of a helix-span-helix dimerisation motif that 
allows homo- and heterodimerisation of the family members. In 
addition, they have a basic DNA binding domain and a proline and 
glutamine rich activation domain. 
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when the cells begin migration. In the later stages of development it is 
detected in the epidermis, facial prominences, branchial arches and limb bud 
progress zones; all regions subject to morphogenic changes. 
 
The phenotype for AP-2α null mice has been studied by homozygous 
knockout217,218.  AP-2α null mice die perinatally with phenotypes characterized 
by failure of closure of the cranial neural tube (exencephaly), failure of closure 
of the ventral body wall, and loss of the radius (forelimb phocomelia).  
Similarly, mutation in the zebrafish tfap2a gene, results in the lockjaw 
phenotype, with severe neural crest defects and failure of differentiation of 
noradrenergic neurons219,220.  
 
Having postulated that such severe phenotypes might mask more subtle 
defects, chimeric mice were generated, with varying proportions of wild type 
and AP-2α-null cells207.  Morphogenetic defects were identified in the chimeric 
mice in five major regions: neural tube, face, eye, body wall and limb buds.  
All these tissues originate from the neural crest.  All these sites involve 
epithelial and mesenchymal cell interactions, suggesting AP-2α may influence 
the expression of genes controlling cell-to-cell communication and migration.  
The final link between these phenotypes is their responsiveness to 
teratogens, such as RA; since aberrant levels of RA lead to similar defects to 
those seen in the AP-2α knockout mice. 
 
AP-2γ plays a crucial role in the development of the placenta 221,222.  
Expression of AP-2γ is first identified in trophoblast cells prior to implantation.  
Trophoblast cells are specialised extra-embryonic cells that play a major role 
in implantation of the embryo.  After implantation, AP-2γ is expressed in the 
trophoblasts and their derivative cells, primary giant cells and diploid cells of 
the trophectoderm.  An interesting observation has shown that AP-2γ and the 
T-box gene Eomes are the only transcription factors expressed in all the 
trophoblast lineages throughout placental development.  In AP-2γ knockout 
mice, severe growth retardation of the embryo results in death by day 7-9 of 
embryonic development.  This is attributed to decreased proliferation of the 
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extra embryonic ectoderm, reducing the number of giant cells, resulting in the 
embryo being deprived of essential nutrients and growth factors. 
 
A number of genes important in extra-embryonic development have been 
identified targets for regulation by AP-2γ. Adenosine Deaminase (ADA) is a 
purine metabolic enzyme, essential for embryogenesis.  Analysis of the 
promoter of the Ada gene identified regions that confer cell type specific 
regulation, an AP-2 binding site was shown to be placental specific, 
suggesting that AP-2 plays an important role in gene regulation within the 
extra-embryonic cells223. Other genes implicated include the matrix 
metalloproteinases224, Transforming growth factor α (TGF-α) and Vascular 
endothelial growth factor, (VEGF)225 involved in cell-to-cell communication, 
migration and carcinogenesis. 
 
1.7.2 AP-2α, AP-2γ in cancer  
The developmental studies described illustrate the importance of AP-2α and γ 
in embryogenesis and provide some indications for their potential associations 
with carcinogenesis. The phenomenon of epithelial-mesenchymal transition 
(EMT) is proposed to be analogous to some aspects of cancer progression; 
since EMT involves a loss of cell polarity, loss of cell-to-cell contact, enhanced 
mobility and an ability to migrate through other tissues.  These properties are 
forbidden to virtually all adult cells, but are acquired by cancer cells to enable 
invasion and metastasis226.   In relation to the extra-embryonic expression of 
AP-2γ, an interesting feature of trophoblast giant cells, shared by cancer cells, 
in addition to their invasiveness and immune resistance is their tolerance of 
polyploidy. 
 
Work done examining AP-2 factors in cancer has suggested opposing roles 
for the respective subtypes: AP-2α has been characterized as a tumour 
suppressor-like protein, while AP-2γ is thought to promote carcinogenesis. 
 
The loss of nuclear AP-2α expression has been associated with malignant 
transformation and melanoma progression in a number of studies.  Similarly, 
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in ovarian cancer cells, overexpression of AP-2α caused reduced cell 
proliferation, invasiveness and tumourgenicity227,228, similar observations have 
been made made in prostate cancer 229,230. 
 
In colon cancer and glioma, levels of AP-2α expression have been inversely 
correlated with tumour grade.  A recent study showed that expressing AP-2α 
in SW480 (AP-2 negative colon cancer cells) suppressed their tumourigenicity 
and invasiveness; while silencing AP-2α by RNAi in KM12C (AP-2α positive 
colon cancer cells) increased their invasiveness though down regulation of E 
cadherin and up-regulation of MMP-9231.  
 
AP-2γ by contrast is over expressed in testicular cancer232,233 and advanced 
ovarian cancer 228 in addition to breast cancer cells.    
 
1.7.3 AP-2 in breast morphogenesis and breast cancer 
The hormonally regulated stages of normal breast development are illustrated 
in Figure 1.4.  IHC studies in pubertal mice revealed that AP-2α and γ show a 
reciprocal pattern of staining with AP-2γ expressed at high levels in the highly 
proliferative “cap cells” at the tips of the developing terminal end bud during 
puberty while AP-2α had stronger staining in the body cells of the ducts.  In 
mature mammary ducts, AP-2γ appears at high levels in myoepithelial cells, 
(derivatives of cap cells) and to a lesser extent in luminal cells (derivatives of 
body cells).  AP-2α is seen in both cell types, while both AP-2α and γ were 
excluded from the stromal compartment.  Overexpression of AP-2α inhibited 
proliferation in the developing mouse mammary glands 234.  These data again 
imply opposing functions for the AP-2 subtypes; with AP-2α associated with 
differentiation while AP-2γ promotes proliferation. 
 
Looking for evidence of the role of AP-2 factors in breast malignancy, in IHC 
studies AP-2α is highly expressed in 17-35% of primary breast cancers, while 
AP-2γ has high expression in 84% of breast cancers.  Co-expression of both 
AP-2 subtypes in the same tumour was associated with ErbB2 positivity235. 
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Examining AP-2α by IHC, Gee et al. found normal breast tissue and DCIS 
samples expressed significantly higher levels of AP-2α (p=0.0001*) compared 
with Invasive breast carcinoma.  AP-2α positive tumours showed low rates of 
proliferation, with a significantly reduced mitotic count and lower tumour 
grade236.  Another IHC study found reduced nuclear AP-2α staining 
associated with more aggressive breast cancers237.  Also in accordance with 
this are data from microarray expression analysis, where TFAP2A expression 
has been inversely correlated with breast cancer grade190. 
 
Independent IHC studies have demonstrated overexpression of AP-2α 
correlates with ER expression in breast cancer, although ERα is not restricted 
to AP-2α expressing tumours235,236.  Expression analysis data concur that 
TFAP2A expression is associated with ER positivity 171,182. 
 
Loss of AP-2α expression is associated with hypermethylation of a CpG island 
in Exon 1 of TFAP2A.  Hypermethylation of this region was not found in 
normal breast tissue but demonstrated in 16% of DCIS and 75% of invasive 
breast tumours, thus providing a mechanism for the observed silencing of the 
gene with progressive disease238. 
 
These studies indicate that AP-2α expression in breast cancer is associated 
with good prognostic features: ER positive, low grade, low proliferation 
tumours; leading to the hypothesis that AP-2α has a tumour suppressor-like 
role in breast carcinoma, consistent with its putative role in other tumour 
types, (see Section 1.7.2). 
 
Intriguingly, a cell line study has linked expression of AP-2α to increased 
chemosensitivity of breast cancer cells.  Blocking endogenous AP-2α by 
siRNA lead to chemoresistance in SW480 cells.  5-aza-2'-deoxycytidine 
induced re-expression of AP-2α in MDA-MB-231 cells, (where AP-2α 
expression is epigenetically silenced) resulted in apoptosis, increased 
chemosensitivity and loss of tumorigenesis upon chemotherapy. However in 
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MDA-MB-231 cells transfected with AP-2α siRNA, 5-aza-2'-deoxycytidine 
treatment failed to have an effect 239.  
 
There is evidence that AP-2γ expression plays a different role in breast 
cancer. IHC studies have associated overexpression of AP-2γ with 
progression from normal epithelium to DCIS and invasive breast carcinoma, 
and with IGF-R1 expression235. Using expression analysis, TFAP2C 
expression was associated with increasing tumour grade in breast cancer190.   
 
Mammary epithelial hyperplasia and a lack of cell differentiation were noted in 
transgenic mice engineered to overexpress AP-2γ, suggesting that AP-2γ 
increases proliferation in benign breast epithelium 240.  
 
A recent study looked at AP-2γ levels in patients with invasive breast cancer 
and showed that staining for AP-2γ in invasive primary tumours correlated 
with poor patient prognosis (Illustrated in Figure 1.14).  Of note, high AP-2γ 
was associated with poor prognosis in ER positive patients, suggesting that 
AP-2γ overexpression may result in hormone resistance in this usually good 
prognosis group6.   
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Figure 1.14 AP-2γ expression and survival.   
Examination of a series of 75 patients with primary invasive breast 
cancer revealed a continuum of AP-2γ immunostaining across the 
samples.  Each sample was assigned a histopathology score (H-score) 
from 1-300 based on the intensity of the staining and the percentage of 
tumour cells stained.  The median H score, (120) was used as a cut-off 
to define “positivity” for subsequent analysis.  For all patients, high AP-
2γ expression correlated with shortened survival time (A). In ER 
positive patients (B) the survival curve separation was more dramatic6.  
A 
B 
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Another study used a PCR approach to examine amplification of the TFAP2C 
gene in breast cancer patients, and the impact this had on disease-free and 
overall survival. This suggested that amplification of TFAP2C was linked to 
reduced disease-free survival, but not overall survival. These findings add 
weight to the theory that AP-2γ is a marker for poor prognosis in breast cancer 
patients241. 
 
In vitro work links the expression of AP-2 and ER which may impact on 
hormone resistance: reporter assays show that both AP-2α and γ can activate 
transcription of ERα by their interaction with AP-2 sites within the UTR of 
Exon 1 of the ERα promoter242,243.  Overexpression of AP-2α and γ by 
adenovirus infection has been shown to cause chromatin remodelling, (by 
inducing the formation of a DNase I hypersensitive site over the ER gene 
promoter) but does not result in re-expression of ER in ER-negative breast 
cancer cell lines244. 
  
In clinical studies, ERα positivity is associated with expression of AP-2α in 
breast carcinoma while AP-2γ doesn’t appear linked to ERα expression 235,245.  
In turn, oestrogen regulates expression of AP-2 proteins in a subtype specific 
manner:  AP-2γ expression is up regulated by oestrogen while AP-2α is down 
regulated in response to oestrogen treatment in ER positive, breast cancer 
derived cell lines246. 
 
1.8  ErbB2 
ErbB2, an 185kDa protein is a member of the Epidermal Growth Factor (EGF) 
receptor tyrosine kinase family, which includes three other closely related 
members, the EGF receptor (EGFR or ErbB1), ErbB3 and ErbB4. The EGFR 
tyrosine kinases are single span transmembrane proteins that couple 
extracellular ligand binding with intracellular signalling pathways. They are 
implicated in a range of biological processes such as proliferation, 
differentiation, cell motility and survival247. 
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Upon activation, the family members homo- or heterodimerise; this leads to 
transphosphorylation, which increases their kinase activity, leading to a 
downstream cascade of signalling.  ErbB3 lacks kinase activity; ErbB2 does 
not bind ligand, however, its extracellular domain retains a conformation 
indicative of ligand binding.  Therefore, ErbB2 is potentially able to 
constitutively dimerise, making it the preferred binding partner for the other 
family members.  
 
1.8.1 ErbB2: role in breast cancer 
ErbB2 is up-regulated in 25-30% of breast cancers, where it is a marker for 
poor prognosis and resistance to hormone therapy131,248.  Trastuzumab, a 
humanised mouse monoclonal antibody directed against ErbB2 has had a 
major impact in the treatment of ErbB2-positive breast cancer.  Although the 
signalling pathways induced by ErbB2 are incompletely characterized, it is 
thought that activation of the PI3K/Akt pathway is important; promoting 
invasion, survival and angiogenesis of overexpressing cells. 
 
In vitro, the transforming capacity of ErbB2 is linked to its expression level.  
Up-regulation of ErbB2 is often due to gene amplification, but can occur with a 
single copy of the gene; overexpressing cells exhibit elevated levels of 
transcription whether or not the gene is amplified 249.  
 
An experimental approach to overexpress ErbB2 in a mouse model used 
transgenic mice carrying the wild type neu (the rat ERBB2 gene) cDNA under 
the control of the mouse mammary tumour virus (MMTV) promoter, this 
generated mice expressing Neu only in mammary epithelial cells. After a 
latent period of ~200 days breast tumours formed in the mice. Interestingly, 
both normal and tumour tissue expressed similar levels of Neu protein; 
however, in the tumours somatic mutations had occurred in the extracellular 
domain of Neu, which conferred an active conformation on the protein, 
suggesting that such mutations are critical antecedents to tumour formation 
through ErbB2 overexpression250.   
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Subsequent studies showed in the tumour cells caused by activated Neu, 
there was an increase in ErbB3 expression.  Furthermore, the ErbB3 in the 
tumour tissue was tyrosine phosphorylated, leading to activation of the PI3K 
pathway. ErbB3 is unable to auto-phosphorylate and relies on 
heterodimerisation with another family member for this to occur. It was 
suggested that the activated form of Neu was responsible for the 
phosphorylation of ErbB3 and these two events are necessary and sufficient 
for tumour initiation 251. 
 
The Neu/ErbB3 relationship observed in transgenic mice is consistent with 
observations in ErbB2 over-expressing human breast cancer cell lines.  
Where inactivation of ErbB2 prevented tyrosine phosphorylation of ErbB3, the 
PI3K pathway was down regulated.  When ErbB3 was reduced, it was 
strongly anti-proliferative and the proliferative effect of ErbB2 could not be 
rescued by the addition of ErbB4, suggesting that ErbB2/ErbB3 heterodimers 
are critical for proliferation and tumour formation 252. 
 
A direct correlation between ErbB2 and ErbB3 expression is observed in 
breast cancer, AP-2 transcription factors are thought to play an important role 
in regulating transcription of both genes 253,254.  
 
1.8.2 ErbB2 and tamoxifen resistance 
The phenomenon of cross talk between growth factor pathways and ER and 
the possibility that enhanced growth factor signalling activity may contribute to 
endocrine resistance has been alluded to previously in Section 1. 4.   
 
The gene expression profiles of 213 breast tumours and 16 breast cancer cell 
lines were analysed to try to identify an ErbB2 overexpression signature.  
Microarray analysis coupled with FISH identified a number of genes in the 
17q12 chromosomal location around the ERBB2 locus that are overexpressed 
when this region is amplified (five out of 29 overexpressed genes).  
Interestingly, eight genes, not located at the 17q12 locus were down regulated 
in response to ERBB2 amplification, including ERα 255. 
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A mouse xenograft model examined the effect of transplantation of ERBB2 
overexpressing MCF7 cells to mouse mammary fat pad.  This resulted in 
tumour formation, vascularisation and up regulation of VEGF 256. In 
ovariectomised mice, tumours did not develop in the absence of oestrogen.  In 
oestrogen-supplemented mice, ERBB2 overexpressing MCF7 tumours grew 
more rapidly than wildtype MCF7 cells.  If oestrogen was stopped and 
tamoxifen started, growth ceased in the control cells, whilst tumours formed 
from ERBB2 overexpressing cells continued to grow257.  These data suggest 
that ERBB2 transfected MCF7 cells are oestrogen-dependent but tamoxifen-
resistant. 
 
This work has been replicated, showing the ERBB2 transfectants were 
tamoxifen resistant, but their in vitro growth was found to be oestrogen 
independent258.  It was also demonstrated that overexpression of ERBB2 led 
to down-regulation of ER and an increase in ligand-independent ER 
phosphorylation.  When a MAPK inhibitor was added to MCF7 cells 
transfected with ERBB2 it restored the inhibitory effect of tamoxifen on cell 
proliferation259. 
 
Increases in endogenous EGFR and ErbB2 expression have been observed 
in MCF7 cells continuously cultured with tamoxifen or Fulvestrant260.  Clinical 
studies endorse the link between EGFR or ErbB2 expression and tamoxifen 
resistance though it appears to be mainly a mechanism of de novo rather than 
acquired resistance.  Newby et al. assessed EGFR and ErbB2 status in 155 
patients who were progressing on tamoxifen treatment.  They found 
expression of either receptor predicted a poor response to tamoxifen.  
However, in 61 patients where paired pre-treatment and relapse specimens 
were available, there was no significant change in expression of either 
receptor, irrespective of the initial response to tamoxifen 261. 
 
A smaller study used tissue microarrays constructed from biopsy samples 
taken pre-treatment and at relapse on adjuvant tamoxifen.  Paired data were 
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available from 39 patients, of whom 29 were ER positive; of the 29 ER 
positive patients, three were ErbB2 positive pre-treatment and remained so at 
relapse.  However a further three patients who were ErbB2 negative pre-
treatment became ErbB2 positive at relapse, thus indicating that ErbB2 
overexpression may accompany the acquisition of tamoxifen resistance in 
some breast tumours131. 
 
Since kinase-mediated growth factor signaling can enhance the activity of ER 
co-activators such as SRC-3, and high levels of co-activators can reduce the 
antagonist effects of tamoxifen120, it is possible that tumours which 
overexpress SRC-3 and ErbB2 may be relatively resistant to tamoxifen.  It has 
been postulated that assessment of SRC-3 levels may improve the predictive 
value of ErbB217.  There is clinical evidence to support this: 187 patients 
treated with tamoxifen and 119 with no adjuvant therapy were studied.  Only 
tumours expressing both high SRC-3 and high ErbB2 had a worse outcome 
with tamoxifen, whereas those with either high ErbB2 or high SRC-3 had a 
good disease-free survival 114.  These data support the hypothesis that 
increased signalling through EGFR/ErbB2 activates MAPK, in turn activating 
ER and SRC-3. The presence of phosphorylated ER and high levels of 
activated SRC-3 may increase the agonist effects of tamoxifen, resulting in 
the development of resistance. 
 
The possibility of cross-talk between EGFR and ER or ErbB2 and ER as a 
mechanism of hormone resistance implies that ErbB2 targeted therapy with 
trastuzumab and the EGFR tyrosine-kinase inhibitor, gefitinib may prove 
useful in the prevention or treatment of tamoxifen resistance.  Sensitisation to 
the effects of the EGFR inhibitor gefitinib, has been reported in MCF7 cells 
continuously cultured with tamoxifen or Fulvestrant 262. 
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1.8.3 AP-2 and ErbB2 in breast cancer 
The relationship between AP-2 transcription factors and ErbB2 
overexpression in breast cancers has been extensively studied.  AP-2 
transcription factors have been implicated in the control of ERBB2 
transcription, through both the proximal promoter and an enhancer element 
located in the first intron, see Section 1.8.4263,264.    
 
A number of IHC studies have been carried out examining expression of AP-2 
and ErbB2 in tumour samples.  Some of the data accumulated has been 
difficult to interpret and compare between different studies, due partly to 
variation in the avidity and specificity of the antibodies used against the AP-2 
subtypes 265.  
 
Turner et al. examined AP-2α, AP-2γ and ERBB2 expression in primary 
tumours from 81 patients with early stage breast cancer.  They found all 
ErbB2 positive cases were also positive for expression of either AP-2α, AP-2γ 
or both.  Furthermore, there was a significant correlation of AP-2α/γ co-
expression with ERBB2 overexpression235. 
 
A study of 144 breast tumours found increased nuclear expression of AP-2α 
was associated with ERBB2 overexpression, ER positivity and good 
prognosis, however AP-2γ was not significantly related to ERBB2 
overexpression, ER or prognosis245. 
 
In another, smaller study, using 86 tumour samples, of which 17% 
overexpressed ERBB2, Gee et al. used a non-specific antibody to AP-2α/β; 
they found AP-2α/β staining was inversely related to expression of ERBB2 
and ERBB3.  AP-2α/β expression was also associated with ER and p21 
positivity, though no association with other clinical parameters was seen236. 
 
A large study has been performed using 425 breast cancer samples, with 
ERBB2 overexpression in 13% of tumours.  The AP-2 antibody, C-18 was 
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described as non-specific for AP-2α/β/γ by the authors but is marketed as AP-
2α specific by Santa Cruz.  The study found a positive association between 
AP-2 expression and ERBB2 overexpression; particularly, when AP-2 staining 
occurred in both cytoplasm and nucleus.  ErbB2 overexpression was 
associated with poor prognosis as expected; AP-2 expression had a lower 
predictive value but was associated with a better prognosis.  These results are 
consistent with a tumour suppressor role for AP-2α and suggest that incorrect 
cellular localisation may be a factor in tumour progression 265,266. 
 
In summary, multiple studies correlate AP-2α with ERBB2 overexpression in 
clinical samples.  AP-2α expression is also linked with good prognosis 
features such as ER positivity, lower levels of proliferation and good 
prognosis235,245,266.  However, there is less IHC evidence to provide a 
consensus associating the expression of AP-2γ with ERBB2 overexpression 
in tumour samples 245,265. 
 
An interesting experiment examined transgenic mice overexpressing ERBB2 / 
AP-2γ.  They showed the incidence of tumours was reduced and their latency 
prolonged in AP-2γ overexpressing mice.  However, a higher proportion of 
bitransgenic mice developed advanced stage disease compared to ERBB2 
expressing controls, consistent with the idea that AP-2γ expression promotes 
tumour progression.  In addition, AP-2γ differentially affected proliferation at 
different stages of progression: proliferation was enhanced at early stages but 
reduced in advanced stages in comparison to control tumors267. 
 
Studies examining ErbB2 and AP-2 have extended to other tumour types. 
Gene copy number, mRNA and protein levels were observed in colon, ovary 
and pancreatic cancer cell lines and compared with two breast cancer cell 
lines: BT474 (amplified ERBB2 locus) and ZR75-1 (single copy ERBB2).  
Interestingly, no correlation between AP-2 expression and ErbB2 
overexpression was detected and there was little evidence of gene 
amplification268 suggesting an alternative mechanism of ErbB2 
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overexpression must occur in non-breast tumour types, for example via 
increased protein or transcript stability. 
 
1.8.4 Transcriptional regulation of ERBB2 by AP-2  
AP-2 was first identified as playing a role in the regulation of ERBB2 using a 
dominant negative form of AP-2 (∆N278), which is able to dimerise with the 
wild type proteins, generating heterodimers that are unable to bind DNA 210.  
Reporter constructs using the first 300bp of the ERBB2 promoter showed that 
on transfection with ∆N278, transcription was down regulated, while the 
opposite occurred on transfection with wild type AP-2.  Further studies 
identified that AP-2α and AP-2γ were largely responsible for the regulation of 
the ERBB2 promoter 254; with AP-2γ expressed in all cell lines over-
expressing ERBB2. 
 
However, cell lines expressing AP-2γ do not always express ErbB2, which 
suggests that signalling pathways activated by ErbB2 over expression are not 
responsible for the over expression of AP-2γ. More recently the presence of a 
second functional AP-2 binding site located at the –501bp position in the 
ERBB2 promoter relative to the transcription start site has been shown 269.  
For maximal ERBB2 promoter activity in reporter assays, both AP-2 sites 
must be intact. However, since no DNase I hypersensitive site is mapped to 
the –500 region, this AP-2 site may be less crucial in the regulation of 
endogenous ERBB2 270. 
 
There is an inverse correlation between ErbB2 and ERα expression in breast 
cancer. Oestrogenic suppression of ERBB2 is mediated both through the 
promoter 254,264 and via an enhancer element in the first intron270.  The ERBB2 
promoter does not contain an ER binding site therefore, the oestrogenic 
suppression must be mediated indirectly.  The oestrogen-suppressible region 
of the ERBB2 promoter has been mapped to the AP-2 binding site.  CAT 
reporter assays showed that mutation of this AP-2 site relieved the oestrogen 
repression.  This oestrogen response may occur through two possible 
mechanisms; either ERα directly down-regulates expression of AP-2 proteins 
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or there is competition between ERα and AP-2 transcription factor complexes 
at the ERBB2 promoter / enhancer for co-factors of transcriptional 
activation264.   
 
The oestrogen repressible enhancer found in the first intron of ERBB2 is the 
major contributor of suppression by ER-α. This site was identified as one of 
six DNase I hypersensitive sites found in the first intron of ERBB2 in breast 
cell lines that over-express the protein.  The location of the ERE was identified 
by a series of deletion constructs driving a CAT reporter.  DNase I footprinting 
identified four transcription factor binding sites, two of which bind to AP-2, the 
others bind CREB/ATF1 and ATFa/JunD respectively 263,270.  However, no 
single site was completely responsible for the oestrogen suppression, in 
addition, there is no oestrogen response element located within this region. 
 
In the absence of direct DNA binding of ERα to the first intronic enhancer, it 
has been postulated that suppression occurs through other means, such as 
competition for co-regulators of transcriptional activation.  Inactivation of the 
various domains of the ER, either alone or in combination revealed that DNA 
binding was not necessary for repression of ERBB2, nor was the AF-1 
domain.  The AF-2, oestrogen binding domain was responsible for 
suppression; mutation of helix 12, which is integral to the formation of AF-2 on 
ligand binding abolishes the suppression, (see Figure 1.6) 271. 
 
SRC-1 is a ligand dependent co-factor for ERα, (see section 1.4,4) 272. 
Overexpression of SRC-1 in a dose-dependent manner was demonstrated to 
restore the activity of ERBB2 in oestrogenic media in ZR75-1 cells. This 
suggests that SRC-1 is limiting within the cell and that competition is occurring 
between the ERα and transcription factors regulating ERBB2 expression for 
the recruitment of co-factors. A mutated form of SRC-1 that is unable to bind 
active ERα was able to restore the activity of ERBB2. These findings suggest 
that SRC-1 is directly involved in the activation of ERBB2 possibly through 
recruitment of co-factors such as CBP/p300 263.   
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1.9 siRNA  
The ability of double stranded RNA, (dsRNA) to specifically silence 
homologous genes was originally observed in 1990, in petunias154.  RNA 
interference (RNAi) is an endogenous pathway that has been exploited using 
synthetic RNA duplexes, termed short interfering RNAs, (siRNAs) which 
mimic intermediates in the RNAi pathway 273.   
 
1.9.1  Mechanism of RNAi 
RNAi is initiated when a cell encounters a double stranded RNA (dsRNA) 
duplex.  In the cytoplasm, the endoribonuclease Dicer cleaves dsRNA >30 
basepairs in length into 21-23nt duplexes with a 2nt overhang at the 3’ end, 
(siRNAs).  siRNAs bind to a multiprotein nuclease complex to form the RNA-
induced silencing complex or RISC.  ATP-dependent unwinding of the siRNA 
duplex is required for activation of RISC, allowing either strand of the siRNA to 
act as a guide for recognition of its complementary target mRNA.    
 
The fate of the target mRNA depends on the degree of complementarity of the 
guide strand to the target.  siRNAs that are exactly complementary to their 
target cause site-specific cleavage of the mRNA target by the RNA 
endonuclease Ago2. The cleaved mRNA is then released and degraded, 
leaving the activated RISC available to find and cleave further target 
mRNA274.  Exogenous, synthetic siRNA sequences are designed to target a 
unique sequence in the coding region of mRNA and are perfectly 
complementary to their target.  Endogenous microRNAs (miRNAs) usually 
bind to the 3’ untranslated region UTR of their target mRNA, with imperfect 
complementarity, they repress gene expression by blocking translation of the 
target mRNA.  Thus, both siRNA and miRNA assemble with and function via 
RISC; their mechanism of gene silencing is interchangeable, depending on 
the degree of base pairing to their target, (see Figure 1.15). 
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siRNA  miRNA 
Figure 1.15. Mechanisms of RNA interference in mammalian cells, 
(from Dykxhoorn et al. 2003)4 
siRNA:  Long double-stranded RNA is cleaved by the 
endoribonuclease Dicer, into siRNAs in an ATP-dependent reaction; 
siRNAs are then incorporated into the RNA-inducing silencing complex 
(RISC). The siRNA duplex is unwound in an ATP dependant manner 
and a single-stranded antisense strand guides RISC to messenger 
RNA with a complementary sequence, resulting in the cleavage of the 
target mRNA.   
miRNA: Initially, the endoribonuclease Drosha processes  
endogenous pre-miRNA transcripts into 70-nucleotide hairpin pre-
miRNAs inside the nucleus. On export to the cytoplasm Dicer cleaves 
these precursors to produce single-stranded 22nt miRNA.   These are 
incorporated into a ribonucleoprotein complex (miRNP) and are guided 
to messenger RNA with a partially complementary sequence, resulting 
in repression of target mRNA translation by obstruction of the 
translation machinery. 
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Early RNAi studies in mammalian cells were hampered by induction of the 
interferon response, which is triggered by dsRNA duplexes >30bp.  The 
interferon response activates a cascade of interferon-stimulated genes (ISGs), 
results in inhibition of protein synthesis and leads to cell death. It can be 
evaded in vitro by reducing the length of dsRNA duplexes to 19-25bp.  This 
was first demonstrated in 2001274. 
 
RNAi compares favourably with previous methods of gene silencing because 
of its superior efficiency.  RNAi allows silencing of a wider range of genes than 
antisense methods and lower concentrations of nucleic acid are required 275.   
 
1.9.2  siRNA design 
Some sequences are more efficient than others at silencing a target gene, this 
is largely determined by the siRNA sequence.  The thermodynamic properties 
of the ends of the siRNA duplex determine which strand of the siRNA duplex 
is functional. The strand with a less tightly paired 5’ end is preferentially 
incorporated into RISC, becoming the “guide” strand 276,277.  
 
Through a systematic analysis comparing the efficacies of 180 siRNA 
sequences targeting two genes, Reynolds et al. determined eight criteria for 
effective siRNA design278.  These criteria have been incorporated into on-line 
siRNA design algorithms such as: http://jura.wi.mit.edu/bioc/siRNAext/ 279.   
 
1.9.3 Off-target effects 
Given the interchangeable nature of siRNA and miRNA, it may seem 
unsurprising that genome-wide microarray analysis of gene expression 
following siRNA revealed off-target effects in genes with partial homology to 
the intended target.  Jackson et al. found that off-target gene silencing can 
occur in mRNAs with as few as 11 contiguous matches to the siRNA “seed” 
region at the 5’ end of the antisense strand280. This number has subsequently 
been revised to 7 contiguous matches 281.  The observed off-target effects on 
gene expression observed are less pronounced than the degree of silencing 
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of the intended target and can be partially abrogated by minimising the dose 
of siRNA.   
 
These findings have led to further refinements in siRNA design criteria with 
more sophisticated sequence comparison tools to filter and exclude candidate 
siRNAs containing sequences homologous to non-target mRNA, based on the 
NCBI BLAST website, (http://www.ncbi.nlm.nih.gov/BLAST/)278,280. Design 
algorithms now include the 3’ UTR of mRNAs as a potential siRNA target site.  
 
For functional genetic studies, two independent siRNA sequences targeted at 
the same gene are often used to control for unforeseen off-target effects.  It is 
also essential that low doses of potent siRNA sequences be used (eg ≤ 20nM) 
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.  A number of studies have elegantly controlled for off-target effects by 
validating the specificity of their knockdown phenotype by re-introducing the 
target gene in an siRNA-resistant form and demonstrating recovery of the 
wildtype phenotype despite ongoing siRNA expression.  Such functional 
controls are the gold standard for RNAi experiments283.   
 
Although the phenomenon of off-target effects due to unintended activity of 
siRNAs was demonstrated by expression microarray, if siRNAs can induce 
miRNA-like translational suppression, the full ramifications of this would only 
be detectable by a proteomics approach.  One study at least has reported 
unexpected off-target effects seen more dramatically at the protein level than 
at the mRNA level; these appeared to be unrelated to the degree of target 
gene silencing 284.   
 
The phenomenon of off target effects means that it is crucial to control 
carefully for siRNA effects before drawing conclusions regarding a gene 
knockdown phenotype. It is also preferable to compare the effects of more 
than one independent siRNA sequence directed against the same target 283.   
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1.9.4 Methods of delivery 
The standard method for introducing 21bp synthetic siRNAs into mammalian 
cells in culture is by the transfection of synthetic siRNA duplexes mixed with 
lipoprotein complexes.  The efficiency with which cells are transfected 
depends to a large extent on the cell line.  Another approach aimed at 
prolonging the RNAi effect is through the stable transfection of DNA vectors 
which drive the expression of short hairpin RNA which is subsequently 
converted to the mature siRNA duplex, (see Materials and Methods, Figure 
2.1). 
 
1.10  Chromatin ImmunoPrecipitation (ChIP) 
1.10.1  Chromatin 
Genomic DNA exists in a highly compacted form called chromatin, comprising 
nucleosomes: 147bp stretches of DNA wrapped around an octamer of four 
histone proteins (H2A, H2B, H3 and H4). The linker histone (H1) and other 
proteins bind between nucleosomes and facilitate further compaction of 
chromatin.  This tight packaging stabilises the chromatin and renders the DNA 
inaccessible for transcription.  Gene transcription may be affected through 
multiple mechanisms including histone modification and chromatin 
remodelling 285-287. 
 
1.10.2   Histone modification 
Histone modification occurs mainly in the so-called N-terminal tails, which 
protrude from the nucleosome surface.  They include the acetylation (ac) and 
methylation (me) of lysine (K) residues and arginine methylation.  Acetylation 
of lysines on H3 and H4, mediated by histone acetyltransferase (HAT) 
enzymes results in destabilisation of histone-DNA interactions and an 
increased propensity for histones to be displaced by chromatin remodelling 
enzymes, making DNA accessible for transcription.  Histone deacetylatases 
(HDACs) reverse this process and are associated with transcriptional 
repression.  Lysine trimethylation (H3K4me3) and arginine dimethylation 
(H4R3me2) are also associated with transcriptionally active promoters while 
other modifications such as lysine methylation (H3K9me2, H3K9me3 and 
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H4K20me3) are associated with chromatin repression288.  Histone 
modification also recruits specific non-histone proteins to chromatin, for 
example: Heterochromatin Protein 1 (HP1) is recruited to methylated H3K9, 
where binding leads to deacetlyase activity and transcriptional repression.  
HP1 binding facilitates further H3K9 methlyation and transmits H3K9me to 
adjacent nucleosomes, it is therefore implicated in the establishment and 
maintenance of a global heterochromatin environment 289. 
 
1.10.3 Chromatin Remodelling   
Nucleosomes exist in equilibrium between a fully and partially wrapped state; 
the likelihood of nucleosomes to become unwrapped is regulated by ATP-
dependant chromatin remodelling complexes, which alter the histone-DNA 
contacts, necessary for displacement of nucleosomes. 
 
1.10.4  Transcription factor recruitment and Pre-Initiation Complex 
(PIC) Assembly 
It is thought that nucleosomal DNA spontaneously unwraps to reveal DNA 
consensus-binding sequences necessary for recruitment of transcription 
factors.  Histone modifications affect the likelihood of a nucleosome to 
remodel, therefore transcription factors may only be able to access their DNA 
binding sites in an appropriate chromatin context.  Studies in yeast have 
shown that nucleosome density at promoter regions is typically lower than that 
at adjacent coding regions 287. 
 
Once bound to a promoter or enhancer, transcription factors stimulate 
transcription via multiple mechanisms.  For example, by recruitment of 
coactivator complexes that comprise HAT and chromatin remodelling 
activities.  These facilitate the further binding of the specific transcription 
factors and affect the chromatin structure to accommodate the recruitment 
and positioning of the PIC.  Transcription factors may then directly interact 
with components the of PIC: stimulating its positioning within the core 
promoter or stimulating its activity once positioned.  
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1.10.5  AP-2, CITED and CBP/p300 
AP-2 proteins can be co-activated by the recruitment of the p300 and CREB-
binding protein (CBP) to their target gene promoter.  Recruitment is mediated 
by the CITED (CBP/p300 interacting transactivators with ED-rich termini) 
family of proteins290-292.  CBP and p300 are two homologous proteins first 
identified through their ability to activate gene transcription293,294.  Subsequent 
studies have shown that this activity is dependant on the coactivation of a 
variety of transcription factors, including AP-2 family members.  CBP and 
p300 interact with gene specific transcription factors, which guide them to their 
target genes.  Once the target gene has been accessed, their intrinsic HAT 
activity is required for acetylation of lysine residues on the histone tails.  
CBP/p300 can also acetylate non-histone chromatin-associated proteins, 
including transcription factors.  Interestingly, autoacetylation by CBP/p300 is 
thought to be required for ordered PIC assembly, 295.  In summary, CBP and 
p300 appear to form a bridge between gene-specific transcription factors and 
the general transcription machinery.  Their intrinsic HAT activity is important 
for establishing a favourable chromatin environment for both specific and 
general transcription machinery.  
 
The majority of transcription factors that bind CBP/p300 do so by direct 
interaction, however AP-2 factors require the adapter protein CITED.  CITED 
proteins act as adapter proteins bringing CBP/p300 to AP-2 factors, allowing 
the co-activation of AP-2 target genes.  All three proteins were co-
immunoprecipitated from U2-OS cells, indicating that they interact with each 
other in vivo 290.   
 
1.10.6 Kinetic ChIP 
Kinetic ChIP examines promoter occupancy over time.  Metivier et al. 
evaluated thepromoter of the ER-α target gene pS2 in MCF7 cells.  In a pain-
staking analysis, they examined 46 transcription factors at 36 time points.  
Figure 1.16 shows some of their data, which demonstrate the cyclical 
interaction of ER with its endogenous promoter and the cyclical, sequential 
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recruitment of co-factors.  They describe the sequential building of a 
transcription complex on a promoter as a “transcriptional clock” 296.  
 
 
Figure 1.16 Kinetic ChIP demonstrating the dynamics of co factor 
recruitment directed by ERα on the pS2 promoter.  Taken from Metivier 
et al 2003 296. 
Kinetic ChIP experiments were performed using the specified antibodies, 
shown on the images.  After 2 hours treatment with α-amanitin, MCF 7 cells 
were washed and placed in media supplemented with 10nM 17β-oestradiol.  
Chromatin was prepared on cells sampled at five minute intervals.  The 
amount of immunoprecipitated pS2 promoter was quantified by real-time PCR.  
Values, expressed as % of the inputs, are the mean of three separate 
experiments.  All ChIP were performed from a single chromatin preparation for 
each time point. 
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1.11 Aims of the project 
 
1.  Molecular profiling of tamoxifen resistant cell lines and tumour samples 
 
• Use microarray technology to compare the RNA expression profiles of 
tamoxifen-sensitive and tamoxifen-resistant cultured breast tumour lines.  
Determine if the standard (5-10µg) and 100ng protocols give the same 
qualitative and quantitative data sets. 
 
• Use observations from the above to inform the expression analysis of laser 
capture microdissected ER positive breast tumour samples with a known 
outcome following tamoxifen therapy.  
 
• Validate selected genes in cell lines (using RT-PCR, Western blotting, 
RNAi) and tumours (using Tissue arrays) and try to correlate with 
response to tamoxifen.  Can the genes identified by placed in pathways to 
elucidate possible mechanisms of tamoxifen resistance? 
 
2.   Role of AP-2 factors in oestrogen repression of ERBB2 expression 
 
• Establish a robust system for the selective knockdown of the two AP-2 
family members found in breast cells (AP-2α and AP-2γ) using RNAi 
technology. 
 
• Investigate the effect of AP-2 knockdown on the expression of ERBB2 in 
hormonally manipulated cells.  Does loss of AP-2α or AP-2γ prevent 
"induction" of ERBB2 in anti-oestrogenic media? 
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CHAPTER 2 – MATERIALS AND 
METHODS 
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2 MATERIALS AND METHODS: 
2.1 Cell culture 
The Tenovus Centre for Cancer Research in Cardiff supplied MCF7 breast 
cancer cell lines and two tamoxifen resistant MCF7 sublines, derived by 
continuous culture in the presence of 10-7M 4-OH tamoxifen: Tamoxifen 
Resistant MCF7 Early (P2) cells, (known as “Early”) were grown for 2 months 
with tamoxifen while Tamoxifen Resistant MCF7 Late (P28) cells, (known as 
(known as “Late”) were grown for a further 4 months260. 
 
Cell lines were cultured as described in Table 2.1.  All cells were regularly 
passaged and screened for Mycoplasma sp. contamination. Cancer Research 
UK (CRUK) MCF7 and T47D cells were grown in 10% CO2 at 37°C.  ZR75-1, 
Tenovus MCF7, and Tamoxifen Resistant MCF7 cells were grown in 5% CO2 
at 37°C 
 
Table 2.1. Cell lines and cell culture conditions 
Cell Line Description Media 
CRUK MCF7 Mammary Carcinoma 
DMEM, 10% Foetal Calf Serum, 
10µg/ml Insulin 
Tenovus MCF7 Mammary Carcinoma 
RPMI + 5% Foetal Calf Serum 
Tamoxifen Resistant 
MCF7 Early P2 or  
Late P28 
Mammary 
Carcinoma 
Phenol red free RPMI, 5% 
charcoal stripped Foetal Calf 
Serum, 4-OH tamoxifen 10-7M 
ZR75-1 Mammary Carcinoma RPMI, 10% Foetal Calf Serum 
T47D Mammary Carcinoma DMEM, 10% Foetal Calf Serum 
Hormone Manipulation 
 
Oestrogen deprivation 
Phenol red free media + 
charcoal stripped foetal calf 
serum 
17β-oestradiol 10-8M 
Fulvestrant (ICI 182780) 10-7M 
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2.2  MTS assay 
MTS assays were carried out according to the Promega CellTiter 96 AQueous 
Non-radioactive Cell Proliferation Assay protocol. 
 
2.3   DAPI staining and Fluorescence microscopy 
Glass coverslips were washed in a 60:40 mix of concentrated hydrochloric 
acid and ethanol for 30 minutes, rinsed in distilled water three times.  
Coverslips were stored in 70% ethanol until required.  Residual ethanol was 
removed by rinsing with PBS, the coverslips were placed in 6-well plates and 
1x106 cells were seeded per well.  
 
The following day, the cells were transfected with fluorescent labelled siRNA.  
After a further 24 hours, the cells were washed twice with PBS and fixed using 
3-4% paraformaldehyde in PBS for 15 minutes at room temperature, (RT) with 
gentle shaking.  The cells were washed twice with PBS for ten minutes.  To 
allow nuclear staining, the cells were permeabilized with 0.1% TritonX-100 in 
PBS for 5 minutes at 4°C. Cells were washed twice with PBS for 10 minutes 
at RT to remove the detergent and then incubated with 1:500 DAPI (Molecular 
Probes) in PBS for 5 minutes.  Finally, the cells were washed twice in PBS.  
The coverslips were carefully removed from the 6-well plates, gently dried on 
tissue paper and mounted onto slides using Permaflour (Immunon).  The 
slides were left overnight at RT to allow the mounting media to dry, then 
stored at 4°C. Slides were viewed using the Olympus BX51 microscope and 
digital photographs taken with Studiolite software (Pixera Corporation).  
 
2.4  Flow cytometry  
Flow cytometry analysis was performed with the assistance of the CRUK 
FACS Laboratory, London Research Institute, Lincoln’s Inn Fields.   
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2.4.1 Annexin V / Propidium Iodide staining 
During early apoptosis, phosphatidylserine (PS) residues, (normally found on 
the inner aspect of the cytoplasmic membrane) are externalised.  Annexin V is 
a specific PS-binding protein used to detect cells undergoing apoptosis; 
propidium iodide binds DNA297. 
 
The overlying cell media was collected to capture any floating cells for 
analysis. Cells were trypsinised and washed with PBS. The cells were fixed in 
ice cold 70% ethanol and incubated for 30 minutes on ice.  Following this, the 
cells were centrifuged at 2000rpm and ethanol was carefully removed.  
Treatment with 100µl of RNase (100µg/ml) for 5 minutes at RT ensured only 
DNA would be stained.  400µl of Annexin V Binding Buffer (Becton Dickinson 
(BD Cat. No. 556454)) was added, followed by 2µl of Annexin V-FITC (BD, 
Cat.No. 556420).  Cells were left for 15 minutes at RT.  Following this, 
propidium iodide was added (5 µg/ml).  Flow cytometry was performed using 
a FACS Calibur (Becton Dickinson). Fluorochromes were excited by a 488nm 
laser and fluorescence was collected between 515 and 545nm for FITC and 
above 580nm for PI.  Forward and right angle scatter was used to define the 
cell population, and pulse processing of the PI signal was used to distinguish 
doublets and cell clumps.  
 
2.5      Paraffin Embedding of Cell Suspensions 
A 2% solution of low melting point agarose in PBS was equilibrated to 37°C.  
Cells were trypsinised, resuspended in PBS, pelleted and re-suspended in 
~200µl PBS.   The cell suspension was gently dripped into ~1ml of molten 
agarose and transferred into the barrel of a 10ml syringe with the nozzle cut 
off.  The agarose was allowed to set, and the resultant disc was transferred to 
25mls 37% formaldehyde solution overnight for fixing.   
 
The discs were run on the automated paraffin embedding process in the 
QMUL Institute of Cancer Tissue Expression Profiling Facility.  Paraffinised 
discs were cut into 5µm sections and mounted on microscope slides, prior to 
further processing either by in situ hybrdisation or immunocytochemistry.  
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2.6  siRNA 
2.6.1   Selecting siRNA sequences 
Sequences specific to AP-2γ and AP-2α were selected for the generation of 
siRNA oligonucleotides using the on-line Qiagen siRNA design tool 
(http://www1.qiagen.com), based on published suggestions for siRNA design 
278,298
. BLAST searches were performed to verify the specificity of the 
sequences to AP-2γ and AP-2α.  Dr Daniella Taverna in Turin provided a 
further AP-2α specific sequence and two additional pre-designed AP-2α 
sequences were ordered from Dharmacon (http://www.dharmacon.com).   
 
Pre-designed oligonucleotide siRNAs specific for HRASL3, CTSD, CAXII were 
also obtained from Dharmacon (http://www.dharmacon.com).  Throughout 
transient transfection experiments, a non-specific random sequence (Qiagen) 
was used as a non-silencing control.  mAP-2γ, a “mismatch” sequence 
contains a single base change (underlined) compared to the AP-2γ G1 
sequence.  Due to the specificity of siRNA, mAP-2γ should not knockdown the 
AP-2γ target mRNA, and was used as a non-silencing control in pRetroSuper 
vectors (Figure 3.1, Figure 5.3).   
 
The siRNA target sequences used in this thesis are summarised in Table 2.2.   
 
2.6.2  Transient Transfection of siRNA oligonucleotides 
Synthetic siRNAs consisted of a 19-nucleotide RNA duplex with a two nt 
overhang at the 3' end.  siRNAs were diluted in the manufacturer’s buffer and 
annealed with a 1 minute incubation at 90°C followed by a 60 minute 
incubation at 37°C, before storage at -20°C.  
 
Initially, the transfection conditions were optimised, comparing transfection 
rates using three different reagents: Oligofectamine, (Invitrogen), 
Lipofectamine 2000, (Invitrogen) and Transmessenger, (Qiagen) for each cell 
line; MCF7, T47D and ZR75-1.  The cells were used at 30-40% confluence 
and transfected in six well plates with 3 different doses of the transfection 
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reagents and a fluorescein-labelled control siRNA, (Qiagen) according to the 
manufacturer’s recommendations.  24 hours later, the transfected cells were 
DAPI stained and observed with fluorescence microscopy.  The number of 
fluorescing cells per the total number of cells in a high power field was 
counted in three representative fields to estimate the proportion of transfected 
cells for each reagent.  (The results from this optimisation experiment are 
summarised in Table 5.1.) 
 
Table 2.2 siRNA Target Sequences 
Target siRNA  Name Target Sequence 5’- 3’ 
G1 GCGGCCCAGCAACTGTGTAAA 
AP-2γ  
G2 CCACACTGGAGTCGCCGAATA 
mAP-2γ  Mismatch G1 GCGGCCGAGCAACTGTGTAAA 
A1 AACATCCCAGATCAAACTGTA   
AP-2α 
A2 GTAGAAGACCCGGGTATTATT 
HRASL3  HRASL3 1 TGAATGAGCTGCGCTATGGTT 
HRASL3  HRASL3 2 TCAAGAAACAAGCGACAAATT 
HRASL3 HRASL3 3 ACAAGTACCAGGTCAACAATT 
CTSD CTSD 1 GAAGAATGGTACCTCGTTTTT 
CTSD CTSD 2 GCACCTACGTGAAGAATGGTT 
CTSD   CTSD 3 GGCACAGACTCCAAGTATTTT 
CAXII      CAXII 1 GAGAATAGCTGGTCCAAGATT 
CAXII      CAXII 2 GGAGAGGACCGCTGAATATTT 
CAXII      CAXII 3 GAGGACCGCTGAATATTACTT 
Non Silencing Control siRNA AATTCTCCGAACGTGTCACGT 
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Oligofectamine at a dose of 3µl per well produced the highest rates of 
transfection in all three cell lines.  Mechanical disruption with a 21G syringe 
needle, to prevent cell clumping when plating out T47D and ZR75-1 cells was 
also found to improve the efficiency of transfection.   
 
MCF7, T47D and ZR75-1 cells at 30–40% confluency were transfected in six 
well plates using Oligofectamine as per the manufacturer’s instructions 
(Invitrogen).  The siRNA was diluted in serum free media to a volume of 
185µl.  In a separate microfuge tube, 3µl of Oligofectamine reagent was 
diluted in 12µl of serum free media, and allowed to equilibrate for 5 minutes. 
The diluted siRNA was then added to the diluted transfection reagent, gently 
mixed and incubated at room temperature for 20 minutes.  Cells were washed 
twice in serum free media; then covered with 800µl of serum free media per 
well.  The transfection complexes were carefully overlaid on the cells (200µl) 
and incubated at 37°C.  Four hours later, 1ml of 2 x complete medium was 
added to each well. 
 
The extent of target knockdown was assayed at time points thereafter by 
either qRT-PCR or Western Blotting.  All the siRNA concentrations quoted in 
this report represent the final siRNA concentration in 1ml.  
 
2.6.3 Short Hairpin RNA Vector Construction   
The pSuper vector was developed in 2002, it directs the expression of short 
hairpin RNA (shRNA), sequences that spontaneously form stem-loop 
structures.  A 49-nt precursor transcript is synthesized consisting of two 19-nt 
“target” sequences separated by a short spacer and followed by five 
thymidines (T5) as a termination signal.  The stem-loop precursor RNA 
mimics endogenous miRNA and is processed in the cell by Dicer into an 
effective 21nt siRNA containing the sense and antisense target sequences, 
see Introduction 1.8.4, Figure 1.13.  An antibiotic resistance marker in the 
vector allows the selection of successfully transfected cells and stable 
expression of the shRNA can be maintained299.  pRetroSuper is based on a 
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retro-viral vector and allows permanent expression of shRNA in mammalian 
cells since viral DNA expression cassettes can integrate into the host cell 
genome and their expression can be maintained indefinitely 300.   
 
Initially, pSuper constructs were made for stable expression of shRNA 
targeting AP-2γ.  However, since these were unsuccessful, pRetroSuper 
constructs were made against AP-2γ using the target sequences G1, G2 and 
the corresponding mismatch non-silencing control, mAP-2γ.  Custom 
oligonucleotides were annealed and ligated into the BglII/HindIII sites of the 
vector.  The correct sequence of inserts was confirmed before use.  The 
resulting siRNAs were identical to the RNA oligonucleotides used for transient 
transfection.  Details of the shRNA expression constructs based on the 
pRetroSuper vector are shown in Figure 2.1300.  
 
 
H1-RNA 
Promoter
5’  – ugagaagucucccagucag
3’-uuacucuucagagggucaguc
u
u c
c g a
g
a
a
Puromycin 
selection 
marker
ugagaagucucccagucaguu
uuacucuucagagggucaguc
Target sequence: sense antisense
sense
antisense
RNA 
hairpin 
siRNA  
 
1 AP-2γ shRNA: 
5’ GATCCCCGGCCCAGCAACTGTGTAAATTCAAGAGATTTACACAGTTGCTGGGCCTTTTTGGAAA 3’ 
 5’ AGCTTTTCCAAAAAGGCCCAGCAACTGTGTAAATCTCTTGAATTTACACAGTTGCTGGGCCGGG 3’ 
2 mAP-2γ shRNA:  
5’GATCCCCGGCCGAGCAACTGTGTAAATTCAAGAGATTTACACAGTTGCTCGGCCTTTTTGGAAA 3’ 
5’AGCTTTTCCAAAAAGGCCGAGCAACTGTGTAAATCTCTTGAATTTACACAGTTGCTCGGCCGGG 3’ 
 
Figure 2.1  pRetroSuper vector for expression of shRNA   
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2.6.4   Generation of shRNA Stable Lines 
The AP-2γ targeting construct, (pRS AP-2γ) the corresponding mismatch non-
silencing control construct (pRS mAP-2γ) and an empty pRetroSuper vector 
(pRS EV) were linearised using Sap1 restriction endonuclease before 
transfection.  Cells were transfected using FuGENE 6 (Roche) following the 
manufacturer’s instructions.  Positive control wells (No selection) and negative 
control wells (No transfection) were also included in the experiment to confirm 
the efficacy of puromycin selection. 
 
48 hours post-transfection, cells were split into selection medium containing 
2.5µg/ml puromycin.  Media was changed every 2-3 days; at 14 days 
selection was continued with 1.25µg/ml puromycin.  Single colonies of 
sufficient cell numbers were transferred onto 96-well plates using cloning 
cylinders.  Single cell clones were then expanded and Western blots were 
performed to determine the knockdown efficiency of individual clones.   
 
2.6 Western blotting  
2.7.1  Whole cell extract 
Whole cell extracts were prepared from 10cm plates at 80-90% confluence.  
Cells were washed three times in ice cold PBS to remove media, and lysed on 
the plate with urea whole cell extract buffer (8M Urea, 1M Thiourea, 0.5% 
CHAPS (Sigma), 50mM DTT, 24mM Spermidine).  Extracts were collected 
with a cell scraper and their protein content estimated using Bradford reagent 
(Biorad) and a BSA standard curve (range 0 – 20µg/ul).  Samples were stored 
at  -80oC. 
 
2.7.2  Western Blotting 
Proteins were resolved on appropriate percentage (6% to 12.5%) SDS 
polyacrylamide gels (National Diagnostics) alongside Molecular Weight 
Rainbow markers (Amersham) to allow size comparison of the detected 
bands. Proteins were transferred onto nitrocellulose membranes (Amersham) 
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using a semi-dry transfer system (Biorad).  After successful transfer, rainbow 
markers were clearly seen on the membrane.  
 
Membranes were blocked using PBS, 5% Marvel, 0.1% Tween-20 for 1 hour 
at RT.  Primary antibody was diluted in blocking solution at antibody 
dependent concentrations and added to the membrane for an hour at RT or 
overnight at 4°C. Membranes were washed 3 times in block solution to 
remove excess primary antibody, then incubated with secondary antibody, 
diluted in block solution for 1 hour at RT.  Finally, membranes were rinsed in 
PBS, 0.1% Tween-20. 
 
Antibody binding was detected either using the Supersignal West Femto 
system (Pierce) according to the manufacturer’s instructions. The blots were 
then exposed to autoradiograph film (Biomax MR, Kodak).  
 
Membranes were stripped using strip buffer (62.5mM Tris-HCl pH 6.7, 2% 
SDS, 100mM β-mercaptoethanol) at 55°C for 15 minutes to remove bound 
antibody. After stripping, the membrane was washed with PBS, 0.1% Tween-
20, before being re-blocked and probed as previously with Ku-70 antibody as 
a loading control.  
 
Table 2.3 Antibodies for western blotting. 
Antigen Animal origin Source Dilution 
Primary antibodies: 
AP-2γ (6E4/4) Mouse  Helen Hurst 1:1000 
AP-2α (3B5) Mouse  Santa Cruz 1:1000 
Ku-70 (C19) Goat  Santa Cruz 1:1000 
STAT-1 (C136) Mouse  Santa Cruz 1:1000 
ErbB2 (3B5) Mouse Calbiochem 1:250 
Secondary antibodies: 
HRP linked Mouse IgG Sheep Amersham 
Pharmacia 1:2500 
HRP linked Goat IgG Mouse Santa Cruz 1:2500 
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2.8  RNA Extraction and Purification 
2.8.1  RNA Purification from cell lines 
All solutions and plasticware used in the protocol were sterile and nuclease-
free to minimise RNase attack.  Cells were washed twice with ice cold PBS.  
500µl TRIZOL reagent (Invitrogen) was added to each well of a six well plate 
of cells.  TRIZOL extracts were collected using cell scraper and homogenised 
by passing through a 21G needle twice.  Homogenised samples were 
incubated for 5 minutes at RT.  100µl chloroform was added, vortexed for 15 
seconds, incubated for 2-3 minutes at RT.  Samples were then centrifuged at 
12,000g for 15 minutes at 4°C and the aqueous upper phase was transferred 
to a new microfuge tube.  Glycogen was added to a final concentration of 
1 µg/µl, 500µl of ice cold 70% ethanol was added and mixed by pipetting.  
The mixture was applied to an RNeasy Mini column (Qiagen) then centrifuged 
for 15 seconds at 8000g.  The RNA clean up protocol was followed, including 
the DNAse I digestion step.  The purified RNA solution was stored at -80°C. 
 
The RNA concentration was estimated by spectrophotometer.  MOPS 
denaturing agarose gel electrophoresis was also used to assess RNA quality 
for RT-PCR samples.  Bioanalyser (Agilent 2100) readings were also taken 
prior to use for RNA samples used to prepare microarray target, using RNA 
6000 NanoChips and reagents (Ambion), in order to assess the extent of 
degradation during RNA extraction, purification and storage. 
 
2.8.2 RNA Purification from frozen tissue samples 
A series of experiments were carried out in order to optimise RNA extraction 
from Laser capture microdissected fresh frozen tissue samples stored in liquid 
nitrogen.  8µm sections were cut in a cryotome and mounted on glass 
microscope slides.  Sections were fixed and stained and dissected as 
described in Methods 2.9.  The optimised protocol for RNA purification 
comprised: TRIZOL homogenisation and phase separation, Qiagen RNeasy 
column, on column DNAse I digest, vac-spin to 10µl.  The quality and quantity 
of RNA extracted was evaluated using the Agilent Bioanalyzer.  
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2.9  Laser capture microdissection (LCM) 
Nuclease free PALM membrane slides (1440-1600 PEN/NF) were prepared 
by UV irradiation at 254nm for 30 mins to sterilise them and improve sample 
adherence.  In a cryotome, at -20°C, 8µm sections were cut from tumour 
blocks and mounted onto slides.  Further 5µm sections were cut at the 
beginning and end of the block and every 10 sections throughout, these were 
mounted onto glass microscope slides.  All sections were stored in the 
cryotome until ready to fix and stain.    
 
Glassware and slide-racks were washed and oven baked for 4 hours at 180°C 
prior to use. Care was taken to work rapidly.  The 8µm sections were 
deparaffinised, air dried for 10 seconds, then hydrated with a 1 minute wash in 
95% ethanol at -20°C, then washed in 70% ethanol at -20°C for 1minute, 
rinsed in DEPC water, blotted followed by Mayer’s Haematoxylin for 20 
seconds, rinsed in DEPC water, washed in Scott’s water for 30 seconds, 
blotted then counterstained with Eosin Y for 10 seconds, rinsed in DEPC 
water briefly.  Sections were then dehydrated as follows: 75% ethanol wash 
for 30 seconds, 95% ethanol wash for 30 seconds, 100% ethanol wash for 30 
seconds.  Finally, slides were fixed by 2 xylene washes of 3 minutes each.  
Slides were air dried for 5 minutes prior to microdissection. 
 
The 5µm sections underwent an automated, standard H & E staining 
dehydration and fixing process, then these slides were covered with a glass 
coverslip, mounted using permafluor.  These slides were used as a guide to 
the morphology of adjacent sections of tissue to aid laser capture 
microdissection. 
 
An informal comparison was made between the PALM microlaser system and 
the Pixcell II Laser capture microscope.  The PALM system was preferred 
since it was possible to process slides faster.  The time taken to process a 
slide using the PALM system was ~30mins compared to ~40 mins on the 
Pixcell II LCM.  Also, the system of catapulting the microdissected cells was 
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more reliable using the PALM microscope.  LCM was carried out as 
recommended by the PALM microlaser systems protocol. Figure 4.4 shows 
typical microscope images from the LCM process. 
 
An optimisation experiment was undertaken to ascertain the extent of RNA 
degradation of the whole mounted frozen tissue at various temperatures 
(18°C, at 10°C and at 4°C).  Results are shown in Figure 4.3, following this 
experiment, the time taken to dissect an LCM slide was limited to 20 minutes.  
 
2.10  Northern blotting 
High quality RNA was extracted from cells and quantitated as described in 
section 2.8.1.  A formaldehyde gel was prepared by dissolving 1% agarose in 
200ml H2O.  The gel was equilibrated to 60°C before addition of 24ml 10X 
MOPS (20.6g MOPS, 3.28g NaOAc, 10ml 0.5M EDTA, pH 7.0 with NaOH, 
H2O up to 500ml) and 6.8ml of 37% Formaldehyde.  RNA was prepared by 
adding 4µl MOPS, 4µl Loading Dye (1mM EDTA, pH8, 50% Glycerol, 0.25% 
Bromophenol blue, 0.25% Xylene Cyanol, up to 20ml with sterile H2O), 7µl 
37% Formaldehyde, 20µl Formamide and sterile H2O plus RNA to a total 
volume of 45µl. Samples were mixed and heated at 55°C for 15 minutes 
before being resolved on the gel at 75V for 3 hours.  Following this, one 
control lane was cut off and stained with Ethidium Bromide to reveal the 18S 
and 28S RNA bands, used as molecular weight markers for the transfer. 
 
The gel was then immersed in 20X SSC for 45 minutes with gentle shaking 
before being set up as an overnight capillary blot with Hybond N+.  The 
following day the membrane was rinsed in 5X SSC, dried at 37°C, then the 
RNA was crosslinked to the membrane by UV.   
 
Hybridization: the membrane was pre-hybridised for three hours in 15ml of 
hybridisation solution (1% SDS, 5x SSC, 5x Denhardt’s solution, 0.1mg/ml 
sonicated salmon sperm DNA) at 65°C.  The probe was labelled with a 32P-
dATP (Amersham) using the random prime labelling kit (Roche). 
Unincorporated nucleotides were removed by passing the probe through a 
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G50 spun column (Pharmacia). The probe was denatured by boiling for 10 
minutes and added to the membrane in 15ml fresh hybridisation solution and 
incubated overnight at 65°C.  Membranes were washed in 2X SSC/ 0.1% 
SDS at RT for ten minutes, washed again in 2X SSC/ 0.1% SDS at an initial 
65°C for ten minutes and a final wash in 0.5X SSC/ 0.1% SDS at an initial 
65°C. After washing membranes were wrapped in Saran wrap and auto-
radiographed using Biomax MR (Kodak) film. 
 
In order to re-probe the membrane with a loading control (such as GAPDH), 
bound probe was stripped from the membrane with 1% SDS at 100°C for 10 
minutes. The membrane was then rinsed with 5X SSC before re-hybridisation. 
 
2.11           qRT-PCR 
2.11.1  Reverse Transcription reaction  
A microgram (µg) of total RNA was used to generate cDNA. Reverse 
transcription reactions were performed using sterile plasticware throughout 
and aerosol filter tips to minimise contamination.  All materials were supplied 
by Applied Biosystems.  The reactions were prepared on ice as follows, 1µg 
total RNA, 5.5mM MgCl2, 2.5mM dNTP mix, 2.5µM Random Hexamers, 
RNase Inhibitor (0.4U/µl), MultiScribe Reverse Transcriptase (1.25U/µl) and 
RNAse free water to make the reaction volume up to 50µl. Samples were then 
transferred to a thermocycler and incubated at 25°C for 10 minutes, 48°C for 
30 minutes followed by 95°C for 5 minutes to inactivate the enzyme.   
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2.11.2  Quantitative “Real Time” PCR reaction 
Pre-designed transcript specific primer-probe sets for “real time” PCR 
reactions were purchased from Applied Biosystems, their details are outlined 
in Table 2.4.  The probe binds the DNA between the two primers; the probe is 
dye-labelled at the 5’ end, a quencher at the 3’ end controls its fluorescence.  
As the PCR reaction proceeds, the dye is cleaved from the probe and 
released from the quencher.  Therefore the fluorescence from the dye 
increases, allowing quantitation of the target sequence as the reaction 
progresses.   
 
PCR reactions (25µl) were prepared in triplicate on a 96-well plate using 15ng 
cDNA per reaction. 2X Universal PCR master mix was combined with the 
primer-probe mix to minimise pipetting error between each well of the plate.  
In addition to the samples, a no template control was included to exclude DNA 
contamination and a no reverse transcriptase control was included to control 
for genomic DNA contamination in the RNA extraction, (this consisted of an 
equivalent amount of a reverse transcription reaction in which the reverse 
transcriptase was omitted).  To assess the efficiency of the PCR reaction and 
to allow relative quantification, a standard curve was run alongside the 
samples. The standard curve used four separate dilutions of cDNA per 
reaction and was prepared in triplicate; 25ng, 6.25ng, 1.5625ng and 0.39ng. 
The PCR reaction was carried out on the 7700 Sequence Detection System 
(Applied Biosystems) using the following program as standard: 50°C for 2 
minutes (AmpErase UNG step), 95°C for 10 minutes to activate the AmpliTaq 
Gold, then 40 cycles of 95°C for 15 seconds, 60°C for 1 minute.  
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2.11.3  qRT-PCR Results Analysis 
All PCR reactions were analysed by agarose gel electrophoresis to ensure the 
presence of a single product under standard PCR conditions, see Figure 2.2.  
 
 
 
 
 
 
 
 
 
 
 
100bp 
AP-2α AP-2γ ERBB2 + 
18S rRNA 
M M M 
Figure 2.2 qRT-PCR products run against 100bp DNA marker on  
a 2% Agarose gel to confirm the size of products and lack of primer 
dimer products.  
Table 2.4  Primer-probe sets used in qRT-PCR assays 
Reagents supplied by Applied Biosystems  
 
Transcript Assay ID Probe Dye Layer 
GAPDH 4310884E VIC 
18S rRNA 4319413E VIC 
TFAP2A Hs00231461_m1 FAM 
TFAP2C Hs00231476_m1 FAM 
ERBB2 Hs00170433_m1 FAM 
ERBB3 Hs00176538_m1 FAM 
NR4A2 Hs00428691_m1 FAM 
ATP1B1 Hs00426868_g1 FAM 
HRASL3 Hs00272992_m1 FAM 
CTSD Hs00157201_m1 FAM 
CAXII Hs00154221_m1 FAM 
SOCS2 Hs00374416_m1 FAM 
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Results were initially analysed using the Sequence Detection software version 
1.9.1 (Applied Biosystems). The amplification plots were observed in both 
linear and semi-log plots, with the background corrected and the threshold 
cycles determined. Following this, the standard curve was plotted: (threshold 
cycle, (Ct) versus starting quantity) showing the slope (PCR efficiency) and 
the correlation coefficient.  A slope of –3.3 indicates a 100% efficient PCR 
reaction with a ten-fold increase in PCR product every 3.3 cycles.  The PCR 
efficiency was considered satisfactory provided the slope measured 3.3 +/- 
0.3 and the correlation coefficient was >98% and if all the “unknown” samples 
fell within the points of the standard curve.   
 
Data was analysed according to the Standard Curve Method for relative 
quantification (http://www.appliedbiosystems.com/).  Standard curves were 
prepared for both the target (e.g. AP-2γ) and the endogenous reference (e.g. 
18s rRNA).  For each experimental sample, the relative quantity of target and 
endogenous reference levels was determined from the appropriate standard 
curve.  The target amount was then divided by the endogenous reference 
amount to obtain a normalised target value.  The transfection control sample 
was used as a calibrator and each of the normalised target values was divided 
by the calibrator normalised target value to generate the relative expression 
levels.  Triplicate samples were used to generate standard errors.   
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Microarray Analysis of Gene Expression 
2.12.1  HG-U133A GeneChip 
All experiments were performed using Affymetrix Human Genome U133A 
high-density oligonucleotide arrays (http://www.affymetrix.com).  The HG-
U133A array consists of >22,000 probe sets representing over 18,000 
transcripts from an estimated 14,500 well-characterised human genes (see 
Introduction 1.5.2). 
 
2.12.2  Target Preparation: 1-10 µg standard protocol  
High quality RNA from each sample was used to prepare biotinylated target 
cRNA, according to the manufacturer’s recommendations 
(http://www.affymetrix.com).  Total RNA was assayed using the Agilent 2000 
Bioanalyser to confirm the concentration and purity of the RNA.  An overview 
of the process is shown in Figure 2.3.  Briefly, the Affymetrix standard protocol 
used 1-10µg of initial total RNA and consisted of one cycle of amplification: 
total RNA was used to generate first-strand cDNA by using a T7-linked 
oligo(dT) primer.  After second-strand synthesis, in vitro transcription was 
performed with biotinylated UTP and CTP.  This labelled cRNA target was 
quantified and fragmented before preparation of the hybridisation cocktail.  
Fragmented, biotin-labeled cDNA was assayed for yield and size distribution 
by electrophoreisis on a denaturing agarose gel.   
 
2.12.3 Target Preparation: 100ng “small sample” protocol 
An outline of the two-cycle protocol is shown in Figure 2.4; it is designed to 
allow target preparation from smaller initial quantities of total RNA, (50-100ng) 
than the standard protocol.  The protocol involves two cycles of IVT, aiming to 
achieve greater linear amplification of the RNA.  Full details are available in 
the GeneChip Eukaryotic Small Sample Target Labeling Assay Version II 
Technical Note, (http://www.affymetrix.com).  Briefly, 100ng of high quality 
total RNA was used to synthesize first strand cDNA using a T7-linked 
oligo(dT) primer. After second-strand synthesis, the ds cDNA was ethanol 
precipitated.  Unlabelled, antisense cRNA was generated by IVT using the 
Ambion MEGAscript T7 Kit. The cRNA was cleaned and the yield determined.  
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For the second cycle of amplification and labeling, 400ng of cRNA was used 
as starting material.  First strand cDNA was reverse transcribed, using 
random hexamers as primers and the second strand was synthesized using a 
T7-linked oligo(dT) primer.  The ds cDNA was cleaned as previously by 
ethanol precipitation.  The second cycle of amplification and labelling by IVT 
was performed with biotinylated UTP and CTP, the resultant labeled cRNA 
was cleaned and yield estimated. Subsequent fragmentation, hybridization, 
washing, and staining steps are performed as described in 2.12.4 or “Section 
3: Eukaryotic Sample and Array Processing, GeneChip Expression Analysis 
Technical Manual” (http://www.affymetrix.com). 
 115
 
 
 
 
 
 
 
 
Figure 2.3  Affymetrix One Cycle Target Labelling 
A detailed description of this process can be found in Section 3: 
Eukaryotic Sample and Array Processing of the GeneChip 
Expression Analysis Technical Manual (http://www.affymetrix.com). 
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Figure 2.4  Affymetrix Two Cycle Target Labelling 
This outlines the 100ng protocol used.  Further details are available in 
the GeneChip Eukaryotic Small Sample Target Labelling Assay 
Version II Technical Note, (http://www.affymetrix.com). 
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2.12.4  Microarray Hybridisation, Staining and Scanning 
Spike-in controls were added to the fragmented cRNA, (15µg per HG-U133A 
array) before overnight hybridisation of the sample to an Affymetrix HG-
U133A human oligonucleotide array.  Arrays were then washed and stained 
with streptavidin-phycoerythrin, before being scanned on an Affymetrix 
GeneChip 3000 scanner.  Images of the arrays were examined by eye to 
confirm scanner alignment, to assess for significant lesions on the surface of 
the chip such as bubbles and scratches, or the presence of high background 
on the slide.  Tracy Chaplin at the Institute of Cancer, Charterhouse Square, 
performed the hybridisation, scanning and image analysis.  Experiments were 
performed in triplicate.   
 
2.12.5  Data Analysis  
Data analysis was performed by Phil East at the CRUK Bioinformatics and 
Biostatistics department, (BABS) using BioConductor155 and by myself, using 
Genespring, (Genespring GX 7.3, Agilent Technologies).  BioConductor is an 
open development software project, providing access to a wide range of 
statistical and graphical approaches for the analysis of genomic data. It works 
through the R open source programming language301.  Data was processed 
from the .cel file format, which contains information on background values and 
perfect match (PM) and mismatch (MM) intensities.  For Genespring, data 
was processed from the .txt files, containing data that has been pre-processed 
by the Affymetrix MAS 5.0 software (http://www.affymetrix.com).   
 
2.12.5.1  Quality Control 
In order to ensure arrays fulfilled the quality control metrics recommended by 
Affymetrix (described in the Data Analysis Fundamentals Manual, Affymetrix), 
and the Tumor Analysis Best Practices Working Group183, data from the .txt 
files were examined and compared with the recommended standards.   Brief 
descriptions of these criteria follow. 
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Initial total RNA: 
The quality and quantity of the source RNA was ascertained by 
spectrophotometry and Agilent biolanalyzer.  Only samples with a 260/280 
ratio of 1.8-2.1 and clear 18S and 28S ribosomal bands on the 
electrophoreisis gel were used for target preparation. 
 
Yield of biotinylated cRNA: 
The efficiency of the IVT reaction was assessed by an expected yield of 
biotinylated cRNA of 4-10 fold greater than the total RNA input.  The cRNA 
should be between 500-3000bp in size and after fragmentation the cRNA 
should be 50-200bp in size.  Only samples passing these criteria were 
hybridized to genechips.  
 
Average background: 
The average background is the level of signal detected by the scanner 
surrounding the signal from the specific features.  Affymetrix suggest average 
background values should be similar and typically in the range 20 to 100.   
 
Percentage Present: 
The percentage of present calls is used to assess the efficiency of chip 
hybridization, it gives ”a general index of chip background and noise” 183.  
“Present” calls are those for which the hybridization to the perfect match 
probes is significantly higher than the mismatch hybridization.  For the HU-
133A chip, it is expected that >25% of probes on the array will be called 
“present”.  
 
The MAS 5.0 software converts the fluorescence signals from the chips into a 
“signal” value and a “detection p value” which is used to assign a “Present”, 
“Marginal” or “Absent” call on each probe set. To generate the p-value, the 
fluorescence intensity of the 11 probe pairs in a probe set is compared and a 
“discrimination score” is calculated for each pair.  The discrimination score is 
the ratio of the target-specific intensity difference of each probe pair (PM - 
MM) to its overall hybridization intensity (PM + MM).  The discrimination score 
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is then compared to a pre-defined threshold and a statistical test, (the one 
sided Wilcoxon’s signed rank test) is used to generate the detection p value.  
The p value reflects the confidence of the detection call.   For example if the 
PM value is much larger than the MM, the discrimination score for that probe 
pair will be close to 1.  If the discrimination scores are close to 1 for the 
majority of pairs in a probe set the probe set will be assigned a “Present call”, 
the calculated detection p value will be low and one can be confident that the 
result is valid, ie the gene is expressed in that sample.  
 
Signal Value: 
The signal value represents the relative expression of a gene.  It is calculated 
using a one-step Tukey’s biweight estimate.  The value of the signal is 
estimated by taking the log value of the PM intensity after subtracting MM 
intensity. Each probe pair in a probe set can contribute to the mean value, 
though the contribution of probe pairs whose signal is closer to the median for 
the probe set is more heavily weighted.  The mean value across the probe set 
is then converted back to a linear scale and expressed as signal.  
 
Scale factor: 
Before data from different arrays are compared, a global normalisation 
method is conducted to minimise variation between arrays. Variation is 
caused by biological and experimental factors throughout the microarray 
protocol, starting from the sample preparation and ending with data 
acquisition.  The scaling or normalisation factors should be comparable 
between arrays.  A large discrepancy in scale factors (>3 fold) indicates 
significant inter-assay variability or sample degradation. 
 
3’ to 5’ ratios for β-actin and GAPDH:  
β-actin and GAPDH are used to assess RNA sample and assay quality.  The 
intensities of the 3’ probe sets for β-actin and GAPDH are compared to the 
intensities of the corresponding 5’ probe sets.  The ratio of the 3’ probe set to 
the 5’ probe set should be no more than 3 for target prepared using the one 
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cycle target labelling procedure.  A high 3΄ to 5΄ ratio indicates degraded RNA 
or inefficient transcription of cDNA or biotinylated cRNA. 
 
Pairwise Scatter Plot: 
These plots were produced in Bioconductor by Phil East, to enable pairwise 
comparison between chips involved in the experiments.  A scatter plot is 
produced by taking data from the chips in pairs; the signal intensities after log2 
transformation for each gene are plotted against each other.  This results in 
genes displaying a difference in signal intensity between the 2 chips being 
plotted off the diagonal while genes showing similar intensities are plotted 
close to the diagonal.  The majority of genes do not vary in intensity between 
chips, (see Figure 3.4). 
 
Comparing the degree of scatter between pairs of chips for all signals from all 
genes on the chips, allows visualisation of gross differences between the 
chips.  It is possible to see if there is any systematic bias between the chips 
plotted at varying levels of signal intensity, (for example, see Figure 3.4). 
 
MVA plot:  
MVA plots display the log intensity ratio, M = log2 (chip 1/chip 2) versus the 
mean log intensity A= log2 √(chip 1 x chip 2).  MVA plots are widely used to 
visualize microarray data; they enable the identification of intensity dependent 
bias in the data (i.e. curvature or 'banana shape').  The “ideal “ MVA plot is 
randomly scattered around the x-axis (M = 0), (for example, see Figure 3.4).  
 
2.12.5.2 Data Correction, Normalisation and Transformation 
The processes of background correction, normalization and summary are 
used to allow the comparison of expression levels between different arrays.  
These are designed to diminish variation in the signal intensities due to non-
biological variation resulting from differences in sample preparation, 
manufacture and the processing of the arrays (labeling, hybridization, and 
scanning).   Without such normalization procedures, the detection of spurious 
differences in gene expression is more likely. 
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Following evaluation and examination of the quality control metrics described 
above, the correction, normalisation and transformation of raw array data took 
place, following a four-step process of Background Correction, Normalisation, 
Perfect Match (PM) / Mismatch (MM) Correction and Summarisation.  A brief 
description of the techniques used in these processes follows.   As stated 
earlier, the analysis of the .cel files was performed by Phil East in the 
BioConductor package, whereas I used  .txt files in Genespring GX 7.3. 
 
Background correction 
Background correction is the process of correcting probe intensities on an 
array by subtracting the background level of signal detected by the scanner.  
The method used in BioConductor was robust multi-array average or RMA, a 
method developed by Irizarry et al.  This correction method uses a model that 
assumes the observed intensity is the sum of an exponential signal 
component and a linear noise component. PM probe intensities are corrected 
using a global model for the distribution of probe intensities302.   
 
Using .txt files in Genespring, background correction was carried out by 
Affymetrix MAS 5.0.  The chip is broken into subgrids, background is 
calculated for each region based on the lowest 2% of probe intensities.  For 
each region, a weighted average background value is calculated using the 
distances of the probe location and the areas surrounding the probes of the 
different regions. Individual probe intensity is then adjusted based upon the 
average background for each region.  
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Normalisation 
Normalisation is the process of removing non-biological variation between 
arrays. All global normalisation methods work on the assumption that there is 
no variability between different microarrays.  
 
In BioConductor, the chips were Quantile normalised.  Quantiles is a 
technique developed by Bolstad et al. and aims to give each chip the same 
empirical distribution.  The method assumes that there is an underlying 
common distribution of intensities across the different experimental samples.  
The principle of the quantiles algorithm is to sort the probe intensities into 
ranks of similar intensity across all the microarrays. A median intensity for 
each rank is then calculated and reattributed to the all the probe sets in the 
originating rank 303.  
 
Affymetrix MAS 5.0 uses a global scaling factor to normalise the data between 
each microarray.  A scaling factor is calculated based on the average of all the 
intensities, after removing the intensities in the lowest 2% and highest 2%. 
This factor is then used to correct the intensities across all the probe sets on 
all the arrays.   
 
The normalization processes used in Genespring GX 7.3 were as follows:  
Data Transformation: Signal Values below 0.01 were set to 0.01.   
Per Chip: Normalize to 50th percentile; each measurement was divided by the 
50th percentile of all measurements in that sample.  The percentile was 
calculated using all genes not marked absent. 
Per Gene: Normalize to median; each gene was divided by the median of its 
measurements in all samples. If the median of the raw values was below 10 
then each measurement for that gene was divided by 10 if the numerator was 
above 10, otherwise the measurement was discarded. 
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Perfect Match / Mismatch Correction 
PM correction is the process of adjusting PM intensities based on information 
from the MM intensity values.  For my data, in Bioconductor “pmonly” 
correction was used.  That is, no PM/MM correction was performed and only 
PM values were used for analysis. It is widely reported that MM probesets 
may be detecting signal as well as non-specific binding and therefore 
including the MM parameter will contribute to the overall noise in the data 
analysis 304.  
 
In MAS 5.0, an ideal MM value is subtracted from the PM intensity value, 
always leaving a positive value. An “artificial” mismatch value is computed 
when the MM intensity is greater than or equal to the PM and results in a PM-
MM that is close to zero.  
 
Summarisation Method  
In order to combine the normalised probe intensities together and to produce 
a single expression measure for each probe set on the array, a summarisation 
method is necessary.  Median polish was used in BioConductor, this uses a 
multi chip linear model fitted to the data from each probe set, the resultant 
value is in log2 scale 302.  MAS 5.0 uses a robust average using 1-step Tukey 
bi-weight on log2 scale. 
 
2.12.5.3 Differential Gene Expression 
Filtering 
Expression profiling experiments are interested in identifying genes that alter 
their expression between two conditions.  To achieve this, the normalised data 
is filtered to include only probe sets that change in expression.  A commonly 
used method is to filter genes based on the fold change between the test and 
reference groups, this is the technique I employed when using Genespring.  
However, when filtering on fold change there is a risk of ignoring genes that 
change significantly but are below the fold change threshold.  A more 
biologically sensitive method is to order genes from low to high standard 
deviation, in order to identify the most variable genes across the conditions 
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analysed.  The top 2500 probe sets with highest variance can then be used in 
clustering and statistical testing.  This was the technique used in 
BioConductor by Phil East. 
 
Hierarchical Clustering  
Hierarchical clustering analysis allows the monitoring of overall patterns of 
gene expression between the normalised arrays, and uses standard statistical 
algorithms to arrange the genes according to a similarity in gene expression 
patterns. The hierarchical clustering was performed using GeneSpring, based 
on the approach used by Eisen305.  This analysis aims to produce a map of 
results where probe sets were grouped together based on similarities in their 
patterns of normalised expression across all of the microarrays.  The similarity 
or dissimilarity between a pair of objects in the data set was found by 
evaluating a distance measure and assuming a normal distribution of gene 
expression values, the Pearson correlation coefficient is used to calculate the 
similarity measure.  The objects are then grouped into a dendrogram by 
linking newly formed clusters.  The same algorithms can then be applied to 
cluster the experimental samples for similarities in there overall patterns of 
gene expression. Hierarchical clustering analysis was performed on the 
normalised, filtered gene expression data. 
 
Statistical Analysis 
The data from the chips prepared from different protocols were normalised 
separately and supervised analysis was used to identify differentially 
expressed genes between the replicate groups (cell lines wildtype vs Late).  
Genes that were differentially expressed between the cells lines were 
identified using Welch’s t-test with a False Discovery Rate (FDR) cutoff of 
0.05, this represents a corrected p-value using Benjamini Hochberg multiple 
testing correction.   
 
Welch's t-test corrects for difference in variability, and does not detect it, 
therefore it is more suitable for microarray data and differential gene 
expression analysis.   
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Multiple testing corrections adjust p-values to correct for the occurrence of 
false positives.  False positives are genes that are identified as significantly 
changing following statistical tests, when their true state is unchanged.  A 
False Discovery Rate of 5% (p-value <0.05) on an array of 54,000 reporters 
would mean that on any size gene list, 2700 genes would be expect to be 
false leads.  The Benjamini and Hochberg FDR correction was applied across 
the significant genes.  This test reduces the number of false positives without 
enriching the number of false negatives, which can be the case for other types 
of correction306.  The p-values are ranked from the smallest to the largest.  
The largest p-value remains as standard, the second largest p-value is 
multiplied by the total number of genes in the gene list of differentially 
expressed genes divided by its rank.  The same approach is repeated with the 
second largest p-value and so on, until no gene is found to be significant.  The 
resulting FDR corrected values mean that a FDR of 5% (FDR corrected p-
value <0.05) on a gene list of 500 would expect 25 to be false positives, 
regardless of the number of reporters on the array. 
 
2.12.6  Gene Ontology  
2.12.6.1 Introduction to Gene Ontology  
Ontology attempts to form a “hierarchical structuring of knowledge about 
things by subcategorising them according to their essential qualities”.  Gene 
ontology, (GO) is used in the analysis of microarray data to try and structure a 
gene list and identify patterns of expression through the identification of 
functionally related genes. The gene ontology consortium 
(http://www.geneontology.org) provides a vocabulary for the consistent 
description of gene products across different databases.  In particular, each 
gene (e.g. TFAP2C) is assigned a term based on its Molecular Function (e.g. 
DNA Binding Transcription Factor), Biological Process (e.g. Regulation of 
Transcription from RNA polymerase II promoter), and Cellular Component 
(e.g. Nucleus).  The annotations are a mixture of those that are manually 
assigned, based on primary and review literature and some are automatically 
assigned based on predicted gene functions.  Each GO term is additionally 
 126
assigned a code based on the strength of the associated evidence and more 
than one term can be assigned to each gene.  The value of GO is limited by 
the quality of the associated research that is used to define each annotation.  
GO terms are organised into a hierarchical structure.  A GO path is where a 
GO term is connected to several other GO terms higher in the GO hierarchy.  
In addition, these paths may intersect or split and several paths may lead to 
an individual gene.   
 
In order to assess patterns in groups of genes within a differential gene 
expression dataset, data can be sorted into broad functional groups based on 
their assigned Biological Process GO terms.  This can be done by hand which 
offers the advantage of deciding the most appropriate terms for each gene 
where two or more differing terms are described.  Alternatively, the analysis 
can be automated.  
 
2.12.6.2 Gene Ontology in Genespring 
Using Genespring GX 7.3, the list of differentially expressed genes obtained 
from the cell line study was analysed so that all the genes were allocated and 
arranged according to their designated GO term.  The software allows one to 
compare the number, (or percentage) of genes on the list in each category 
with the number, (or percentage) of genes on the whole chip in each category.  
It is then possible to evaluate whether certain functions are over-represented 
by the gene list.  A p-value estimates the statistical significance of the overlap, 
i.e. the likelihood that it is a coincidence that the number of genes occurs both 
in the gene list and the category.  The list of differentially expressed genes 
was filtered for those categories with a p-value <0.05 ie only genes with 
statistically significantly over-represented categories remained in the list.   
 
This analysis may be biased towards genes with a clearly defined Affymetrix 
and GO annotation and is therefore less helpful when trying to identify novel 
gene associations. Since a gene may have multiple designated functions it 
remains important to interpret the role of a gene in a given context. 
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2.13 Riboprobe preparation 
Riboprobes for in situ hybridisation of cells and tissue were produced. (The 
protocol and reagents used were recommended by Roche, full details are 
available in: Chapter 4 RNA labelling by IVT of DNA by DIG; DIG Application 
Manual for Nonradioactive In Situ Hybridisation, from Roche).  IMAGE clones 
were obtained for the target genes and cloned into the pCDNA3.1 vector.  
200-300bp restriction enzyme (RE) fragments of the inserts were subcloned 
into a pBluescript II (+) vector.  The inserts were sequenced bi-directionally to 
check the sequences and their orientation in the vector. A BLASTn search 
was performed to check that the probe sequences obtained were unique.  IVT 
was performed to produce DIG-labelled 200-300bp RNA probes. Both sense 
and antisense probes were produced: antisense probes provide a control for 
estimation of background or non-specific hybridization, sense probes 
specifically hybridise with target mRNA. 
 
The size of the probes was checked by agarose gel electrophoresis and the 
extent of DIG incorporation was estimated by spotting serial dilutions of the 
probes onto a nitrocellulose membrane, probing with an HRP-linked anti-DIG 
antibody, then comparing the chemoluminescence to a control DIG-labelled 
RNA, shown in Figure 2.5. 
 
The staining protocol for the riboprobes was optimized using paraffin 
embedded cell line suspensions.  Hybridization was carried out by an 
automated system on the Ventana machine by Krishna Caulee in the Institute 
of Cancer Pathology department. 
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Figure 2. 5  Estimating the IVT yield for riboprobes 
A – 1% Agarose gel stained with ethidium bromide allows 
comparison of the size of the three pairs of riboprobes with an RNA 
ladder. 4µl of each probe was loaded and used to estimate the 
concentration of the labelled probes. 
B – Dot Blot to estimate DIG incorporation. Serial dilutions of the 
probes were made, spotted onto a nylon membrane, probed with 
anti-digoxygenin Fab fragments conjugated to Alkaline phosphatase.  
Chemoluminesccent detection allows the intensities of the new 
probes to be compared with control DIG labelled RNA of known 
concentration. 
B 
A 
 129
2.14  Kinetic Chromatin ImmunoPrecipitation Assay 
All ChIP assays were performed in collaboration with Karsten Friedrich.  We 
used techniques described by Metivier et al. to perform “kinetic” ChIP assays 
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.   ZR-75-1 cells were “synchronised” in G1 phase by 24 hours of serum 
starvation, then treatment with α-amanatin (to a final concentration of 2.5µM 
for 60 mins) was used to strip the chromatin of active transcriptional 
complexes.  The cells were then washed and treated with oestrogen (to 10-8M 
17β-oestradiol), allowing transcriptional release.  The cells were collected 
every 5 minutes for 60 minutes and ChIP assays were performed on samples 
from each time point to assess binding of protein components to the 
oestrogen repressible enhancer in the first intron of ERBB2.     
 
2.14.1  Preparation of soluble chromatin 
Cells were assayed at approximately 70-80% confluence on a 15cm plate.  
Chromatin was cross-linked by the addition of formaldehyde to a final 
concentration of 1% and incubated at 37°C for 10 minutes. Cross-linking was 
stopped by the addition of glycine to a concentration of 0.125M and incubated 
at RT for 5 minutes with gentle rocking. Cells were washed twice with ice cold 
PBS then scraped down in 5ml PBS + Complete Proteinase Inhibitors (Roche) 
and pelleted at 3,000g for 5 minutes at 4°C.  The supernatant was removed 
and the cell pellet was gently resuspended in 1ml per plate of cell lysis buffer 
(5mM PIPES pH 8.0, 85mM KCl, 0.5% NP40, and Complete Proteinase 
Inhibitors).  Cells were incubated on ice for 10 minutes to allow the hypotonic 
buffer to swell them.  They were lysed by centrifugation to pellet the nuclei 
fraction (5,000g for 5 minutes, 4°C).  The pellet was resuspended in 500µl per 
3x plates of nuclei lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 
8.1) and incubated for 10 minutes at 4 °C.  Chromatin was sheared to an 
average length of 500bp by sonication on ice, (10 second pulse followed by a 
10 second rest for a total of 24 cycles at 30% amplitude on the Sonics 
Vibracell VCX500 using a 0.3cm tip).  After sonication, debris was pelleted by 
centrifugation at 14,000g for 10 minutes at 10°C and the supernatant 
transferred to a clean tube. At this point chromatin could be snap frozen in 
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liquid nitrogen and stored at –80°C.  Typically, three 15cm plates yielded 
enough chromatin to perform 10 IP reactions. 
2.14.2   ImmunoPrecipitation 
Chromatin was diluted 2.5 fold in IP buffer (0.5 % Titron X100, 2 mM EDTA, 
20 mM Tris-HCl pH 8.1, 100 mM NaCl, plus protease inhibitors) before being 
pre-cleared using 50% (w/v) blocked Protein A Sepharose (PSA).  PSA beads 
were blocked as follows: two washes, followed by a 2 hour gentle rotation at 
4°C, in 2X volume of IP buffer with 0.1 mg/ml sonicated herring sperm DNA 
(Sigma B8894) and 0.2 mg/ml BSA (Invitrogen 15634-017), followed by a final 
wash in 1x IP buffer prior to use.  500µl of 50% (w/v) blocked PSA beads 
were added to the 1250µl of diluted chromatin (50µl of beads per IP reaction) 
and incubated by gentle rotation at 4°C for 1 hour.  The PSA beads were 
removed by centrifugation at 2,000g for 3 minutes and the supernatant 
transferred to a clean tube. 
 
Antibody Animal Origin 
Amount of 
Antibody Source (Cat#) 
AP-2γ (KF3) Rabbit 10µl Lab Reagent 
Acetylated-H4 Rabbit 1µl Upstate (06-866) 
 
Table 2.5  Antibodies used in ChIP assays  
Amount (µl) corresponds to the volume of antibody added to a tenth of the 
chromatin extracted from three 70-80% confluent 15cm plates of ZR-75-1 
cells (~5µg of antibody per 106 cells).  
 
Equivalent amounts of chromatin were aliquoted for each IP reaction; the 
reactions were incubated overnight at 4°C with gentle mixing. The antibodies 
used are shown in Table 2.5, amounts of each antibody were previously 
determined by Karsten Friedrich.   A no antibody control was included as a 
background comparator for IP experiments and a mock sample was set up 
containing no chromatin to give an indication of DNA contamination.   
 
The immune complexes were collected by adding 50 µl of blocked 50% (w/v) 
PSA to each sample and incubating on a rotating platform at 4°C for 1 hr.  
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The PSA beads were pelleted by centrifugation at 2,000g for 3 minutes at RT.  
The supernatant for the no antibody control was kept for use as the “total 
input” sample.  All other supernatants were discarded.  The PSA beads were 
washed for three minutes on a rotating platform using 1 ml of wash solution 
and then centrifuged for 3 minutes at 2,000g at RT using the following wash 
solutions: 
Wash One: 2mM EDTA, 20mM Tris-HCl [pH 8.0], 0.1% SDS, 1% Titron X100, 
150mM NaCl 
Wash Two: 2mM EDTA, 20mM Tris-HCl [pH 8.0], 0.1% SDS, 1% Titron X100, 
500mM NaCl  
Wash Three: 1mM EDTA, 10mM Tris-HCl [pH 8.0], 1% NP-40, 1% 
Deoxycholate, 0.25M LiCl 
TE wash: 1mM EDTA, 10mM Tris-HCl [pH 8.0], (repeated twice). 
 
After the centrifugation, the remaining TE was removed as far as possible 
without disrupting the PSA beads. The antibody/chromatin complexes were 
eluted from the PSA by adding 150µl elution buffer (1% SDS, 50mM NaHCO3) 
and shaking at 1000rpm for at least 30minutes at RT. Eluates were 
centrifuged at 14,000g for 1 minute to pellet PSA and supernatant was 
removed to a clean tube.  DNA was then isolated using Qiagen QiaQuick spin 
columns, following the Qiagen protocol.  50µl of purified DNA was eluted from 
a column and 5µl was used in a quantitative real time PCR reaction. 
2.14.3   Quantitative PCR for ChIP  
Quantitative “real time” PCR for ChIP was performed using specific primer 
pairs to the oestrogen repressible enhancer in the first intron of ERBB2 and 
measured using SYBR green as a detector.  SYBR green dye intercalates into 
dsDNA and produces a fluorescent signal. The intensity of the signal is 
proportional to the amount of dsDNA present in the reaction.  Therefore, as 
the PCR reaction progresses, the signal intensity increases.   
 
PCR reactions (25µl) were prepared in triplicate on a 96-well plate using 5µl of 
eluted DNA per reaction. 2X SYBR green master mix (Applied Biosystems) 
was combined with the primers EEF3 and EER3 to a final concentration of 
 132
0.5µM.  In addition to the samples, a no template control was included to 
assess DNA contamination of the samples, a standard curve was also run 
alongside the samples to assess the efficiency of the PCR reaction and to 
allow relative quantification. The standard curve used three dilutions of “total 
input” chromatin and was prepared in triplicate; 1/100, 1/500, 1/1000. The 
PCR reaction and initial data analysis were carried out as described in Section 
2.11.  The relative quantities of each PCR reaction were calculated from the 
standard curve of input chromatin.  The “no-antibody control” quantity was 
then subtracted from the specific antibody quantity and expressed relative to 
the 1/1000 dilution of the total input chromatin.  
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CHAPTER 3 – RESULTS 
 
Expression profiling of MCF7 derived 
breast cancer cell lines. 
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3 RESULTS: Expression profiling of MCF7 derived breast 
cancer cell lines. 
The Tenovus Centre for Cancer Research in Cardiff supplied the following 
breast cancer cell lines: MCF7 wildtype and two tamoxifen resistant MCF7 
sublines; tamoxifen-resistant MCF7 Early (P2) and tamoxifen-resistant MCF7 
Late (P28).  The tamoxifen resistant MCF7 sublines were derived by 
continuous culture of the cells in the presence of 10-7M 4-OH tamoxifen.  The 
development of these cells was designed to mimic as closely as possible the 
clinical emergence of tamoxifen resistance in breast cancer in vivo 260. 
 
I hoped firstly to confirm that the tamoxifen resistant MCF7 sublines showed a 
differential response to tamoxifen compared to their wildtype counterparts and 
to investigate their growth rates under varying oestrogenic conditions.  Initially, 
I plotted the growth of the cells under different hormone conditions to define 
their growth rate and performed MTT assays, growing the different lines under 
increasing concentrations of tamoxifen in order to define their sensitivity to the 
drug.   
 
Once the growth of the cell lines was characterised, a cDNA expression array 
study was proposed in order to identify genes associated with the 
development of tamoxifen resistance in breast cancer.   
 
A cell line study offers a number of advantages; there is unlimited source 
mRNA, so data can be replicated with relative ease.   The cell population is 
homogeneous and unlike clinical samples, uncontaminated by non-carcinoma 
cells, therefore minimising inter-replicate variability.  One would expect that 
the cell lines involved; tamoxifen sensitive MCF7 wildtype and tamoxifen 
resistant MCF7 Early and Late cells will be very closely related and therefore 
the number of genes identified with significant changes in expression should 
be minimised, thus making the data analysis and subsequent investigation of 
the genes identified more manageable, since a lot of background “noise” due 
to tumour heterogeneity should be reduced, (see Introduction 1.6).  
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The major disadvantage of using MCF7 cell lines for this investigation is the 
applicability of the data obtained.  We may find out key genes and pathways 
driving the emergence of tamoxifen resistance in these particular MCF7 cells 
but the extent to which a cell line model reflects changes found in vivo 
remains open to question and criticism307.  Obviously, subsequent validation 
of genes identified by this study using clinical specimens will be essential to 
ascertain the real value of our findings.     
 
The Affymetrix expression microarray platform was chosen for the study, 
using HG-U133A chips with labelled cDNA target prepared by the Affymetrix 
standard protocol.  Initially, we considered using two-colour Sanger spotted 
arrays for our study since they offer cost benefits, however the Affymetrix 
system offered the advantages of being a widely used and accepted platform, 
Affymetrix reagents, arrays and their annotation are of extremely high quality 
and reproducibility. The HG-U133A chips allowed expression profiling of a 
greater number of genes than the equivalent genome-wide Sanger array 
available at the time (22K vs 13K).  Since we planned to expand the project to 
use larger numbers of chips for clinical samples, the Affymetrix automated 
scanning system meant less time would be spent manually checking the spot 
quality.  The disadvantages of relying on the somewhat cryptic Affymetrix 
MAS 5.0 software for initial data interpretation could be circumvented at our 
institute with the help of our bioinformatics service and their expertise with 
Bioconductor, (see Introduction 1.5.2).  
 
I planned to hybridise triplicate chips for each of the three cell lines and to 
analyse the data myself using Genespring GX 7.3 software and with the help 
of the CRUK bioinformatics service, using Bioconductor (R), a free software 
environment for statistical computing (http://www.r-project.org/).   
 
I proposed to validate the mRNA abundance of selected genes identified as 
differentially expressed in the three cell lines using qRT-PCR and in situ 
hybridisation, (ISH) and at the protein level using western blotting and 
immunocytochemistry.  Following validation of these genes in the cell lines I 
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hoped to investigate their expression in selected tamoxifen resistant and 
tamoxifen sensitive tissue samples using ISH and immunohistochemistry 
(IHC).   
 
I also planned to investigate the selected genes in functional studies using the 
cell lines. By looking at the effects of over-expressing or silencing genes 
associated with tamoxifen resistance / sensitivity and ascertaining whether 
these manoeuvres had an effect on the cells response to tamoxifen or any 
other demonstrable phenotype. 
 
3.1 Comparing growth of MCF7 wildtype cells and tamoxifen 
resistant MCF7 sublines under different hormone conditions. 
3.1.1 Cell counts comparing growth of MCF7 wildtype cells and 
tamoxifen resistant sublines under different hormone conditions.   
On day zero 100,000 cells from each of the three different cell lines (MCF7 
wildtype, TAM R MCF7 Early and TAM R MCF7 Late) were seeded in 
triplicate onto 6 well plates, using their normal media. The tamoxifen resistant 
lines were grown in phenol red free media with charcoal stripped serum and 
tamoxifen, (see Methods, Table 2.1).  The following day, the cells were 
washed twice in PBS and their media was changed to either:  
A) Wildtype media (RPMI + 5% Fetal Calf Serum),  
B) Wildtype media with 17β-oestradiol added to 10-8 M,  
C) Phenol red free media with charcoal stripped serum and 4-OH 
tamoxifen added to 10-7M, (the usual media for the tamoxifen resistant 
MCF7 cells) 
D) Phenol red free media with charcoal stripped serum and fulvestrant (a 
pure anti-oestrogen) added to 10-7 M, (see Introduction 1.5.2)   
 
The cells were trypsinised and the numbers per ml were estimated using a 
coulter counter each day for the following 6 days in triplicate. Figure 3.1 
shows the results from this experiment, the mean value for each time point is 
plotted and error bars indicate the standard deviation for each point.  
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These graphs were used to estimate the growth rate of the cells under 
different conditions, by fitting an exponential curve and taking the growth 
constant from the equation for the curve. The doubling times of the cells can 
be derived from the growth rate, using the “rule of 70”, see below.  The values 
obtained are expressed in the table below. The growth rates of each of the 
cell lines are plotted in Figure 3.2.    
 
Equation of curve:  x(t)=x0ekt      
Where:  x = number of cells after time (t), in days 
x0 = initial number of cells 
k = growth rate 
e = base of a natural logarithm, ~2.718 
 
When the population has doubled, x = 2.x0  
2x0 = x0ekt 
ekt = 2 
kt = ln of 2 ≈ 0.70 
 
Doubling time (in days) =     70 
                      Daily % Growth rate 
 
Table 3.1: Growth rates and doubling times of MCF7 wildtype cells and 
tamoxifen resistant sublines (Tam R Early and Tam R late) under 
different hormone conditions.  
 
 
 
Daily % Growth Rate Doubling Time (in Days) 
 wildtype Tam R Early Tam R Late Wildtype Tam R Early Tam R Late 
Wildtype Media 49 37 42 1.4 1.9 1.7 
17ß-oestradiol 59 52 63 1.2 1.3 1.1 
Tamoxifen 37 51 58 1.9 1.4 1.2 
Fulvestrant 24 49 64 2.9 1.4 1.1 
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Looking at Figure 3.1A where the cells were grown in “wildtype media”, ie with 
no tamoxifen added, all three lines grow at comparable rates, the wildtype 
cells appear to have a slight advantage over the tamoxifen resistant sublines, 
this is confirmed in Figure 3.2.  When 17β-oestradiol is added shown in Figure 
3.1B, the growth rates of all three cell lines increases from ~45% daily growth 
rate to ~60% daily growth rate.  With the addition of tamoxifen, a differential 
response is seen in Figure 3.1C; the wildtype MCF7 growth rate subsides 
significantly while the tamoxifen resistant cell lines increase their growth 
above that in Figure 3.1A.  A similar pattern is seen in Figure 3.1D, indicating 
that there may be cross resistance in the tamoxifen resistant cell lines to the 
pure anti-oestrogen fulvestrant.  The growth of the wildtype cells appears to 
be more dramatically inhibited by fulvestrant than by tamoxifen.  
 
3.1.2: Comparing sensitivity to tamoxifen in MCF7 wildtype cells and 
tamoxifen resistant sublines (Tam R Early and Tam R late). 
Figure 3.2 shows the results from an MTS assay performed to compare the 
sensitivity to tamoxifen of MCF7 wildtype cells and the tamoxifen resistant 
sublines (Tam R Early and Tam R Late).  Equal numbers of cells from the 
different lines were seeded onto 96 well plates.  The following day, 4-OH 
tamoxifen was added to the media in 10 fold serial dilutions, the final 
concentrations of tamoxifen in the wells ranged from 10-4M to 10-10M.  The 
control cells were grown in media with no tamoxifen added.  The media alone 
wells contained no cells. 
 
After 48 hours, cell proliferation rates were assayed using an MTS assay kit, 
(see Methods 2.2).  Six wells were assayed for each data point and error bars 
show the standard deviation of the mean.  This experiment was repeated 
three times with similar results, representative data from a single assay are 
shown in Figure 3.2. 
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Figure 3.1: Cell counts comparing growth of MCF7 wildtype cells 
and tamoxifen resistant sublines (Tam R Early and Tam R late) 
under different hormone conditions.   
Equal numbers of cells were seeded on day zero onto 6 well plates.  On 
day 1 the media was changed as follows: 
A - Wildtype media (RPMI + 5% Fetal Calf Serum) 
 B - media with 17β-oestradiol added to 10-8 M  
 C - media with tamoxifen added to 10-7 M   
 D - media with Fulvestrant added to 10-7 M   
Media was changed every 48 hours as above.  Cells were harvested 
and counted each day for the following 6 days.  Three wells were used 
for each time point, the mean is shown and error bars indicate the 
standard deviation for each point. 
+ 17β-oestradiol B 
0
500000
1000000
1500000
2000000
2500000
3000000
3500000
4000000
1 2 3 4 5 6
Days
C
e
ll
 
c
o
u
n
t
D 
+ Fulvestrant 
0
500000
1000000
1500000
2000000
2500000
3000000
3500000
4000000
1 2 3 4 5 6
Day
C
e
ll
 
c
o
u
n
t
 140
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As expected, the tamoxifen resistant cell lines showed increased proliferation 
in tamoxifen-containing media when compared with the wildtype MCF7 cells.  
For all three lines, growth was completely inhibited by tamoxifen at a 
concentration of 10-4M.  However at 10-5M 4-OH-tamoxifen, the resistant cell 
lines (Tam R Early and Tam R Late) proliferated at a high, near normal rate, 
while proliferation of the wildtype cells remained severely inhibited. The MCF7 
wildtype cells only regained their normal proliferation at a tamoxifen 
concentration of  ~10-9M.  This assay also shows that the proliferation of the 
resistant cell lines increased in the presence of tamoxifen (at concentrations 
10-6M to 10-9M), when compared with “control” media, with no tamoxifen 
added.  This is consistent with the data in Table 3.1. 
Figure 3.2: Comparing growth of MCF7 wildtype cells and tamoxifen 
resistant sublines (Tam R Early and Tam R late) under different 
hormone conditions.   
MTS Assay reflecting proliferation rates of Wildtype MCF7 and tamoxifen 
resistant sublines treated with 4-OH tamoxifen from 10-4M to 10-10M 
concentrations.  Control indicates cell grown in media with no tamoxifen 
added.  Mean values from 6 wells were used for each data point.  Error 
bars indicate standard deviation of the mean.   
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3.2 Expression profiling of MCF7 derived breast cancer cell 
lines. 
3.2.1 Expression profiling of MCF7 wildtype and tamoxifen resistant 
MCF7 early and late breast cancer cell lines. 
Cells were grown in the appropriate media described in Table 2.1, (Methods) 
prior to RNA harvesting.  Total RNA was extracted from the three different cell 
lines and treated with DNase to remove any genomic DNA contamination (see 
Methods 2.8.1). The total RNA was assayed using the Agilent 2000 
Bioanalyser to confirm the concentration and purity of the RNA.  A 
hybridisation cocktail was prepared for each experimental sample using the 
Affymetrix standard protocol using one cycle of amplification from either 5µg 
or 10µg of total RNA (see Methods, Figure 2.3).  Fragmented, biotin-labeled 
cDNA was assayed for yield and size distribution by electrophoreisis in a 
denaturing agarose gel, (see Methods, 2.12.2). The hybridization cocktail was 
hybridised to an Affymetrix human oligonucleotide array, HG-U133A, (see 
Introduction 1.5.2, Fugure 1.8 and Methods 2.12.1).  The chips were scanned 
using the GeneArray Scanner 3000, and raw data analysed using the 
Affymetrix Microarray suite software (MAS version 5.0). Tracy Chaplin 
performed the hybridization, scanning and image analysis of the microarray 
chips, at our Institute (see Methods 2.12). The experiment was performed in 
triplicate, using separate RNA preparations.  The data analysis was performed 
using Genespring GX 7.3 software, by myself and in BioConductor by Phil 
East (CRUK BABS).  The goal of these analyses was to identify genes that 
were differentially expressed between the three cell lines (wildtype, Early and 
Late). Data analysis included transformation and normalization of gene 
expression to reduce non-biological variation in the data, (see Methods 
2.12.5).  
 
3.2.2 Quality control of samples  
The Tumor Analysis Best Practices Working Group 183 has suggested a 
number of quality control metrics as “best practice” in assessing the quality of 
Affymetrix expression data.  These criteria and the values obtained for each of 
the expression arrays hybridized in this experiment are listed in Table 3.2 
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below, together with the identifiers for each of the chips and the quantities of 
initial tRNA used for target preparation. 
 
The quality and quantity of the source RNA should be ascertained either by 
spectrophotometry, (where the 260/280 ratio should be >1.8), agarose gel 
electrophoresis or an Agilent biolanalyzer, to obtain clear 18S and 28S 
ribosomal bands.  The results of these analyses are shown in column 4, Table 
3.2.   
 
The extent of degradation of the source RNA can also assessed by analysis 
of data from internal controls on the microarray chip.  Affymetrix chips include 
control probe sets for 5 housekeeping genes, (eg GAPDH). Three separate 
probe sets for each of these genes are present on the array, these are 
complementary to sequences at each end of the mRNA and the middle, they 
are called respectively the 3’, 5’ and M probe sets.  Since mRNA degradation 
proceeds from the 5’ end, increased signal intensities from the 3’ probes 
compared to the 5’ signal for the same gene indicate RNA degradation.  The 
larger the gene, the larger the acceptable ratio; a 3’ to 5’ ratio of <3 for 
GAPDH is recommended, (see column 7, Table 3.2). 
 
The efficiency of the IVT reaction in target preparation is assessed with an 
expected yield of biotinylated cRNA of 4-10 fold greater than the total RNA 
input, (column 5, Table 3.2).  The cRNA should be between 500-3000bp in 
size and after fragmentation the cRNA should be 50-200bp in size.    
 
The efficiency of the chip hybridization is assessed by the percentage of 
present calls, as described in Methods 2.12.5.  Labelled “%P” on Table 3.2, 
column 6  “Present” calls are those for which the hybridization to the perfect 
match probes is significantly higher than the mismatch hybridisation.  The 
recommendation is that for the HU-133A chip over 25% of probes on the array 
are called “present” 183.  
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Table 3.2 Quality control (QC) metrics for HG-U133A chips, using the 
standard Affymetrix protocol.  
 
 
The Tumor Analysis Best Practices Working Group recommend that samples 
that do not meet the recommended values for these criteria should be 
discarded 183.  From Table 3.2 it is apparent that all the samples used in this 
study, using the standard Affymetrix protocol and 5 or 10µg tRNA starting 
material pass the recommended criteria, and that there are no wide variations 
in the QC metrics for the samples and the chips used.  
 
3.2.3  Data Analysis  - Normalisation and scaling 
Data analysis using Bioconductor was carried out by Phil East in the CRUK 
Bioinformatics and Biostatistics department. Using Bioconductor, the 
Affymetrix .cel files were quantified and quantile normalized using RMA, 
(robust multi-array average) see Methods 2.12.5 302. 
  
The Genespring GX 7.3 normalization processes used are described in 
Methods 2.12.5).  
 
 Target preparation Chip hybridisation  
Cell line + 
replicate 
number: 
Chip file name 
initial 
RNA 
µg 
260:280  
 total RNA 
cDNA 
amplification 
%P 
GAPDH 
3':5' ratio 
Recommended values - 1.8-2.1 > 4 fold >25% <3 
Wildtype 1 MCF7_wt_A.txt 10 2.1 6.2 51 1.06 
Wildtype 2 MCF7np_wt2.txt 5 2 9 47.7 1 
Wildtype 3 MCF7np_wt3_A.txt 5 1.8 9.4 48.8 0.97 
Early 1 MCF7_E_A.TXT 10 2.1 6.4 51.8 0.99 
Early 2 MCF7np_E_A.txt 5 2 10 50.2 0.82 
Early 3 MCF7np_E3_A.txt 5 1.9 6 51.1 0.9 
Late 1 MCF7_L_A.TXT 10 2.1 5.9 45.2 1.04 
Late 2 MCF7np_L2.txt 5 2.1 9.4 46.9 0.92 
Late 3 MCF7np_L3_A.txt 5 1.8 8.6 49.4 0.9 
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3.2.4 Data analysis – Unsupervised hierarchical clustering of samples 
The normalized data from the chips was then used for unsupervised 
hierarchical clustering per chip.  The chips were clustered according to the 
signal from every gene on the array using a hierarchical clustering method 
with a Pearson correlation similarity measure (see Methods 2.12.5.5).  The 
resulting dendrogram and heat map are shown in Figure 3.3.  The colour bar 
represents the different cell lines with blue representing wildtype MCF7 cells, 
red Early and green Late.  This figure shows that three of the chips 
(Wildtype1, Early 1, Late1) cluster together, away from their replicate groups 
indicating that they are more similar to each other that to the rest of the chips 
in the experiment.   The rest of the chips cluster according to their cell line 
rather than according to their replicate group.   
 
It may be that the three samples (Wildtype1, Early 1, Late1) show greater 
apparent similarity in their expression data due to a change in the target 
preparation protocol used.  In the time between the preparation of the different 
series of replicates, an alteration in the Affymetrix protocol was made.  
Because this cell line study was proposed as a pilot study for two larger 
studies, I felt that it was reasonable to update the protocol so that most of the 
chips in this study would be comparable to the chips used subsequently.  
Thus, a higher amount of source RNA was used in the preparation of the 
target mixes (Wildtype1, Early 1, Late1) than in subsequent hybridization 
cocktails.  A different IVT kit was also used which, although it contained the 
same primer, had a T7 polymerase from a different manufacturer and used 
slightly different incubation times and buffers. Despite the differences that the 
unsupervised hierarchical clustering revealed, the chips were thought to be 
similar enough to allow subsequent analysis of the data all together.  Looking 
at the dendrogram it can also be seen that the “Early” and “Late” chip 
replicates cluster closely together, away from their parent line and are thus 
more similar to each other than to the wildtype chips.  
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Another method of comparing data between the chips is by pairwise scatter 
and MVA plots, (see Methods 2.12.5.1).  These are shown in Figures 3.4 and 
3.5. 
 
Comparing the degree of scatter between pairs of chips for all signals from all 
genes on the chips, allows visualisation of the differences between the chips.  
This reinforces the findings of the unsupervised hierarchical clustering, since 
replicates 2 and 3 from each line demonstrate tighter plots.  All chips show 
linear scatter of signal across a wide dynamic range. 
 
The MVA plots using the data from my experiments demonstrate that there is 
a linear scatter of signal across a wide dynamic range.  These plots indicate 
that taken as a whole, the chips in the experiment do not show any severe 
systematic bias and are largely comparable.  Therefore all these chips went 
forward for further data analysis. 
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Figure 3.3 Heat map and Dendrogram resulting form 
unsupervised hierarchical clustering per chip.  
Chips were clustered according to the signal from every gene on the 
array using hierarchical clustering with a Pearson correlation 
similarity measure.  The colour bar represents the different cell lines 
with blue representing wildtype MCF7 cells, red Early and green 
Late.  Three of the chips (Wildtype1, Early 1, Late1) cluster together, 
away from their replicate groups.  The rest of the chips cluster 
according to their cell line rather than according to their replicate 
group.   
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Figure 3.4 Pairwise scatter and MVA plots for wildtype and Early 
chips.  
Plots comparing gene expression data from all the possible pairs of 
hybridised chips are shown in a matrix.  The scatter plots show the 
signal intensities after log2 transformation for each gene on the 
microarray chip plotted against each other.  MVA plots display the 
log intensity ratio M = log2 (chip 1 / chip 2) versus the mean log 
intensity A= log2 √ (chip 1 x chip 2).  Note that for the MVA plots, a 
varying y-axis is used.   
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Wildtype 1 
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Figure 3.5  Pairwise scatter and MVA plots for wildtype and 
Late chips.   
Plots comparing gene expression data from all the possible pairs of 
hybridised chips are shown in a matrix.  The scatter plots show the 
signal intensities after log2 transformation for each gene on the 
microarray chip plotted against each other.  MVA plots display the 
log intensity ratio M = log2 (chip 1 / chip 2) versus the mean log 
intensity A= log2 √ (chip 1 x chip 2).  Note that for the MVA plots, a 
varying y-axis is used.   
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Figure 3.6 shows scatter and MVA plots for the replicate group mean values, 
ie for each cell line.  These plots give an idea of the degree of differential 
expression between the three different cell lines.  The scatter plots, (A-C) 
show the presence of a greater degree of scatter between the wildtype 
comparisons (wildtype vs Late (C) and wildtype vs Early (B)) compared with 
the plot of Early vs Late (A), indicating some differential expression between 
the wildtype and tamoxifen resistant cell lines.   
Looking at the scale used on the y axis of the MVA plot Early vs Late (D) it is 
again possible to see that their gene expression profiles are more closely 
matched than in the wildtype comparisons, (E and F). 
3.2.5  Identification of differentially expressed genes 
Differential genes were identified between the groups using a t-test with a 
False Discovery Rate (FDR) cutoff of 0.05. This represents a corrected p-
value using Benjamini Hochberg multiple testing correction 306, (see Methods 
2.12.5.3).  Figure 3.7 shows a line graph of the expression profiles for all the 
genes on the chip with the statistically significant differentially expressed 
genes coloured in black. 
 
A total of 155 differentially expressed probe sets were identified, representing 
140 different genes; 70 of which were identified as significantly over-
expressed and 70 were identified as under-expressed in the tamoxifen 
resistant MCF7 derived sublines.  These genes are listed in two separate 
tables, 3.3 and 3.4.  The genes are shown with their description, probe id and 
gene symbol, the log mean intensities for each line is shown, following this is 
the fold change measured from Early to wildtype and the Late to wildtype 
lines.  The genes are listed in order according to their level of fold change.  
Where fold change is >2 for the over-expressed genes or <0.5 for the under-
expressed genes it is highlighted in bold in these columns.  Where more than 
one probe set appears in the list representing the same gene, they are listed 
together at the level of the highest fold change.  An indication of where in the 
cell   line series a statistically significant change was found is also given.  If a 
statistically significant change was found between Early and wildtype, “1” is 
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placed in the “E vs wt” column, if comparison of the wildtype and Late 
expression levels did not achieve significance, “0” is placed in the “L vs wt” 
column. 
 
Looking down the list of differentially expressed genes identified one can pick 
out a number of features.  Among the genes up-regulated in tamoxifen 
resistant cells 4 out of 70 appear more than once (AKRICI, UGT1A6, ATP1B1, 
SORL1), of the down-regulated genes, 6/70 appear more than once, (CA12, 
FERL1, SULF1, PPP3CA, DEGS2, VIL2).  It seems reassuring that these 
genes have been identified by independent probe sets.  However, according 
to the Affymetrix HG-U133A data sheet, the chip comprises 18,400 transcripts 
representing 14,500 genes, assuming that the “doubling up” of probe sets 
representing the same gene occurs randomly through the genome, one would 
expect ~20% of genes (3,900/18,400) to be represented by more than one 
probe set rather than the 8.5% (13/153) identified by our experiment.  This 
disparity may have occurred because the redundancy in the probe sets does 
not occur randomly, ie some genes may be over-represented on the chip 
because their original probe sets do not hybridise efficiently with their target, 
or well-characterised genes of particular interest may have been selected to 
be over-represented.  The data supplied by Affymetrix does not divulge 
whether such selection took place during the development of the chip.   
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Wildtype 
Late 
Early 
Figure 3.6: Scatter and MVA plots for the replicate group (cell line) 
mean values.   
These plots give an idea of the degree of differential expression 
between the three different cell lines; MCF7 wildtype, Early and Late.  
The scatter plots, (A-C) show the presence of a greater degree of 
scatter between the wildtype comparisons (wildtype vs Late (C) and 
wildtype vs Early (B)) compared with the plot of Early vs Late (A), 
indicating some differential expression between the wildtype and 
tamoxifen resistant cell lines.   
Looking at the scale used on the MVA plot Early vs Late, (D) it is again 
possible to see that their gene expression profiles are more closely 
matched that in the wildtype comparisons, (E and F). 
A B 
C D 
E F 
Pairwise scatter plots 
MVA plots 
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Figure 3.7 Line graph showing differential gene expression 
between replicate groups (cell lines). 
The expression profiles for all of the genes on the chips are shown 
with genes over expressed compared to wildtype plotted in red and 
under expressed genes compared to wildtype shown in green.  Fold 
change with respect to wildtype is shown on the y-axis.  The 
statistically significant genes (140) are plotted in black.  These genes 
are listed in Tables 3.3 and 3.4.  Significantly differentially expressed 
genes were identified comparing expression levels between the cell 
lines, using a t-test with a False Discovery Rate (FDR) cut-off of 
0.05.  
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Table 3.3: Genes identified as significantly upregulated in Tamoxifen 
resistant MCF7 derived cell lines:  
Log mean signal 
intensity  Fold Change Significant change  
Description Symbol wt E L  E vs wt L vs wt E vs wt L vs wt probe id 
AKR1C1 6.34 10.33 10.29 15.92 15.44 1 1 211653_x_at 
AKR1C1 7.62 10.57 10.48 7.69 7.23 1 1 216594_x_at aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1 20-
alpha (3-alpha)-hydroxysteroid dehydrogenase) AKR1C1 7.67 10.52 10.46 7.20 6.93 1 1 204151_x_at 
aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2 bile 
acid binding protein 3-alpha hydroxysteroid dehydrogenase, type III) AKR1C2 7.08 10.49 10.49 10.60 10.63 1 1 209699_x_at 
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II) AKR1C3 4.05 7.04 6.15 7.96 4.30 1 1 209160_at 
UDP glycosyltransferase 1 family, polypeptide A6 UGT1A6 5.65 8.41 9.56 6.81 15.10 0 1 215125_s_at 
UDP glycosyltransferase 1 family, polypeptide A3 UGT1A3 6.83 9.43 10.64 6.08 14.09 0 1 208596_s_at 
UDP glycosyltransferase 1 family, polypeptide A9 UGT1A9 7.12 9.68 10.63 5.90 11.43 1 1 204532_x_at 
UDP glycosyltransferase 1 family, polypeptide A1 UGT1A1 7.15 9.67 10.69 5.75 11.69 1 1 207126_x_at 
neutrophil cytosolic factor 2 (65kDa, chronic granulomatous disease, autosomal 
2) NCF2 5.11 8.13 6.39 8.12 2.44 1 0 209949_at 
ATPase, Na+/K+ transporting, beta 1 polypeptide ATP1B1 7.55 9.92 10.54 5.19 7.93 1 1 201242_s_at 
ATPase, Na+/K+ transporting, beta 1 polypeptide ATP1B1 8.34 10.31 10.82 3.90 5.56 1 1 201243_s_at 
G protein-coupled receptor 37 (endothelin receptor type B-like) GPR37 4.54 6.87 5.88 5.04 2.54 1 0 209631_s_at 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 12 (GalNAc-T12) GALNT12 7.22 9.55 9.59 5.02 5.18 1 1 218885_s_at 
suppressor of cytokine signaling 2 SOCS2 5.96 8.27 8.17 4.97 4.63 1 1 203372_s_at 
distal-less homeo box 2 DLX2 5.02 7.29 7.61 4.81 6.01 1 1 207147_at 
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UDP glycosyltransferase 1 family, polypeptide A6 UGT1A6 7.18 9.33 10.16 4.41 7.87 0 1 206094_x_at 
chondroitin beta1,4 N-acetylgalactosaminyltransferase ChGn 5.44 7.37 6.91 3.82 2.77 1 0 219049_at 
glutathione peroxidase 2 (gastrointestinal) GPX2 6.81 8.65 8.80 3.59 3.97 1 1 202831_at 
opsin 3 (encephalopsin, panopsin) OPN3 7.22 9.03 8.10 3.50 1.85 1 0 219032_x_at 
myristoylated alanine-rich protein kinase C substrate MARCKS 7.99 9.62 9.66 3.08 3.16 1 1 201670_s_at 
coxsackie virus and adenovirus receptor CXADR 5.85 7.40 7.46 2.94 3.07 1 1 203917_at 
sortilin-related receptor, L(DLR class) A repeats-containing SORL1 5.67 7.07 7.25 2.66 3.00 0 1 212560_at 
sortilin-related receptor, L(DLR class) A repeats-containing SORL1 7.29 8.11 8.38 1.76 2.13 1 1 203509_at 
bone morphogenetic protein 7 (osteogenic protein 1) BMP7 8.44 9.84 9.99 2.63 2.92 1 1 209590_at 
spermidine/spermine N1-acetyltransferase SAT 7.12 8.50 8.80 2.60 3.21 1 1 210592_s_at 
KIAA0657 protein KIAA0657 7.49 8.84 8.65 2.55 2.23 1 1 212775_at 
ATP-binding cassette, sub-family G (WHITE), member 2 ABCG2 7.20 8.51 8.69 2.49 2.81 1 1 209735_at 
acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A 
thiolase) ACAA2 9.40 10.64 10.75 2.36 2.55 0 1 202003_s_at 
calcium/calmodulin-dependent protein kinase II CaMKIINalpha 7.39 8.53 8.41 2.21 2.03 1 1 218309_at 
tetraspanin 3 TSPAN3 7.73 8.86 9.21 2.18 2.77 1 1 200973_s_at 
early growth response 1 EGR1 6.93 8.03 8.48 2.15 2.95 0 1 201694_s_at 
lamin B receptor LBR 7.86 8.96 8.46 2.14 1.52 1 0 201795_at 
interferon-stimulated transcription factor 3, gamma 48kDa ISGF3G 7.30 8.37 7.92 2.10 1.53 1 0 203882_at 
adhesion molecule with Ig-like domain 2 AMIGO2 6.18 7.23 7.73 2.07 2.94 0 1 222108_at 
aldo-keto reductase family 1, member B10 (aldose reductase) AKR1B10 5.30 6.35 6.28 2.07 1.97 1 1 206561_s_at 
basic leucine zipper transcription factor, ATF-like BATF 8.04 9.09 8.24 2.07 1.15 1 0 205965_at 
FN5 protein FN5 6.32 7.36 7.10 2.07 1.72 1 0 219806_s_at 
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squamous cell carcinoma antigen recognized by T cells 2 SART2 6.44 7.46 7.50 2.02 2.08 1 1 218854_at 
FLJ20160 protein FLJ20160 4.01 4.99 4.97 1.97 1.95 1 1 219858_s_at 
pleckstrin homology-like domain, family A, member 1 PHLDA1 5.60 6.57 6.19 1.96 1.50 1 0 218000_s_at 
receptor-interacting serine-threonine kinase 4 RIPK4 7.49 8.44 8.40 1.94 1.88 1 1 221215_s_at 
NAD(P)H dehydrogenase, quinone 1 NQO1 9.99 10.91 10.78 1.89 1.73 1 0 201468_s_at 
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 ABCC3 7.98 8.89 9.52 1.88 2.93 0 1 208161_s_at 
DNA polymerase-transactivated protein 6 DNAPTP6 8.74 9.64 8.85 1.86 1.08 1 0 222154_s_at 
small fragment nuclease DKFZP566E144 8.23 9.12 8.63 1.85 1.31 1 0 218194_at 
transcription factor 7-like 1 (T-cell specific, HMG-box) TCF7L1 6.16 7.02 7.44 1.82 2.43 1 1 221016_s_at 
sorcin SRI 8.81 9.67 9.80 1.81 1.99 1 1 208921_s_at 
guanylate cyclase 1, soluble, beta 3 GUCY1B3 5.06 5.87 5.70 1.76 1.56 1 0 203817_at 
glutaminyl-peptide cyclotransferase (glutaminyl cyclase) QPCT 4.97 5.76 6.05 1.74 2.12 1 1 205174_s_at 
lysyl oxidase LOX 3.60 4.37 4.08 1.71 1.39 1 0 215446_s_at 
neuroblastoma, suppression of tumorigenicity 1 NBL1 7.80 8.54 7.97 1.67 1.13 1 0 37005_at 
hypothetical protein DKFZp762E1312  8.55 9.29 8.95 1.67 1.32 1 0 218726_at 
RNA binding motif, single stranded interacting protein 1 RBMS1 8.23 8.97 8.97 1.67 1.67 1 1 209868_s_at 
natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide 
receptor C) NPR3 5.61 6.35 6.71 1.67 2.14 0 1 219789_at 
forkhead box D1 FOXD1 7.00 7.72 7.80 1.65 1.74 1 1 206307_s_at 
NAD(P)H dehydrogenase, quinone 1 NQO1 11.17 11.85 11.90 1.61 1.66 1 1 210519_s_at 
chromosome 10 open reading frame 38 C10orf38 6.18 6.86 7.04 1.60 1.81 0 1 212771_at 
aldehyde dehydrogenase 3 family, member A2 ALDH3A2 9.67 10.34 10.20 1.59 1.44 1 0 202053_s_at 
G protein-coupled receptor 143 GPR143 6.00 6.65 7.07 1.57 2.10 0 1 206696_at 
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nuclear receptor subfamily 4, group A, member 2 NR4A2 4.68 5.33 5.86 1.57 2.27 0 1 204621_s_at 
neural precursor cell expressed, developmentally down-regulated 5 NEDD5 9.63 10.28 10.22 1.57 1.50 1 1 200778_s_at 
dual specificity phosphatase 10 DUSP10 5.62 6.26 6.28 1.55 1.58 0 1 221563_at 
hypothetical protein FLJ20618 TI-227H 8.92 9.53 9.57 1.52 1.56 0 1 212337_at 
ARP1 actin-related protein 1 homolog B, centractin beta (yeast) ACTR1B 8.30 8.90 8.71 1.52 1.33 1 0 202135_s_at 
hypothetical protein FLJ10901 FLJ10901 7.68 8.28 7.70 1.51 1.01 1 0 219010_at 
hypothetical protein FLJ20605 FLJ20605 5.63 6.19 6.27 1.47 1.55 0 1 219527_at 
high density lipoprotein binding protein (vigilin) HDLBP 8.10 8.64 8.82 1.46 1.65 0 1 221767_x_at 
deltex 4 homolog (Drosophila) DTX4 6.93 7.46 7.70 1.44 1.71 0 1 212611_at 
phosphatidylinositol 4-kinase, catalytic, alpha polypeptide PIK4CA 7.07 7.58 7.62 1.43 1.47 0 1 207081_s_at 
NCK adaptor protein 2 NCK2 8.14 8.62 8.67 1.40 1.44 0 1 203315_at 
integral membrane protein 2C ITM2C 7.40 7.88 8.20 1.40 1.73 0 1 221004_s_at 
hypermethylated in cancer 2 HIC2 6.27 6.72 6.82 1.36 1.47 0 1 212964_at 
vinculin VCL 8.61 8.96 9.40 1.27 1.73 0 1 200931_s_at 
kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) KMO 4.83 5.04 5.40 1.16 1.49 0 1 211138_s_at 
 
 
 157
 
Table 3.4: Genes identified as significantly downregulated in Tamoxifen resistant 
MCF7 derived cell lines: Log mean signal intensity  Fold Change Significant change  
 Description symbol wt E L E vs wt L vs wt E vs wt  L vs wt  probe id 
PDZ domain containing 1 PDZK1 7.30 4.62 4.21 0.16 0.12 1 1 205380_at 
carbonic anhydrase XII CA12 10.03 7.73 7.04 0.20 0.13 1 1 203963_at 
carbonic anhydrase XII CA12 9.52 7.70 7.03 0.28 0.18 1 1 210735_s_at 
carbonic anhydrase XII CA12 8.32 6.29 5.93 0.24 0.19 1 1 204508_s_at 
carbonic anhydrase XII CA12 10.13 8.29 7.75 0.28 0.19 1 1 214164_x_at 
adaptor-related protein complex 1, gamma 1 subunit AP1G1 10.22 8.20 7.73 0.25 0.18 1 1 215867_x_at 
chromosome 16 open reading frame 45 C16orf45 8.43 5.94 6.18 0.18 0.21 1 1 212736_at 
cathepsin D (lysosomal aspartyl protease) CTSD 10.42 8.32 8.21 0.23 0.21 1 1 200766_at 
cellular retinoic acid binding protein 2 CRABP2 9.08 6.91 7.02 0.22 0.24 1 1 202575_at 
growth differentiation factor 15 GDF15 9.00 7.27 7.00 0.30 0.25 1 1 221577_x_at 
early growth response 3 EGR3 7.95 6.05 6.05 0.27 0.27 1 1 206115_at 
stanniocalcin 2 STC2 9.63 8.03 7.91 0.33 0.30 1 1 203439_s_at 
neuropeptide Y receptor Y1 NPY1R 5.94 4.48 4.22 0.36 0.30 1 1 205440_s_at 
dystrobrevin, alpha DTNA 7.90 6.63 6.24 0.41 0.32 0 1 205741_s_at 
fer-1-like 3, myoferlin (C. elegans) FER1L3 9.27 7.23 7.62 0.24 0.32 1 1 201798_s_at 
fer-1-like 3, myoferlin (C. elegans) FER1L3 8.48 6.53 6.86 0.26 0.33 1 1 211864_s_at 
RNA binding protein with multiple splicing RBPMS 8.76 7.52 7.13 0.42 0.32 0 1 209487_at 
neuron navigator 2 NAV2 6.41 5.07 4.81 0.40 0.33 1 1 218330_s_at 
ganglioside-induced differentiation-associated protein 1 GDAP1 7.36 6.12 5.85 0.42 0.35 1 1 221279_at 
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HRAS-like suppressor 3 HRASLS3 7.86 6.46 6.37 0.38 0.36 1 1 209581_at 
WNT1 inducible signaling pathway protein 2 WISP2 8.38 7.12 6.91 0.42 0.36 0 1 205792_at 
sulfatase 1 SULF1 6.44 4.64 5.00 0.29 0.37 1 1 212354_at 
sulfatase 1 SULF1 6.42 5.00 5.47 0.38 0.52 1 1 212344_at 
adenylate cyclase 9 ADCY9 7.01 5.62 5.59 0.38 0.37 1 1 204497_at 
protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform 
(calcineurin A alpha) PPP3CA 10.47 8.95 9.17 0.35 0.41 1 0 202457_s_at 
protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform 
(calcineurin A alpha) PPP3CA 10.28 8.76 8.95 0.35 0.40 1 1 202429_s_at 
seven in absentia homolog 2 (Drosophila) SIAH2 9.47 8.28 8.17 0.44 0.40 0 1 209339_at 
solute carrier family 39 (zinc transporter), member 8 SLC39A8 8.76 7.60 7.53 0.45 0.43 0 1 219869_s_at 
protease, serine, 8 (prostasin) PRSS8 8.32 7.79 7.10 0.69 0.43 0 1 202525_at 
phosphoserine phosphatase-like PSPHL 5.71 5.04 4.55 0.63 0.45 0 1 205048_s_at 
armadillo repeat containing, X-linked 2 ARMCX2 7.48 7.26 6.33 0.86 0.45 0 1 203404_at 
chromosome 16 open reading frame 35 C16orf35 8.76 7.67 7.63 0.47 0.46 1 1 210672_s_at 
DEGS1 8.31 6.62 7.20 0.31 0.46 1 0 207431_s_at 
degenerative spermatocyte homolog 1, lipid desaturase (Drosophila) DEGS1 6.35 4.97 5.56 0.38 0.58 1 0 209250_at 
protein predicted by clone 23733 HSU79274 7.35 5.91 6.25 0.37 0.47 1 1 204521_at 
kinesin family member 5C KIF5C 6.33 5.92 5.25 0.75 0.47 0 1 203129_s_at 
FK506 binding protein 11, 19 kDa FKBP11 8.62 7.95 7.56 0.63 0.48 0 1 219118_at 
UDP-glucose ceramide glucosyltransferase UGCG 8.17 6.86 7.11 0.40 0.48 1 0 204881_s_at 
ras homolog gene family, member D RHOD 9.83 8.93 8.78 0.53 0.48 0 1 209885_at 
FK506 binding protein 11, 19 kDa FKBP11 9.28 8.40 8.28 0.54 0.50 1 1 219117_s_at 
 159
UDP-galactose-4-epimerase GALE 8.33 7.36 7.35 0.51 0.51 1 1 202528_at 
BCL2-associated athanogene 3 BAG3 10.19 9.24 9.28 0.52 0.53 1 1 217911_s_at 
asparagine synthetase ASNS 9.16 8.64 8.25 0.70 0.53 0 1 205047_s_at 
villin 2 (ezrin) VIL2 8.28 7.64 7.38 0.64 0.53 1 1 208623_s_at 
villin 2 (ezrin) VIL2 8.65 8.20 7.89 0.73 0.59 0 1 208622_s_at 
villin 2 (ezrin) VIL2 8.39 7.84 7.67 0.68 0.61 0 1 217234_s_at 
GTP cyclohydrolase I feedback regulator GCHFR 6.66 5.84 5.78 0.57 0.54 0 1 204867_at 
tumor protein D52-like 2 TPD52L2 9.39 8.92 8.51 0.72 0.54 0 1 201379_s_at 
trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) TFF1 12.86 12.52 11.99 0.79 0.55 0 1 205009_at 
3-hydroxybutyrate dehydrogenase (heart, mitochondrial) BDH 8.03 7.02 7.17 0.50 0.55 1 1 211715_s_at 
trophoblast glycoprotein TPBG 10.72 10.12 9.87 0.66 0.56 0 1 203476_at 
solute carrier family 16 (monocarboxylic acid transporters), member 1 SLC16A1 8.46 7.03 7.62 0.37 0.56 1 0 202236_s_at 
ADP-ribosylation factor-like 3 ARL3 8.72 7.88 7.90 0.56 0.57 1 1 202641_at 
phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole 
succinocarboxamide synthetase PAICS 10.07 9.51 9.25 0.68 0.57 0 1 201013_s_at 
armadillo repeat containing, X-linked 1 ARMCX1 4.45 3.52 3.64 0.53 0.57 1 1 218694_at 
potassium channel tetramerisation domain containing 5 KCTD5 8.71 7.91 7.90 0.58 0.57 1 1 218474_s_at 
Rho-related BTB domain containing 3 RHOBTB3 7.13 6.40 6.34 0.60 0.58 1 1 216048_s_at 
lysyl oxidase-like 2 LOXL2 6.91 5.55 6.12 0.39 0.58 1 0 202998_s_at 
aldolase C, fructose-bisphosphate ALDOC 7.71 6.89 6.92 0.57 0.58 1 1 202022_at 
L1 cell adhesion molecule L1CAM 7.45 6.43 6.70 0.49 0.59 1 0 204584_at 
hypothetical protein LOC51321 LOC51321 9.87 9.43 9.12 0.74 0.59 0 1 218167_at 
XTP3-transactivated protein A XTP3TPA 10.75 10.10 10.05 0.64 0.62 0 1 218069_at 
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leucine carboxyl methyltransferase 1 LCMT1 8.96 8.28 8.26 0.62 0.62 1 1 221515_s_at 
keratin 15 KRT15 5.59 5.21 4.89 0.77 0.62 0 1 204734_at 
serine hydroxymethyltransferase 2 (mitochondrial) SHMT2 7.30 6.91 6.62 0.76 0.62 0 1 214095_at 
queuine tRNA-ribosyltransferase domain containing 1 QTRTD1 6.51 6.16 5.84 0.78 0.63 0 1 219178_at 
golgi associated, gamma adaptin ear containing, ARF binding protein 2 GGA2 8.04 7.54 7.39 0.70 0.64 0 1 210658_s_at 
ras homolog gene family, member D RHOD 10.82 10.28 10.19 0.69 0.64 0 1 31846_at 
eukaryotic translation initiation factor 2B, subunit 1 alpha, 26kDa EIF2B1 9.15 8.58 8.52 0.67 0.65 1 1 201632_at 
sialyltransferase 7D ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-
acetyl galactosaminide alpha-2,6-sialyltransferase) SIAT7D 5.75 5.07 5.14 0.62 0.65 1 0 221551_x_at 
mitochondrial ribosomal protein L28 MRPL28 9.25 8.61 8.64 0.64 0.65 1 1 204599_s_at 
kelch domain containing 4 KLHDC4 7.90 7.47 7.31 0.74 0.67 0 1 221219_s_at 
solute carrier family 3 (activators of dibasic and neutral amino acid transport), 
member 2 SLC3A2 10.33 9.52 9.74 0.57 0.67 1 0 200924_s_at 
procollagen C-endopeptidase enhancer 2 PCOLCE2 4.44 3.85 3.89 0.66 0.68 1 1 219295_s_at 
proteasome (prosome, macropain) 26S subunit, non-ATPase, 9 PSMD9 9.84 9.43 9.29 0.75 0.68 0 1 207805_s_at 
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 SULT1A1 9.48 8.98 8.93 0.71 0.68 0 1 215299_x_at 
carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 CHST6 7.18 6.44 6.85 0.60 0.80 1 0 221059_s_at 
DKFZp564J157 protein 
DKFZP564J
157 10.27 10.05 9.74 0.86 0.69 0 1 217794_at 
EGF-like-domain, multiple 5 EGFL5 7.50 6.50 7.07 0.50 0.74 1 0 212830_at 
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Although it is not possible to go into detailed discussion of all the genes 
identified on these lists I have selected a number of genes from Tables 3.3 
and 3.4 to briefly describe their role and any relevant data which may give an 
indication of their potential function / effect in the tamoxifen resistant cell lines.  
The genes I have chosen to describe are those where there is some indication 
they may have a plausible connection with the phenomenon of tamoxifen 
resistance. 
 
Starting with the most over represented genes either in frequency or levels of 
differential expression, I explored the functions of the gene products mainly 
using the Genecards website, (www.genecards.org) and identified genes with 
known roles in the literature to key areas such as cancer, endocrine / steroid 
pathways, breast or prostate cancer, drug resistance.  The genes I discuss 
here are not an exhaustive list but rather those that I felt shed some light on 
the mechanism of tamoxifen resistance in this cell system or may have a 
potentially interesting role or relevance.  For those genes thought to be 
“interesting” I also looked for their known associates, eg co-factors, 
substrates, targets where applicable. Where the relevant “associates” were 
also identified by this experiment as differentially expressed, I have mentioned 
them too. 
 
A number of genes from the same class are highly represented in the list of 
differentially expressed genes.  For example, three different Aldo-keto 
reductases are upregulated.  AKRs catalyze the conversion of aldehydes and 
ketones to alcohols utilizing NADH and/or NADPH as a cofactor.  The three 
AKRs significantly up-regulated in this experiment (AKR1C1, AKR1C2 and AKR1C3) are the 
family members which act on 3α-hydroxysteroids, these isoforms show high sequence 
homology but distinct substrate and tissue specificity.  All three isoforms are detected in 
normal breast tissue and are down regulated in breast tumours and breast cancer cell lines 
including MCF7 cells308. 
 
These enzymes are important in the interconversion of 3 ketosteroids with 3αhydroxysteroids 
as well as 17-ketosteroids with 17β-hydroxysteroids, (see Figure 1.5, Introduction).   In vivo 
they are thought to act predominantly as reductases due to the NADPH/NADP+ ratio in the 
 162
cytoplasm.  They catalyse the conversion of progesterone to its inactive form, 20α- 
dihydroxyprogesterone (20α-OHP), the conversion of 5 α-dihydro-testosterone (5α-
dht) into 3β-Diol, and oestrone to 17β-oestradiol309.  AKR1C3 is also known 
as 17β-hydroxysteroid dehydrogenase type V, its role in the steroidogenesis 
pathway is illustrated in Figure 1.5 where it is denoted 17βHSD.  It has been 
postulated that the observed down regulation of these enzymes in breast 
tumours (~4 fold) may result in higher levels of 5α pregnane-3, 20-dione, a 
progesterone metabolite that promotes proliferation308.   
 
It is not clear from the literature whether AKR1C1, AKR1C2 and AKR1C3 can use 4-
OH tamoxifen or its metabolites as a substrate. Their marked up-regulation in 
this context (~7 fold) is intriguing; their potential roles in this context are 
discussed more fully in Section 6.1. Of note, NAD(P)H dehydrogenase, 
quinone 1 (NQO1) is also significantly up-regulated,in the tamoxifen resistant 
cell lines (~2 fold).  NQO1 provides a co-factor necessary for AKR activity, 
(see Discussion 6.1).  
 
The next most significantly up-regulated genes on the list are four UDP 
glycosyltransferases (UGT1A1, UGT1A3, UGT1A6 and UGT1A9).  These 
enzymes are involved in the next step in the path of steroid catabolism; they 
catalyze glucuronidation, an important pathway that enhances the elimination 
of many lipophilic substances by conversion to more water-soluble 
compounds.  The observed up-regulation of these genes (5-15 fold) provides 
a mechanism for increasing the elimination of tamoxifen from the resistant 
cells. 
 
The discovery that the most up-regulated genes identified by this study 
include 7 members of two gene families involved in steroid metabolism and 
that these enzymes can be placed consecutively in the steroid catabolic 
pathway gives some degree of confidence in the data obtained from the 
microarrays.  The agreement in the genes identified provides a form of in 
silico validation and the identification of these particular genes makes 
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biological sense in the context of expression profiles of closely related MCF7 
cells that differ only in their exposure and response to 4-OH tamoxifen. 
 
Further down Table 3.3, two genes from the ABC transporter family appear 
(ABCG2 and ABCC3); these proteins transport substances across the cell 
membrane.  ABCG2 is also known as human breast cancer resistance protein 
and is thought to play a major role in multi-drug resistance.  It exports toxic 
substances from the cell including tamoxifen 310.  The specific function of 
ABCC3 has not yet been determined, however it is a member of the MRP 
subfamily, also involved in multi-drug resistance, it is also thought to play a 
role in the excretion of organic anions.  Again, the observed up-regulation of 
these genes (2-3 fold) probably represents a mechanism for excretion of 
tamoxifen and its metabolites, (see Introduction 1.4). 
 
In Table 3.4, Sulfotransferase1A1, (SULT1A1) is another gene involved in the 
metabolism of 4-OH tamoxifen, it catalyses the sulfation of 4-OH tamoxifen.  
SULT1A1 was identified in this study as significantly down regulated in the 
tamoxifen resistant cell lines, (see Introduction 1.4).   
 
A genetic polymorphism (SULT1A1*2) has been described, which renders the 
SULT1A1 enzyme approximately two fold less active, this polymorphism has 
been associated with an increased risk of the development of breast and other 
cancers in several studies 311. It has also been shown to predict response to 
tamoxifen in patients with breast cancer312. Among tamoxifen treated patients, 
those who were homozygous for the SULT1A1*2 low activity allele, (n=23) 
had three times the risk of death compared to those who were homozygous 
for the common allele (SULT1A1*1) or heterozygous (n= 137).  Among 
patients who did not receive tamoxifen there was no association between 
survival and SULT1A1 genotype (n=177) 312. 
 
Hypermethylation of the SULT1A1 promoter regions, resulting in reduced 
expression of the enzyme, is also associated with breast cancer, occurring in 
~60% of breast tumours compared to ~20% of normal breast tissue313.  This 
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may be the mechanism of reduced SULT1A1 transcription in the tamoxifen 
resistant cell lines in our study. 
 
The sulfation of 4-OH tamoxifen and other steroid compounds is generally 
thought to result in their inactivation and enable more rapid excretion, 
therefore it was unexpected to find that increased activity of SULT1A1 offers a 
therapeutic advantage in tamoxifen treated patients.  Nowell et al suggested 
that active sulfation by SULT1A1 may enhance the bioavailability of 4-OH-
tamoxifen by providing a reservoir of inactivated metabolites which can be 
desulfated by sulfatase (expressed in breast tumours) and recovered to the 
active 4-OH-tamoxifen, leading to a prolonged anti-oestrogen effect 312.  
Interestingly, our study also identified Sulfatase 1 (SULF1) as also being 
significantly downregulated in the tamoxifen resistant cells. Our observations 
are therefore consistent with the concept that 4-OH tamoxifen and its 
metabolites may be shuttled between these two enzymes and effectively 
“recycled“.   
 
Bone morphogenetic protein 7, (BMP7) expression was up-regulated in 
tamoxifen resistant MCF7 cells.  This secreted signaling molecule from the 
TGF-β family was recently found to be over-expressed in 71% of primary 
breast tumours 314.  In prostate cancer cell lines up-regulation of BMP7 has 
been associated with protection from stress-induced apoptosis and it has 
been proposed to contribute to tumour progression in prostate cancer. 
Overexpression of BMP7 in benign prostate hypertrophy cell lines resulted in 
reduced proliferation, whereas in prostate cancer cell lines it caused epithelial 
mesenchymal transformation (EMT), increased cell motility, invasiveness and 
decreased cell adhesion 315. 
 
However, a recent study examining this gene may also serve as a note of 
caution by its demonstration of the peculiar nature of MCF7 cells.  The copy 
number of BMP7 in MCF7 cells was estimated to be massively amplified at 
54.3, the gene was also found to have an increased copy number in a 
proportion of primary breast tumours (16%, n=125).  Increased BMP7 copy 
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number was significantly associated with high tumour grade and high 
proliferation rates, however the primary tumours showed a much more 
moderate degree of gene amplification than MCF7 cells. Also, mRNA levels 
showed no significant correlation between BMP7 expression and clinico-
pathological parameters 314.  
 
AMIGO2 also features in Table 3.3.  It is a transmembrane protein, recently 
identified as a member of the leucine rich repeat superfamily.  Structural 
analysis has suggested that it may function as a signaling cell adhesion 
molecule although its downstream targets have not been elucidated.  It has 
recently been identified as playing a role in gastric adenocarcinogenesis.  In 
normal tissues, AMIGO2 is most highly expressed in breast, ovarian, uterus 
and cervix tissue, perhaps indicating a physiological role in female 
reproduction or induction by female reproductive hormones.  Tumour profiling 
microarrays revealed overexpression of AMIGO2 in 45% of gastric 
adenocarcinomas and high levels of expression in 25% of primary breast 
tumours.  Stable expression of AMIGO2 antisense in AGS, a gastric 
adenocarcinoma cell line resulted in increased ploidy, chromosomal instability, 
reduced cell adhesion, migration and a near complete abrogation of 
tumourgenicity when the cells were injected into nude mice 316.  Therefore, 
overexpression of AMIGO2 in tamoxifen resistant cells may be consistent with 
a more aggressive cancer phenotype in these cells. 
 
Examining the genes from Table 3.4; seven in absentia homologue 2, (SIAH2) 
is a ubiquitin E3 ligase and a known oestrogen responsive gene.  Up-
regulation of SIAH2 in response to oestrogen is thought to cause a  “global 
de-repression” of transcription mediated through its targeting of the crucial 
repressive cofactor NCoR for proteasomal degradation in ER positive breast 
cancer cells, (see Introduction, Table1.3).  In a study examining the short-term 
response of serum starved breast cancer cells (MCF7 and ZR75-1) to either 
17β-oestradiol, 4-OH tamoxifen, raloxifene or fulvestrant, differential 
regulation of SIAH2 was observed. 17β-oestradiol caused a 4.5 fold induction 
of SIAH2 while all other treatments showed no response in SIAH2.  siRNA 
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directed against SIAH2 ablated the reduction in NCoR usually observed 
following oestrogen treatment.  It was suggested that tamoxifen’s ER 
antagonist activity depends on maintaining high levels of NCoR mediated 
through low SIAH2 levels 317. 
 
In our study, SIAH2 is significantly downregulated (0.4 fold) in tamoxifen 
resistant cells. This is consistent with the observation that SIAH2 is an 
oestrogen responsive gene since the wildtype MCF7 cells are not serum 
starved and are therefore in relatively oestrogenic media. It would require 
dynamic hormone treatment studies to ascertain whether this level of SIAH2 is 
higher or lower than that found in the MCF7 wildtype cells following acute 
exposure to 4-OH tamoxifen.   It is possible that the level or activity of SIAH2 
observed in the Early and Late cells, chronically exposed to 4-OH tamoxifen 
has increased relative to its level during acute oestrogen withdrawal in 
wildtype MCF7 cells, thus allowing sufficient NCoR degradation to overcome 
the NCoR-mediated repression of transcription. It is also possible that the 
observed downregulation of SIAH2 in tamoxifen resistant MCF7s has other 
consequences, since it triggers the ubiquitin-mediated degradation of many 
substrates, including the antiapoptotic proteins BAG1 and TRAF2.   
Levels of NCoR and NCoR2 in this study are illustrated in Figure 5.11. 
  
Cellular retinoic acid binding protein II, (CRABPII) was also found to be 
downregulated in our tamoxifen resistant cells.  CRABPII binds retinoic acid 
(RA) and delivers it to the RA receptor, thereby enhancing retinoic acid 
signaling.  Overexpression of CRABPII in MCF7 cells was shown to increase 
their sensitivity to retinoic acid induced growth inhibition, while stable 
expression of CRABPII antisense rendered the cell relatively resistant to 
RA318.  Again, the down regulation of CRABPII identified in tamoxifen resistant 
MCF7s is consistent with this data.  Furthermore, certain RA induced genes 
(eg NAV2) are also downregulated in the tamoxifen resistant cells possibly 
indicating that RA signaling is indeed down regulated in these cells.  
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Looking further through the lists, a number of cancer-associated genes are 
identified as significantly differentially expressed.  The majority of genes 
identified by the expression profiling of these cell lines “make sense”, that is, 
oestrogen-responsive genes are down regulated in tamoxifen treated, 
tamoxifen resistant cell lines (eg WISP2, CTSD, TFF1, STC2).  Proapoptotic, 
tumour suppressor genes are down regulated (PPP3CA, UGCG).  There are 
some exceptions, whose presence is unexpected, for example; BAG3, LXOL2 
are downregulated and anti-apoptotic / tumour promoting, while HIC2 is up-
regulated in the tamoxifen resistant cells. 
 
Comparing our results with those from other studies searching for modulators 
of tamoxifen resistance it was interesting to see some genes in common.  
Shown in Figure 3.8, are seven genes identified in a functional screen for 
genes associated with tamoxifen resistance in ZR75-1 cells by Drossers et 
al.8, with their mean levels of expression identified in our study.  The 3 genes 
that were independently identified in our study (ERBB2, NEDD9, and STX1A) 
as significantly differentially expressed in the resistant MCF7 cells are 
highlighted with an asterisk.   
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CAXII 
Figure 3.8  Expression levels of seven tamoxifen resistance 
associated genes.  APP, CBFA2T3, EGFR, ERBB2, 
KIAA0513, NEDD9, NRG1 and STX1A were identified 
independently in a functional screen for tamoxifen resistance 
genes in ZR75-1 cells8, where cells were infected with retroviral 
cDNA libraries derived from human placenta, brain and mouse 
embryo. Cells were then selected for proliferation in the 
presence of tamoxifen, integrated cDNAs were identified by 
sequence similarity searches. The seven genes above were 
identified in multiple tamoxifen resistant cell colonies. 
Expression levels of the genes in our MCF7 derived cells are 
shown, (5-10µg protocol). CBFA2T3, EGFR, ERBB2, 
KIAA0513, NEDD9, NRG1 and STX1A are up-regulated in the 
tamoxifen resistant MCF7, but only NEDD9 achieved statistical 
significance. 
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3.2.6 Ontology of genes identified as differentially expressed in 
Tamoxifen resistant MCF7 cells 
Ontology attempts to form a “hierarchical structuring of knowledge about 
things by subcategorising them according to their essential qualities”. Gene 
ontology (GO) is used in the analysis of microarray data to try and structure a 
gene list and identify patterns of expression through the identification of 
functionally related genes. The gene ontology consortium 
(http://www.geneontology.org) provides a vocabulary for the consistent 
description of gene products across different databases.  The names used to 
describe the categories are known as GO terms.  Each entry in GO has a 
unique number and term name. 
 
Using Genespring GX 7.3, the list of differentially expressed genes obtained 
from the cell line study was analysed so that all the genes were allocated and 
arranged according to their designated GO term.  The software allows one to 
compare the number, (or percentage) of genes on the list in each category 
with the number, (or percentage) of genes on the whole chip in each category.  
It is then possible to evaluate whether certain functions are over-represented 
by the gene list.  A p-value estimates the statistical significance of the overlap, 
i.e. the likelihood that it is a coincidence that the number of genes occurs both 
in the gene list and the category.  The principle of sequential categorisation 
and sub-categorisation is illustrated in a series of Venn diagrams in Figure 
3.9.   
 
The list of differentially expressed genes was filtered for those categories with 
a p-value <0.05 ie only genes with statistically significantly over-represented 
categories remained in the list.  This left a total of 55 genes; their ontologies 
are listed in Table 3.5.  In the first column, (“∆ in TAM R”) a notation of “UP” is 
given for those genes that were identified as up regulated in the tamoxifen 
resistant cell lines.  
 
This method again highlights that the categories of “lipid metabolism”, “lipid 
transport”, “steroid metabolism”, “xenobiotic metabolism” and “response to a 
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biotic stimulus” are over-represented in the list of genes differentially 
expressed between tamoxifen resistant versus tamoxifen sensitive MCF7 cell 
lines.  The majority of genes in these categories are up regulated in the 
tamoxifen resistant cells.   
 
Although this method of gene selection may seem a slightly convoluted way of 
trying to pick out patterns of gene expression and leaves only a small 
selection of genes in this analysis, it has the advantage of being impartial and 
objective.  It enables the linking of genes with the same function together even 
if they are involved in discrete pathways.  One of the problems with this type 
of analysis is that it relies entirely on the annotation of a gene in the GO 
database.  Members of the consortium regularly update the database on a 
voluntary basis, but certain genes remain where their role is unknown, 
controversial or poorly defined.  This analysis is therefore biased towards 
genes with a clearly defined Affymetrix and GO annotation and so is less 
helpful when trying to identify novel gene associations. Since a single gene 
may have multiple designated functions it remains important to interpret the 
role of a gene in a given context.  
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Figure 3.9 Venn diagrams to illustrate process of gene 
ontology in Genespring GX 7.3.  Each diagram represents the 
significantly differentially expressed genes in our experiment in a 
given GO category; the proportion of genes in each sub-category 
are represented and listed on the adjacent legends, with their p 
values.  Sub-categories are sequentially expanded to fully explore 
the ontology tree, as indicated by the arrows.  
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∆  in 
TAM 
R Probe id: Description: 
Genes in 
% of Genes 
in Category 
 
Genes in 
List in  
Category 
% of Genes in 
List in 
Category  p-Value 
GO:6066: alcohol metabolism 302 1.996 6(5) 4.92(4.1) 0.0356 
 202022_at aldolase C, fructose-bisphosphate      
 202528_at galactose-4-epimerase, UDP-      
UP 203509_at sortilin-related receptor, L(DLR class) A repeats-containing      
UP 212560_at sortilin-related receptor, L(DLR class) A repeats-containing      
 215299_x_at Human phenol sulfotransferase (STP1) gene, last exon and partial cds.      
UP 221767_x_at high density lipoprotein binding protein (vigilin)      
GO:9628: response to abiotic stimulus 451 2.980 9(7) 7.4(5.7) 0.0108 
UP 201468_s_at NAD(P)H dehydrogenase, quinone 1      
UP 210519_s_at NAD(P)H dehydrogenase, quinone 1      
UP 204151_x_at aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)    
UP 216594_x_at aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)    
UP 202831_at glutathione peroxidase 2 (gastrointestinal)      
UP 206094_x_at UDP glycosyltransferase 1 family, polypeptide A10      
UP 209735_at ATP-binding cassette, sub-family G (WHITE), member 2      
UP 219032_x_at opsin 3 (encephalopsin, panopsin)      
 203439_s_at stanniocalcin 2      
GO:6805: xenobiotic metabolism 54 0.357 5(3) 4.1 (2.5) 0.0001 
GO:9410: response to xenobiotic stimulus 56 0.370 5(3) 4.1(2.5) 0.0001 
UP 201468_s_at NAD(P)H dehydrogenase, quinone 1      
UP 210519_s_at NAD(P)H dehydrogenase, quinone 1      
UP 204151_x_at aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)    
UP 216594_x_at aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)    
UP 206094_x_at UDP glycosyltransferase 1 family, polypeptide A10      
GO:6629: lipid metabolism 691 4.566 14(11) 11.48(9.0) 0.001 
UP 202003_s_at acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase)      
UP 202053_s_at aldehyde dehydrogenase 3 family, member A2      
Table 3.5 Gene ontology for differentially expressed genes identified by expression profiling tamoxifen resistant vs wildtype MCF7 
cells. Ontology results were filtered for a p-value of <0.05 ie genes in categories which are significantly over-represented by this gene list 
compared to all genes on the chip.  The column “∆ in Tam R” indicates genes up-regulated in the tamoxifen resistant cell lines.  
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UP 203509_at sortilin-related receptor, L(DLR class) A repeats-containing      
UP 212560_at sortilin-related receptor, L(DLR class) A repeats-containing      
 204881_s_at UDP-glucose ceramide glucosyltransferase      
UP 207126_x_at UDP glycosyltransferase 1 family, polypeptide A10      
UP 207081_s_at phosphatidylinositol 4-kinase, catalytic, alpha polypeptide      
 207431_s_at degenerative spermatocyte homolog, lipid desaturase (Drosophila)      
 209250_at degenerative spermatocyte homolog, lipid desaturase (Drosophila)      
UP 209160_at aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II)      
UP 209699_x_at aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III) 
UP 211653_x_at aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III) 
 215299_x_at Human phenol sulfotransferase (STP1) gene, last exon and partial cds.      
UP 221767_x_at high density lipoprotein binding protein (vigilin)      
GO:6869: lipid transport 83 0.548 3(2) 2.46(1.6) 0.0295 
UP 203509_at sortilin-related receptor, L(DLR class) A repeats-containing     
UP 212560_at sortilin-related receptor, L(DLR class) A repeats-containing     
UP 221767_x_at high density lipoprotein binding protein (vigilin)      
GO:6636: fatty acid desaturation 5 0.033 2(1) 1.64(0.82) 0.0006 
 207431_s_at degenerative spermatocyte homolog, lipid desaturase (Drosophila)    
 209250_at degenerative spermatocyte homolog, lipid desaturase (Drosophila)    
GO:6677: glycosylceramide metabolism 6 0.040 1 0.82 0.0474 
GO:6679: glucosylceramide biosynthesis 4 0.026 1 0.82 0.0319 
 204881_s_at UDP-glucose ceramide glucosyltransferase      
GO:6725: aromatic compound metabolism 136 0.899 4 3.279 0.0243 
 201013_s_at phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase   
UP 211138_s_at kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)     
UP 212771_at hypothetical protein LOC221061      
 215299_x_at Human phenol sulfotransferase (STP1) gene, last exon and partial cds.    
GO:6726: eye pigment biosynthesis 6 0.040 1 0.82 0.0474 
UP 206696_at G protein-coupled receptor 143      
GO:6730: one-carbon compound metabolism 45 0.297 3(1) 2.46(0.82) 0.0057 
 203963_at carbonic anhydrase XII      
 204508_s_at carbonic anhydrase XII      
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 210735_s_at carbonic anhydrase XII      
GO:6789: bilirubin conjugation 1 0.007 1 0.82 0.0080 
GO:6787: porphyrin catabolism 5 0.033 1 0.82 0.0397 
UP 207126_x_at UDP glycosyltransferase 1 family, polypeptide A10     
GO:6809: nitric oxide biosynthesis 19 0.126 3(2) 2.46(1.6) 0.0004 
UP 201468_s_at NAD(P)H dehydrogenase, quinone 1      
UP 210519_s_at NAD(P)H dehydrogenase, quinone 1      
 204867_at GTP cyclohydrolase I feedback regulatory protein     
GO:6880: intracellular sequestering of iron ion 4 0.026 1 0.82 0.0319 
UP 208921_s_at sorcin      
GO:6941: striated muscle contraction 43 0.284 2 1.639 0.047 
 205741_s_at Homo sapiens dystrobrevin, alpha (DTNA), transcript variant 7, mRNA.    
UP 208921_s_at sorcin      
GO:7016: cytoskeletal anchoring 24 0.159 3(1) 2.46(0.82) 0.0009 
 208622_s_at villin 2 (ezrin)      
 208623_s_at villin 2 (ezrin)      
 217234_s_at villin 2 (ezrin)      
GO:7176: regulation of epidermal growth factor receptor activity 4 0.026 1 0.82 0.0319 
GO:30838: positive regulation of actin filament polymerization 5 0.033 1 0.82 0.0397 
UP 203315_at NCK adaptor protein 2      
GO:7266: Rho protein signal transduction 33 0.218 2(1) 1.64(0.82) 0.0289 
 209885_at ras homolog gene family, member D      
 31846_at ras homolog gene family, member D      
GO:7271: synaptic transmission, cholinergic 14 0.093 2(1) 1.64(0.82) 0.0055 
UP 201468_s_at NAD(P)H dehydrogenase, quinone 1      
UP 210519_s_at NAD(P)H dehydrogenase, quinone 1      
GO:7274: neuromuscular synaptic transmission 6 0.040 1 0.82 0.0474 
 205741_s_at Homo sapiens dystrobrevin, alpha (DTNA), transcript variant 7, mRNA.    
GO:7398: ectoderm development 113 0.747 4 3.279 0.0132 
UP 202053_s_at aldehyde dehydrogenase 3 family, member A2      
 202575_at cellular retinoic acid binding protein 2      
 204734_at keratin 15      
 204881_s_at UDP-glucose ceramide glucosyltransferase      
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GO:7586: digestion 61 0.403 4 (3) 3.279(2.5) 0.0015 
 205009_at trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in)    
UP 207126_x_at UDP glycosyltransferase 1 family, polypeptide A10     
UP 209699_x_at aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III) 
UP 211653_x_at aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III 
GO:7623: circadian rhythm 23 0.152 2 1.639 0.0146 
 206115_at bridging integrator 3      
UP 219032_x_at opsin 3 (encephalopsin, panopsin)      
GO:8015: circulation 158 1.044 4 3.279 0.039 
 211864_s_at fer-1-like 3, myoferlin (C. elegans)      
 201798_s_at fer-1-like 3, myoferlin (C. elegans)      
UP 203817_at guanylate cyclase 1, soluble, beta 3      
UP 208921_s_at sorcin      
GO:8202: steroid metabolism 184 1.216 5(4) 4.1 (3.3) 0.0167 
UP 203509_at sortilin-related receptor, L(DLR class) A repeats-containing     
UP 212560_at sortilin-related receptor, L(DLR class) A repeats-containing     
UP 207126_x_at UDP glycosyltransferase 1 family, polypeptide A10     
 215299_x_at Human phenol sulfotransferase (STP1) gene, last exon and partial cds.    
UP 221767_x_at high density lipoprotein binding protein (vigilin)      
GO:8210: estrogen metabolism 6 0.040 1 0.82 0.0474 
 207126_x_at UDP glycosyltransferase 1 family, polypeptide A10     
GO:8544: epidermis development 94 0.621 4 3.279 0.0070 
UP 202053_s_at aldehyde dehydrogenase 3 family, member A2      
 202575_at cellular retinoic acid binding protein 2      
 204734_at keratin 15      
 204881_s_at UDP-glucose ceramide glucosyltransferase      
GO:8616: queuosine biosynthesis 2 0.013 1 0.82 0.0161 
GO:6400: tRNA modification 5 0.033 1 0.82 0.0397 
GO:46129: purine ribonucleoside biosynthesis 2 0.013 1 0.82 0.0161 
 219178_at queuine tRNA-ribosyltransferase domain containing 1    
GO:9190: cyclic nucleotide biosynthesis 32 0.211 2 1.639 0.0273 
UP 203817_at guanylate cyclase 1, soluble, beta 3      
 204497_at adenylate cyclase 9      
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GO:15718: monocarboxylic acid transport 23 0.152 3(2) 2.5(1.6) 0.0008 
 202236_s_at solute carrier family 16 (monocarboxylic acid transporters), member 1    
UP 209699_x_at aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III)  
UP 211653_x_at aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III 
GO:15722: canalicular bile acid transport 3 0.020 2 1.639 0.0002 
GO:15721: bile acid transport 5 0.033 2 1.639 0.0006 
UP 209699_x_at aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III) 
UP 211653_x_at aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III 
GO:15728: mevalonate transport 4 0.026 1 0.82 0.0319 
 202236_s_at solute carrier family 16 (monocarboxylic acid transporters), member 1    
GO:46942: carboxylic acid transport 98 0.648 4(2) 3.3(1.6) 0.0081 
GO:15849: organic acid transport 98 0.648 4 3.279 0.0081 
 200924_s_at solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2   
 202236_s_at solute carrier family 16 (monocarboxylic acid transporters), member 1    
UP 209699_x_at aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III) 
UP 211653_x_at aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III 
GO:18298: protein-chromophore linkage 1 0.007 1 0.82 0.0081 
UP 219032_x_at opsin 3 (encephalopsin, panopsin)      
GO:50653: chondroitin sulfate proteoglycan biosynthesis, polysaccharide chain biosynthesis 2 0.013 1 0.82 0.0161 
UP 219049_at chondroitin beta1,4 N-acetylgalactosaminyltransferase      
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3.2.7 Selection of genes for validation / further investigation 
I selected six genes from the list of differentially expressed genes to use for 
further investigation.  The purpose of this was initially to validate the findings 
from the expression analysis data, and also to investigate further a group of 
genes that appeared, after literature review to be of interest as potential 
players in the mechanism of tamoxifen resistance. 
 
The method of selection was partly pragmatic, partly speculative; I looked for 
genes that showed sufficient fold change to be a good candidate for validation 
and I favoured genes where multiple probe sets had been identified as 
differentially expressed.  I tried to choose genes that “looked interesting”, by 
examining any available evidence about their known functions and any 
disease associations, but I also wanted to avoid genes which were already 
under intense investigation.  It was also important to choose genes that had 
roles that we were capable of investigating, that our group or institute had 
some expertise in or could obtain access to relevant assays. 
 
The genes that were selected for further validation and investigation were as 
follows: HRASLS3, Carbonic anhydrase XII, Cathepsin D, ATP1B1, 
suppressor of cytokine signalling (SOCS2) and NR4A2. 
 
HRAS like suppressor 3, (HRASLS3) was originally isolated as a gene 
specifically expressed in rat fibroblasts resistant to malignant transformation 
by the activated HRAS gene 319,320.  It is thought to function as a tumour 
suppressor that may be involved in interferon-dependent cell death.  It is 
known to be down regulated in several human cancers, including breast and 
ovarian cancer 321.  In our study HRASLS3 was found to be down regulated 
~3 fold in tamoxifen resistant cells.   
 
Carbonic anhydrase XII (CAXII) was shown to be down-regulated 4-10 fold on 
4 independent probe sets in our cell line study.  A tumour associated carbonic 
anhydrase, its expression has been shown to be inducible in breast cancer 
cell lines and to correlate with ER positivity and good prognosis in primary 
invasive breast cancer 322.  
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Cathepsin D, (CTSD) is a lysosomal aspartyl protease whose expression can 
be regulated by oestrogen.  It is over-expressed by epithelial breast cancer 
cells and has been shown to be an independent marker of poor prognosis 
being correlated with the incidence of clinical metastasis.  Paradoxically, 
cathepsin D is also involved in apoptosis.  Its observed  ~5-fold down-
regulation in tamoxifen resistant cells may therefore be due to oestrogen 
opposition or possibly due to increased survival signalling in these cells. 
 
ATPase, Na+/K+ transporting, beta 1 polypeptide, (ATP1B1) belongs to the 
Na+/K+ -ATPases, an integral membrane protein responsible for establishing 
and maintaining gradients of Na and K ions across the plasma membrane. 
This enzyme is composed of two subunits, a large catalytic subunit (alpha) 
and a smaller glycoprotein subunit (beta). The beta subunit regulates the 
number of sodium pumps transported to the plasma membrane and is 
encoded by multiple genes. This gene encodes a beta 1 subunit and was 
shown to be upregulated in tamoxifen resistant cells (~5 fold) on 2 
independent probe sets. 
 
SOCS2 encodes a member of the suppressor of cytokine signalling (SOCS) 
family.  In our study it was up-regulated ~5 fold in tamoxifen resistant MCF7 
cells.  SOCS2 protein can interact with the cytoplasmic domain of insulin-like 
growth factor-1 receptor (IGF1R), and is thought to be involved in the 
regulation of IGF1R mediated cell signalling, thus may contribute to alternative 
mitogenic signalling associated with tamoxifen resistance. 
 
Nuclear receptor subfamily 4, group A, member 2, (NR4A2) encodes an 
orphan member of the steroid-thyroid hormone-retinoid receptor superfamily.  
In this study, NR4A2 was modestly but consistently upregulated ~2 fold in 
tamoxifen resistant cells.  NR4A2 has been shown to regulate a number of 
genes involved in steroid metabolism and also to suppress apoptosis in 
tumour cells in vitro 323,324.  Either or both of these actions may contribute to 
tamoxifen resistance. 
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3.3 Validation of selected genes by quantitative RT-PCR / 
immunocytochemistry in cell lines 
 
For each of the three cell lines, (Wildtype MCF7, tamoxifen resistant Early and 
Late MCF7 cells) total RNA was extracted and treated with DNase to remove 
any genomic DNA contamination.  Quantitative RT-PCR, (qRT-PCR) was 
performed on the samples using Taqman pre-developed assay reagents 
(PDARs) from Applied Biosystems, (See Methods 2.11.2).  The results for the 
qRT-PCR are shown in Figure 3.10B as fold change from wildtype MCF7, the 
results from the microarray experiments are shown in Figure 3.10A for 
comparison.  These charts confirm that the levels of gene expression obtained 
from the microarray results correlate with the levels of expression in these 
lines as measured by qRT-PCR.    
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Figure 3.10: Relative expression of HRASLS3, Cathepsin D 
(CTSD) CAXII, NR4A2, ATP1B1 and SOCS2 measured by cDNA 
microarray (A) and by qRT-PCR (B) in MCF7 cells.   
A - Fold change relative to MCF7 wildtype cells in tamoxifen resistant 
Early and Late MCF7 cells measured by cDNA microarray. 
B - Fold change relative to MCF7 wildtype cells in tamoxifen resistant 
Early and Late MCF7 cells measured by qRT-PCR, using Taqman 
pre-developed assay reagents (PDARs) from Applied Biosystems.   
Expression levels were normalized to the endogenous control 18S 
rRNA.  From this, the relative expression levels broadly correlate 
between the different methods, validating the expression array 
results. 
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I went on to investigate the levels of expression of these genes across a panel 
of breast cancer cell lines using qRT-PCR.  The results are shown in Figure 
3.11, normalized to the endogenous control and relative to MCF7 wildtype 
cells.  Error bars indicate the standard deviation from triplicate measurements. 
The genes in 3.11A (NR4A2, ATP1B1, SOCS2) were over-expressed in the 
tamoxifen resistant MCF7 cells; the genes in 3.11B (HRASLS3, CTSD, CAXII) 
were down regulated in the tamoxifen resistant MCF7 cells.  The cell lines 
assayed were as follows: wildtype MCF7, ZR75-1, oestrogen deprived ZR75-1 
which were grown in phenol red free media with charcoal stripped serum for 3 
months, T47D, oestrogen deprived T47D, (grown in phenol red free media 
with charcoal stripped serum for 3 months) and three ER-negative cell lines; 
CAL-51, MDA-MB-436, MDA-MB-231. A wide variation in expression levels 
for the different genes is seen.   
 
Looking at NR4A2 levels in Figure 3.11A, this gene is expressed at generally 
low levels apart from in MCF7 and ZR75-1.  It appears to be down regulated 
following oestrogen deprivation in ZR75-1 cells, unlike the findings in 
tamoxifen resistant MCF7s but is up-regulated in oestrogen deprived T47D.   
 
ATP1B1 shows a similar pattern to NR4A2, in that it is down regulated in the 
oestrogen deprived ZR75-1 cells but up-regulated in oestrogen deprived 
T47D.   It is expressed at the lowest levels in MCF7 cells.  
 
Expression of SOCS2 appears to be higher following oestrogen deprivation in 
the ER positive cell lines since it is upregulated in tamoxifen resistant MCF7 
cells, oestrogen deprived T47D and Oestrogen deprived ZR75-1.  SOCS2 is 
also expressed in ER negative cell lines, interestingly, higher levels of SOCS2 
expression seem to correlate in these lines with more invasive, tumourigenic 
phenotypes.  MDA-MB-436 are non-invasive in vitro and non tumourigenic in 
mice, they express low levels of SOCS2.  MCF7, T47D and ZR75-1 cells are 
non-invasive in vitro but can form tumours in mice given oestrogen 
supplementation, whilst MDA-MB-231 and CAL-51 are highly invasive and 
tumourigenic in mice and express the highest levels of SOCS2. 
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Looking at HRASL3 in Figure 3.11B, it is less abundant in the oestrogen 
deprived ZR75-1 and oestrogen deprived T47D which would correlate with 
HRASL3 downregulation in tamoxifen resistant MCF7 cells. It appears to be 
expressed at relatively high levels in ER negative cell lines. 
 
CTSD and CAXII show similar patterns of expression, they are both 
expressed at the highest level in MCF7 cells, they are both downregulated in 
the oestrogen deprived cells and they both are poorly expressed in the ER 
negative cells.    
 
Having confirmed expression of HRASLS3, CAXII, CTSD, ATP1B1, SOCS2, 
NR4A2 at the mRNA level in the MCF7 cell lines, I wanted to investigate the 
protein expression of these gene products both in the MCF7 cell lines and 
subsequently in tissue samples.  However, for the majority of these genes, 
suitable antibodies were not available and there was insufficient time to 
produce new antibodies for each of the proteins.   
 
Dr A Waheed at St Louis University kindly donated a rabbit anti-human CAXII 
antibody.  This was used for immuncytochemical staining of paraffin 
embedded MCF7 cells fixed in suspension, shown in Figure 3.12.  The CAXII 
antibody staining is brown and the nuclei are counterstained blue.  The 
wildtype cells exhibit dense cytoplasmic staining of CAXII.  Both early and late 
tamoxifen-resistant sublines show reduced staining for CAXII, as expected 
from the expression array data.  
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Figure 3.11 Relative expression of NR4A2, ATP1B1, SOCS2, 
HRASLS3, CTSD and CAXII measured by qRT-PCR across a 
panel of breast cancer cell lines.   
Relative abundance relative to MCF7 wildtype cells normalized to the 
endogenous control 18S rRNA in the following cell lines: wildtype 
MCF7 (MCF7wt), ZR75-1, oestrogen deprived ZR75-1 (OD ZR75-1)  
grown in phenol red free media with charcoal stripped serum for 3 
months, T47D, oestrogen deprived T47D (OD T47D) grown in phenol 
red free media with charcoal stripped serum for 3 months, and the 
ER negative cell lines CAL-51, MDA-MB-436, MDA-MB-231.  The 
genes in 3.10A, (NR4A2, ATP1B1, SOCS2) were over-expressed in 
the tamoxifen resistant MCF7 cells; the genes in 3.10B, (HRASLS3, 
CTSD, CAXII) were down regulated in the tamoxifen resistant MCF7 
cells.  
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 A 
B C 
Figure 3.12: Immunocytochemistry on MCF7 cell suspensions 
examining CAXII expression.  
A - MCF7 wildtype, B - Tam R Early MCF7, C - Tam R Late MCF7  
The wildtype cells exhibit dense cytoplasmic staining of CAXII, seen 
as brown, the nuclei are counterstained in blue.  Both Early and Late 
tamoxifen resistant sublines show less staining for CAXII, as 
expected form the expression array data.   
Staining was performed by Krishna Caulee at the QMUL Institute of 
Cancer Tissue Expression Profiling Facility. 
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For validation of the remainder of the genes (ATP1B1, SOCS2, NR4A2) I 
produced riboprobes for in-situ hybridisation of cells and tissue (see Methods 
2.13 and Figure 2.5).   HRASL3 did not contain any convenient RE sites for 
sub-cloning, so riboprobes were not prepared for this gene. 
 
The riboprobes were optimized using paraffin embedded cell line 
suspensions.  Hybridization was carried out by an automated system on the 
Ventana machine by Krishna Caulee in the Institute of Cancer Pathology 
department, see Table 3.6.  The “antisense” probes provide a control for 
estimation of background or non-specific hybridization.  The “sense” probes 
specifically hybridise with target mRNA in the cells. 
 
 
ATP1B1 NR4A2 SOCS2                Riboprobe: 
Cell line: 
S 
AS S AS S AS 
MCF7 wt - - + (+) + - 
MCF7 Tam R Early + - + (+) + - 
MCF7 Tam R Late + - + (+) + - 
 
Table 3.6:  In situ hybridization results for ATP1B1, SOCS2, NR4A2 
riboprobes. 
AS indicates results obtained for antisense probe, S indicates results obtained 
for the sense probes.  The strength of staining was estimated and scored by 
myself and Krishna Caulee, when “blinded” to the probes under investigation.   
  +   indicates positive staining with the probe, 
 (+)  indicates weakly positive staining,  
   -  indicates absent staining. 
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3.4 Functional studies using the selected genes in MCF7 
derived cell lines 
3.4.1 siRNA knockdown of HRASLS3, Carbonic anhydrase XII, and 
Cathepsin D. 
Dharmacon supplied three siRNA duplexes for each of these genes, which 
were identified as downregulated in the tamoxifen resistant cell lines.  The 
RNA duplexes were transfected into wildtype MCF7 cells using oligofectamine 
and the level of gene silencing was assayed by qRT-PCR (see Methods for 
optimized transfection protocol and siRNA sequences).  Initially, all three 
siRNA sequences for each gene were screened for efficacy by transfection 
seperately at the recommended dose of 100nM final concentration.  All three 
siRNA sequences were found to be effective at this dose (data not shown).  
 
Ideally, the amount of siRNA introduced should be minimized in order to 
reduce the possibility of off-target effects. The amount of siRNA necessary for 
effective gene silencing was therefore optimized by the transfection of 
different quantities of each of the siRNAs to a final concentration of either 
25nM or 12.5nM siRNA.  The results of this optimization are shown in Figure 
3.13. Effective gene silencing was observed (<20% control) for all three 
siRNA sequences for each gene.  Only HRASL3 sequence 2 at a final 
concentration of 12.5nM appeared to be ineffective.  This is likely to be due to 
poor transfection efficiency in these cells or it may be that the siRNA is less 
effective at a lower dose. 
 
To further characterize the siRNA transfected cells, Annexin V and Propidium 
Iodide staining was performed and the cells were analysed by FACS to 
ascertain whether changes in rates of cell death or apoptosis were observed 
following knockdown of these genes (see Methods 2.4.1).  The percentage of 
living, dead and apoptotic cells are shown in Figure 3.14.  Comparing cells 
with HRASL3, CAXII or CTSD knockdown with the “NON” cells, transfected 
with a non-silencing control sequence, there appears to be little change in the 
degree of cell death and apoptosis over and above that observed in the 
control cells.  CTSD alone shows a marginal increase in the rates of 
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apoptosis.  However, no consistent alteration in rates of cell death and 
apoptosis were observed in the other samples.  This experiment was repeated 
with similar results (not shown).    
 
The rates of cell growth in response to tamoxifen treatment and oestrogen 
withdrawal were also investigated by sequentially counting siRNA-transfected 
cells grown in different media, shown in Figure 3.15.  Again no dramatic 
differences were seen in cell growth under differing hormonal conditions 
(tamoxifen, oestrogen deprivation) following transient transfection with the 
siRNA sequences.   It was not possible to perform MTS assays on these cells 
to test their sensitivity to different concentrations of tamoxifen because, 
following transfection with siRNA, the cells were unable to tolerate being 
transferred to new tissue culture dishes, the majority of the cells failing to re-
attach when this was attempted.  
 
The investigations following manipulation of these genes in the cells that were 
feasible within the time constraints of the project were limited. Alternative 
approaches will be explored in the final discussion.  
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Figure 3.13: siRNA silencing of HRASLS3, CAXII and CTSD, 
optimising dose and sequence. Wildtype MCF7 cells were 
transfected with 3 different siRNA sequences for each gene (eg 
HRAS1, HRAS2, HRAS3), at 2 doses (final concentration 25nM or 
12.5nM). Cells were harvested 48 hours following transfection. 
Relavtinve expression of the relevant genes was measured by qRT-
PCR.  Results were normalised to the endogenous control GAPDH 
and are shown relative to expression in untreated cells.  A – Relative 
abundance of HRASL3.  B - Relative abundance of Carbonic 
Anhydrase XII (CAXII). C - Relative abundance of Cathepsin D 
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Figure 3.14: Flow cytometry following Annexin V and Propidium 
Iodide staining, examining the effects of HRASL3, CAXII, CTSD 
knockdown on cell survival in MCF7 wildtype cells.  
Cells were harvested and stained 72 hours following transfection with 
specific siRNAs or non-silencing control.  “Transfection reagent” cells 
were treated with oligofectamine alone.  “Non-silencing cells” were 
transfected with a non-silencing control sequence.  The effects of two 
independent siRNA sequences for each gene were compared.  siRNAs 
were transfected for a final concentration of 12.5nM.  An increase in cell 
death is seen with the addition of transfection reagent and also following 
the use of the non-silencing control.  No dramatic increase in cell death 
seen consistently on silencing of HRASL3, CAXII.  However there 
appears to be a marginal increase in the proportion of apoptotic cells 
following silencing of CTSD. 
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Figure 3.15: Cell counts examining the effects of HRASL3, CAXII 
and CTSD siRNA knockdown on cell proliferation in hormone 
manipulated MCF7 wildtype cells.  
Cells were transfected with specific siRNAs to HRASL3, CAXII, CTSD, 
non-silencing control or mock transfected with oligofectamine 
“Transfection reagent”, “untreated” cells were not transfected. The 
effects of two independent siRNA sequences for each gene were 
compared.  siRNAs were transfected to a final concentration of 12.5nM.  
24 hours following siRNA transfection, the media was changed to either 
10-8M β-oestradiol containing media, oestrogen deprived media or 
media containing 10-7M 4-OH tamoxifen.  After a further 48 hours, the 
cells were counted using a coulter counter.  The mean cell counts per ml 
in duplicate experiments are shown and error bars indicate the standard 
deviation of the mean.  Reduced numbers of cells are obtained following 
oestrogen deprivation or the addition of tamoxifen in all the samples.  
There appears to be no additional effect from silencing HRASL3, CAXII 
or CTSD. 
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3.4.2 Overexpression of NR4A2, ATP1B1 and SOCS2 in MCF7 wildtype 
cells  
IMAGE clones were obtained for the genes that had been identified as over-
expressed in the tamoxifen resistant cell lines.  The cDNA inserts from the 
IMAGE clones were subcloned into pcDNA3.1 vectors and sequences were 
checked.  Radiolabelled protein was made from each construct via IVT to 
confirm that each vector was capable of expressing a protein of the expected 
size, see Figure 3.16.    
 
The pcDNA3.1 vectors were transfected into wildtype MCF7 cells and stably 
transfected cells were selected using neomycin.  A kill curve was performed 
which gave 800µg/ml as an appropriate dose for selection, resulting in 100% 
cell death within two weeks for untransfected cells.  After two weeks, the level 
of neomycin selection was reduced to 500µg/ml “maintenance “ neomycin.  
Over the next three months, individual colonies of cells were grown up and 
transferred into 24 well plates once they had a achieved a suitable size. 
 
Eventually, once the colonies had attained sufficient numbers, cells were 
harvested for RNA purification and the levels of gene expression were 
assayed using qRT-PCR.  From this experiment, a total of 24 NR4A2 colonies 
were obtained, ten ATP1B1 colonies were obtained and five SOCS2 colonies.  
The results for five of each of the stable colonies, which were assayed by 
qRT-PCR, are summarised below, (Table 3.7). 
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NR4A2  ATP1B1  SOCS2 
EV1 0.8 EV1 0.9 EV1 0.8 Control, 
empty vector EV2 1.0 EV2 1.0 EV2 1.0 
NR1 1.5 ATP1 0.8 S1 0.4 
NR3 1.8 ATP2 2.4 S2 1.0 
NR10 2.7 ATP3 0.5 S5 1.7 
NR15 1.8 ATP7 0.3 S3 1.0 
Colonies 
from cells 
transfected 
with 
expression 
constructs NR25 1.3 ATP10 2.7 S4 0.8 
  
Table 3.7. Relative expression of NR4A2, ATP1B1 and SOCS2 in MCF7 
cell stably transfected with pcDNA3.1 expression constructs measured 
by qRT-PCR.  Values were normalized to the endogenous control 18SrRNA 
and are given relative to expression in cells stably transfected with the empty 
vector pcDNA3.1 (EV2).  
 
Moderate levels of over-expression of the relevant genes in comparison to 
cells transfected with vector alone (EV1 and EV2) are seen in a number of the 
colonies obtained.  The colonies selected for further study are highlighted in 
bold.  Three clones of cells over-expressing NR4A2 were selected (NR3, 
NR10 and NR15) two colonies over-expressing ATP1B1 were selected (ATP2 
and ATP10).  One colony over-expressing SOCS2 (S5) was selected.   
 
These cells were used to perform an MTS assay to ascertain the proliferation 
of the cells in response to increasing concentrations of 4-OH tamoxifen.  The 
results of this are not shown since no significant differences were seen in the 
proliferation rates of the transfected cells compared to wildtype when 
incubated with tamoxifen. 
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Figure 3.16: Autoradiograph of 35S-methionine labelled IVT  
products confirming the size of proteins expressed from 
pcDNA3.1 constructs with NR4A2, ATP1B1 and SOCS2 inserts.  
TnT coupled transcription/translation kit (Promega) was used to 
transcribe the vector inserts and subsequently translate the RNA 
template into protein. Radio-labelled 35S-methionine, was included in 
the incubation and proteins were separated by electrophoresis on a 
denaturing SDS-PAGE gel prior to autoradiography.   
Protein bands of the expected size were obtained from all three 
constructs. 
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3.5 SUMMARY: 
• The three MCF7 cell lines (wildtype, Tam R Early and Tam R Late) 
showed comparable rates of growth in media without tamoxifen. 
 
• The three MCF7 cell lines (wildtype, Tam R Early and Tam R Late) 
showed a similar increase in growth on addition of 17β-oestradiol to 10-
8M. 
 
• In the presence of 4-OH tamoxifen at 10-7M, the tamoxifen resistant 
MCF7 sublines, Tam R Early and Tam R Late showed increased 
growth, while wildtype MCF7 cells showed significantly inhibited 
growth. 
 
• In the presence of fulvestrant at 10-7M, the tamoxifen resistant MCF7 
sublines showed increased growth compared to the wildtype MCF7 
cells. 
 
• At increasing concentrations of tamoxifen, the wildtype MCF7 cells 
showed progressively reduced proliferation from 10-8M.  In contrast, the 
tamoxifen resistant MCF7 sublines showed maximal proliferation in the 
range 10-8M to 10-5M tamoxifen 
 
• All three MCF7 cell lines (wildtype, Tam R Early and Tam R Late) 
showed no proliferation at 10-4M tamoxifen. 
 
• Quality control metrics for 100% (9/9) of the HG-U133A chips 
hybridised were found to be satisfactory indicating that the initial RNA 
preparation, cDNA target preparation and chip hybridisation were of an 
acceptable standard. 
 
• Pairwise analysis of the data obtained from the expression arrays by 
scatter and MVA plots demonstrated a reasonable degree of similarity 
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between the chips and a linear scatter of signal across a wide dynamic 
range, indicating that the chips were comparable. 
 
• Scatter and MVA plots for the replicate group mean values 
demonstrated a greater degree of similarity between the resistant cell 
lines than between the wildtype and resistant pairs. 
 
• 140 differentially expressed genes were identified comparing replicate 
groups of cells lines, using a t-test with a false discovery rate cutoff of 
0.05 
 
• A number of known oestrogen responsive genes were independently 
identified in the study as down-regulated in tamoxifen treated cells, 
providing some in silico validation for the expression analysis. 
 
• A striking feature from the list of differentially expressed genes was the 
presence of a number of genes involved in steroid metabolism and 
transport.  These features were identified both by a subjective, 
literature-based analysis of the gene lists and by an objective, gene 
ontology approach. 
 
• A number of the genes identified can be placed in consecutive or 
closely related positions in pathways leading to enhanced inactivation 
and excretion of tamoxifen and metabolites in the resistant lines by the 
down-regulation of a putative tamoxifen recycling pathway (SULF1 and 
SULT1A1) and concurrent up-regulation of catabolic enzymes (AKRs 
and UGTs) and transport molecules (ABCs).  
 
• Some of the genes identified are already known to influence the clinical 
response to tamoxifen (ABCs and SULT1A1) in breast cancer. 
 
• A number of these genes have not previously featured in expression 
analysis of tamoxifen resistance in breast cancer and their presence 
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provides the basis for further research into their potential clinical 
significance in tamoxifen resistance. 
 
• Six genes were selected for further validation and investigation as 
follows: HRASLS3, Carbonic anhydrase XII, Cathepsin D, ATP1B1, 
suppressor of cytokine signalling (SOCS2) and NR4A2. 
 
• qRT-PCR estimation of the abundance of the six genes (HRALSL3, 
CAXII, CTSD, ATP1B1, SOCS2, NR4A2) in the MCF7 cell lines 
correlated well with the expression analysis data, thus providing further 
validation for the results obtained from the microarrays. 
 
• Immunocytochemical analysis of CAXII expression in MCF7 cell 
suspensions provided validation for the array results for this gene at the 
protein level. 
 
• A comparative analysis was made of the abundance of the six selected 
genes (HRALSL3, CAXII, CTSD, ATP1B1, SOCS2, NR4A2) across a 
panel of ER positive and ER negative breast cancer cell lines by qRT-
PCR; demonstrating that the expression of these genes is not confined 
to MCF7 cells. 
 
• Comparison in expression of the selected genes (HRALSL3, CAXII, 
CTSD, ATP1B1, SOCS2, NR4A2) in oestrogen deprived T47D and 
ZR75-1 cells and their wildtype counterparts by qRT-PCR 
demonstrated some similarities in differential expression to the patterns 
seen in the tamoxifen resistant MCF7 cells, indicating that these genes 
may be involved in mechanisms of oestrogen independent growth that 
are common to a variety of breast cancer cell lines and therefore may 
have broader applicability in clinical samples.    
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• Expression of HRASL3, CAXII and CTSD, (down-regulated in 
tamoxifen resistant MCF7 cells) was successfully silenced by transient 
transfection with specific siRNA sequences in wildtype MCF7 cells. 
 
• Using FACS analysis following Annexin V and Propidium Iodide 
staining, rates of cell death and apoptosis were estimated following 
siRNA knockdown of HRASL3, CAXII and CTSD in wildtype MCF7 
cells.  A marginal increase in apoptosis was seen in cells following 
CTSD knockdown. 
 
• The effects of HRASL3, CAXII and CTSD siRNA knockdown were 
examined by assessing proliferation of hormone manipulated MCF7 
cells.  No significant effects were observed following siRNA knockdown 
of these genes. 
 
• Expression constructs containing NR4A2, ATP1B1 and SOCS2 (up-
regulated in tamoxifen resistant MCF7cells) were made and stably 
transfected into wildtype MCF7 cells after bi-directional sequencing and 
IVT confirming the size of the protein products. 
 
• The effect of tamoxifen on the growth of cells stably transfected with 
NR4A2, ATP1B1 and SOCS2 was investigated by MTS assay, no 
differences in tamoxifen sensitivity were found. 
 
• Sense and antisense riboprobes were created for the following genes: 
ATP1B1, SOCS2 and NR4A2 for ISH. 
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CHAPTER 4 – RESULTS 
 
Towards a clinical study of expression 
analysis of tamoxifen resistant breast 
cancer 
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4 RESULTS: Towards a clinical study of expression 
analysis of tamoxifen resistant breast cancer  
Following the cell line study described in Chapter 3, a retrospective clinical 
study was planned using expression profiles of frozen tissue samples, aiming 
to identify patterns of gene expression associated with resistance and 
sensitivity to tamoxifen. 
 
The samples for this clinical study were to be provided by the GSTT/KCL 
Breast Tissue Bank.  A number of fresh frozen samples dating back to the 
1980s are stored within this bank.  Of particular interest to us were samples 
from patients who had participated in the EORTC 10850 & 10851 studies 
325,326
.  These clinical trials, which were carried out in the 1980s compared 
surgical treatments in 400 elderly patients with primary breast cancer (>70 
years old). Patients were randomised to either treatment with a modified 
radical mastectomy or wide local excision, (WLE). Following surgery, all 
patients received tamoxifen 20mg a day for life, or until evidence of recurrent 
disease.  It was also known that there were samples present from the WLE 
arm of the trial where the tumour had been incompletely excised and the 
patients had not undergone any further surgical intervention.    
 
I have alluded to some of the problems in studying tamoxifen resistance in 
breast cancer in the Introduction, (Section 1.6).  Factors such as: the 
heterogeneity of individual patients, tumour heterogeneity, (morphology, 
receptor status, grade), multi-modal treatments received and the need for long 
term follow up make expression analysis of tamoxifen resistance a difficult 
task. We were hopeful therefore that the samples in the GSTT/KCL Breast 
Tissue Bank would provide a unique opportunity for the study of tamoxifen 
resistance.  The main advantages of using these tumour samples were as 
follows: 
• Long-term, detailed follow up of the patients. 
• Clinical response unconfounded by other treatments, including a small 
number of tumours where the primary tumour was effectively left in situ 
(margin positive, WLE samples). 
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• There were a small number of paired primary and recurrent tumours 
following treatment with tamoxifen.  These provided an opportunity for 
examining the changes in expression profile in the same individual, 
from the same primary pre- and post-exposure to tamoxifen. By 
analysing paired primary and recurrent tumour samples from the same 
individual it is hoped that much of the “noise” due to individual and 
tumour heterogeneity may be excluded from the analysis, enabling the 
identification of a smaller group of biologically relevant genes which 
characterise tamoxifen resistance 
• The samples were selected from a population for whom the 
prolongation of tamoxifen’s effectiveness is highly clinically relevant. 
For elderly patients who may not be physically robust enough to 
undergo treatment with cytotoxic agents, a greater understanding of the 
pathways leading to tamoxifen resistance could be particularly useful. 
• The fresh frozen samples were thought to have been carefully stored 
with good preservation of RNA. 
 
Ethical approval from the local research ethics committee and permission 
from the GSTT/KCL tumour bank committee were necessary to obtain the 
tumour samples. 
 
Since the expression profile obtained from a cDNA microarray depends to a 
large extent on the population of cells from which it originates, Laser Capture 
Microdissection, (LCM) was proposed as a method of selecting and 
separating the various cell populations from a tissue section.  Following LCM, 
purified RNA from the carcinoma cells selected would be used for DIG-
labelled cDNA target preparation and hybridisation to Affymetrix GeneChip 
Human genome HG-U133A microarray chips.  To enable this, pilot studies 
were necessary to establish techniques for laser capture microdissection, 
efficient isolation of RNA from the stored tumour material and validation of 
techniques for expression profiling from small amounts of RNA.  I planned to 
use tumour material from the same era, stored under the same conditions as 
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samples in the proposed study to optimise protocols for LCM and RNA 
purification.   
 
I planned to use RNA from the MCF7 derived tamoxifen sensitive and 
resistant (Late) cell lines to investigate two further methods of target 
preparation for expression profiling. The two target preparation methods 
required different amounts of starting material; the 1µg protocol required 1µg 
of initial total RNA while the 100ng protocol required 100ng of total RNA and 
involved two cycles of amplification to prepare the cDNA target (see Methods 
2.12, Figures 2.3 and 2.4).  I aimed to use the data from the cell line study 
described in Chapter 3 (one cycle target labelling, using 5-10µg starting 
material) and from the literature to perform in silico validation of these 
protocols to establish whether they were robust methods of expression 
profiling suitable for use with the precious stored frozen tumour samples from 
the tumour bank. 
 
4.1 Clinical Study Design 
A retrospective, nested case-control study was planned, using expression 
profiling of frozen tissue samples from patients with a known outcome 
following tamoxifen therapy to examine the changes in gene expression in 
breast cancer samples in a cohort of patients exposed to tamoxifen.   
 
4.1.1 Sample Selection: 
Samples were selected from patients participating in the EORTC 10850 & 
10851 studies whose primary tumours were stored in the Guy's & St Thomas' 
NHS Foundation Trust / King's College London (GSTT/KCL) Breast Tissue 
Bank. A scheme of the selection process is shown in Figure 4.1 below. 
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The sample groups to be compared were as follows: 
• “Tamoxifen Sensitive”: ER/PgR positive (ER +ve), incompletely excised 
tumour, (Margin +ve) without recurrence after 10 years   
• “Tamoxifen Resistant": ER/PgR positive (ER +ve) tumours with paired 
frozen samples of primary tumour and recurrence on tamoxifen paired 
to the sensitive group where possible for patient age, menopausal 
status, tumour grade and histological type 
 
Samples for validation and the preliminary LCM studies were taken 
from unselected, ER positive tumours. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Scheme of sample selection process. 
 
4.1.2 Sample Numbers 
Using the histopathology reports, tumour bank database and clinical records 
of patients participating in the EORTC 10850 & 10851 studies, I screened the 
available frozen samples to identify and ascertain numbers of eligible 
samples, (Figure 4.1) 
 
With the help of the Breast pathology laboratory at GSTH, the original paraffin 
embedded blocks of the primary tumours were reviewed by Dr Corrado 
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D’Arrigo to confirm the morphology and grade of selected tumour specimens.  
Repeat IHC analysis was performed on paraffin sections to confirm ER, PgR 
and ErbB2 status of the samples.  This was done to ensure the tumours were 
selected on the basis of modern IHC and pathological criteria.  The 
methodology and standards of reporting breast tumour pathology have 
evolved significantly since these samples were originally processed.  The 
presence and location of the fresh frozen tumour samples in the bank was 
also confirmed.  The final numbers of eligible, screened samples for the study 
are summarised below, (Table 4.1).  
 
Table 4.1:  Summary of the proposed sample numbers   
 
4.1.3 Ethical Approval, sponsorship, tumour bank committee 
The study protocol was submitted to the East London and the City Local 
Research Ethics Committee for independent review and study approval was 
obtained.  Barts / QMUL kindly agreed to provide sponsorship and indemnity 
for the project.  An application for approval by the GSTT/KCL Breast Tissue 
Bank committee was approved after a lengthy delay (see Discussion). This 
effectively meant that the samples were no longer available for use within the 
time frame of this project therefore the following data is limited to my 
preliminary work for this study. 
Sample type:  Primary Recurrence Total no. of 
Samples: 
Total no. of 
Individuals 
Sensitive 5 - Fresh 
Frozen & 
Paraffin  
Resistant 10 10 
25 15 
 
Paraffin  Validation 50  50 50 
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4.2 RNA Purification from cell lines 
Initial studies were carried out using tiny samples of breast cancer cell lines to 
optimise the method of RNA extraction from small numbers of cells.  103-105 
MCF7, T47D or ZR75-1 cells were typically used for these experiments. 
Phenol-chloroform extraction was compared to extraction using Trizol.  The 
use of phase lock tubes were evaluated, these are designed to increase the 
yield following phase separation during phenol-chloroform extraction of 
nucleic acid by providing a physical gel barrier between the aqueous and 
organic phases in the microtube.  However when dealing with small volume 
samples, the phase lock tubes did not separate the phases successfully, 
therefore these were rejected.  Two different “carrier” substances were 
evaluated (glycogen and linear polyacrylamide (LPA)) for enhancing the yield 
of RNA following ethanol precipitation, glycogen was found to be preferable 
since it increased the yield of RNA more efficiently.   
 
The use of RNeasy purification columns were also evaluated and the loss of 
RNA compared to that from ethanol-precipitating the RNA.  Although at lower 
concentrations of RNA (eg <20ng/µl) the percentage yield obtained from 
ethanol precipitation was higher (85% vs 70% with a column), the RNeasy 
columns were more reliable since there was no danger of occasionally losing 
a precipitated RNA pellet.  On column and off column DNAse I digestion were 
also evaluated; on column DNase digestion resulted in marginally higher 
yields overall so this was preferred. 
 
Finally, the optimised protocol for cell line RNA extraction was tested on tissue 
samples cut into 8µm sections in a cryotome (2 sections per sample).  The 
quality and quantity of RNA extracted was evaluated by analysis using the 
Agilent Bioanalyzer.  The optimised protocol comprised: TRIZOL 
homogenisation and phase separation, Qiagen RNeasy column, on column 
DNAse I digest, vac-spin to 10µl, (see Methods 2.8.2). 
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4.3 Optimising RNA yield and quality from tissue samples 
Given the heterogeneous nature of breast tumour pathology, the advantage of 
using laser capture microdissection was to allow the expression profiling of 
carcinoma cells rather than the other elements in a tumour sample, for 
example blood vessels, stroma, inflammatory cells, necrotic tissue, which 
might otherwise interfere with the data obtained from the microarrays.  
 
Frozen samples from 2 cases of ER positive primary breast cancer from 
1980s were used to optimise the LCM protocol and estimate the number of 
slides needed for micro-dissection per sample.  A comparison was made of 
RNA yield and quality following different steps of the LCM protocol to 
ascertain a robust, fast protocol for fixing, staining and dehydrating the tissue.  
A balance needed to be struck between over manipulating the tissue and 
potentially allowing endogenous RNAses to degrade mRNA in the sample and 
under-processing the sample which made it difficult to visualise the tissue 
under the microscope, making the LCM procedure less accurate and more 
time consuming. 
 
The mean RNA yields using the optimised protocol (see Methods 2.8.2) 
following three extractions for each condition were as follows: 
Untreated:      510ng/mg 
(RNA extracted directly from homogenised sample) 
Whole Mount:     540ng/slide 
(RNA extracted following cutting, staining, mounting an 8µm section) 
Laser Capture Microdissected:   280ng/slide 
(RNA extracted after processing as above plus LCM of carcinoma cells) 
 
The quality of the RNA purified from the tissue following LCM was assayed by 
the Agilent nanodrop an OD 260 / 280 ratio between 2.1-1.9 was deemed 
acceptable.  
 
A further analysis was performed to examine the rate of deterioration of RNA 
in the tissue samples over time at different temperatures to ascertain whether 
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optimum conditions could be found to store the slides immediately prior to and 
during LCM, (Figure 4.2).  It was not expected that the RNA yield should be 
less when the slides were incubated at lower temperatures, since endogenous 
RNAses would work more efficiently at temperatures closest to 37˚C.  I 
postulated that the degradation of RNA in the tissue was related to the 
humidity of the environment rather that the ambient temperature.  This would 
account for the marked reduction in RNA yield seen in the 10˚C water bath 
and to a lesser extent in the fridge at 4˚C.  It appeared that the degradation of 
RNA was quite gradual at room temperature.  I determined that LCM 
dissection should be limited to 20 mins at room temperature, and there was 
no advantage gained in storing the slides at 4˚C or trying to cool the 
microscope platform.    
 
An informal comparison of the protocols used with the Pixcell II LCM and the 
PALM LCM was also made.  I preferred the PALM system; since I found it 
was faster and more user-friendly.  The time taken to process a slide using 
the PALM system was ~30mins compared to ~40 mins on the Pixcell II LCM.  
Also, the system of catapulting the microdissected areas of cells was more 
reliable using the PALM microscope.  
 
Figure 4.3 shows typical microscope images from the LCM process (see 
Methods).  8µm sections were taken from the tumour blocks, mounted onto 
PALM slides and subjected to the optimised, truncated haematoxylin and 
eosin (HE) staining, dehydration and fixing protocol (see Methods section 
2.9).  5µm sections were also taken at the beginning and end of the block and 
every 10 sections throughout, mounted onto an ordinary glass slide and 
underwent a standard, more prolonged HE staining, dehydration and fixing, 
these slides were covered with Permafluor mount and a glass coverslip.  The 
5µm slides with standard staining provided higher quality images and better 
resolution of the tissue morphology.  These were helpful as a guide for 
equivocal areas in the images obtained from the 8µm, uncovered sections 
used for dissection.   
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Figure 4.2  Bar graph showing the RNA yield from sections of 
breast tissue after incubation at different temperatures for 
various times.  
A sample of stored fresh frozen breast tissue was cut into 8µm 
sections.  The sections on sterile glass slides were allowed to 
incubate a 3 different temperatures: Room temperature on the bench 
18˚ C, at 10˚ C in a water bath and at 4˚C in a fridge.  At the time 
points indicated (0mins, 5mins, 15mins and 30mins), the sections 
were harvested and RNA extracted using the optimised protocol (see 
Methods 2.8.2).  The yields obtained for each slide are plotted on the 
graph.    These are the results from a single experiment. 
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Figure 4.3: Laser capture microdissection of breast tumour  
A – Fresh frozen breast tumour section (5µm) on a glass slide, fixed 
and stained with haematoxylin and eosin, with a coverslip overlaid.   
B - 8µm section on a PALM slide (no coverslip) following rapid H&E 
staining, prior to LCM. 
C - 8µm section on a PALM slide following LCM of carcinoma tissue; 
darkening at the margin of dissection can be seen due to local 
heating of the tissue. A faint rim is also seen inside the dissected 
area corresponding to the cut edge of the film covering the slide. 
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It was encouraging to be able to extract high quality total RNA from frozen 
samples stored in the same bank and from the same era as those we 
proposed to use in the study.  It therefore seemed likely that the tumour 
samples had been successfully stored under carefully controlled conditions.  It 
was also encouraging that the amounts of RNA extracted following LCM were 
sufficient to make either target preparation protocol feasible.   If the 100ng 
protocol were used, it would only be necessary to microdissect a single slide 
to provide sufficient total RNA for a microarray.  If the 1ug protocol were 
considered then approximately 5 slides would need to be microdissected per 
microarray.  This would depend to some extent on the cellularity of the 
samples, I felt that dissecting ~5 slides per chip would still be feasible for a 
small study of 25 chips.   
 
4.4 Comparison of 1ug and 100ng target preparation protocols. 
Expression profiles from tamoxifen-resistant (late) and wildtype MCF7 cell 
lines were produced using the Affymetrix GeneChip Human genome (HG-
U133A) high-density oligonucleotide arrays. Comparisons were made 
between three different target-labelling protocols, (5-10ug, 1ug, 100ng). 
Triplicate chips were hybridized for each cell line with each target preparation 
protocol.  A summary of the chips hybridized is shown below in Table 4.2.  
(Data from the chips hybridized using the 5-10µg protocol were discussed 
previously in Chapter 3) 
 
Starting Target    Outline of Total No  
material:      Preparation:        protocol of Chips: 
100ng  Two-cycle amplification   Figure 2.4  8 
1µg  One-cycle amplification   Figure 2.3  6 
5-10µg One-cycle amplification   Figure 2.3  9  
 
Table 4.2 A summary of the Affymetrix protocols for comparison 
including the number of chips hybridized 
 
The criteria used for QC metric for Affymetrix chips determined by the Tumour 
Analysis Best Practices Working Group are outlined in Chapter 3, (Section 
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3.2.2).  Reviewing the results displayed in Table 4.3; using the 100ng 
protocol, involving two cycles of amplification, 3 out of 8 chips were rejected 
due to poor QC metrics.  Table 3.2 shows the QC metrics from the 5-10µg 
protocol chips, for comparison.  The aberrant results, which were grounds for 
rejection of the three chips, are highlighted in bold in Table 4.3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3  QC metrics for HG-U133A chips using 100ng and 1ug 
protocols 
 
Two of the 100ng chips were rejected due to high GAPDH 3':5' ratio 
measurements.  The GAPDH 3’:5’ ratio reflects the extent of RNA degradation 
during target preparation and also the efficiency of the IVT reaction.  
Degradation of source RNA is likely to be a problem specifically related to the 
two-cycle amplification protocol, (see Discussion 6.2 for further explanation).  
It is possible to see from the cRNA yield after the second round of 
amplification that the IVT reaction was inefficient for these two chips  (Column 
6, Table 4.3). 
 Target preparation Chip hybridisation 
Amplification Protocol, Cell 
line + replicate 
number: 
Chip file name initial RNA 
260:280 
total 
RNA Round 
1 
Round 
2 
%P GAPDH 3':5' ratio 
Recommended values - 1.8-2.1 > 4 >400 >25% <3 
1µg Late 1 ONE_L1_A.txt 1 µg 1.8 83 - 49.6 0.87 
1µg Late 2 ONE_L2_A.txt 1 µg 1.8 61 - 50.3 0.96 
1µg Late 3 ONE_L3_A.txt 1 µg 1.8 70 - 50.2 1.54 
1µg wildtype 1 ONE_wt1_A.txt 1 µg 2 64 - 47.7 0.92 
1µg wildtype 2 ONE_wt2_A.txt 1 µg 2 69 - 45.5 0.89 
1µg wildtype 3 ONE_wt3_A.txt 1 µg 2 46 - 49.0 0.91 
100ng Early 1 MCF7_SSE 100ng 2.1 9.2 350 42.5 7.23 
100ng Late 1 MCF7_SSL 100ng 1.8 12 276 46.2 4.14 
100ng Late 2 MCF7_ssL2 100ng 1.8 8.3 876 46.9 2.27 
100ng wildtype 2 MCF7_ssWT2 100ng 2 3.8 724 48.0 2.17 
100ng wildtype 3 MCF7_ss_wt3 100ng 2 7.7 699 42.6 1.93 
100ng wildtype 4 MCF7_ss_wt4 100ng 2 8.4 728 41.4 2.41 
100ng Late 3 MCF7_ss_L3 75ng 1.8 4.5 672 49.7 1.91 
100ng Late 4 MCF7_ss_L4 75ng 1.8 3.9 985 24.8 1.51 
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One of the chips, “100ng Late 4” was rejected due to high background, this 
was flagged up on visual review of the chip following scanning and was 
measured by the scanner as an average background of 546, while all the 
other chips in the study showed an average background of ~50.   Using the 
QC metrics from The Tumour Analysis Best Practices Working Group report 
this shows up as a low percent present <25%183.  The possible reasons for 
this high background reading are considered further in the Discussion 
(Section 6.2). 
 
From the QC metrics, I felt an unacceptably high proportion of chips from the 
100ng protocol were lost due to poor quality QC metrics and that the 100ng 
protocol would not be suitable for expansion into a clinical study.  However, I 
went on with data analysis including the 100ng chips to further investigate the 
data obtained.  In order to allow comparison of triplicate replicate groups for 
the 100ng protocol, we included in the analysis the “100ng Late 4” chip with 
high background.  The “100ng Early 1” and “100ng Late 1” chips were 
excluded from the analysis. 
 
4.4.1 Data analysis of Affymetrix 1µg and 100ng chips 
The results from chips obtained by each of the different target preparation 
protocols were analysed separately, in the same manner described in Chapter 
3.  Initially, dendrograms were obtained by unsupervised hierarchical 
clustering of the data (Figure 4.4).   From this we can see that the chips from 
both protocols are able to cluster the chips according to the cell line. 
 
MVA and scatter plots were obtained comparing chip pairs from the different 
target preparation protocols, (Figure 4.5 - 1µg and Figure 4.6 - 100ng).  From 
Figure 4.6, the “100ng Late 4” chip with high background is not comparable to 
the other chips involved in the experiment.  This is shown by an asymmetrical 
pattern in the MVA plots for 100ng Late 4, a greater degree of scatter in the 
MVA plots and bent,  “banana-shaped “ scatter plots, which correlate over a 
smaller dynamic range than the other chip pairs.  This is because a 
disproportionate number of low signal intensities are present in the data from 
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the 100ng Late 4 chip, making it incomparable with the other chips in the 
experiment. 
 
Figure 4.7 shows scatter and MVA plots for the replicate group mean values, 
ie for each cell line.  If 4.7A, the 1µg protocol data is compared with that 
obtained from the 5-10µg protocol in Figure 3.6, a similar pattern of 
symmetrical variation over a wide dynamic range is seen.  For the 100ng 
protocol in 4.7B, an asymmetrical pattern in the MVA plot is seen and the 
scatter plot is distorted into a “banana-shape “.  Again this is due to the 
influence of the 100ng Late 4 chip. 
 
4.4.2 Differential gene expression from 1µg and 100ng chips 
The data from chips prepared from the different protocols were normalised 
separately, (using the methods previously described in Chapters 2 and 3, 
Section 2.12.5).  Supervised analysis was used to identify differentially 
expressed genes between the replicate groups (cell lines Wildtype vs Late).  
Differential genes were identified between the groups using a t-test with a 
False Discovery Rate (FDR) cutoff of 0.05. This represents a corrected p-
value using Benjamini Hochberg multiple testing correction. 
 
The number of probe sets identified as differentially expressed comparing wt 
and Late replicate groups from the 1µg protocol was 2773.   This figure differs 
somewhat from the 155 differentially expressed probesets identified from the 
5-10µg protocol described in chapter 3, (Section 3.2.5) suggesting a wider 
variation in the signal intensities using the 1 µg protocol.  For the purposes of 
this report, this large genelist has been filtered for fold change < 0.5 or >2.0, 
leaving 103 probesets, (corresponding to 91 genes) remaining, these are 
listed in Table 4.4. 
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Figure 4.4:  Heat map and Dendrogram resulting form 
unsupervised hierarchical clustering per chip.  
Chips were clustered according to the signal from every gene on the 
array using hierarchical clustering with a Pearson correlation 
similarity measure. The colour bar represents the different cell lines 
with blue representing wildtype MCF7 cells, red Late.   
A  - 1µg protocol; the chips cluster according to their cell line.   
B - 100ng protocol; 2 of the wildtype chips cluster together, 100ng 
Late 4 clusters away from all the other chips.   
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Figure 4.5 Pairwise scatter and MVA plots for 1µg protocol 
chips, wildtype and Late.   
Plots comparing gene expression data from all the pairs of hybridised 
chips are shown in a matrix. The scatter plots show the signal 
intensities after log2 transformation for each gene on the microarray 
chip plotted against each other.  MVA plots display the log intensity 
ratio M = log2 (chip1 / chip 2) versus the mean log intensity A = log2 √ 
(chip
 
1 x chip 2). Note that for the MVA plots, a varying y-axis is 
used.   
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Figure 4.6 Pairwise scatter and MVA plots for 100ng protocol 
chips; Wildtype and Late.   
Plots comparing gene expression data from all the pairs of hybridised 
chips are shown in a matrix. The scatter plots show the signal 
intensities after log2 transformation for each gene on the microarray 
chip plotted against each other.  MVA plots display the log intensity 
ratio M = log2 (chip1 / chip 2) versus the mean log intensity A = log2 √ 
(chip
 
1 x chip 2). Note that for the MVA plots, a varying y-axis is 
used.   
 
 
Late 4 
Late 2 
Late 3 
Wildtype 2 
Wildtype 3 
Wildtype 4 
MVA plots 
Pairwise scatter plots 
 216
 
Figure 4.7 Scatter and MVA plots of the mean values for the 
replicate groups (cell lines Late and Wildtype) using the two 
different protocols (1µg and 100ng).   
These plots give an idea of the degree of differential expression 
between the three different cell lines.   
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Figure 4.8 Graphs plotting the log ratios of Late against wildtype 
(WT) derived from each protocol (5-10µg, 1µg and 100ng) 
against each other.  
These graphs give an indication of the variability in fold change 
between the protocol groups.  Graphs C,F,G,H (ie those derived from 
the 100ng protocol) result in a wider, more uneven distribution of 
data points than those involving only the 5-10µg and 1µg protocols.  
This is confirmed by the correlation coefficients of the plots, (Table 
4.6). 
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Due to the problem with the outlying “100ng Late 4” chip, with high 
background there were no statistically significant genes identified at a 0.05 
FDR threshold for the 100ng protocol.  Instead, the “top 100” statistically 
significant genes were listed for this protocol, and subsequently filtered by a 
fold change above (<0.5 or >2.0) between the replicate groups wt and Late.  
This resulted in selection of only 20 genes, therefore this parameter was 
adjusted to encompass a wider fold change of <0.8 or >1.2, resulting in the 
selection of 57 probesets representing 54 genes, listed in Table 4.5. 
 
4.4.3 Comparison of the 5-10µg protocol with 1µg and 100ng protocols 
Graphs were plotted to show the log ratios of the replicate groups: Late 
against wt derived from each protocol against the others, in pairs. These 
graphs, (Figure 4.8) give an indication of the variability in fold change between 
the protocol groups.  The correlation coefficients for each of the comparisons 
were calculated and are summarized in Table 4.6 below.   
 
Protocols compared:  correlation 
coefficient: 
5-10µg vs. 1µg 0.7421321 
5-10µg vs. 100ng 0.6540457 
1µg vs. 100ng 0.4833632 
 
Table 4.6 Correlation coefficients obtained from pairwise comparison of 
the log ratios of the cell line replicate groups in HG-U133A chips 
prepared by different Affymetrix protocols 
 
From Table 4.6, looking at the correlation coefficients obtained, the 5-10µg 
and the 1µg protocols are most similar, followed by the 5-10µg and 100ng 
protocols.  The 1µg and 100ng protocols are the most dissimilar.  To put these 
measurements into perspective, the replicate group means for the 5-10µg 
Late and the 5-10µg wildtype correlate with a coefficient of 0.9905344.   
 
From this analysis, the biggest source of variation in the data is due to the 
protocol used to prepare the target for hybridization rather than the source of 
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the RNA.  This is demonstrated both in the unsupervised analysis and in the 
correlation coefficients above.  It was expected that the cell lines compared 
would be very similar to each other, however it is surprising that alterations in 
the protocol produce such profound effects on the expression profiles 
obtained.  
 
A comparison was made between the lists of differentially expressed genes 
obtained from the 5-10µg protocol and those identified from the 1µg and 
100ng chips.  In both Tables 4.4 and 4.5, those genes which were also 
identified as differentially expressed by the standard, 5-10µg protocol are 
denoted “TRUE” in the final column of the table.  A comparison was also 
made using the full, (unfiltered) genelists for each protocol, this is illustrated 
by a Venn diagram in Figure 4.9.  The genelists for the shared genes are 
given in the adjacent tables a, b and c.  Columns 2, 3 and 4 of the tables in 
Figure 4.9 show the number of probesets identified by analysis with each of 
the protocols for a given gene. 
 
4.4.4 Comparison of the cell line expression analysis data from three 
Affymetrix protocols (5-10µg, 1µg and 100ng) with known players 
in tamoxifen resistance. 
Throughout the analysis above I have taken the “standard” data as the 5-10µg 
protocol, the data described in Chapter 3.  I was concerned that there may 
also be a measurement bias present in the 5-10µg protocol gene expression 
profiles.  Because the 5-10µg and the 1µg protocols were very similar to each 
other, the differences in the data obtained when comparing all three protocols 
may in part be due to the similarities in their measurement bias rather than 
reflecting a hierarchy of closeness to the genes which are “truly” differentially 
expressed in the different cells lines.  Therefore, I also wanted to compare the 
data obtained to data from an independent source. 
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          Protocol: 
 
Genelist: 
5-10µg 
(155) 
1µg 
(2773) 
100ng 
(100) 
Literature 
search 
“key players” 
115 
2(2) CTSD 
TFF1 
7(10):  CTSD 
TFF1 
EGFR 
NCOR1 
CITED2 
SERPINE2                                 
FGF13 
0 
Meijer et al. 
7 
1(1) NEDD9 4(4):    EGFR 
 NEDD9 
 KIAA513 
 APP 
0 
Prowse 
27 
0 2(3): KIAAO372   
 ILCST 
1(1): 
RPL34 
 
Table 4.7: Summary of tamoxifen resistance relevant genes shared 
between our cell line experiments and genelists created from three 
independent sources.  
The number of genes in each list is given in bold, the corresponding number 
of probesets is in brackets.  Each column represents the lists of differentially 
expressed genes identified in expression analysis comparing wildtype MCF7 
cells with tamoxifen resistant MCF7 cells, using three different protocols (5-
10µg, 1µg and 100ng).  Each row represents genelists of genes associated 
with tamoxifen resistance from different, independent sources.  The gene 
symbols listed are those genes common to both lists. 
 
I drew up a list of “key player” genes from the literature; consisting of 115 
genes associated with tamoxifen resistance.  Secondly, I obtained data from 
Dr David Prowse who was investigating gene expression in fibroblasts treated 
with short-term tamoxifen; a list of 27 genes induced in the fibroblasts after 24 
hours incubation with tamoxifen.   (Although there are now a plethora of 
studies identifying tamoxifen resistance / response associated genes though 
cDNA microarray158,193,327,328 which would form closer comparators to our 
study, at the time I was conducting my experiments there was little similar 
data.  This genelist was made available to me as a work in progress, it 
seemed reasonable to use it as an independent source of tamoxifen response 
genes) 
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Finally, I used the genelist identified by Meijer et al. from their functional 
screen to identify genes associated with tamoxifen resistance.  In this study, 
ZR75-1 breast cancer cells were infected with retroviral cDNA libraries and 
then selected for proliferation in the presence of 4-OH tamoxifen.  Integrated 
sequences of 25 candidate genes were subsequently identified.  I chose this 
study since it identified tamoxifen resistance associated genes through a 
different approach to expression analysis8 (see Chapter 3, Figure 3.8). 
 
Table 4.7 summarises the handful of genes common to both lists.  Looking at 
Table 4.7, one can see that the 1µg protocol has the largest number of “hits” 
ie more genes in common with the independent or predicted genelists, 
however many more genes were identified as differentially expressed by the 
1µg protocol.  As a proportion of genes from the “parent genelist”, the 
percentage of genes in common are as follows: 5-10µg protocol 3/155 = 
1.9%, 1µg protocol 17/2773 = 0.6%, 100ng protocol 1/100 = 1%.  Therefore, 
the 5-10µg protocol identified proportionately more genes validated by 
independent sources, although this comparison is obviously limited by the 
small numbers of genes in common.  More remarkable perhaps is how few 
genes are found in common, examining the same area of interest, even 
considering that the genelists were obtained using different model systems 
and different techniques.  As mentioned in the Introduction, (Section 1.5.6) 
Fan et al. concluded there was little clinical significance in the low numbers of 
concordant genes found in predictive studies of breast cancer using 
expression analysis 191.   
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Log mean signal 
intensity  Table 4.4: Genes identified as significantly differentially expressed in 
tamoxifen resistant MCF7 derived cell lines – 1ug protocol filtered 
for fold change <0.5 or >2.0 
 
symbol Late wt 
log ratio 
L:wt 
L:wt  
Fold ∆ 
 
probe id 
vs 
5-10ug 
NA GREB1 3.34 8.74 -5.40 0.02 205862_at   
PDZ domain containing 1 PDZK1 4.88 8.62 -3.74 0.07 205380_at TRUE 
adaptor-related protein complex 1, gamma 1 subunit AP1G1 6.62 9.68 -3.06 0.12 215867_x_at   
carbonic anhydrase XII CA12 6.86 9.91 -3.04 0.12 203963_at TRUE 
carbonic anhydrase XII CA12 6.95 9.92 -2.96 0.13 214164_x_at TRUE 
carbonic anhydrase XII CA12 6.25 9.07 -2.82 0.14 210735_s_at TRUE 
cellular retinoic acid binding protein 2 CRABP2 6.27 9.02 -2.75 0.15 202575_at TRUE 
carbonic anhydrase XII CA12 5.20 7.79 -2.59 0.17 204508_s_at TRUE 
growth differentiation factor 15 GDF15 6.73 9.16 -2.43 0.19 221577_x_at   
heat shock 22kDa protein 8 HSPB8 7.77 9.99 -2.22 0.21 221667_s_at   
early growth response 3 EGR3 5.29 7.42 -2.13 0.23 206115_at TRUE 
signal sequence receptor, gamma (translocon-associated protein gamma) SSR3 5.21 7.34 -2.13 0.23 217790_s_at   
solute carrier family 16 (monocarboxylic acid transporters), member 7 SLC16A7 4.48 6.61 -2.13 0.23 207057_at   
cathepsin D (lysosomal aspartyl protease) CTSD 6.90 8.98 -2.08 0.24 200766_at TRUE 
neuropeptide Y receptor Y1 NPY1R 3.98 6.05 -2.08 0.24 205440_s_at TRUE 
ganglioside-induced differentiation-associated protein 1 GDAP1 5.74 7.81 -2.07 0.24 221279_at TRUE 
solute carrier family 16 (monocarboxylic acid transporters), member 6 SLC16A6 5.85 7.86 -2.01 0.25 207038_at TRUE 
WNT1 inducible signaling pathway protein 2 WISP2 6.35 8.30 -1.95 0.26 205792_at TRUE 
dystrobrevin, alpha DTNA 6.02 7.92 -1.90 0.27 205741_s_at TRUE 
dehydrogenase/reductase (SDR family) member 2 DHRS2 5.27 7.17 -1.90 0.27 214079_at   
armadillo repeat containing, X-linked 1 ARMCX1 4.11 5.93 -1.83 0.28 218694_at TRUE 
par-6 partitioning defective 6 homolog beta (C. elegans) PARD6B 4.61 6.40 -1.79 0.29 214827_at   
stanniocalcin 2 STC2 6.46 8.20 -1.74 0.30 203439_s_at TRUE 
S100 calcium binding protein A14 S100A14 8.37 10.06 -1.69 0.31 218677_at   
v-myb myeloblastosis viral oncogene homolog (avian)-like 1 MYBL1 4.19 5.77 -1.58 0.33 213906_at   
glutathione peroxidase 3 (plasma) GPX3 5.65 7.20 -1.56 0.34 201348_at   
eukaryotic translation elongation factor 1 alpha 2 EEF1A2 9.61 11.16 -1.55 0.34 204540_at   
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RNA binding protein with multiple splicing RBPMS 6.59 8.12 -1.53 0.35 209487_at TRUE 
fer-1-like 3, myoferlin (C. elegans) FER1L3 6.49 8.00 -1.51 0.35 211864_s_at TRUE 
NA HSU79274 6.16 7.66 -1.50 0.35 204521_at   
fer-1-like 3, myoferlin (C. elegans) FER1L3 7.53 9.01 -1.48 0.36 201798_s_at TRUE 
chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) CXCL12 5.11 6.55 -1.44 0.37 209687_at   
solute carrier family 7, (cationic amino acid transporter, y+ system) 
member 11 SLC7A11 5.92 7.34 -1.42 0.37 209921_at   
NA P8 6.44 7.86 -1.41 0.38 209230_s_at   
HRAS-like suppressor 3 HRASLS3 6.32 7.71 -1.39 0.38 209581_at TRUE 
polymerase (RNA) III (DNA directed) polypeptide K, 12.3 kDa POLR3K 8.30 9.69 -1.39 0.38 218866_s_at   
UDP-glucose ceramide glucosyltransferase UGCG 7.19 8.57 -1.38 0.38 204881_s_at TRUE 
sulfatase 1 SULF1 5.81 7.16 -1.35 0.39 212354_at TRUE 
phosphoserine phosphatase-like PSPHL 5.16 6.50 -1.34 0.40 205048_s_at   
NA PARG1 5.89 7.21 -1.32 0.40 203910_at   
aldehyde oxidase 1 AOX1 6.53 7.84 -1.31 0.40 205083_at   
villin 2 (ezrin) VIL2 6.82 8.13 -1.31 0.40 208621_s_at TRUE 
glycerophosphodiester phosphodiesterase domain containing 3 GDPD3 6.29 7.60 -1.31 0.40 219722_s_at   
serum/glucocorticoid regulated kinase-like SGKL 3.15 4.45 -1.30 0.41 220038_at   
GA binding protein transcription factor, beta subunit 2, 47kDa GABPB2 7.01 8.30 -1.28 0.41 206173_x_at   
amphiregulin (schwannoma-derived growth factor) AREG 9.46 10.71 -1.25 0.42 205239_at   
aldehyde oxidase 1 AOX1 6.41 7.66 -1.25 0.42 205082_s_at   
trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) TFF1 12.52 13.76 -1.25 0.42 205009_at TRUE 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 2 SLC7A2 4.80 6.04 -1.24 0.42 207626_s_at   
arginase, type II ARG2 5.20 6.43 -1.23 0.43 203946_s_at   
                
UDP glycosyltransferase 1 family, polypeptide A6 UGT1A6 10.17 5.63 4.54 23.26 215125_s_at TRUE 
glycoprotein (transmembrane) nmb GPNMB 8.96 4.47 4.49 22.45 201141_at   
UDP glycosyltransferase 1 family, polypeptide A3 UGT1A3 10.96 6.74 4.22 18.62 208596_s_at TRUE 
aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1 
20-alpha (3-alpha)-hydroxysteroid dehydrogenase) AKR1C1 9.95 6.09 3.86 14.56 211653_x_at TRUE 
UDP glycosyltransferase 1 family, polypeptide A9 UGT1A9 10.71 6.97 3.74 13.38 204532_x_at TRUE 
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aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2 
bile acid binding protein 3-alpha hydroxysteroid dehydrogenase, type III) AKR1C2 10.36 6.67 3.69 12.90 209699_x_at TRUE 
fibrillin 2 (congenital contractural arachnodactyly) FBN2 7.44 3.87 3.57 11.90 203184_at   
distal-less homeo box 2 DLX2 8.50 4.94 3.56 11.82 207147_at TRUE 
UDP glycosyltransferase 1 family, polypeptide A1 UGT1A1 11.06 7.51 3.55 11.72 207126_x_at TRUE 
aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1 
20-alpha (3-alpha)-hydroxysteroid dehydrogenase) AKR1C1 10.48 7.01 3.48 11.12 204151_x_at TRUE 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 12 (GalNAc-T12) GALNT12 10.00 6.65 3.35 10.18 218885_s_at TRUE 
prostaglandin E receptor 4 (subtype EP4) PTGER4 7.46 4.23 3.23 9.41 204897_at   
suppressor of cytokine signaling 2 SOCS2 8.57 5.38 3.18 9.08 203372_s_at TRUE 
UDP glycosyltransferase 1 family, polypeptide A6 UGT1A6 10.13 6.98 3.14 8.84 206094_x_at TRUE 
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II) AKR1C3 7.26 4.14 3.12 8.71 209160_at TRUE 
aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1 
20-alpha (3-alpha)-hydroxysteroid dehydrogenase) AKR1C1 9.96 6.85 3.12 8.67 216594_x_at TRUE 
NA ChGn 7.36 4.27 3.09 8.52 219049_at TRUE 
ATPase, Na+/K+ transporting, beta 1 polypeptide ATP1B1 11.09 8.14 2.95 7.70 201242_s_at TRUE 
ATPase, Na+/K+ transporting, beta 1 polypeptide ATP1B1 10.57 7.76 2.81 7.01 201243_s_at TRUE 
adducin 3 (gamma) ADD3 7.52 4.79 2.73 6.63 201034_at   
suppressor of cytokine signaling 2 SOCS2 9.44 6.85 2.59 6.04 203373_at   
glutathione peroxidase 2 (gastrointestinal) GPX2 8.59 6.01 2.58 5.97 202831_at TRUE 
sortilin-related receptor, L(DLR class) A repeats-containing SORL1 7.24 4.68 2.56 5.91 212560_at TRUE 
E74-like factor 5 (ets domain transcription factor) ELF5 7.64 5.09 2.55 5.85 220625_s_at   
adducin 3 (gamma) ADD3 7.64 5.10 2.54 5.81 201753_s_at   
tripartite motif-containing 2 TRIM2 6.79 4.28 2.51 5.68 202342_s_at   
cytochrome b reductase 1 CYBRD1 7.68 5.19 2.49 5.61 217889_s_at   
bone morphogenetic protein 7 (osteogenic protein 1) BMP7 12.10 9.66 2.45 5.46 209591_s_at TRUE 
dehydrogenase/reductase (SDR family) member 8 DHRS8 7.31 4.89 2.42 5.36 217989_at   
G protein-coupled receptor 37 (endothelin receptor type B-like) GPR37 6.67 4.28 2.39 5.24 209631_s_at   
spermidine/spermine N1-acetyltransferase SAT 8.69 6.31 2.38 5.19 203455_s_at  
acyl-Coenzyme A dehydrogenase, long chain ACADL 6.53 4.16 2.37 5.16 206068_s_at   
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LY6/PLAUR domain containing 1 LYPDC1 8.19 5.83 2.37 5.15 212909_at   
platelet derived growth factor C PDGFC 8.21 5.90 2.31 4.96 218718_at   
integrin, beta 6 ITGB6 6.19 3.90 2.29 4.89 208083_s_at   
coxsackie virus and adenovirus receptor CXADR 8.20 5.94 2.26 4.80 203917_at   
bone morphogenetic protein 7 (osteogenic protein 1) BMP7 10.48 8.22 2.26 4.78 211259_s_at TRUE 
NA AMIGO2 8.65 6.45 2.20 4.60 222108_at TRUE 
zinc finger protein 36, C3H type-like 2 ZFP36L2 11.24 9.04 2.20 4.59 201368_at   
Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse) MEIS2 6.96 4.81 2.16 4.47 207480_s_at   
jagged 1 (Alagille syndrome) JAG1 6.40 4.28 2.13 4.37 209099_x_at   
spermidine/spermine N1-acetyltransferase SAT 9.01 6.89 2.12 4.35 210592_s_at   
midline 1 (Opitz/BBB syndrome) MID1 6.28 4.17 2.11 4.31 203637_s_at   
connective tissue growth factor CTGF 6.38 4.27 2.11 4.30 209101_at   
MyoD family inhibitor domain containing MDFIC 6.41 4.30 2.10 4.30 211675_s_at   
NA FLJ11259 8.52 6.41 2.10 4.30 218627_at   
nuclear receptor subfamily 4, group A, member 2 NR4A2 6.54 4.45 2.09 4.26 216248_s_at TRUE 
acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme 
A thiolase) ACAA2 11.03 8.98 2.05 4.15 202003_s_at TRUE 
neutrophil cytosolic factor 2 (65kDa, chronic granulomatous disease, 
autosomal 2) NCF2 6.85 4.81 2.04 4.11 209949_at TRUE 
dickkopf homolog 1 (Xenopus laevis) DKK1 10.66 8.63 2.02 4.07 204602_at   
NA FLJ21272 7.41 5.40 2.01 4.03 220467_at   
laminin, beta 1 LAMB1 6.52 4.52 2.00 4.00 201505_at   
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Log mean signal 
intensity  
Table 4.5: Genes identified as significantly differentially expressed in 
tamoxifen resistant MCF7 derived cell lines – 100ng protocol top 100, 
filtered for <0.8 / >1.2 fold change 
 
symbol Late wt 
log ratio 
L:wt 
L:wt  
Fold ∆ 
vs 
5-10ug 
  
vs 1ug 
  
probe id 
adaptor-related protein complex 1, gamma 1 subunit AP1G1 7.88 10.73 -2.84 0.14   TRUE 215867_x_at 
carbonic anhydrase XII CA12 7.45 10.05 -2.60 0.17 TRUE TRUE 203963_at 
PDZ domain containing 1 PDZK1 6.17 8.60 -2.43 0.19 TRUE TRUE 205380_at 
cellular retinoic acid binding protein 2 CRABP2 6.96 8.98 -2.01 0.25 TRUE TRUE 202575_at 
stanniocalcin 2 STC2 7.13 9.12 -1.99 0.25 TRUE TRUE 203439_s_at 
RNA binding protein with multiple splicing RBPMS 7.17 8.78 -1.61 0.33 TRUE TRUE 209488_s_at 
carbonic anhydrase XII CA12 6.21 7.71 -1.49 0.35 TRUE TRUE 204508_s_at 
solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 regulator 1 SLC9A3R1 9.65 11.05 -1.40 0.38   TRUE 201349_at 
neuropilin 1 NRP1 7.35 8.60 -1.24 0.42   TRUE 210510_s_at 
sodium channel, nonvoltage-gated 1 alpha SCNN1A 8.66 9.84 -1.17 0.44   TRUE 203453_at 
eukaryotic translation initiation factor 4 gamma, 2 EIF4G2 10.14 11.27 -1.13 0.46     200004_at 
fer-1-like 3, myoferlin (C. elegans) FER1L3 7.05 8.10 -1.05 0.48 TRUE TRUE 211864_s_at 
GDP dissociation inhibitor 2 GDI2 7.86 8.76 -0.90 0.54   TRUE 200008_s_at 
chromobox homolog 3 (HP1 gamma homolog, Drosophila) CBX3 9.84 10.74 -0.89 0.54   TRUE 200037_s_at 
HLA-B associated transcript 1 BAT1 10.32 11.15 -0.83 0.56     200041_s_at 
interleukin enhancer binding factor 2, 45kDa ILF2 9.96 10.77 -0.81 0.57     200052_s_at 
GDP dissociation inhibitor 2 GDI2 11.30 12.11 -0.81 0.57   TRUE 200009_at 
ADP-ribosylation factor 3 ARF3 9.93 10.74 -0.81 0.57     200011_s_at 
splicing factor, arginine/serine-rich 9 SFRS9 10.17 10.95 -0.78 0.58     200044_at 
asparaginyl-tRNA synthetase NARS 10.01 10.80 -0.78 0.58   TRUE 200027_at 
ribosomal protein L35 RPL35 10.76 11.49 -0.73 0.60     200002_at 
jumping translocation breakpoint JTB 11.43 12.14 -0.71 0.61     200048_s_at 
heterogeneous nuclear ribonucleoprotein C (C1/C2) HNRPC 10.69 11.40 -0.70 0.61     200014_s_at 
YY1 transcription factor YY1 10.05 10.73 -0.68 0.62     200047_s_at 
ras homolog gene family, member A RHOA 10.68 11.35 -0.68 0.63     200059_s_at 
discoidin domain receptor family, member 1 DDR1 10.25 10.86 -0.61 0.66     1007_s_at 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 DDX5 10.65 11.26 -0.61 0.66   TRUE 200033_at 
proteasome (prosome, macropain) subunit, beta type, 2 PSMB2 10.64 11.24 -0.60 0.66   TRUE 200039_s_at 
bradykinin receptor B2 BDKRB2 6.40 6.99 -0.59 0.67   TRUE 205870_at 
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eukaryotic translation initiation factor 3, subunit 7 zeta, 66/67kDa EIF3S7 10.24 10.80 -0.55 0.68     200005_at 
enhancer of rudimentary homolog (Drosophila) ERH 10.87 11.41 -0.54 0.69     200043_at 
calpain, small subunit 1 CAPNS1 9.40 9.93 -0.53 0.69   TRUE 200001_at 
ribosomal protein S13 RPS13 11.96 12.48 -0.52 0.70     200018_at 
Parkinson disease (autosomal recessive, early onset) 7 PARK7 11.55 12.06 -0.51 0.70   TRUE 200006_at 
signal recognition particle 14kDa  SRP14 11.09 11.59 -0.51 0.70     200007_at 
TAR DNA binding protein TARDBP 10.20 10.70 -0.50 0.71     200020_at 
ribosomal protein L6 RPL6 11.96 12.45 -0.49 0.71     200034_s_at 
defender against cell death 1 DAD1 10.83 11.31 -0.48 0.72     200046_at 
dullard homolog (Xenopus laevis) DULLARD 8.47 8.95 -0.48 0.72     200035_at 
ribosomal protein L11 RPL11 11.08 11.55 -0.47 0.72     200010_at 
ribosomal protein L9 RPL9 12.10 12.56 -0.47 0.72   TRUE 200032_s_at 
ribosomal protein L24 RPL24 11.32 11.74 -0.41 0.75     200013_at 
PRP8 pre-mRNA processing factor 8 homolog (yeast) PRPF8 9.48 9.86 -0.38 0.77   TRUE 200000_s_at 
ATP-binding cassette, sub-family F (GCN20), member 1 ABCF1 9.57 9.95 -0.38 0.77     200045_at 
ribosomal protein L17 RPL17 12.21 12.56 -0.35 0.78     200038_s_at 
non-POU domain containing, octamer-binding NONO 11.20 11.54 -0.33 0.79   TRUE 200057_s_at 
eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa EIF3S5 11.33 11.65 -0.32 0.80   TRUE 200023_s_at 
growth arrest-specific 6 GAS6 9.19 8.90 0.29 1.23     1598_g_at 
septin 2 SEP2 10.00 9.63 0.37 1.29 TRUE   200015_s_at 
G protein-coupled receptor 143 GPR143 7.54 6.80 0.73 1.66 TRUE TRUE 206696_at 
UDP glycosyltransferase 1 family, polypeptide A3 UGT1A3 8.54 6.69 1.86 3.63 TRUE TRUE 208596_s_at 
UDP glycosyltransferase 1 family, polypeptide A9 UGT1A9 10.57 7.64 2.93 7.61 TRUE TRUE 204532_x_at 
UDP glycosyltransferase 1 family, polypeptide A1 UGT1A1 10.73 7.69 3.04 8.22 TRUE TRUE 207126_x_at 
AKR1C1 10.32 7.16 3.16 8.94 TRUE TRUE 216594_x_at aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1 20-
α (3-α)-hydroxysteroid dehydrogenase) AKR1C1 11.24 7.92 3.32 10.00 TRUE TRUE 204151_x_at 
UDP glycosyltransferase 1 family, polypeptide A6 UGT1A6 10.12 6.73 3.40 10.53 TRUE TRUE 215125_s_at 
aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2 
bile acid binding protein 3-α hydroxysteroid dehydrogenase, type III) AKR1C2 11.13 7.58 3.55 11.73 TRUE TRUE 209699_x_at 
 228
 
A: List of genes shared between standard, 1ug and 100ng identified as differentially 
expressed between wt and Late MCF7 derived tamoxifen resistant cells  
Symbol 5-10ug 1ug 100ng description 
CA12 4 4 2 carbonic anhydrase XII 
AKR1C1 3 3 2 
aldo-keto reductase family 1, member C1 (dihydrodiol 
dehydrogenase 1 20-alpha (3-alpha)-hydroxysteroid 
dehydrogenase) 
UGT1A9 1 1 1 UDP glycosyltransferase 1 family, polypeptide A9 
UGT1A6 2 2 1 UDP glycosyltransferase 1 family, polypeptide A6 
UGT1A3 1 1 1 UDP glycosyltransferase 1 family, polypeptide A3 
UGT1A1 1 1 1 UDP glycosyltransferase 1 family, polypeptide A1 
STC2 1 2 1 stanniocalcin 2 
RBPMS 1 2 1 RNA binding protein with multiple splicing 
PDZK1 1 1 1 PDZ domain containing 1 
GPR143 1 1 1 G protein-coupled receptor 143 
FER1L3 2 2 1 fer-1-like 3, myoferlin (C. elegans) 
CRABP2 1 1 1 cellular retinoic acid binding protein 2 
AP1G1 1 1 1 adaptor-related protein complex 1, gamma 1 subunit 
AKR1C2 1 2 1 
aldo-keto reductase family 1, member C2 (dihydrodiol 
dehydrogenase 2 bile acid binding protein 3-alpha hydroxysteroid 
dehydrogenase, type III) 
 
 
 
 
 
 
 
C: Genes identified by both standard and 1ug protocols as differentially 
expressed comparing wt and Late MCF7 derived tamoxifen resistant cells 
Symbol 5-10ug 1ug 100ng description 
B: Genes identified in standard protocol alone as differentially expressed between wt and 
Late MCF7 derived tamoxifen resistant cells 
Symbol 5-10ug 1ug 100ng description 
TPBG 1   trophoblast glycoprotein 
TCF7L1 1   transcription factor 7-like 1 (T-cell specific, HMG-box) 
NBL1 1   neuroblastoma, suppression of tumorigenicity 1 
KRT15 1   keratin 15 
ISGF3G 1   interferon-stimulated transcription factor 3, gamma 48kDa 
FLJ10901 1   NA 
DNAPTP6 1   NA 
CHST6 1   carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 
C10orf38 1   chromosome 10 open reading frame 38 
SEP2 1   septin 2 
Figure 4.9 Venn Diagram, comparing results from three 
expression analysis protocols (standard 5-10µg in blue, 1µg in
red and 100ng in yellow).  The numbers of differentially expressed 
gene  identified are given in each intersecting group and the 
number of probe sets in a group is given in brackets. 
5-10µg 
100ng 
1µg 
14 
(16) 
0 
(2589) 
0 
111 
(167) 
9 (9) 
(84) 
Table C 
overleaf 
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Symbol 5-10ug 1ug 100ng description 
RBMS1 1 4  
RNA binding motif, single stranded interacting 
protein 1 
GGA2 1 4  
golgi associated, gamma adaptin ear 
containing, ARF binding protein 2 
VIL2 3 3  villin 2 (ezrin) 
SULF1 2 3  sulfatase 1 
SLC39A8 1 3  
solute carrier family 39 (zinc transporter), 
member 8 
SLC16A1 1 3  
solute carrier family 16 (monocarboxylic acid 
transporters), member 1 
SHMT2 1 3  
serine hydroxymethyltransferase 2 
(mitochondrial) 
SAT 1 3  spermidine/spermine N1-acetyltransferase 
RHOBTB3 1 3  Rho-related BTB domain containing 3 
PPP3CA 2 3  
protein phosphatase 3 (formerly 2B), catalytic 
subunit, alpha isoform (calcineurin A alpha) 
PHLDA1 1 3  
pleckstrin homology-like domain, family A, 
member 1 
NR4A2 1 3  
nuclear receptor subfamily 4, group A, 
member 2 
NQO1 2 3  NAD(P)H dehydrogenase, quinone 1 
MARCKS 1 3  
myristoylated alanine-rich protein kinase C 
substrate 
FLJ20618 1 3  NA 
BMP7 1 3  
bone morphogenetic protein 7 (osteogenic 
protein 1) 
     
ALDH3A2 1 3  
aldehyde dehydrogenase 3 family, member 
A2 
UGT1A6 2 2  
UDP glycosyltransferase 1 family, polypeptide 
A6 
UGCG 1 2  UDP-glucose ceramide glucosyltransferase 
Symbol 5-10ug 1ug 100ng description 
TSPAN3 1 2  tetraspanin 3 
SULT1A1 1 2  
sulfotransferase family, cytosolic, 1A, phenol-
preferring, member 1 
ST6GALNA
C4 1 2  
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 4 
SORL1 2 2  
sortilin-related receptor, L(DLR class) A 
repeats-containing 
SOCS2 1 2  suppressor of cytokine signaling 2 
RHOD 2 2  ras homolog gene family, member D 
PAICS 1 2  
phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole 
succinocarboxamide synthetase 
NPR3 1 2  
natriuretic peptide receptor C/guanylate 
cyclase C (atrionatriuretic peptide receptor C) 
LOX 1 2  lysyl oxidase 
KMO 1 2  
kynurenine 3-monooxygenase (kynurenine 3-
hydroxylase) 
KIF5C 1 2  kinesin family member 5C 
KIAA0657 1 2  NA 
HIC2 1 2  hypermethylated in cancer 2 
HDLBP 1 2  
high density lipoprotein binding protein 
(vigilin) 
 
 
GUCY1B3 1 2  guanylate cyclase 1, soluble, beta 3 
FLJ20605 1 2  NA 
FKBP11 2 2  FK506 binding protein 11, 19 kDa 
DUSP10 1 2  dual specificity phosphatase 10 
DTNA 1 2  dystrobrevin, alpha 
DEGS1 2 2  
degenerative spermatocyte homolog 1, lipid 
desaturase (Drosophila) 
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Symbol 5-10ug 1ug 100ng description 
     
ATP1B1 2 2  
ATPase, Na+/K+ transporting, beta 1 
polypeptide 
ABCC3 1 2  
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 3 
XTP3TPA 1 1  NA 
WISP2 1 1  WNT1 inducible signaling pathway protein 2 
VCL 1 1  vinculin 
TPD52L2 1 1  tumor protein D52-like 2 
TFF1 1 1  
trefoil factor 1 (breast cancer, estrogen-
inducible sequence expressed in) 
SRI 1 1  sorcin 
SLC3A2 1 1  
solute carrier family 3 (activators of dibasic 
and neutral amino acid transport), member 2 
SIAH2 1 1  seven in absentia homolog 2 (Drosophila) 
SART2 1 1  
squamous cell carcinoma antigen recognized 
by T cells 2 
RIPK4 1 1  receptor-interacting serine-threonine kinase 4 
QTRTD1 1 1  
queuine tRNA-ribosyltransferase domain 
containing 1 
QPCT 1 1  
glutaminyl-peptide cyclotransferase 
(glutaminyl cyclase) 
PSPHL 1 1   
phosphoserine phosphatase-like 
 
     
PSMD9 1 1  
proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 9 
PRSS8 1 1  protease, serine, 8 (prostasin) 
PIK4CA 1 1  
phosphatidylinositol 4-kinase, catalytic, alpha 
polypeptide 
PCOLCE2 1 1  procollagen C-endopeptidase enhancer 2 
OPN3 1 1  opsin 3 (encephalopsin, panopsin) 
Symbol 5-10ug 1ug 100ng description 
NPY1R 1 1  neuropeptide Y receptor Y1 
NCK2 1 1  NCK adaptor protein 2 
NCF2 1 1  
neutrophil cytosolic factor 2 (65kDa, chronic 
granulomatous disease, autosomal 2) 
MRPL28 1 1  mitochondrial ribosomal protein L28 
LOXL2 1 1  lysyl oxidase-like 2 
LOC51321 1 1  NA 
LCMT1 1 1  leucine carboxyl methyltransferase 1 
LBR 1 1  lamin B receptor 
L1CAM 1 1  L1 cell adhesion molecule 
KLHDC4 1 1  kelch domain containing 4 
KCTD5 1 1  
potassium channel tetramerisation domain 
containing 5 
ITM2C 1 1  integral membrane protein 2C 
HSU79274 1 1  NA 
HRASLS3 1 1  HRAS-like suppressor 3 
GPX2 1 1  glutathione peroxidase 2 (gastrointestinal) 
GPR37 1 1  
G protein-coupled receptor 37 (endothelin 
receptor type B-like) 
GDF15 1 1  growth differentiation factor 15 
GDAP1 1 1  
ganglioside-induced differentiation-associated 
protein 1 
 
GCHFR 1 1   GTP cyclohydrolase I feedback regulator 
GALNT12 1 1   
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 12 (GalNAc-
T12) 
GALE 1 1   UDP-galactose-4-epimerase 
FOXD1 1 1   forkhead box D1 
FN5 1 1   NA 
FLJ20160 1 1   NA 
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Symbol 5-10ug 1ug 100ng description 
EIF2B1 1 1   
eukaryotic translation initiation factor 2B, 
subunit 1 alpha, 26kDa 
EGR3 1 1   early growth response 3 
EGR1 1 1   early growth response 1 
EGFL5 1 1   EGF-like-domain, multiple 5 
DTX4 1 1   deltex 4 homolog (Drosophila) 
DLX2 1 1   distal-less homeo box 2 
DKFZp762E
1312 1 1   NA 
DKFZP566
E144 1 1   NA 
DKFZp564J
157 1 1   NA 
CXADR 1 1   coxsackie virus and adenovirus receptor 
CTSD 1 1   cathepsin D (lysosomal aspartyl protease) 
ChGn 1 1   
NA 
 
     
CaMKIIN 
alpha 1 1   NA 
C16orf45 1 1   chromosome 16 open reading frame 45 
C16orf35 1 1   chromosome 16 open reading frame 35 
Symbol 5-10ug 1ug 100ng description 
BDH 1 1   3-hydroxybutyrate dehydrogenase  
BATF 1 1  
basic leucine zipper transcription factor, ATF-
like 
BAG3 1 1  BCL2-associated athanogene 3 
ASNS 1 1  asparagine synthetase 
ARMCX2 1 1  armadillo repeat containing, X-linked 2 
ARMCX1 1 1  armadillo repeat containing, X-linked 1 
ARL3 1 1  ADP-ribosylation factor-like 3 
AMIGO2 1 1  NA 
ALDOC 1 1  aldolase C, fructose-bisphosphate 
AKR1C3 1 1  
aldo-keto reductase family 1, member C3 (3-
alpha hydroxysteroid dehydrogenase, type II) 
AKR1B10 1 1  
aldo-keto reductase family 1, member B10 
(aldose reductase) 
ADCY9 1 1  adenylate cyclase 9 
ACTR1B 1 1  
ARP1 actin-related protein 1 homolog B, 
centractin beta (yeast) 
ACAA2 1 1  
acetyl-Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A 
thiolase) 
ABCG2 1 1  
ATP-binding cassette, sub-family G (WHITE), 
member 2 
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4.5 SUMMARY: 
• Samples from GSTT tissue bank were assessed for their 
relevance to our study’s aim to identify genes associated with 
tamoxifen resistance 
 
• A small group of frozen tumour samples were identified with 
unique properties,  (comprising: detailed, long term follow up, 
good preservation of samples, paired samples of primary and 
metastases, hormone positive, margin positive samples, elderly 
population, hormone monotherapy) suggesting their expression 
analysis may be relevant in providing insights into tamoxifen 
resistance. 
 
• This group of tumour samples were screened (candidate samples 
were identified from pathology records, clinical data was verified 
from clinical notes, the presence of the samples in the bank was 
confirmed and their morphology was reviewed and repeat IHC 
test were carried out for ER, PgR and ErbB2) 
 
• Screened samples provided the basis for the design of a 
retrospective expression analysis study. 
 
• Successful applications were made to the following committees:  
The East London and the City Local Research Ethics Committee 
for ethical approval, to Barts / QMUL to provide sponsorship and 
indemnity for the project, and to the GSTT/KCL Breast Tissue 
Bank committee to allow use of the tissues. 
 
• Pilot studies were carried out as follows: 
• Optimisation of LCM techniques: staining, laser capture  
• Optimisation of RNA yield from small samples of cells and 
stored tissue. 
• Optimisation of expression analysis from small samples 
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• Comparison of the Affymetrix one cycle (5-10µg and 1µg) protocol 
with the two cycle (100ng) amplification protocol was made.  
Microarray chips were analysed separately and the results 
compared. 
 
• QC Metrics confirmed the two cycle (100ng) amplification protocol 
suffered with high rates of chip rejection 
 
• Unsupervised clustering demonstrated the 1µg protocol out 
performs the 100ng protocol, evidenced by clustering of replicate 
groups together. 
 
• Scatter and MVA plots for individual chips in the two protocols 
appear comparable however the 100ng protocol chip (Late4) is an 
isolated outlier with high background. 
 
• Scatter and MVA plots for the replicate groups using the 100ng 
and 1µg protocols reveal a skewed distribution for the 100ng 
protocol. 
 
• Examining the lists of differentially expressed genes identified, the 
correlation coefficients obtained demonstrate that more genes are 
shared between the 5-10µg and 1µg protocols that with the two 
cycle, 100ng amplification protocol.  
 
• The elements for a clinical study were in place however it was not 
possible to proceed due to extraordinary delays by the custodians 
of the tumour bank. 
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CHAPTER 5 – RESULTS 
 
Knockdown of AP-2α and AP-2γ by 
RNA interference.   
Investigating the effects on ERBB2 
expression in hormonally 
manipulated breast cancer cells. 
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5 RESULTS:  Knockdown of AP-2α and AP-2γ by RNA 
interference.  Investigating the effects on ERBB2 
expression in hormonally manipulated breast cancer cells 
 
RNA interference is an endogenous pathway, now well established as a 
powerful technique allowing the specific knockdown of targeted genes. 
The AP-2 transcription factors are a developmentally regulated family of 
DNA binding proteins. The role AP-2α and AP-2γ play in breast cancer is a 
major focus of research in our lab, (see Introduction 1.6) we were 
therefore interested in developing tools for silencing them.  Previous 
attempts at silencing expression of these genes by antisense methods, 
including morpholinos were unsuccessful.  
 
Initially, I cloned potential siRNA sequences against AP-2γ into the short 
hairpin expression vector, pSuper and attempted to reduce AP-2γ levels in 
MCF7 cells using short-term transfection of these plasmid constructs.  
However, plasmid transfection was relatively inefficient and I saw little 
effect on AP-2γ levels when the whole population was harvested and 
assayed using western blotting.   
 
My next approach was therefore to design siRNA sequences against AP-
2α and AP-2γ, for transient transfection of dsRNA; to confirm that 
reasonable levels of transfection efficiency could be obtained using these, 
then to see if they were effective at silencing our target genes in the 
following breast cancer cell lines: MCF7, ZR75-1, T47D.  Following this, I 
planned to use the most active sequences to construct pRetro-Super-
based vectors to drive the expression of short hairpin RNA (shRNA) so 
that stable cell lines with AP-2γ knockdown could be established.   
 
Using these AP-2 knockdown cells, I hoped to investigate further the effect 
of AP-2 loss on ERBB2 expression in hormonally manipulated cells.  
Previous work in our lab and elsewhere has suggested that AP-2 factors, 
particularly AP-2α and AP-2γ may antagonise the oestrogenic repression 
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of ERBB2 expression in breast cancer cells.  More recent evidence from 
an immunohistochemical study using clinical samples by our collaborators 
at the Tenovus centre has correlated over-expression of AP-2 factors with 
tamoxifen resistance in breast cancer samples (see Introduction 1.8.3 and 
Figure 1.12)6. 
 
Our model suggests that the oestrogen-bound ER competes with AP-2 for 
shared co-factors (CITED2, CBP/p300) at an oestrogen repressible 
enhancer within the first intron of ERBB2 263,270.  These earlier studies 
relied on the transfection of reporter constructs and in vitro investigation of 
transcription factor binding.  To investigate this further, work was planned 
using dynamic Chromatin Immunoprecipitation (ChIP) to try and 
demonstrate AP-2 occupancy in this region of the endogenous ERBB2 
gene. 
 
5.1 RNA interference using synthetic siRNA directed 
against AP-2α and AP-2γ in breast cancer cell lines 
Qiagen's web-based design tool was used to identify optimal 21nt target 
regions within the cDNA sequence of both AP-2α and γ, according to the 
Reynolds et al. siRNA design criteria 278. BLASTn searches were carried 
out to exclude eligible sequences with significant homology to other 
human mRNA. The successful target sequences selected are shown in 
Methods 2.6.1, Table 2.2.   In total, four siRNAs were tested for AP-2γ and 
seven for AP-2α, of these, two proved useful for each gene.  In order to 
control for off-target effects caused by the siRNAs, the effects of two 
independent sequences for each gene were compared.  In addition, a non-
silencing siRNA control sequence (Qiagen) was used for comparison, 
(http://www.qiagen.com/). 
 
In order to optimise transfection conditions for siRNA in the ER positive 
breast lines MCF7, T47D and ZR75-1, the following transfection reagents 
were tried: Lipofectamine 2000 (Invitrogen), Transmessenger (Qiagen) 
and Oligofectamine (Invitrogen).  To estimate the rates of transfection, a 
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fluorescein-labelled control oligonucleotide from Qiagen was used.  Cells 
were seeded onto cover slips in 6 well plates.  The following day they were 
transfected at varying doses of transfection reagent and fluorescein-
labelled control siRNA according to the manufacturer’s recommendations.  
24 hours later, the transfected cells were DAPI stained and observed 
using fluorescence microscopy.  Three separate, representative fields 
were chosen and the number of fluorescing cells / the total number of cells 
in a high power field was counted to estimate the percentage of 
transfected cells for each reagent.  The mean values are shown below as 
% Fluorescence in Table 5.1.   Oligofectamine at a dose of 3µl per six well 
plate was found to produce the highest rates of transfection in all three cell 
lines, (Figure 5.1 A).  Transmessenger was also found to be effective 
although higher rates of cell death were observed in the MCF7 line 
following transfection and the protocol was found to be more complex than 
that for Oligofectamine.  Mechanical disruption with a 21G syringe needle 
to prevent cell clumping was also found to be helpful when plating out the 
T47D and ZR75-1 cells to obtain efficient transfection.  
 
Table 5.1 Optimising transfection of siRNA: comparison of the 
efficiencies of three different transfection reagents in three cell lines.  
  MCF7 ZR75-1 T47D 
   + Syringe  + Syringe  + Syringe 
Transfection 
Reagent: 
Dose 
µl 
% Fluorescence 
 
% Fluorescence 
 
% Fluorescence 
 
Oligofectamine 2 40 38 32 46 6 12 
Oligofectamine 3 48 45 34 61 27 42 
Oligofectamine 4 46 42 29 35 24 28 
lipofectamine 4 21   12  15 
lipofectamine 10 30   21  5 
lipofectamine 20 9   9  10 
Transmessenger 4 32  7 21  22 
Transmessenger 8 41  37 52  31 
Transmessenger 12 45  13 26  10 
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I initially assayed the AP-2γ siRNAs following transfection into MCF7 cells; 
protein levels were measured by Western blotting (see Methods 2.7).  This 
line has high levels of endogenous AP-2γ, but significant knockdown was 
seen 48 hours after transfection.  This effect was further characterised in a 
time course experiment where transfected cells were assayed for AP-2γ 
expression over a week (Figure 5.1 B & C).  AP-2γ expression was 
undetectable between 24 and 96 hours post-transfection.  The onset of 
silencing by siRNA depends on the half-life of the protein targeted.  The 
duration of on-going gene silencing in successfully transfected cells 
depends mainly on the rate of cell division, which results eventually in a 
dilution of activated RISC in daughter cells.  The induction of silencing 
within 24 hours implies that AP-2γ is depleted relatively quickly from the 
cells.  Duration of 3-5 days silencing is typical for rapidly dividing cells 
such as these.  
 
Since MCF7 cells express barely detectable levels of AP-2α, two other ER 
positive lines; T47D and ZR75-1 cells were used to assay the efficacy of 
AP-2α siRNAs.  Despite reasonable rates of transfection (~50%), and 
successful parallel down regulation of AP-2γ, in ZR75-1 and T47D cells, it 
was not initially possible to demonstrate down regulation of AP-2α,  
(results not shown).  Four different AP-2α specific oligonucleotides were 
tried without success.  A further 2 siRNAs were obtained from Dharmacon 
resulting in one successful sequence.  Another useful sequence was 
provided thanks to collaboration with Dr Daniella Taverna, (see Table 2.2).  
It is unusual to find that 5 carefully designed siRNA sequences are 
assayed without success, (see Discussion 6.3). 
 
Following the discovery of two effective siRNAs for each gene, I titrated 
the amount of siRNA transfected to find the lowest effective dose for gene 
silencing.  This is important to minimise off-target effects caused by siRNA 
and to avoid the triggering of innate immune responses in the cells due to 
introduction of siRNA, (see Introduction 1.9.3).  Figure 5.2 shows that the 
sequences were effective at reducing protein levels even at low siRNA 
doses, (final concentration 12.5 nmol). 
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Figure 5.1:  AP-2γ siRNA transient transfection in MCF7 cells 
A - Fluorescence microscopy to estimate transfection rates. Cells were 
DAPI stained 24 hrs after transfection of fluorescein-labelled dsRNA with 
Oligofectamine. (Magnification x 400) 
B - Western blot confirming activity of AP-2γ siRNAs (G1 and G2). 
C - Western blot showing the time course of AP-2γ knockdown.  Lanes 3-
9: cells transfected with AP-2γ siRNA G1, harvested as indicated 
following transfection. 
For both blots: NE: Nuclear extract from untreated MCF7s; Remaining 
lanes (5µg whole cell extract per well); Non-silencing: cells transfected 
with non-silencing control dsRNA; Mock transfection: cells treated with 
oligofectamine, harvested at 72 hours. Blots were probed for AP-2γ; and 
re-probed for Ku70 as a loading control. 
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 240
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Western Blots showing AP-2α siRNA transient 
transfection in ZR75-1 cells 
 A - Silencing of AP-2α expression 72 hours following transient transfection 
with siRNA sequences A1 and A2.  A3 was one of 5 unsuccessful siRNAs 
assayed. Non-silencing cells were transfected with a control siRNA.  Mock 
transfected cells were treated with Oligofectamine only. 
 B - Western blot demonstrating both siRNA sequences (A1 and A2) 
effective in silencing AP-2α at the lowest dose of 12.5nM.  Cells were 
harvested 72 hours post transfection with varying doses of AP-2α siRNA 
sequences: 50 = siRNA final concentration of 50nM, 25=25nM, 
12.5=12.5nM. Lane 7 cells were transfected with both A1 and A2 with a 
final concentration of 25nM of each. For both blots: 10µg of whole cell 
extract loaded, membranes were probed for AP-2α, Ku70 was used as a 
loading control.  
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5.2 Stable AP-2γ RNA interference using shRNA 
generated by pRetro-Super constructs in ZR75-1 and T47D 
cells  
In order to generate stable cell lines with AP-2γ knockdown, a short hairpin 
shRNA insert was designed based on the most efficient AP-2γ siRNA 
target sequence, (see Methods 2.6.3) and cloned into the pRetro-Super 
vector by Chris Williams in our lab, (see Methods, Figure 2.2).  pRetro-
Super includes a Puromycin selection marker 299. 
  
Initially, ZR75-1 cells were chosen for this study since they are ER 
positive, express both AP-2α and γ, and have been extensively analysed 
in the past by our laboratory for hormonal regulation of ERBB2 expression 
263,270
.  Successful transfection was confirmed using a pRetro-Super 
construct containing a GFP insert (pRS GFP), (Figure 5.3A).  Prior to 
transfection, Puromycin concentrations were optimised for selection of the 
cells.  Cells were transfected with the following constructs: pRetro-Super + 
AP-2γ shRNA sequence (pRS AP-2γ), pRetro-Super + mAP-2γ, a 
mismatch control (pRS mAP-2γ), or the empty vector (pRS Empty) (see 
Methods; Figure 2.1).  Selection with Puromycin (2.5µg/ml) was 
commenced 48 hours later.  The positive controls (No selection) were 
overgrown by day 4.  At 10 days: small colonies (10-20 per well) of 
transfected cells were visible while no colonies of cells were visible in the 
negative control (No transfection) wells.  Proliferation of cells transfected 
with either pRS AP-2γ or pRS mAP-2γ, appeared slower than proliferation 
of cells transfected with the empty vector.  After day 14, selection was 
continued with 1.25µg/ ml Puromycin.  After 6 weeks the cells transfected 
with AP-2γ constructs (pRS AP-2γ or pRS mAP-2γ) had died.  Colonies of 
cells transfected with the empty plasmid continued to thrive and were 
successfully transferred onto new plates. The experiment was repeated in 
this cell line and in MCF7 cells with similar results.  After 2 weeks 
selection, a handful of resistant colonies emerged, but by 6 weeks the 
cells transfected with plasmids containing pRS AP-2γ or pRS mAP-2γ 
failed to thrive. 
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I chose to repeat the experiment using T47D cells, another ER positive 
breast cancer line that contains appreciable levels of AP-2γ.  Unlike ZR75-
1 cells, T47D expresses mutant p53; this may protect the cells from 
whatever mechanism was causing their demise.  Resistant colonies of 
T47D cells did emerge and were expanded.  15 colonies transfected with 
pRS AP-2γ were assayed for AP-2γ expression by western blotting, of 
these, only 2 colonies; Clone 4 and Clone 11  (Cl.4 +Cl.11) were found to 
have significantly reduced AP-2γ protein levels, shown in Figure 5.3B.   
Colonies transfected with pRS mAP-2γ were also obtained and as 
expected were found to contain normal levels of AP-2γ, Figure 5.3B. 
 
5.3 Endogenous levels of AP-2α, AP-2γ and ERBB2 in 
breast cancer cells lines MCF7, T47D and ZR75-1 
While stable knockdown lines were being generated, I carefully 
characterised the endogenous levels of AP-2 factors in ER positive breast 
tumour lines.  Figure 5.4 shows the relative abundance of our genes of 
interest (ERBB2, AP-2α and γ in the breast cancer cell lines MCF7, T47D 
and ZR75-1 and their variation in response to hormone manipulation, 
measured by quantitative RT-PCR.  Cells were grown for 72 hours in each 
of the different media before harvesting, RNA purification and quantitative 
RT-PCR, (see Methods 2.11).  N denotes normal media, OD: Oestrogen-
deprived media, ICI: Media with Fulvestrant added.  The results were 
normalised using the endogenous control 18S rRNA and expressed in 
relation to the levels in T47D cells grown in normal media.  In addition, 
previous data from our lab, estimating ERα levels has been placed into the 
scheme: ERα (in molecules per cell): MCF7 107, T47D 105, ZR75-1 104.  
 
Additional data regarding the hormonal regulation of these genes was also 
obtained by re-examining the data obtained from expression analysis of 
the three MCF7 derived cell lines wildtype (wt), Early (E), Late (L), 
obtained after 3 and 6 months continuous growth in tamoxifen containing 
media  (see Chapter 3). 
 243
 
 
 
 
 
 
 
Figure 5.3: Reduction of AP-2γ in T47D cells stably transfected with 
pRETRO-SUPER shRNA constructs.  
A - Fluorescence microscopy of ZR75-1 cells 24 hours after transfection 
with pRS-GFP construct, confirming that a proportion of cells were 
successfully transfected. (Magnification x 400) 
B - Western Blot of 10µg whole cell extract showing partial silencing of AP-
2γ in cells transfected with pRS constructs directed against AP-2γ.  WT 
indicates untransfected T47D cells, pRS EMPTY cells were transfected 
with the empty vector, pRS mAP-2γ cells contain constructs expressing an 
AP-2γ siRNA point mutant, pRS AP-2γ Cl.4 and Cl.11 indicate cells 
derived from single colonies transfected with construct expressing the AP-
2γ specific shRNA sequence, (see Figure 2.2).  Blots were probed for AP-
2γ; Ku70 was used as a loading control.  
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Figure 5.4: Relative expression of ERBB2, AP-2α and AP-2γ in 
hormone manipulated ER positive breast cancer cell lines: MCF7, 
ZR75-1 and T47D.   
Illustrated by the time line above, cells were grown in different media 
as follows: N: Normal media, OD: Oestrogen-deprived media, ICI:  
Media with fulvestrant added (see Table 2.1 for doses and media).  
The relative expression of our genes of interest was measured by qRT-
PCR. Values were normalised to 18S rRNA and are expressed relative 
to untreated T47D cells.  Previous work from Prof Hurst’s lab 
estimating levels of ERα in these different cell lines is illustrated below.  
De-repression of ERBB2 upon oestrogen withdrawal is evident in all 
cell lines; AP-2α levels mirror this response in T47D and ZR75-1 cells.  
In contrast, AP-2γ increases in response to increasing concentrations 
of oestrogen.  
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EGFR epidermal growth factor receptor 
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 
TFAP2A transcription factor AP-2 alpha 
TFAP2B transcription factor AP-2 beta 
TFAP2C transcription factor AP-2 gamma 
ESR1 estrogen receptor 1 
pS2 trefoil factor 1 (estrogen-inducible sequence) 
PCAF p300/CBP-associated factor 
NCOA3 nuclear receptor coactivator 3 
NCOR2 nuclear receptor co-repressor 2 
BCAR3 breast cancer anti-estrogen resistance 3 
CITED1 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1 
CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 
CRI1 CREBBP/EP300 inhibitory protein 1 
Figure 5.5 A and B: Relative abundance of ERBB2, AP-2 family 
members and co-factors in tamoxifen resistant MCF7 cells 
measured by cDNA microarray.  A - Three MCF7 derived cell lines 
were used: MCF7 WT, wildtype cells, MCF7 E, (Early) cells were 
grown in tamoxifen media for 3 months, MCF7 L (Late) cells were 
grown in tamoxifen media for 6 months. Expression profiles were 
obtained for each line using Affymetrix HU133A chips, (see Methods 
2.12 + Chapter 3).  Examining this data, expression levels of selected 
genes were obtained and are shown above.  Mean, normalised values 
for each gene are shown, where possible, values for >1 probeset were 
taken and the mean value is shown, together with the number of 
probesets examined.  Table B details the full names of the genes 
whose probesets were used. 
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Figure 5.6: Correlation between total AP-2 and ERBB2 / 3 
expression following hormone manipulation and / or AP-2 siRNA in 
breast cancer cell lines.   
Results from RT-PCR and cDNA microarray in 3 different breast cancer 
cell lines (MCF7, T47D, ZR75-1) were collated.  Total AP-2, (AP-2α + 
AP-2γ) was calculated and plotted against ERBB2 in A, B, and C.  In D, 
Total AP-2 is plotted against ERBB3 level for ZR75-1 cells only.  This 
was done to examine the effects on expression of these genes of 
varying oestrogenic conditions and following AP-2 siRNA knockdown in 
T47D and ZR75-1 cells.  For B, C, and D, the data series are coloured 
according to the media conditions.  This illustrates a consistent positive 
correlation between total AP-2 and ERBB2/3 in different cell lines 
following various manipulations. The relationships between individual 
AP-2 isoforms and ERBB2 and ERBB3 were also compared but found 
to be less closely and consistently correlated (data not shown).  
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Figure 5.5 summarises results for ERBB2, AP-2 factors and a number of 
related co-factors.  The variation in expression levels in these genes was 
relatively modest, (<2 fold) so they did not pass Genespring filters for 
significantly differentially expressed genes used in the study in Chapter 3.  
However, some of these genes showed consistent expression levels 
across a number of probe sets representing the same gene.  The number 
of probe sets represented by each column is shown under the x-axis.  
 
Examining Figures 5.4 and 5.5, it can be seen that the levels of AP-2α 
broadly correlate with ERBB2 expression across the three cell lines and 
upon withdrawal of 17β-oestradiol in T47D and ZR75-1 cells.  This agrees 
with previous in vitro observations 210,249,254,268,269,329,330 and the majority of 
clinical studies 235,245,265,   (see Introduction 1.7.3 and Figure 5.5). 
 
Expression of AP-2α does not appear to correlate with the levels of ER in 
the three different cell lines as would be expected from the previous IHC 
data 235,236,245,266.  However, all three cell lines are ER positive and AP-2α 
positive.  Looking within the MCF7 derived cell lines in Figure 5.5; a 
correlation of ERα and AP-2α can be seen, although these cells express 
very low levels of AP-2α. 
 
Increasing levels of 17β-oestradiol results in a reduction in the level of AP-
2α, seen in Figure 5.4 and 5.5.  This is consistent with previous findings 
that AP-2α mRNA is down regulated in response to oestrogen treatment in 
ER positive breast tumour derived cell lines 246.  17β-oestradiol has also 
been shown to reduce the transactivating properties of AP-2α in vitro 264.  
 
AP-2γ in contrast, shows a positive correlation with ERα expression in 
Figure 5.4, as would be expected from an oestrogen target gene (see 
Introduction 1.7.2).  However in Figure 5.5 with tamoxifen resistant cells, 
ERα expression increases in “Early” passage cells and then reduces in 
“late” passage cells after continued exposure to tamoxifen, whereas levels 
of AP-2γ progressively reduce during tamoxifen treatment.  AP-2γ 
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positively correlates with increasing levels of 17β-oestradiol as would be 
expected. (Figure 5.4 and Figure 5.5) 
 
From my data, high AP-2γ expression is not associated with increased 
ERBB2 expression either in the microarray data in Figure 5.5 or from qRT-
PCR in Figure 5.4.  This concurs with published IHC studies 235,245,331 
where no correlation between AP-2γ and ERBB2 has been found, (See 
Introduction 1.7.3).  
 
However, a correlation between total AP-2 (α plus γ) and ERBB2 
overexpression in the hormone-manipulated cells is shown in Figure 5.6.  
This was first shown in the IHC data from clinical specimens 235. 
Interestingly, in an unpublished study from our lab, (see Introduction 1.7.3) 
although ERBB2 did not correlate with either AP-2 isoform alone, high total 
AP-2 was associated with an increase in phosphorylated  (active) ERBB2.  
 
Figure 5.7 overleaf, is an attempt to illustrate the findings described above, 
summarising the relationships between AP-2 factors, ERBB2, ERα in the 
cell lines used in this study and also the effect of changes in oestrogen 
level.  
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5.4 Does AP-2 knockdown affect expression of ERBB2 in 
hormonally manipulated cells? 
In order to test the relationships between levels of AP-2 factors and 
ERBB2 further, I wanted to manipulate AP-2 levels in the cell lines using 
siRNA reagents described in the early part of this chapter. Initially, 
hormone manipulated MCF7 and ZR75-1 breast cancer cells were 
transiently transfected with AP-2γ siRNA and levels of ERBB2 expression 
were assayed by Northern blotting, see Figure 5.8.  
 
The cells were pre-treated with 17β-oestradiol, fulvestrant (ICI 182780), or 
their normal media for 24 hours before transfection with siRNA.  Following 
a further 48 hours incubation, RNA was extracted for Northern blotting.  
Blots were probed for the following mRNA species: pS2, an oestrogen 
responsive ER target gene used to demonstrate correct hormonal 
manipulation; AP-2γ, to demonstrate the effect of the AP-2γ specific 
siRNA; ERBB2, to investigate whether the loss of AP-2γ prevents 
induction of ERBB2 in anti-oestrogenic media and finally β-actin as a 
loading control, (Figure 5.8).  Sources of the radiolabelled probes are 
found in Bates and Hurst 270. 
 
Figure 5.7: AP-2α, AP-2γ, ERα and ERBB2 and the effect of 17β-
oestradiol in MCF7, ZR75-1 and T47D cell lines 
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From Figure 5.8, as expected, pS2 expression increases in 17β-
oestradiol-treated cells  (Lanes 3,4 and 9,10) and is reduced in 
Fulvestrant-treated cells (Lanes 5, 6 and 11,12) indicating that hormone 
manipulation of the cells was effective. Meanwhile, ERBB2 expression has 
the opposite pattern, seen in MCF7 cells (lanes 9-12).  Knockdown of AP-
2γ appears to have been partially successful (Lanes 2, 4, 6, 8, 10, 12).  
However there is little discernable effect on the expression of ERBB2.  The 
diffuse bands obtained from the ERBB2 probe and the variation in loading 
(Lanes 1 and 6) makes it difficult to interpret this blot further. 
 
The ERBB2 mRNA is large and this may be partly responsible for the 
diffuse appearance of its bands on Northern blotting. I therefore turned to 
quantitative RT-PCR to try and improve the quantitation of ERBB2 
expression subsequent to hormone manipulation. It is also possible that 
the degree of knockdown of AP-2γ was insufficient to allow detection of 
any meaningful change in expression levels of ERBB2 in the context of 
this rather complex experiment.  
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Figure 5.8:  Northern blot: Examining the effect of AP-2γ 
knockdown on ERBB2 expression in hormone manipulated breast 
cancer cells.    
Northern blot using total RNA from ZR75-1 cell (lanes 1-6) and MCF7 
cells (lanes 7-12).  The cells were grown in different media as indicated: 
Lanes 3,4,9 and 10 cells were grown in appropriate media plus 10-8M 
17β-oestradiol, Lanes 5,6, 11and 12, cells were grown in appropriate 
media with the addition of 10-7M fulvestrant (see Table 2.1).  As 
indicated by the timeline above, following hormone manipulation, cells 
were transfected with AP-2γ siRNA (Lanes 2,4,6,8,10,12) and incubated 
for a further 48 hours prior to harvesting.  A single blot was successively 
hybridised with radiolabelled cDNA probes as indicated, (see section 
2.10).  Bates and Hurst detail the origins of the probes 270.   
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It was hoped that using lines with stable knockdown of AP-2γ would avoid 
much of the sample-to-sample variation observed when using short-term 
transfections.  Figure 5.9 shows the effects of hormone manipulation on 
levels of ERBB2 mRNA in the two T47D sub-lines Cl4 and CL11, stably 
transfected with pRetro-Super expressing AP-2γ shRNA, described above.  
From the figure, it is possible to see that levels of AP-2γ are lower in Cl.4 
and Cl.11, both in normal media and in media with fulvestrant added.  As 
has been observed previously, levels of ERBB2 in these cells are low in 
normal oestrogenic media but increase 5-6 fold in the control cells (wt, EV, 
and mAP-2γ).  The two AP-2γ knockdown lines (Cl.4 and Cl.11) however 
show slightly reduced levels of ERBB2 after anti-oestrogen treatment, 
compared to the three controls.  However the reduction is not as 
significant as would be expected if AP-2γ alone was absolutely required 
for increased ERBB2 expression in anti-oestrogenic media.  Surprisingly, 
there is no appreciable reduction in the levels of ERBB2 expression in the 
presence of 17β-oestradiol in the cells with stable AP-2γ knockdown.   
Levels of AP-2α increase in these cells and this implies that both family 
members control ERBB2 expression similarly and can compensate for 
each other.   
 
One major problem with the stable clones however was that they did not 
exhibit the hoped for reduction in sample-to-sample variation in AP-2γ 
levels.  Subsequent experiments showed sometimes near normal levels of 
AP-2γ suggesting that despite continued Puromycin selection, cells in the 
population were progressively losing expression of the shRNA.  
Reluctantly therefore, I returned to the short term expression format used 
in Figure 5.8, although I adjusted the time course of the experiment so that 
for future experiments the induction of RNAi mediated gene silencing took 
place before hormone manipulation was commenced. 
 
Figure 5.10 shows the effects of transient transfection with AP-2α and AP-
2γ siRNA followed by hormone manipulation in T47D cells.  Panels A and 
B show the effects of AP-2 RNAi on expression of each AP-2 isoform.  The 
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siRNA-induced knockdown is not complete; some expression of the AP-2 
factors is still seen.  This is usual for this method of gene silencing.  
 
 
 
 
 
 
 
Figure 5.9: Relative abundance of ERBB2, AP-2α and AP-2γ in 
hormone manipulated T47D cells with stable knockdown of AP-2γ.   
T47D cells were stably transfected with pRETRO-SUPER constructs as 
follows: WT wildtype, untreated cells; EV stably transfected with pRS 
Empty Vector; Cl4 and Cl11 stably transfected with pRS AP-2γ shRNA 
constructs.  Transfected cells were selected as described in text and 
resultant colonies assayed for AP-2γ (Figure 5.3).  Following the time 
line above, the various cell sublines were seeded and after 24 hours 
the media was replaced to contain either 17β-oestradiol or fulvestrant 
(an oestrogen antagonist).  Quantitative RT-PCR was used to compare 
the relative expression of ERBB2, AP-2α and AP-2γ.  This graph 
shows mean values combined from 2 independent experiments. 
Expression levels were normalised using the endogenous control 18S 
rRNA and are shown relative to wt T47D expression.  Student’s T test p 
value = 0.001 Comparing mean ERBB2 values for non shRNA (WT, 
EV, mut) to AP2-γ shRNA (Cl 4 & Cl 11) in fulvestrant media. 
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Figure 5.10: Relative abundance of ERBB2, AP-2α and AP-2γ in 
hormone manipulated T47D cells following AP-2 knockdown, 
measured by qRT-PCR.  Transient siRNA was used to knockdown AP-
2α (A1, A2) or AP-2γ (G1, G2) individually and together (A1+G1, 
A2+G2). CON indicates control, untransfected cells, NON cells were 
transfected with non-silencing control siRNA.  Blue bars indicate cells 
grown in media with 17β-oestradiol added, red bars indicate cells grown 
in oestrogen depleted media.  The timing of the various manipulations is 
illustrated in the time line at the top of the Figure.  After harvest, cells 
were processed for RNA extraction to measure levels of AP2 factors, (A 
and B) and ERBB2, (C) using qRT-PCR (see Methods 2.11). These 
graphs show mean values combined from two independent 
experiments. Expression levels were normalised using endogenous 
control β-actin and are shown relative to control T47D in 17β-oestradiol 
expression. 
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In Figure 5.10A, knockdown of AP-2α (A1 + A2) results in ~20% 
expression compared to control samples, (con + non). In Figure 5.10B, 
knockdown of AP-2γ (G1 + G2) results in ~40% expression compared to 
the control cells (con + non).  Oestrogenic regulation of the AP-2 factors 
continued to be seen following RNAi mediated gene silencing; upon 
oestrogen depletion, AP-2α increased ~two fold, whereas AP-2γ 
expression decreased also by ~two fold.   When both AP-2α and γ siRNA 
sequences were transfected in combination (A1+G1, A2+G2) AP-2α 
knockdown still appeared to be more effective than AP-2γ knockdown; AP-
2γ expression was ~60% of the control, (con, non) while AP-2α expression 
was ~20% of the control.    
 
Looking at Figure 5.10C, a reduction in the level of ERBB2 normally 
attained on oestrogen withdrawal is seen when either AP-2 isoform is 
knocked down.  However, this appears to be more dramatic in the cells 
with AP-2α knockdown compared to AP-2γ knockdown.  The control 
samples (con, non) showed a five-fold induction of ERBB2 on oestrogen 
withdrawal; knockdown of AP-2γ (G1 or G2) reduced this to a three-fold 
increase; knockdown of AP-2α (A1 or A2) resulted in only a two-fold 
increase in ERBB2 on oestrogen withdrawal. 
 
The effects of transient knockdown on the expression of both ERBB2 and 
ERBB3 were then investigated using tamoxifen treated ZR75-1 cells 
(shown in Figures 5.11 - 5.13). These experiments were also performed 
using oestrogen withdrawal to elicit a response, with similar results (not 
shown). Figure 5.11C shows again that knockdown of AP-2 factors, 
particularly AP-2α; resulted in a reduction in the levels of ERBB2 attained 
on addition of tamoxifen.  
 
 Figure 5.12 shows levels of ErbB2 measured on a Western blot for ZR75-
1 cells.  Again, knockdown of either AP-2 isoform AP-2α, AP-2γ or both 
AP-2α and γ resulted in a reduction in the extent of derepression of 
ERBB2 on withdrawal of 17β-oestradiol.  This implies that both AP-2α and 
AP-2γ positively regulate the expression of ERBB2 in the absence of 
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oestrogen.  This is consistent with the idea that AP-2 factors enhance the 
expression of ERBB2/3 via their specific binding sites in the 
promoter/regulatory regions of these genes, and furthermore that this is a 
potential mechanism for poor response to hormone treatment in breast 
cancer patients on hormone treatment. 
 
Figure 5.13 demonstrates also that the oestrogen responsiveness of the 
related ERBB3 gene is also abrogated by siRNA-mediated knockdown of 
AP-2α or AP-2γ in ZR75-1 cells. 
 
However, unexpectedly AP-2α knockdown results in little or no change in 
ERBB2 expression in the presence of oestrogen (Figure 5.10C, 5.11.  The 
possible explanations for this may be that either oestrogen bound ER is 
dominant over AP-2 regulation of ERBB2 expression or perhaps that 
siRNA knockdown achieved in our experiments was incomplete and 
therefore did not get below the threshold necessary to show a reduction in 
ERBB2 with the loss of AP-2α in oestrogenic media. 
 
In Figure 5.11C, knockdown of AP-2γ alone (G1, G2) resulted in a slight 
increase in ERBB2 under oestrogenic conditions (blue bars).  Looking at 
Figure 5.13, a similar pattern is seen with ERBB3.  Figure 5.12 shows that 
when protein levels are assessed there is no increase in ErbB2, neither is 
this evident on AP-2γ silencing in T47D cells (Figures 5.9, 5.10) Possible 
reasons for this inconsistency in the data include that it is within the error 
range of the RT-PCR experiment.  However the results appear to be 
consistent when measured following transfection with two independent 
siRNA sequences for each gene.  It may be that this is a cell-specific 
anomaly; ZR75-1 cells express much higher levels of AP-2α compared to 
AP-2γ, therefore on knockdown of AP-2α, proportionately more AP-2 is 
lost from the cell. As shown in Figure 5.11A + B, when AP-2γ is knocked 
down, there is a reciprocal increase in the amount of AP-2α in the cells 
grown in oestrogenic conditions and this may give rise to the increase in 
relative abundance of ERBB2 detected by qRT-PCR in Figure 5.11.  
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Figure 5.11: Relative abundance of ERBB2 and AP-2 factors in 
hormone manipulated ZR75-1 cells with AP-2 knockdown, 
measured by qRT-PCR.   Transient siRNA was used to knockdown AP-
2α (A1, A2) or AP-2γ (G1, G2) individually and together (A1+G1, 
A2+G1). CON indicates control, untransfected cells, NON are cells 
transfected with a non-silencing siRNA.  Cells were then subjected to 
hormone manipulation with either addition of 17β-oestradiol (blue bars) 
or tamoxifen (red bars).  Expression levels were normalised using 
endogenous control β-actin and are shown relative to CON ZR75-1 in 
17β-oestradiol.  A - shows the relative expression of AP-2α, B - shows 
the relative expression of AP-2γ, C - shows the relative expression of 
ERBB2.  Figure 5.13 shows the expression of ERBB3 in the same 
samples. 
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Figure 5.12: Western Blot showing the effects on ERBB2 of AP-2 
knockdown in hormone manipulated ZR75-1 cells.  
Transient siRNA was used to knockdown AP-2α (A1) or AP-2γ (G1) 
individually and together (A1+G1). Wildtype indicates untransfected 
cells, CON (Control) cells were treated with oligofectamine, NON 
(non-silenced) cells were transfected with a control dsRNA sequence.  
Cells were then treated with either 17β-oestradiol or grown in 
oestrogen deprived media.  10µg of whole cell extract was blotted to 
membranes and probed for ErbB2, then reprobed for Ku-70 as a 
loading control, (see Methods 2.7). 
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Figure 5.13: Relative abundance of ERBB3 in hormone manipulated 
ZR75-1 cells with AP-2 knockdown, measured by qRT-PCR. 
Transient siRNA was used to knockdown AP-2α (A1, A2) or AP-2γ (G1, 
G2) individually and together (A1+G1, A2+G1).  CON indicates control, 
untransfected cells, NON cells were transfected with a non-silencing 
siRNA control.  Cells were then subjected to hormone manipulation with 
either the addition of 17β-oestradiol, (blue bars) or tamoxifen, (red bars).  
The oestrogenic regulation of ERBB3 can clearly be seen in the CON 
and NON samples. The de-repression of ERBB3 on withdrawal of 
oestrogen is reduced following knockdown of AP-2.  Figures 5.11A and 
B show the level of AP-2 isoforms in these samples and Figure 5.11C 
shows concomitant levels of ERBB2. Expression levels were normalised 
using endogenous control β-actin and are expressed as relative to 
levels in CON ZR75-1 in 17β-oestradiol. 
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However, this does not account for the responses shown when both 
isoforms are knocked down (A1G1/A2G1).  This response looks like an 
aggregate of the responses seen for the knockdown of individual isoforms.   
 
We know from the difficulty in isolating colonies after stable transfection 
with AP-2 shRNA that knockdown of AP-2 is toxic to cells, therefore 
perhaps simultaneous knockdown of both isoforms results in cell death.  
The expression levels seen in these samples may reflect a mixed 
population of surviving cells, some with AP-2α knockdown and some with 
AP-2γ knockdown.   
 
To investigate this further, transiently transfected ZR75-1 cells were 
stained with Annexin V and Propidium Iodide 72 hours following transient 
transfection with AP-2 siRNAs.  The results of flow cytometry analysis are 
shown in Figure 5.14.  From this, increased rates of cell death can be seen 
with AP-2 knockdown.  This is most marked with combined AP-2α and AP-
2γ knockdown, less marked with AP-2γ knockdown and least marked with 
AP-2α knockdown. The effects appear to be independent of the siRNA 
sequence used. 
 
Given the inconsistency between the qRT-PCR data and Western blot 
data, the other possibility is that there is further post-translational 
regulation of ERBB2.  Although this is possible, there is no indication of 
this from other sources.    
 
5.5 Kinetic ChIP to examine binding of AP-2γ and other 
components of the transcription complex to the oestrogen 
repressible enhancer in Intron 1 of ERBB2 
We hoped that kinetic ChIP, (a technique described in Introduction 1.10 
and Methods 2.14) would allow us to demonstrate in ZR75-1 cells binding 
of AP-2 to the endogenous oestrogen repressible enhancer in Intron 1 of 
ERBB2.  This region is thought to contribute significantly to the 
oestrogenic suppression of ERBB2, discussed in Introduction 1.8.4.   
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The results for this are shown in Figures 5.15A and B.   A one-hour time 
course is shown; samples were taken every 5 minutes following release 
from α-amanatin treatment, which halts all transcription.  Figure 5.15A 
shows the responses after cross-linked chromatin was probed with an AP-
2γ specific antibody.  Figure 5.15B shows the response following use of an 
antibody to Acetylated Histone 4.  Immuno-precipitated DNA sequences 
specific to the ERBB2 oestrogen repressible enhancer in the first intron 
were then amplified and expressed as a percentage of total input. 
 
Comparing this data to that obtained by Frank Gannon’s lab where similar 
experiments were carried out on the endogenous promoter of the 
oestrogen regulated pS2 gene, we see a similar pattern of response, both 
in the time course and in the amplitude of response (see Figure 1.16) 296.  
There appear to be cyclical responses lasting ~20 minutes.  The initial 
cycle is of lower amplitude.  This has been interpreted as an initial, 
unproductive cycle of chromatin remodelling coinciding with the initial low 
amplitude peak at ~20 minutes, followed by further productive cycles of 
active transcription, coinciding with the second, higher amplitude peaks of 
AP-2 and Ac-H4.  These results add further evidence to the idea that AP-
2γ participates in the transcriptional regulation of ERBB2 via its specific 
binding sites within the first intronic enhancer of ERBB2.  
 
Subsequent experiments carried out by Karsten Friedrich confirmed that, 
concurrent with the increase in AP-2γ occupancy of the ERBB2 enhancer 
region an increase in occupancy of the AP-2 associated transcriptional 
machinery: CITED2 and CBP/p300 could also be demonstrated. (Helen 
Hurst, personal communication). 
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Figure 5.14: FACS analysis following Annexin V and Propidium 
Iodide staining, examining the effects of AP-2 knockdown on cell 
survival in ZR75-1 cells.  
Cells were harvested and stained 72 hours following transfection with 
AP-2 specific siRNAs or non-silencing control.  Mock-transfected cells 
(CON) were treated with oligofectamine alone.  Non silenced cells 
(NON) were transfected with a non silencing control RNA.    
Increased cell death is seen with AP-2 siRNA; this is greatest with 
combined AP-2α and γ knockdown, less marked with AP-2α and least 
evident with AP-2γ knockdown. 
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Figure 5.15: Kinetic ChIP in α-amanitin treated ZR75-1 cells. 
ZR75-1 cells were treated with α-amanatin to halt transcription; 
following transcriptional release and the addition of oestrogenic 
media, samples were collected taken every 5 minutes over a time 
course of one hour.  Chromatin was cross-linked and protein-DNA 
complexes were immuno-precipitated with AP-2γ specific antibody, 
results shown in Panel A and an antibody to Acetylated Histone 4, in 
Panel B. 
Immuno-precipitated DNA sequences specific to the oestrogen 
repressible enhancer in the first intron of ERBB2 were then amplified, 
quantitated and expressed as a percentage of total input, (see 
Methods 2.14.3). 
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5.6 SUMMARY 
 
• Successful knockdown of AP-2α and AP-2γ using 2 independent 
siRNA sequences for each AP-2 isoform was achieved in the 
following breast cancer cell lines MCF7, T47D, ZR75-1.   
 
• The patterns of AP-2α and AP-2γ and ERBB2 expression observed 
following hormone manipulation of cell lines ZR75-1, MCF7, T47D 
concur with the majority of previous in vitro data and clinical data: 
ERBB2 and AP-2α negatively correlate with oestrogen treatment 
AP-2γ correlates positively with oestrogen 
 
• The effects of AP-2 knockdown on ERBB2 expression were noted 
in T47D and ZR75-1 cells.  Knockdown of either AP-2α or AP-2γ 
resulted a reduction in the derepression of ERBB2 on oestrogen 
withdrawal, suggesting that both AP-2 factors positively regulate 
ERBB2 expression in the absence of 17β-oestradiol. 
 
• Unexpectedly, AP-2α siRNA appears to have a greater effect on 
abolishing the rise in ERBB2 expression on oestrogen withdrawal 
than AP-2γ siRNA. 
 
• siRNA of AP-2α or AP-2γ or both had little effect on levels of 
ERBB2 in the presence of 17β-oestradiol measured by qRT-PCR. 
 
• Increased expression of ERBB2 mediated by AP-2 factors in the 
absence of oestrogen provides a potential mechanism for hormone 
resistance of breast cancers that overexpress AP-2 factors.  
 
• FACS analysis showed that there was an increase in cell death 
secondary to AP2 knockdown. AP-2α and AP-2γ > AP-2α > AP-2γ. 
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• Kinetic ChIP showed the oestrogen-repressible enhancer in the 
first intron of ERBB2 was cyclically permissive to the binding of AP-
2γ.  The epigenetic marker AcH4, (Acetylated Histone 4) indicated 
that AP-2γ binding correlated with active transcription. 
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6 DISCUSSION 
6.1  Expression profiling of MCF7 derived breast cancer 
cell lines: 
It was encouraging to demonstrate that the tamoxifen resistant lines 
were relatively resistant to tamoxifen when compared to their wildtype 
counterparts. Indeed, the tamoxifen resistant sublines exhibit maximal 
growth when exposed to physiologically relevant levels of tamoxifen, 
indicating that they are to some extent dependant on tamoxifen.  
Inhibition of growth of the wildtype MCF7 cells shown in the MTS assay 
occurred at similar concentrations of tamoxifen to those seen by 
investigators at the Tenovus centre, which was also encouraging 260.   
 
The apparent cross-resistance to fulvestrant demonstrated by the 
tamoxifen resistant MCF7 sublines is intriguing and has not been 
previously described in this subline.  Some previous models of acquired 
resistance to oestrogen deprivation retain fulvestrant sensitivity332,333 
while other tamoxifen resistant MCF7 derived cells are fulvestrant 
resistant334.   It would perhaps be interesting to use expression ananlysis 
to try and identify the features specific to fulvestrant resitance and 
characterise differences in the tamoxifen resistance between these 
sublines of resistant cells.  It is also significant that the resistant cells 
respond with an increase in their growth rate on addition of physiological 
levels of 17β-oestradiol, in a similar fashion to the wildtype MCF7 cells.  
This has been described previously in studies of long-term oestrogen 
deprivation332,333. 
 
Although it is less technically challenging to produce high quality RNA 
and cDNA target from cell lines it was gratifying that the QC metrics for 
all the chips were found to be well within recommended margins. 
 
The observation through unsupervised hierarchical clustering that the 
first batch of replicates (wildtype 1, Early 1 and Late 1) clustered 
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separately from the rest of the chips shows the sensitivity of cDNA 
expression techniques (Figure 3.3). It is not possible to say whether the 
discrepancy observed arose due to the use of a larger starting quantity 
of tRNA in target preparation or whether it was due to a difference in the 
reverse transcriptase enzyme used.  One would expect the data 
obtained in this experiment to be highly reproducible; these assays were 
all performed using the same platform, by the same investigator, in the 
same lab.  This observation begs the question of whether these assays 
will be reproducible under more challenging conditions; for example in 
the clinical setting or utilising very small quantities of initial RNA.  It is 
interesting to note that since this work was carried out, a number of new 
techniques have been developed aiming to improve the accuracy and 
reproducibility of expression analysis using small amounts of starting 
material335,336. 
 
Examining the genes identified as significantly differentially expressed 
using the cDNA expression data implicated various different 
mechanisms that could contribute to the resistance to 4-OH tamoxifen 
observed in these cells: 
 
Increased elimination of tamoxifen by increased expression of 
glucuronidating enzymes: UDP glycosyltransferases (UGT1A1, 
UGT1A3, UGT1A6, UGT1A9) in addition to the up-regulation of efflux 
transporters such as ABCG2 and ABCC3  
Reduction in the “recycling” of sulfated tamoxifen by the down regulation 
of the enzymes SULT1A1 and SULF1 
Increased expression of 3 Aldo-keto reductase (AKR) enzymes specific 
to 3α and 17β-hydroxysteroids (AKR1C1, AKR1C2, AKR1C3) and their 
co-factor (NQO1).   
 
The role of the AKR enzymes in this context is not clear, (see Section 
3.2.5).  AKR1C1-1C3 expression has been found to be lower in breast 
tumour tissue compared to normal breast tissue308.   Up-regulation of 
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AKR1C1, C2 and C3 has been previously described as a non-specific 
response to chemotherapeutic agents in cancer cells, (personal 
communication Trevor Penning).  Also tamoxifen has been described as 
inhibiting the activity of some AKR enzymes337.   
 
Although the ability of AKR enzymes to utilise tamoxifen as a substrate 
has not been described, given that tamoxifen is structurally related to 
their various known substrates, (oestrone, 5α-DHT, 20α-OHP), it is 
tempting in this context to propose that they may act directly on 
tamoxifen to convert it to an inactive form.  Alternatively, AKR activity 
may lead to an increase in the available pool of precursor steroids for 
conversion to 17β-oestradiol, thus enabling cell growth in the absence of 
exogenous oestrogen337,338.   
 
Given the knowledge that the tamoxifen resistant cell lines Early and 
Late remain oestrogen responsive, one can postulate that a precursor 
synthesis role for the AKR enzymes may be important.  The idea that the 
resistant cells have an enhanced ability to interconvert or synthesize 
oestrogen to maintain growth is consistent with the observation that 
these cells respond to exogenous oestrogen in a similar way to their 
wildtype counterparts.  Since, in this model one would expect 
downstream signalling pathways from the oestrogen activated ER to be 
intact and at the same level of regulation or readiness as in the wildtype 
cells.   
 
Whether such precursor steroids can be formed from endogenous 
sources or from 4-OH tamoxifen itself is not clear.  From my cell growth 
studies (Figure 3.2B) it appears that the tamoxifen resistant lines exhibit 
a degree of dependence on tamoxifen for maximal growth.  Within a 
certain range of concentrations (up to 10-5M) there appears to be a dose 
response to increasing concentrations of tamoxifen in the Tam R Late 
cells, whilst the opposite is true of the wildtype cells.  Again it is tempting 
to propose that if the AKR enzymes could enable an interconversion of 
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4-OH tamoxifen to steroid precursors with pro-proliferative effects this 
would be consistent with the features of dose responsiveness and 
tamoxifen-dependence observed in the resistant lines.   
 
By contrast, the differential regulation of all the other enzymes described 
above (UGT, SULT1A1 and SULF1) collectively enhances the 
inactivation and excretion of tamoxifen from the cells.  From this, one 
would not predict that increasing concentrations of tamoxifen would 
enhance cell growth, (see Figure 6.1). 
 
Having selected only 140 genes from 22,000 it is remarkable that ~10% 
of the genes identified as differentially expressed can be placed directly 
into inter-related key pathways of tamoxifen metabolism, (see Tables 
3.3, 3.4, Figure 6.1).  From the results described in Chapter 3, Section 
3.2.5, a picture emerges of the induction of multiple mechanisms for 
enhanced inactivation and excretion of tamoxifen and its metabolites in 
the resistant cell lines via the simultaneous down regulation of a possible 
tamoxifen recycling pathway (SULF1 and SULT1A1) and concurrent up-
regulation of other catabolic enzymes (AKRs and UGTs) and transport 
molecules (ABCs).   It is even more encouraging that some of these 
genes are known to influence the clinical response to tamoxifen (ABCs 
and SULT1A1).  These findings augur well for the possibility that other 
expression changes identified may have clinical relevance.  Examining 
Figure 3.8 and Table 4.7, it is encouraging that the genes identified are 
consistent with data obtained from other studies, in particular, where 
these genes have been identified as relevant to the phenomenon of 
tamoxifen resistance by completely independent methods.    
 
However, one should exercise caution before over-interpreting the role 
of genes identified by expression profiling, since their presence on a list 
of differentially expressed genes coupled with data about their likely 
targets and substrates does not necessarily fully explain their function, 
just because they fit neatly into a speculative model, (such as Figure 6.1)  
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The observed down regulation of Sulfatase 1, (SULF1) may have other 
consequences in addition to its potential for reducing intracellular 
tamoxifen “recycling” (see Chapter 3, Section 3.2.5).  SULF1 is also 
expressed on the cell surface where it has been shown to modulate 
signalling by heparin binding growth factors (eg FGF2 and heparin 
binding epidermal growth factor).  Its expression is down regulated in a 
variety of cancer cell lines including breast cancer derived lines.  
Downregulation of SULF1 is observed in 75% of primary ovarian 
tumours.  Re-expression of SULF1 in ovarian cancer cell lines resulted 
in reduced sulfation of heparin sulfate proteoglycans (HSPGs).  Reduced 
phosphorylation of receptor tyrosine kinases that require sulfated 
HSPGs as co-receptors was also observed. The cells showed reduced 
proliferation and increased sensitivity to apoptosis339.  Thus, down 
regulation of SULF1 in tamoxifen resistant cells may also result in 
enhanced growth factor signaling and increased cell survival signaling.  
It would be interesting to investigate whether the expression of this 
enzyme is down regulated in both the cytoplasmic and extracellular 
compartments in the tamoxifen resistant cells. 
 
Although the upregulation of AKR enzymes has not previously been 
described as a potential mechanism in the development of tamoxifen 
resistance, it is known that their activity can be abrogated by the use of 
NSAIDS, (non-steroidal anti-inflammatory drugs) which incidentally also 
appear to have a chemoprotective effect in the prevention of breast 
cancer 340.  It would be interesting to assay the tamoxifen resistant 
MCF7 derived cells for the effect of a NSAID or COX-2 inhibitor on their 
growth and compare this with the effect on wildtype MCF7 cells.  If the 
tamoxifen resistant cells were more susceptible to NSAIDs it would 
support the theory that AKRs may contribute to endocrine insensitivity, 
or at least that tamoxifen resistant cells were dependant on AKR activity 
for maximal growth.  Of note, another study has found that transfection 
of COX2 in MCF7 cells resulted in selective resistance to tamoxifen 341. 
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Figure 6.1: Proposed pathways involving differentially 
expressed genes identified in the cell line microarray study.  
Overexpressed genes or gene families are shaded in red, while 
under-expressed genes identified are shaded in green.  The 
dotted arrows represent processes where it is proposed that AKR 
enzymes may participate, although unconfirmed by other sources.  
See Chapter 3, Section 3.2.5 for the individual probe sets and their 
level of expression in the different MCF7 derived cell lines 
(wildtype vs tamoxifen resistant Early and Late). 
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I was able to validate the microarray data for six selected genes, 
(HRASLS3, CTSD, CAXII, NR4A2, ATP1B1 and SOCS2) at the RNA 
level (Figure 3.10) and at the protein level for two of the genes, (CAXII 
and ATP1B1), (Figure 3.12 and Table 3.6).  Looking at Table 3.6, (in situ 
hybridization results for validation of ATP1B1, SOCS2 and NR4A2 
riboprobes), the results for NR4A2 indicate non-specific binding of the 
antisense riboprobe resulting in “high background”.  The SOCS2 
riboprobe results demonstrate a different problem, while the antisense 
probe does not bind, the sense probe does not seem to distinguish 
between the wildtype and tamoxifen resistant cell lines.  The possible 
explanations for this are: there is little difference in the levels of SOCS2 
mRNA in the three cell lines despite changes in RNA detected by our 
previous experiments, or that the sense probe is binding non-specifically 
to another sequence.    
  
Looking at Figure 3.15, it was disappointing not to be able to 
demonstrate an alteration in tamoxifen sensitivity in the siRNA-
transfected cells following hormone manipulation.  This may be a true 
negative result, that knockdown of HRASL3, CAXII or CTSD does not 
affect resistance to tamoxifen.  The effect of down regulating these 
genes individually maybe only one of multiple changes necessary for the 
increased resistance observed in the tamoxifen resistant MCF7 cell 
lines.    
 
The experiment can be criticised for the use of transient transfection with 
siRNA, since this perturbs the cells (a non specific increase in cell death 
was seen in all cells treated with the transfection reagent, this was 
increased when cells were transfected with a NON-silencing “control 
siRNA duplex, Figure 3.14).  These non-specific effects may mask any 
increased resistance to tamoxifen or oestrogen deprivation in the cells 
successfully transfected.  Equally, the time frame of transient 
transfection of the cells may be too short to allow the full effects of gene 
knockdown on tamoxifen resistance to manifest.  Furthermore, the 
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degree of gene knockdown effected by transient siRNA may be too 
much or too little to mimic the changes that occurred in the tamoxifen 
resistant MCF7 cells. 
 
Further investigation looking for more subtle changes such as the 
knockdown cells’ oncogenic properties, such as their invasiveness or 
anchorage-independent growth might have revealed more positive 
results.  In addition, an inducible system for gene knockdown may have 
been useful, allowing observation of changes over the longer term and 
excluding changes due to the transfection reagent.   
 
Proponents of 3D culture systems have criticized the practice of culturing 
cells on plastic in a 2D monolayer.  It is argued that 3D systems where 
“spheroids” of cells form are phenotypically closer to cells growing in 
vivo, in terms of cell to cell contact, polarization of cells and regulation of 
growth and proliferation342.  However even these systems, which try and 
mimic native tissue architecture, do not involve communication between 
tumour cells and the stroma or immune system, widely thought to be 
influential on tumour behaviour in vivo. 
 
When looking for new genes and potential pathways for tamoxifen 
resistance, the interpretation of results from expression profiling 
experiments and the selection of genes to investigate further is fraught 
with difficulties.  Different genes have been studied to different extents and 
have better or less well defined roles in the literature.  There are examples 
of genes that have multiple roles, multiple functions, and differing 
downstream effects in different contexts, for instance, many transcription 
factors’ effects vary according to cell type, developmental stage, or as a 
result of exogenous stimuli.  Different model systems and assays may 
result in different proposals for the role of a gene; they may demonstrate 
effects which seem inconsistent but in context may be logical e.g. a gene 
which has been shown to decrease apoptosis in one context may 
physiologically be concerned with the process of differentiation therefore 
one may find “unexpectedly” that it is down regulated in the resistant 
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phenotype.   Also the nature of tamoxifen, which exhibits oestrogenic and 
anti-oestrogenic effects in different tissues may result in potentially 
unforeseen or unexpected regulation of genes.   
 
This study is limited by its use of a single cell line, MCF7 to model 
tamoxifen resistance, it may have been improved by the utilisation of 
further tamoxifen resistant, ER positive cell lines, for example derived from 
T47D or ZR75-1 cells.  Unfortunately, initial attempts to raise these 
resistant lines were unsuccessful, although they have been described in 
the literature 343,344.  Using only MCF7 cells and their tamoxifen resistant 
derivatives cannot be expected to reflect the panoply of pathways to 
tamoxifen resistance found in human breast cancers, for example there 
may be genes in MCF7 cells which are irreversibly inactivated via 
methylation or deacetylation which could play a role in tamoxifen 
resistance in tumours.  
 
The range of cell lines available to use as models for breast cancer has 
been criticized, as has the reliance on MCF7 cells in breast cancer 
studies.  Reviewing the properties of breast cancer cells lines, Lacroix 
concludes that MCF7 cells are “reasonably acceptable models for tumour 
cells in luminal epithelial like ER positive, ERBB2 negative tumours”, (see 
Figure 1.11)307.   
 
For reasons such as these, this cell line study was only ever intended as a 
prelude to a further clinical expression analysis study using tumour 
samples, as described in Chapter 4 and discussed overleaf in Section 6.2. 
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6.2 Clinical study of expression analysis of tamoxifen 
resistant breast cancer 
Looking at the sample selection for the clinical study, the paired samples 
offered by the GSTH/KCH tumour bank were of particular interest for a 
microarray study since potentially these represent samples for 
comparison where the confounders of individual and tumour 
heterogeneity have been ruled out.  It was hoped that they could provide 
the basis for a study where a relatively small number of highly relevant 
genes could be identified from clinical samples (see Introduction 1.6) 
 
The tumours left in situ and treated with tamoxifen alone would be 
unique to this study since in recent or current clinical practice an 
incompletely excised primary tumour would not be left in situ.  Women 
who present with metastatic disease are often treated initially with 
hormone therapy but in that scenario, there would usually only be biopsy 
material at presentation. Although FNA samples have been used 
successfully for microarray analysis of breast cancer samples345,  felt 
that using biopsy material rather than excision specimens would be more 
technically demanding because of the small amount of material available 
and would also raise doubts over whether the sample obtained could be 
considered representative of the whole tumour346.  Biopsy specimens 
are also less likely to have their original tissue architecture intact and to 
be contaminated to a greater extent by non-tumour tissue (skin, blood, 
fat) than tumours that have been excised en bloc.  
 
To obtain paired samples from women with metastatic disease treated 
with tamoxifen would have been interesting.  However since these 
samples were not available in the tumour bank, it would have required 
the design of a prospective study and this would have taken even longer 
to carry out.  In addition, it would have required patients to undergo 
additional biopsies upon disease progression, since it is not routine 
practice to re-biopsy the site of progressing disease, this would have 
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posed an ethical dilemma, subjecting women to unnecessary 
intervention.  
 
Finally, the patients in EORTC 10850 & 10851 studies were given 
tamoxifen for life, which is again unique to these studies, therefore all 
relapses which occurred evolved in patients being treated with tamoxifen 
 
It was very disappointing to be unable to offer any clinical data in this 
thesis.  After screening specimens from the GSTT tumour bank I was 
committed to using these samples, in addition I felt these samples 
offered important advantages that I have outlined above.  Although 
approaches were made to obtain specimens from other sources, it was 
not possible to secure comparable samples.  I hope in this discussion to 
contextualise some of the problems we faced.  
 
The storage and management of human tissue samples in the UK in 
recent years has become a politically sensitive issue, following the public 
outcry at the Alder Hey scandal, which emerged at the end of 1999.  The 
report of the Redfern Inquiry into Alder Hey was published on 30 
January 2001.  It found that between 1988-95, Prof Dick Van Velzen, a 
pathologist had instigated and overseen the unnecessary retention of 
tissue samples, whole organs and body parts of children without 
consent.  In addition, samples were stored without proper record 
keeping.  The Chief Medical Officer performed a census that showed 
that the retention of tissue samples without formal consent was 
widespread in the UK. In response to the Redfern Inquiry, the 
government promised legislative reform taking into account its 
recommendations.  The Human Tissue Act received Royal Assent on 
15th November 2004 and came into force in September 2006.   
 
At the time of my study proposal, there was considerable uncertainty 
surrounding the use of stored tissue for research.  Perhaps as a 
consequence of this, the administration of the Headley Atkins breast 
tissue bank at GSTH was over-hauled whilst I was carrying out the 
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preliminary work for this clinical study.  The administration of the breast 
tissue bank was transferred from Cancer Research UK to Kings College, 
a new committee was set up to oversee the management of the tissue 
bank; to approve the use of samples and to ensure proper record 
keeping.  A moratorium was placed on the use of all tissue samples 
whilst these new systems were put in place. It took 2 years for the 
GSTT/KCL Breast Tissue Bank committee to be formed and then meet.  
My study protocol and application for samples was approved in May 
2006.  However, the specimens were not released since further systems 
were being put in place to establish an appropriate charging scale and to 
protect the intellectual property rights of the university.  The samples 
were released in Autumn 2007.  Unfortunately, these events precluded 
my carrying out the planned clinical study.  Colleagues in Professor 
Hurst’s team are carrying out this study, using the preliminary data and 
protocols described.  
 
During the time I spent awaiting local approval to use the selected 
tumour specimens, there was widespread speculation that the events at 
Alder Hey and the recommendations of the Redfern Inquiry might result 
in draconian measures in the forthcoming legislation.  There were fears 
that only tissues obtained with written informed consent for use in 
research could be utilised, meaning that all the selected tissues would 
be beyond use, unless retrospective consent could be obtained.    
 
Speculation was fuelled by lurid media reports, which conflated the 
events at Alder Hey with routine practice in pathology departments in the 
UK.  Although retention of tissue samples is widespread, in most tissue 
banks a sample ~1cm3 from an affected organ is retained, this is a far 
cry from the retention of children’s body parts.  Little emphasis was given 
to the concept that retaining a sample for future study may be in the 
patient’s interest  (eg the storage of breast primary tumours has enabled 
their re-testing for Her2 status following improvements in the assay and 
the emergence of Herceptin as an effective, targeted treatment).  The 
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storage of samples may also be of value to other family members, in the 
case of rare or familial disease.    
 
In the application for the ethical approval of my study, I explained in 
some detail the ethical issues as I saw them regarding the use of these 
samples, as follows:   
 
The patients involved were not asked for informed consent regarding 
use of their samples.  However written, informed consent for 
participation in the EORTC 10850 & 10851 trials was sought and 
obtained.  The patients were all >70 years old with a diagnosis of breast 
cancer when they were recruited in the early 1980s.  It is likely that the 
majority of these women have subsequently died.  It is not practicable to 
obtain consent from these individuals.  Contacting surviving patients or 
their relatives in order to seek consent for participation in this study may 
cause significant distress. 
 
The women participating in the original trials were a self−selected group, 
whose actions promoted and supported research.  Tumour samples are 
a pre-requisite for advancing research into cancer.  In my experience, 
most patients with cancer do not have an emotional attachment to their 
tumour samples, they do not propose keeping tumour samples for burial 
at a later date and are hugely supportive of furthering research that may 
benefit themselves or other patients. 
 
This tissue had been in storage for over 20 years and represents a 
valuable resource in terms of both the financial investment made to set 
up the tumour bank and maintain it, but also in the scarcity of fresh 
frozen tissue with long-term follow−up.  Breast cancer has the ability to 
recur after decades of apparent quiescence, therefore studying patients 
with long-term follow up is important.  The shelf life of stored tissue is not 
infinite so it is also essential to balance the wish to conserve precious 
material against the desire to employ it usefully. 
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The steps taken to address the ethical issues raised are as follows: 
i) Small sample number (25 frozen samples and 50 paraffin embedded 
samples) 
ii) Small sample size (0.5 cubic cm), therefore in most cases, a 
remainder of tumour will continue to be stored for use by other groups. 
iii) The patients need take no further action in order for their samples to 
be used in the study. 
iv) Tumour samples, clinical data and subsequent published data will be 
anonymised. 
v) Conclusions from the study will be published and available to the 
public and wider research community 
 
I proposed to used laser capture microdissection, (LCM) to select tumour 
cells for expression analysis, in order to reduce the variability of 
expression profiles obtained due to sampling error and to ensure the 
analysis of tumour cells rather than connective tissue or normal breast 
tissue.  Other studies have addressed this issue in a variety of ways, 
some have selected samples for expression profiling by selecting only 
those tumours that are highly cellular163.  This represents a degree of 
selection bias for the samples studied and given that relatively few 
samples were available for the study we felt that we could not afford this 
luxury, especially since we planned to select paired samples of tumours, 
if they varied widely in their cellularity, both samples might be excluded if 
one of them was poorly cellular or highly vascular.  Therefore we hoped 
that by using LCM our samples for analysis would be more consistent 
and we would be able to use a wider range of tumours as starting 
material.   
 
Other studies have taken whole samples without pre-selecting them for 
cellularity, this has perhaps been reflected in some of the results 
obtained, for example “lymphocyte” clusters present in some series of 
breast tumour profiles161.  This approach may be advantageous since it 
has the ability to identify patterns influenced by surrounding stromal 
tissue expression in addition to expression in the cancer cells.  The 
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stromal and immune responses may be crucial in clinical tumour 
progression, but in order to be able to “learn” the characteristic profiles of 
for example an “infiltration” profile for further analysis it would be 
necessary to use large numbers of samples, which were not available.  
We were aiming at a small study and trying to minimise the degree of 
noise in the profiles obtained, and we were interested in changes in 
expression in the carcinoma cells rather than surrounding tissue. 
 
LCM and staining protocols were optimised through trial and error by 
comparing the images obtained under the microscope and yield of RNA 
from whole sections that had undergone different times of stain, fix and 
dehydration.   
 
Examining the quality control metrics for the 3 different Affymetrix 
protocols used (Table 4.3 and Results 4.4), I was not able to positively 
identify the reason for the isolated high background reading (100ng Late 
4); It is a problem which has been described by other users of the 
Affymetrix platform.  The UK Affy users group have suggested the 
following potential causes of the problem: 
problems with the fluidics station maintenance – this is unlikely to be the 
cause since this chip was processed simultaneously with three others on 
the fluidics station, which had no signs of high background. 
inaccurate quantitation of the labelled cRNA -  this is possible but 
unlikely given the use of the nanodrop which offers highly accurate 
readings at low concentrations and low volumes. 
re-mixing of precipitated material following centrifugation of the 
hybridisation cocktail – this difficult to exclude  
trace ethanol from the cRNA clean up – again this is unlikely since the 
cRNA samples were processed together in the same way, using a  spin 
column technique with an extra step specifically to dry the membrane 
before eluting the cRNA from the column 
coloured micro centrifuge tubes – this can be discounted since these 
were not used in the preparation of the samples 
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chip manufacturing problems - this is unlikely since the chip was from 
the same batch as 2 other chips that were processed without incident. 
 
Other than the re-mixing of precipitated material following centrifugation 
of the hybridisation cocktail, the suggested causes can be discounted.  It 
is not therefore possible to say whether the high background was related 
to the protocol used for the preparation of the hybridisation protocol.    
 
Two further 100ng chips were rejected due to high GAPDH 3':5' ratio 
measurements.  This can be attributed to the 100ng protocol since the 
GAPDH 3':5' ratio indicates the extent of degradation of source RNA and 
also the efficiency of the IVT reaction.  Smaller quantities of dilute RNA 
are more prone to degradation and one of the dangers inherent in the 2 
cycle amplification protocol is that amplification of incomplete fragments 
of RNA will occur to a larger extent than is likely following a one cycle 
amplification protocol.  
 
Using the 100ng protocol, 25% (2/8) of the chips were discarded due to 
problems inherent in the protocol (enhanced RNA degradation).  I felt 
that this was an unacceptably high rate of sample loss for consideration 
for expansion into a clinical study,  <10% would have been an 
acceptable rate of loss.   I think this ably demonstrates the value of a 
pilot study. 
 
In conclusion, RNA purification from LCM samples, though technically 
demanding, appears to be feasible.  The 100ng protocol with 2 cycles of 
amplification, appears to be less a lessly robust and is therefore 
unsuitable for expansion into a clinical study, (the high rates of discarded 
chips and the skewed distribution of MVA plots when using the 100ng 
protocol provide evidence for this).  Thus, the extra time spent on LCM 
to obtain more starting material seems worthwhile in order to allow the 
use of a protocol involving a single cycle of amplification.  
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Comparing the 1µg to the 5µg protocol, the results were more 
encouraging, the QC metrics in Tables 3.2 and 4.3 reveal that the chips 
produced with both protocols were technically successful.   Figure 6.2 
illustrates that using either protocol, the chips cluster by cell line.  The 
tamoxifen resistant lines “Early” and “Late” cluster together more closely 
than Wildtype and Early or Wildtype and Late as expected.  In addition, 
replicate chips using each protocol cluster together. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Heatmap and dendrogram resulting from unsupervised 
hierarchical clustering per chip. 
Chips were clustered according to the signal from every gene on the 
array using hierarchical clustering with a Pearson correlation similarity 
measure.  The colour bar labelled “line” represents the different cell 
lines, and the lower colour bar illustrates the different protocols used to 
produce the chips, (see key on right). 
 
Late 
Early 
Wildtype 
Normal protocol 5 µg 
1µg protocol 
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Many more differentially expressed genes were identified using the 1µg 
protocol rather that the 5µg protocol when replicate groups (cell lines) 
were compared.  This may suggest that a consequence of using less 
initial material resulted in greater variability in the results.  However it 
may also be due to the lack of an “early” tamoxifen resistant replicate 
group for the 1µg protocol, ie more chips are being analysed from the 
5µg experiment.     
 
It may not be helpful to try to compare gene lists obtained from our 
experiment to those obtained from different model system or a different 
platform (see Results Section 4.4.4, Table 4.7).  Previous studies 
addressing the apparent lack of concordance between genes identified 
in clinical microarray studies have concluded that different studies may 
have identified activation or downregulation of the same pathways but 
with different genes as markers 191. 
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6.3 Knockdown of AP-2α and AP-2γ by RNA 
interference.  Investigating the effects on ERBB2 
expression in hormonally manipulated breast cancer cells 
Examining AP-2α and ERBB2 expression levels in breast cancer cell 
lines, (MCF7, ZR75-1, T47D) my data consistently showed that levels of 
ERBB2 and AP-2α correlate positively while those of ERBB2 and AP-2γ 
do not.  This agrees with the majority of findings from previous in vitro 
data and clinical studies, (see Introduction 1.7.3 and Figure 5.7).  
However, it seems somewhat paradoxical given the postulated tumour 
suppressor role of AP-2α.  It has been suggested that the observed 
increase in AP-2α level in ERBB2 overexpressing cells occurs as an 
insufficient attempt to halt the increase in proliferation due to high levels 
of ERBB2 266.  
 
Following siRNA knockdown of AP-2α, my data suggests that AP-2α 
positively regulates ERBB2 expression in the absence of 17β-oestradiol.  
This contradicts the idea that the AP-2α increase observed is a 
secondary event.  It is concordant with previous evidence that the 
functional AP-2 binding sites in the oestrogen repressible enhancer in the 
first intron of ERBB2 are important in the modulation of ERBB2 
expression (in the short term at least) i.e. that elevated AP-2α causes 
over-expression of ERBB2270. 
 
Furthermore, my in vitro data show a more dramatic reduction of ERBB2 
with knockdown of AP-2α than AP-2γ. This suggests that AP-2α is more 
influential in increasing ErbB2 levels after oestrogen withdrawal than AP-
2γ.  Again, given the proposed tumour suppressor role of AP-2α and 
oncogenic role of AP-2γ this is puzzling.  In addition, there are clinical 
observations linking AP-2α overexpression in primary tumours with 
reduced proliferation and good prognosis while AP-2γ overexpression is 
associated with poor prognosis (see Introduction 1.7.3).  In Pellikanen’s 
study, AP-2α negative, ErbB2 positive tumours were associated with 
increased proliferation and poor prognosis; AP-2α positive, ErbB2 
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negative tumours were associated with low proliferation and good 
prognosis.  In two other studies, low nuclear AP-2α in the primary tumour 
was associated with poor prognosis235,237 and in a further IHC study from 
our lab, increased AP-2γ was found to be an independent predictor of 
poor prognosis in patients treated with tamoxifen6. 
 
If overexpression of ERBB2 on oestrogen withdrawal, mediated by AP-2 
factors, is a major driver of hormone resistance in breast cancer leading 
to failure of anti-oestrogen therapy one would expect AP-2γ to be the 
isoform with most influence over ERBB2 expression in all conditions, but 
particularly during hormone manipulation of ER positive breast tumours 
and derived cell lines.   
 
The observation of a differential short term versus long-term effect on 
ErbB2 regulation may provide a possible explanation for these results.  
Looking at the expression analysis results, following long-term hormone 
manipulation of MCF7 cells (see Figure 5.5), although an initial rise in 
ERBB2 is seen in tamoxifen resistant MCF7 Early cells, this falls despite 
continued exposure to tamoxifen in the Late cells. 
 
My data, using AP-2 siRNA, was collected using short-term experiments, 
observing changes in ERBB2 expression over 3-5 days, under conditions 
where the cells are arresting their growth due to the lack of AP-2.  Figure 
5.14 shows that cells with AP-2 knockdown exhibited higher rates of cell 
death compared to control cells.  It is possible that further mechanisms 
lead to a “re-setting” of the level of ERBB2 expression upon prolonged 
oestrogen deprivation or tamoxifen treatment. 
 
Examining Figure 5.6 B, C, D where Total AP-2 is plotted against ERBB2 
it is possible to see that addition of tamoxifen stimulates an intermediate 
rise in ErbB2 but oestrogen deprivation (or fulvestrant treatment) 
stimulates a steeper increase in ErbB2.   This seems likely to be due to 
the extent of oestrogen deprivation ie that treatment with fulvestrant or 
oestrogen deprivation results in lower ER activation than treatment with 
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tamoxifen.  Clinically, there is a consensus that more profound oestrogen 
deprivation (from the use of an aromatase inhibitor rather that tamoxifen) 
is superior in both the prevention and treatment of breast cancer, 
(discussed in Section1.3.3).  The more marked increase in Erbb2/3 seen 
with oestrogen deprivation / fulvestrant use therefore appears not to be 
clinically significant in the majority of patients.   
 
However there is evidence emerging that for certain patients, the 
interaction of ErbB2 and ER signalling is an important mechanism for 
tamoxifen resistance.  For example; some patients’ tumours convert from 
ErbB2 negative to ErbB2 overexpressors following endocrine treatment 
91,347
.    A recently reported sub-group analysis of ATAC showed that 
patients with ErbB2 overexpressing tumours received less benefit from 
adjuvant anastrazole than ErbB2 negative patients.  No significant 
difference in relapse rate was seen between ErbB2 positive patients 
treated with anastrazole vs tamoxifen348.  Of note, this was not replicated 
in sub group analysis of BIG1-98 where aromatase inhibitor appeared 
superior to tamoxifen in both ErbB2 positive or ErbB2 negative patients.   
 
The Tandem trial, a randomised, phase II study in >200 ER positive, 
ErbB2 positive postmenopausal women with advanced breast cancer, 
compared herceptin and anastrazole combined with anastrazole alone 
and reported a significant improvement in progression free survival in the 
combination arm 349.   
 
Figure 5.6 and my data from Chapter 5 suggest that Total AP-2 levels 
correlate closely with the levels of ErbB2 and ErbB3 upon oestrogen 
deprivation.  It would be fascinating to measure tumour total AP-2 in a 
prospective clinical trial looking at combined ErbB2 and ER blockade.  If 
positive, AP-2 might be an important biomarker for this mechanism of 
tamoxifen resistance; for identifying a subgroup of patients whose ErbB2 
expression is reactive or sensitive to ER antagonism.  For such patients 
combined blockade of ErbB2 and ER might be a helpful strategy. 
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It may be that Total AP-2 or AP-2γ levels are more influential on the long-
term regulation of ERBB2 expression than AP-2α alone, i.e. that high 
levels of AP-2γ or Total AP-2 result in a more sustained rise in ErbB2 or 
activation of a pathway that constitutively activates ErbB2 which 
correlates more closely with clinical hormone resistance.  This suggested 
model is illustrated below in Figure 6.3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 A scheme to illustrate the observed relationship of AP-2 
factors (AP-2α and γ) and ERBB2 during hormone manipulation and 
the effects of siRNA directed against AP-2α and γ in MCF 7 cells.  
This illustrates the observed levels of ERBB2 (y axis) and the effects of 
silencing AP-2α and AP-2γ (see Key) under oestrogenic and non 
oestrogenic conditions (labelled β-E2 + or -) over time (x axis) in three 
different ER positive breast cancer cell lines, (MCF7, T47D and ZR75-1).  
The y axis is also labelled AP-2α, to emphasize that higher expression of 
ERBB2 correlates with increased AP-2α levels.  MCF7 express very little 
AP-2α, T47D progressively more, while ZR75-1 express significant 
amounts.  All units are arbitrary. 
 
TIME 
AP-2α > AP-2γ  
modulates 
ERBB2 in 
presence of 
oestrogen 
ERBB2 
ZR75-1 
MCF7 
T47D 
Control 
AP-2γ siRNA 
AP-2α siRNA 
AP-2α  
AP-2γ / Total AP-2  
modulates long term 
ERBB2 response in 
absence of oestrogen 
β-E2 
- + - + - + 
KEY: 
Wildtype Early Late 
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An unpublished observation from the IHC study by Gee et al. was that 
increased Total AP-2 was associated with increased levels of 
phosphorylated ErbB26, (personal communication Prof Hurst).  Although 
tamoxifen resistant ZR75-1 cells and T47D cell lines have been 
established they seem more difficult to raise; since we were only able to 
establish tamoxifen resistant sub-lines in MCF7 cells, having tried to 
establish tamoxifen resistant ZR75-1 and T47D cell lines without 
success.  Of these cell lines, MCF7 has the highest levels of AP-2γ.  In 
the literature too, MCF7 cells are mostly used for the establishment of 
resistant cell lines.  
 
The effects of AP-2 factors on other pathways may also be influential in 
determining the overall clinical response.  Thus, the pro-proliferative 
influences of AP-2γ would be expected to exacerbate its effects on 
ERBB2.  Whereas for AP-2α, its effects on expression of ERBB2 may be 
compensated for by its other anti-proliferative, pro-apoptotic effects 
elsewhere. 
 
It is possible that the sub-group of primary breast cancers which over 
express AP-2γ (identified by the IHC study) may be “primed” for anti-
oestrogen resistance; that is, if AP-2γ is less responsive to oestrogen 
deprivation in these cells, leading to continued AP-2γ expression despite 
oestrogen withdrawal, this would result in over expression of ERBB2 and 
increased proliferation, however this is purely speculative.  
 
Alternatively, the observed results may be a consequence of the 
efficiency of siRNA knockdown, i.e. AP-2α knockdown was more efficient 
that AP-2γ.  If I was only able to partially knockdown AP-2γ the effects of 
AP-2γ loss may have been masked or under-estimated.  Previous work 
by myself and other members of the Hurst lab has demonstrated the AP-
2 factors are relatively resistant to silencing.  As mentioned in Results, 
Chapter 5, multiple attempts by different methods were made 
unsuccessfully; (antisense methods including morphlinos, vector based 
siRNA with pSUPER) prior to successful knockdown with siRNA transient 
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transfection described.  Furthermore, AP-2α was silenced only after 
seven different carefully selected sequences had been employed.   
 
The possible reasons for this are that the target gene is essential for cell 
survival therefore knockdown is detrimental to the cell.  Looking at Figure 
5.14, an increased death rate in knockdown cells is observed.  However 
there are many examples of successful knockdown of genes previously 
thought to be essential for survival.  Indeed, there are commercially 
available siRNA libraries with sequences targeting every gene in the 
genome.  Alternatively, some genes’ secondary or tertiary mRNA 
structure may influence their accessibility for interaction with RISC (AP-2 
factors may have peculiarly folded and / or protein bound mRNA, and 
AP-2γ to a greater extent than AP-2α). 
 
Sequence-specific differences in the efficiency of knockdown are 
common when using siRNA. This is thought to be due to competition for 
limiting factors in the RNAi pathway, for example certain sequences are 
preferentially incorporated into the RISC complex, due to their 
thermodynamic stability, other sequences are more efficient at mediating 
target mRNA cleavage because Ago2 “Slicer” the RISC RNase has 
preferences for certain nts in specific positions 278.  It is intriguing that 
when both AP-2α and γ siRNAs are transfected simultaneously, both 
isoforms appear to match each other’s level of knockdown closely.   
 
If further time were available, it would be helpful to examine protein 
levels in ZR75-1 cells, to see if upon AP-2 knockdown a reduction of 
ERBB2 expression in both oestrogenic conditions and upon withdrawal 
of oestrogen can be demonstrated.  It would also be interesting to further 
explore the role of AP-2 in breast cancer, for example looking at AP-2 
levels in the normal population, to see if high levels if AP-2γ could be a 
marker for women at increased risk of breast cancer. 
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